Diagnosis of multiple sclerosis: 2017 revisions of the Mc

Lancet Neurology, The
17, 162-173
DOI: 10.1016/s1474-4422(17)30470-2

Citation Report

#	Article	IF	Citations
1	The current role of MRI in differentiating multiple sclerosis from its imaging mimics. Nature Reviews Neurology, 2018, 14, 199-213.	4.9	157
2	Free light chains in the cerebrospinal fluid. Do we still need oligoclonal IgG?. Clinical Chemistry and Laboratory Medicine, 2018, 56, 1011-1014.	1.4	5
3	Complexity of MS management in the current treatment era. Neurology, 2018, 90, 761-762.	1.5	4
4	Coexistence of systemic lupus erythematosus and multiple sclerosis. A case report and literature review. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2018, 4, 205521731876833.	0.5	7
5	Challenges and needs in experimental therapies for multiple sclerosis. Current Opinion in Neurology, 2018, 31, 263-267.	1.8	9
6	Diagnosing MRI-negative autoimmune diseases. Neurology: Neuroimmunology and NeuroInflammation, 2018, 5, e457.	3.1	5
7	Evaluation of Cobas 8000Â® for the quantification of albumin and IgG in serum and cerebrospinal fluid. Clinical Biochemistry, 2018, 56, 105-108.	0.8	2
8	To diagnose or not to diagnose? Timing is the question: balancing early diagnosis of multiple sclerosis with misdiagnosis. Expert Review of Neurotherapeutics, 2018, 18, 355-357.	1.4	1
9	2017 McDonald MS diagnostic criteria: Evidence-based revisions. Multiple Sclerosis Journal, 2018, 24, 92-95.	1.4	43
10	Paediatric multiple sclerosis: early diagnosis as a first step. The Lancet Child and Adolescent Health, 2018, 2, 161-162.	2.7	1
11	Optimal Intereye Difference Thresholds in Retinal Nerve Fiber Layer Thickness for Predicting a Unilateral Optic Nerve Lesion in Multiple Sclerosis. Journal of Neuro-Ophthalmology, 2018, 38, 451-458.	0.4	46
12	Clinical applications of ultra-high field magnetic resonance imaging in multiple sclerosis. Expert Review of Neurotherapeutics, 2018, 18, 221-230.	1.4	20
13	Progress in multiple sclerosis â€" from diagnosis to therapy. Nature Reviews Neurology, 2018, 14, 72-74.	4.9	8
14	Evolving diagnostic criteria for multiple sclerosis. Lancet Neurology, The, 2018, 17, 118.	4.9	9
15	Preservation of neuronal function as measured by clinical and MRI endpoints in relapsing-remitting multiple sclerosis: how effective are current treatment strategies?. Expert Review of Neurotherapeutics, 2018, 18, 203-219.	1.4	8
16	MRI and laboratory features and the performance of international criteria in the diagnosis of multiple sclerosis in children and adolescents: a prospective cohort study. The Lancet Child and Adolescent Health, 2018, 2, 191-204.	2.7	86
17	2017 Japanese guidelines for multiple sclerosis and neuromyelitis optica: Achievements and challenges. Clinical and Experimental Neuroimmunology, 2018, 9, 4-6.	0.5	0
18	Do spinal cord lesions matter in patients with clinically isolated syndrome and early MS?. Multiple Sclerosis Journal, 2018, 24, 430-431.	1.4	5

#	Article	IF	Citations
19	White paper by the Society for CSF Analysis and Clinical Neurochemistry: Overcoming barriers in biomarker development and clinical translation. Alzheimer's Research and Therapy, 2018, 10, 30.	3.0	40
20	Commentary on the ECTRIMSâ€“EAN guideline for pharmacological treatment of multiple sclerosis. Therapeutic Advances in Neurological Disorders, 2018, 11, 175628641877037.	1.5	2
21	Diagnosis of multiple sclerosis through the lens of ultra-high-field MRI. Journal of Magnetic Resonance, 2018, 291, 101-109.	1.2	11
22	NeurobehÃ§et, multiple sclerosis or overlap syndrome? A case report. Neurological Sciences, 2018, 39, 1625-1627.	0.9	2
23	Headache and Its Management in Patients With Multiple Sclerosis. Current Treatment Options in Neurology, 2018, 20, 10.	0.7	25
24	MRI in multiple sclerosis: clinical and research update. Current Opinion in Neurology, 2018, 31, 249-255.	1.8	25
25	OCT is an alternative to MRI for monitoring MS â€“ Commentary. Multiple Sclerosis Journal, 2018, 24, 705-706.	1.4	2
26	Multiple sclerosis. Lancet, The, 2018, 391, 1622-1636.	6.3	1,204
27	Secondary antibody deficiency in neurology. Current Opinion in Allergy and Clinical Immunology, 2018, 18, 481-488.	1.1	8
28	The role of optical coherence tomography in neuro-ophthalmology. Annals of Eye Science, 0, 3, 35-35.	1.1	16
29	Geostatistical Analysis of White Matter Lesions in Multiple Sclerosis Identifies Gender Differences in Lesion Evolution. Frontiers in Molecular Neuroscience, 2018, 11, 460.	1.4	8
30	The International Multiple Sclerosis Visual System Consortium: Advancing Visual System Research in Multiple Sclerosis. Journal of Neuro-Ophthalmology, 2018, 38, 494-501.	0.4	15
31	Sociodemographic, environmental and lifestyle risk factors for multiple sclerosis development in the Western region of Saudi Arabia. Journal of King Abdulaziz University, Islamic Economics, 2018, 39, 808-814.	0.5	16
32	Multiple sclerosis: Diagnosis and Differrential Diagnosis. Noropsikiyatri Arsivi, 2018, 55, S1-S9.	0.2	38
33	Early predictors of conversion in patients with clinically isolated syndrome: a preliminary Egyptian study. Egyptian Journal of Neurology, Psychiatry and Neurosurgery, 2018, 54, .	0.4	1
34	Professionalism-Multiple Sclerosis. Neurology Today: an Official Publication of the American Academy of Neurology, 2018, 18, 47-47.	0.0	0
35	Disease-modifying therapies for multiple sclerosis. BMJ: British Medical Journal, 2018, 363, k4674.	2.4	76
36	Multiple Sclerosis and Variants. , 2018, , 1-41.		3

#	Article	IF	Citations
37	Investigating the Role of MicroRNA and Transcription Factor Co-regulatory Networks in Multiple Sclerosis Pathogenesis. International Journal of Molecular Sciences, 2018, 19, 3652.	1.8	40
39	Multiple sclerosis. Nature Reviews Disease Primers, 2018, 4, 43.	18.1	767
41	Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disorders: Toward a New Spectrum of Inflammatory Demyelinating CNS Disorders?. Frontiers in Immunology, 2018, 9, 2753.	2.2	49
42	Central Nervous System Involvement in Common Variable Immunodeficiency: A Case of Acute Unilateral Optic Neuritis in a 26-Year-Old Italian Patient. Frontiers in Neurology, 2018, 9, 1031.	1.1	6
43	Factors associated with time from first-symptoms to diagnosis and treatment initiation of Multiple Sclerosis in Switzerland. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2018, 4, 205521731881456.	0.5	16
44	Should Spinal MRI Be Routinely Performed in Patients With Clinically Isolated Optic Neuritis?. Journal of Neuro-Ophthalmology, 2018, 38, 502-510.	0.4	1
45	Anti-Myelin Oligodendrocyte Glycoprotein and Human Leukocyte Antigens as Markers in Pediatric and Adolescent Multiple Sclerosis: on Diagnosis, Clinical Phenotypes, and Therapeutic Responses. Multiple Sclerosis International, 2018, 2018, 1-9.	0.4	9
46	Ellen Grass Memorial Lecture: Clinical Neurophysiology in the Treatment of Disease. Neurodiagnostic Journal,the, 2018, 58, 203-212.	0.1	0
47	Multiple Sclerosis: A Global Concern with Multiple Challenges in an Era of Advanced Therapeutic Complex Molecules and Biological Medicines. Biomedicines, 2018, 6, 112.	1.4	12
48	The Persisting Significance of Oligoclonal Bands in the Dawning Era of Kappa Free Light Chains for the Diagnosis of Multiple Sclerosis. International Journal of Molecular Sciences, 2018, 19, 3796.	1.8	34
49	Genome-wide DNA methylation changes in CD19+ B cells from relapsing-remitting multiple sclerosis patients. Scientific Reports, 2018, 8, 17418.	1.6	42
50	Differences in Intercellular Communication During Clinical Relapse and Gadolinium-Enhanced MRI in Patients With Relapsing Remitting Multiple Sclerosis: A Study of the Composition of Extracellular Vesicles in Cerebrospinal Fluid. Frontiers in Cellular Neuroscience, 2018, 12, 418.	1.8	35
52	Multiplex Matrix Metalloproteinases Analysis in the Cerebrospinal Fluid Reveals Potential Specific Patterns in Multiple Sclerosis Patients. Frontiers in Neurology, 2018, 9, 1080.	1.1	17
53	Determining the Etiology of Internuclear Ophthalmoplegia in a Patient with a Cardiac Pacemaker and		

#	Article	IF	Citations
59	Serum GFAP as a biomarker for disease severity in multiple sclerosis. Scientific Reports, 2018, 8, 14798.	1.6	164
60	Relevance of KFLC quantification to differentiate clinically isolated syndrome from multiple sclerosis at clinical onset. Clinical Neurology and Neurosurgery, 2018, 174, 220-229.	0.6	10
61	Therapeutic Advances and Challenges in the Treatment of Progressive Multiple Sclerosis. Drugs, 2018, 78, 1549-1566.	4.9	36
62	Functional Connectivity in Multiple Sclerosis: Recent Findings and Future Directions. Frontiers in Neurology, 2018, 9, 828.	1.1	66
63	Differential Gray Matter Vulnerability in the 1 Year Following a Clinically Isolated Syndrome. Frontiers in Neurology, 2018, 9, 824.	1.1	12
64	Visual Evoked Potentials as a Biomarker in Multiple Sclerosis and Associated Optic Neuritis. Journal of Neuro-Ophthalmology, 2018, 38, 350-357.	0.4	38
65	NEDA-3 status including cortical lesions in the comparative evaluation of natalizumab versus fingolimod efficacy in multiple sclerosis. Therapeutic Advances in Neurological Disorders, 2018, 11, 175628641880571.	1.5	9
66	Guidelines of the Polish Medical Society of radiology for the routinely used MRI protocol in patients with multiple sclerosis. Neurologia I Neurochirurgia Polska, 2018, 52, 638-642.	0.6	3
67	Multiple sclerosis: clinical aspects. Current Opinion in Neurology, 2018, 31, 752-759.	1.8	324
68	Is the dual-task cost of walking and texting unique in people with multiple sclerosis?. Journal of Neural Transmission, 2018, 125, 1829-1835.	1.4	9
69	Rebound After Fingolimod and a Single Daclizumab Injection in a Patient Retrospectively Diagnosed With NMO Spectrum Disorderâ€"MRI Apparent Diffusion Coefficient Maps in Differential Diagnosis of Demyelinating CNS Disorders. Frontiers in Neurology, 2018, 9, 782.	1.1	5
70	The Central Vein: FLAIR Signal Abnormalities Associated with Developmental Venous Anomalies in Patients with Multiple Sclerosis. American Journal of Neuroradiology, 2018, 39, 2007-2013.	1.2	11
72	Clinical utility of anti-MOG antibody testing in a Danish cohort. Multiple Sclerosis and Related Disorders, 2018, 26, 61-67.	0.9	10
73	Pediatric Multiple Sclerosis: an Update. Current Neurology and Neuroscience Reports, 2018, 18, 76.	2.0	29
74	Brazilian Consensus for the Treatment of Multiple Sclerosis: Brazilian Academy of Neurology and Brazilian Committee on Treatment and Research in Multiple Sclerosis. Arquivos De Neuro-Psiquiatria, 2018, 76, 539-554.	0.3	22
76	Learning from other autoimmunities to understand targeting of B cells to control multiple sclerosis. Brain, 2018, 141, 2834-2847.	3.7	43
77	Glial Fibrillary Acidic Protein Antibody: Another Antibody in the Multiple Sclerosis Diagnostic Mix. Journal of Neuro-Ophthalmology, 2018, 38, 281-284.	0.4	3
78	Interleukin-6, S-Nitrosothiols, and Neurodegeneration in Different Central Nervous System		

#	Article	IF	Citations
79	Laboratory Performance on Reporting Monoclonal Gammopathy During Cerebrospinal Fluid Oligoclonal Banding Analysis from External Quality Assessment Surveys. journal of applied laboratory medicine, The, 2018, 3, 261-266.	0.6	2
80	2017 revisions of McDonald criteria shorten the time to diagnosis of multiple sclerosis in clinically isolated syndromes. Journal of Neurology, 2018, 265, 2684-2687.	1.8	35
81	Delayed treatment of MS is associated with high CSF levels of IL-6 and IL-8 and worse future disease course. Journal of Neurology, 2018, 265, 2540-2547.	1.8	38
83	Search for a prognostic biomarker in multiple sclerosis: a step in the right direction?. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 1015-1015.	0.9	0
84	Impact of the 2017 revisions to McDonald criteria on the diagnosis of multiple sclerosis. Multiple Sclerosis Journal, 2018, 24, 1786-1787.	1.4	26
85	Applying the 2017 McDonald diagnostic criteria for multiple sclerosis. Lancet Neurology, The, 2018, 17, 497.	4.9	3
86	Conventional and advanced MRI in multiple sclerosis. Revue Neurologique, 2018, 174, 391-397.	0.6	8
87	Applying the 2017 McDonald diagnostic criteria for multiple sclerosis. Lancet Neurology, The, 2018, 17, 496-497.	4.9	11
88	Applying the 2017 McDonald diagnostic criteria for multiple sclerosis. Lancet Neurology, The, 2018, 17, 498.	4.9	17
89	Applying the 2017 McDonald diagnostic criteria for multiple sclerosis. Lancet Neurology, The, 2018, 17, 497-498.	4.9	10
90	Applying the 2017 McDonald diagnostic criteria for multiple sclerosis. Lancet Neurology, The, 2018, 17, 498-499.	4.9	2
91	Applying the 2017 McDonald diagnostic criteria for multiple sclerosis â€“ Authors' reply. Lancet Neurology, The, 2018, 17, 499-500.	4.9	35
94	MRI in multiple sclerosis: what is changing?. Current Opinion in Neurology, 2018, 31, 386-395.	1.8	28
95	The Role of Extracellular Adenosine Generation in the Development of Autoimmune Diseases. Mediators of Inflammation, 2018, 2018, 1-10.	1.4	38
96	Increases in fatigue do not change spasticity scores in persons with multiple sclerosis. Neurodegenerative Disease Management, 2018, 8, 143-150.	1.2	2
97	RecomendaÃ§Ãµes e Consensos do Grupo de Estudos de Esclerose MÃºltipla e da Sociedade Portuguesa de Neurorradiologia sobre RessonÂ¢ncia MagnÃ©tica na Esclerose MÃºltipla na PrÃ¡tica ClÃnica: Parte 1. Acta Medica Portuguesa, 2018, 31, 281.	0.2	0
98	Radiologically isolated syndrome in children: Current knowledge and future directions. Multiple Sclerosis and Related Disorders, 2018, 24, 79-84.	0.9	4
99	Pharmacotherapy in Secondary Progressive Multiple Sclerosis: An Overview. CNS Drugs, 2018, 32, 499-526.	2.7	18

#	Article	IF	Citations
100	Monitoring Progressive Multiple Sclerosis with Novel Imaging Techniques. Neurology and Therapy, 2018, 7, 265-285.	1.4	14
101	Multiple Sklerose und andere autoimmune ZNS-Erkrankungen. , 2018, , 1-103.		0
102	Retinal ganglion cell loss in neuromyelitis optica: a longitudinal study. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 1259-1265.	0.9	100
103	Neurofilaments and 10-year follow-up in multiple sclerosis. Multiple Sclerosis Journal, 2018, 24, 1301-1307.	1.4	61
104	Searching for neurodegeneration in multiple sclerosis at clinical onset: Diagnostic value of biomarkers. PLoS ONE, 2018, 13, e0194828.	1.1	32
105	Application of the 2017 Revised McDonald Criteria for Multiple Sclerosis to Patients With a Typical Clinically Isolated Syndrome. JAMA Neurology, 2018, 75, 1392.	4.5	95
106	Clinical monitoring of multiple sclerosis should routinely include spinal cord imaging â€“ No. Multiple Sclerosis Journal, 2018, 24, 1537-1539.	1.4	4
107	Neuromyelitis optica spectrum disorder and multiple sclerosis in a Sardinian family. Multiple Sclerosis and Related Disorders, 2018, 25, 73-76.	0.9	4
108	Cerebrospinal fluid free kappa light chains and kappa index perform equal to oligoclonal bands in the diagnosis of multiple sclerosis. Clinical Chemistry and Laboratory Medicine, 2018, 57, 210-220.	1.4	24
109	Clinical trials in multiple sclerosis: milestones. Therapeutic Advances in Neurological Disorders, 2018, 11, 175628641878549.	1.5	7
110	Establishing the diagnosis of multiple sclerosis in Croatian patients with clinically isolated syndrome: 2010 versus 2017 McDonald criteria. Multiple Sclerosis and Related Disorders, 2018, 25, 99-103.	0.9	26
111	Predicting cognitive decline in multiple sclerosis: a 5-year follow-up study. Brain, 2018, 141, 2605-2618.	3.7	113
112	Applicability of McDonald 2010 and Magnetic Resonance Imaging in Multiple Sclerosis (MAGNIMS) 2016 Magnetic Resonance Imaging Criteria for the Diagnosis of Multiple Sclerosis in Sri Lanka. Journal of		

#	Article	IF	Citations
118	Genetic Determinants of Antibody Levels in Cerebrospinal Fluid in Multiple Sclerosis: Possible Links to Endogenous Retroviruses. International Journal of Molecular Sciences, 2018, 19, 786.	1.8	5
119	The Effect of Three Different Strategies Based on Motor Task Performance on Neuromuscular Fatigue in Healthy Men and Men with Multiple Sclerosis. Medicina (Lithuania), 2018, 54, 33.	0.8	3
120	Clinical Application of 2017 McDonald Diagnostic Criteria for Multiple Sclerosis. Journal of Clinical		

#	Article	IF	Citations
136	Diagnostics of autoimmune neurodegeneration using fluorescent probing. Scientific Reports, 2018, 8, 12679.	1.6	4
137	The relevance of ceramides and their synthesizing enzymes for multiple sclerosis. Clinical Science, 2018, 132, 1963-1976.	1.8	32
138	Retinal imaging with optical coherence tomography: a biomarker in multiple sclerosis?. Eye and Brain, 2018, Volume 10, 47-63.	3.8	66
139	Inclusion of optic nerve involvement in dissemination in space criteria for multiple sclerosis. Neurology, 2018, 91, e1130-e1134.	1.5	43
140	Multiple sclerosis and mixed microbial infections. Direct identification of fungi and bacteria in nervous tissue. Neurobiology of Disease, 2018, 117, 42-61.	2.1	39
141	The Radiologically Isolated Syndrome: An Opportunity to Prevent Multiple Sclerosis in Children. Pediatric Neurology, 2018, 85, 13-15.	1.0	1
143	Precision medicine for multiple sclerosis promotes preventative medicine. Annals of the New York Academy of Sciences, 2018, 1420, 62-71.	1.8	12
144	Improved Detection of New MS Lesions during Follow-Up Using an Automated MR Coregistration-Fusion Method. American Journal of Neuroradiology, 2018, 39, 1226-1232.	1.2	17
145	Multiple sclerosis pathogenesis: missing pieces of an old puzzle. Reviews in the Neurosciences, 2018, 30, 67-83.	1.4	16
146	Three-Tesla MRI does not improve the diagnosis of multiple sclerosis. Neurology, 2018, 91, e249-e257.	1.5	26
147	Commentary on Al Hussona et al. â€˜New-onset seizures as a sole clinical presentation of multiple sclerosisâ€™. Multiple Sclerosis Journal, 2019, 25, 298-299.	1.4	0
148	Application of the 2017 McDonald diagnostic criteria for multiple sclerosis in Korean patients with clinically isolated syndrome. Multiple Sclerosis Journal, 2019, 25, 1488-1495.	1.4	31
149	Cortical and meningeal pathology in progressive multiple sclerosis: a new therapeutic target?. Reviews in the Neurosciences, 2019, 30, 221-232.	1.4	5
150	Pure spinal multiple sclerosis: A possible novel entity within the multiple sclerosis disease spectrum. Multiple Sclerosis Journal, 2019, 25, 1189-1195.	1.4	8
151	Magnetic resonance imaging as a prognostic disability marker in clinically isolated syndrome: A systematic review. Acta Neurologica Scandinavica, 2019, 139, 18-32.	1.0	12
152	Abnormal venous postural control: multiple sclerosis-specific change related to gray matter pathology or age-related neurodegenerative phenomena?. Clinical Autonomic Research, 2019, 29, 329-338.	1.4	6
153	MRI quality control for the Italian Neuroimaging Network Initiative: moving towards big data in multiple sclerosis. Journal of Neurology, 2019, 266, 2848-2858.	1.8	16
154	Initiation of first disease-modifying treatment for multiple sclerosis patients in the Czech republic from 2013 to 2016: Data from the national registry ReMuS. Multiple Sclerosis and Related Disorders, 2019, 35, 196-202.	0.9	9

#	Article	IF	Citations
155	Changing patterns of multiple sclerosis in Korea: Toward a more baseline MRI lesions and intrathecal humoral immune responses. Multiple Sclerosis and Related Disorders, 2019, 35, 209-214.	0.9	1
156	Lipid profile of cerebrospinal fluid in multiple sclerosis patients: a potential tool for diagnosis. Scientific Reports, 2019, 9, 11313.	1.6	43
157	Ensayo pictÃ³rico: DiagnÃ³stico diferencial radiolÃ³gico en Esclerosis MÃºltiple. Revista Chilena De Radiologia, 2019, 25, 5-18.	0.2	0
158	Pregnancy and multiple sclerosis: Clinical effects across the lifespan. Autoimmunity Reviews, 2019, 18, 102360.	2.5	23
159	The predictive value of CSF multiple assay in multiple sclerosis: A single center experience. Multiple Sclerosis and Related Disorders, 2019, 35, 176-181.	0.9	13
160	Targeted metabolomics approach for identification of relapsingâ€“remitting multiple sclerosis markers and evaluation of diagnostic models. MedChemComm, 2019, 10, 1803-1809.	3.5	18
162	Multiple sclerosis in resource-limited settings. Neurology, 2019, 93, 176-180.	1.5	8
163	Evaluation of the Central Vein Sign as a Diagnostic Imaging Biomarker in Multiple Sclerosis. JAMA Neurology, 2019, 76, 1446.	4.5	119
164	Multiple Sclerosis and Variants. , 2019, , 727-767.		0
165	Cerebrospinal fluid neurofilament light chain predicts disease activity after the first demyelinating event suggestive of multiple sclerosis. Multiple Sclerosis and Related Disorders, 2019, 35, 228-232.	0.9	20
166	Optimizing 3D FLAIR to detect MS lesions: pushing past factory settings for precise results. Journal of Neurology, 2019, 266, 2786-2795.	1.8	3
167	Prevalence and Incidence of Multiple Sclerosis in the City of Biancavilla. Neuroepidemiology, 2019, 53, 108-114.	1.1	6
168	Use of gadolinium for MRI diagnostic or surveillance studies in patients with MS. Neurology, 2019, 93, 239-240.	1.5	3
169	MRI of acute optic neuritis (ON) at the first episode: Can we predict the visual outcome and the development of multiple sclerosis (MS)?. Radiologia Medica, 2019, 124, 1296-1303.	4.7	12
170	Pharmacodynamic assessment of cell-bound natalizumab on PBMC samples stored in liquid nitrogen. Journal of Immunological Methods, 2019, 473, 112632.	0.6	3
171	Radiologically isolated syndrome is antiquated amidst evolving McDonald criteria for multiple sclerosis. CNS Spectrums, 2021, 26, 307-309.	0.7	2
172	Esclerosis mÃºltiple. Medicine, 2019, 12, 4587-4597.	0.0	3
173	A prospective, observational study on conversion of clinically isolated syndrome to multiple sclerosis during 4-year period (MS NEO study) in Taiwan. PLoS ONE, 2019, 14, e0202453.	1.1	5

#	Article	IF	Citations
174	Evaluation of Myelin Radiotracers in the Lysolecithin Rat Model of Focal Demyelination: Beware of Pitfalls!. Contrast Media and Molecular Imaging, 2019, 2019, 1-10.	0.4	7
175	Drug Treatment of Clinically Isolated Syndrome. CNS Drugs, 2019, 33, 659-676.	2.7	12
176	McArdle Sign: A Specific Sign of Multiple Sclerosis. Mayo Clinic Proceedings, 2019, 94, 1427-1435.	1.4	7
177	A mathematical model to predict the evolution of retinal nerve fiber layer thinning in multiple sclerosis patients. Computers in Biology and Medicine, 2019, 111, 103357.	3.9	9
178	Two Sides to Every Story: Perspectives from Four Patients and a Healthcare Professional on Multiple Sclerosis Disease Progression. Neurology and Therapy, 2019, 8, 185-205.	1.4	14
179	Trials and therapies in secondary progressive MS, simplified. Nature Reviews Neurology, 2019, 15, 431-432.	4.9	7
180	Brain volume dynamics in multiple sclerosis. A case-control study. Neurological Research, 2019, 41, 936-942.	0.6	5
181	A single nucleotide polymorphism within Ninjurin 2 is associated with risk of multiple sclerosis. Metabolic Brain Disease, 2019, 34, 1415-1419.	1.4	11
182	Free light chains in cerebrospinal fluid of multiple sclerosis patients negative for IgG oligoclonal bands. Clinica Chimica Acta, 2019, 496, 117-120.	0.5	14
183	GM-CSF and CXCR4 define a T helper cell signature in multiple sclerosis. Nature Medicine, 2019, 25, 1290-1300.	15.2	140
184	A unique case of multiphasic ADEM or what else?. Multiple Sclerosis and Related Disorders, 2019, 35, 73-75.	0.9	1
185	Plasma proteome in multiple sclerosis disease progression. Annals of Clinical and Translational Neurology, 2019, 6, 1582-1594.	1.7	21
186	Early highly effective versus escalation treatment approaches in relapsing multiple sclerosis. Lancet Neurology, The, 2019, 18, 973-980.	4.9	99
187	TREM2 R47H (rs75932628) variant is unlikely to contribute to Multiple Sclerosis susceptibility and severity in a large Greek MS cohort. Multiple Sclerosis and Related Disorders, 2019, 35, 116-118.	0.9	8
188	Coming off cannabis: a cognitive and magnetic resonance imaging study in patients with multiple sclerosis. Brain, 2019, 142, 2800-2812.	3.7	23
189	Improving acute demyelinating lesion detection: which T1-weighted magnetic resonance acquisition is more sensitive to gadolinium enhancement?. Arquivos De Neuro-Psiquiatria, 2019, 77, 485-492.	0.3	2
190	Diagnosis and Management of Progressive Multiple Sclerosis. Biomedicines, 2019, 7, 56.	1.4	53
191	Using biomarkers to predict clinical outcomes in multiple sclerosis. Practical Neurology, 2019, 19, 342-349.	0.5	5

#	Article	IF	Citations
192	Improving Detection of Multiple Sclerosis Lesions in the Posterior Fossa Using an Optimized 3D-FLAIR Sequence at 3T. American Journal of Neuroradiology, 2019, 40, 1170-1176.	1.2	7
193	Gadolinium Retention in the Brain: An MRI Relaxometry Study of Linear and Macrocyclic Gadolinium-Based Contrast Agents in Multiple Sclerosis. American Journal of Neuroradiology, 2019, 40, 1265-1273.	1.2	24
195	Advances in brain imaging in multiple sclerosis. Therapeutic Advances in Neurological Disorders, 2019, 12, 175628641985972.	1.5	56
196	Correlation between auto/mitophagic processes and magnetic resonance imaging activity in multiple sclerosis patients. Journal of Neuroinflammation, 2019, 16, 131.	3.1	31
197	Patients With Epileptic Seizures and Multiple Sclerosis in a Multiple Sclerosis Center in Southern Germany Between 2003â€“2015. Frontiers in Neurology, 2019, 10, 613.	1.1	22
198	Hair cortisol concentration, cognitive, behavioral, and motor impairment in multiple sclerosis. Journal of Neural Transmission, 2019, 126, 1145-1154.	1.4	8
199	Neuronal damage and neuroinflammation markers in patients with autoimmune encephalitis and multiple sclerosis. Metabolic Brain Disease, 2019, 34, 1473-1485.	1.4	24
200	Does CSF pleocytosis have a predictive value for disease course in MS?. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, e584.	3.1	13
201	Aquaporin-4 and MOG autoantibody discovery in idiopathic transverse myelitis epidemiology. Neurology, 2019, 93, e414-e420.	1.5	26
202	Recessive Charcot-Marie-Tooth and multiple sclerosis associated with a variant in MCM3AP. Brain Communications, 2019, 1, fcz011.	1.5	3
203	Paediatric acquired demyelinating syndromes. Paediatrics and Child Health (United Kingdom), 2019, 29, 468-475.	0.2	4
204	Sexual Dysfunction in Patients with Multiple Sclerosis from Argentina: What are the Differences Between Women and Men?. Sexuality and Disability, 2019, 37, 521-539.	0.4	11
205	Granger causality analysis in combination with directed network measures for classification of MS patients and healthy controls using task-related fMRI. Computers in Biology and Medicine, 2019, 115, 103495.	3.9	33
206	Metronidazole induced encephalopathy: case report and discussion on the differential diagnoses, in particular, Wernicke's encephalopathy. Journal of Radiology Case Reports, 2019, 13, 1-7.	0.2	5
207	Therapeutic Apheresis in Acute Relapsing Multiple Sclerosis: Current Evidence and Unmet Needsâ€”A Systematic Review. Journal of Clinical Medicine, 2019, 8, 1623.	1.0	19
208	Transcranial Magnetic Stimulation as a Potential Biomarker in Multiple Sclerosis: A Systematic Review with Recommendations for Future Research. Neural Plasticity, 2019, 2019, 1-22.	1.0	31
209	Therapeutic Plasma Exchange in Multiple Sclerosis and Autoimmune Encephalitis: a Comparative Study of Indication, Efficacy and Safety. Brain Sciences, 2019, 9, 267.	1.1	12
210	Are oligoclonal bands associated to lower retinal layer thickness at the time of relapsing remitting multiple sclerosis diagnosis? Evidence from an exploratory study. Autoimmunity Reviews, 2019, 18, 102365.	2.5	1

#	Article	IF	Citations
211	Association of cerebrospinal fluid kappa free light chains with the intrathecal polyspecific antiviral immune response in multiple sclerosis. Clinica Chimica Acta, 2019, 498, 148-153.	0.5	7
212	Combined Cerebrospinal Fluid Neurofilament Light Chain Protein and Chitinase-3 Like-1 Levels in Defining Disease Course and Prognosis in Multiple Sclerosis. Frontiers in Neurology, 2019, 10, 1008.	1.1	56
213	Reduced serum immunoglobulin G concentrations in multiple sclerosis: prevalence and association with disease-modifying therapy and disease course. Therapeutic Advances in Neurological Disorders, 2019, 12, 175628641987834.	1.5	31
216	Prevalence of multiple sclerosis in Cuenca, Ecuador. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2019, 5, 205521731988495.	0.5	0
217	Diagnostic ability of multifocal electroretinogram in early multiple sclerosis using a new signal analysis method. PLoS ONE, 2019, 14, e0224500.	1.1	5
218	An asymptomatic new lesion on MRI is a relapse and should be treated accordingly â€“ No. Multiple Sclerosis Journal, 2019, 25, 1843-1845.	1.4	5
219	An asymptomatic new lesion on MRI is a relapse and should be treated accordingly â€“ Commentary. Multiple Sclerosis Journal, 2019, 25, 1845-1847.	1.4	3
220	Immunomodulatory receptors are differentially expressed in B and T cell subsets relevant to autoimmune disease. Clinical Immunology, 2019, 209, 108276.	1.4	17
221	Spinal cord syndromes in patients with systemic lupus erythematosus: differentiating lupus myelitis, neuromyelitis optica, and multiple sclerosis. Lupus, 2019, 28, 1656-1662.	0.8	16
222	The correlation between dyslipidemia and cognitive impairment in multiple sclerosis patients. Multiple Sclerosis and Related Disorders, 2019, 36, 101415.	0.9	27
223	Ocrelizumab for multiple sclerosis. The Cochrane Library, 2019, , .	1.5	1
224	Patient education for fatigue in people with multiple sclerosis. The Cochrane Library, 0, , .	1.5	0
225	Transcranial direct current stimulation (tDCS) for improving fatigue, motor function, and pain in people with multiple sclerosis. The Cochrane Library, 0, , .	1.5	1
226	Brain lesion distribution criteria distinguish demyelinating diseases in China. Annals of Clinical and Translational Neurology, 2019, 6, 2048-2053.	1.7	9
227	Progressive dopaminergic defect in a patient with primary progressive multiple sclerosis. Multiple Sclerosis and Related Disorders, 2019, 36, 101385.	0.9	2
228	Inter-leg Distance Measurement as a Tool for Accurate Step Counting in Patients with Multiple Sclerosis. , 2019, 2019, 6413-6417.		3
229	Complete horizontal gaze palsy due to bilateral paramedian pontine reticular formation involvement as a presentation of multiple sclerosis: a case report. BMC Neurology, 2019, 19, 254.	0.8	6
230	Frontispiece: Recent Contributions to the Coordination Chemistry of Beryllium. Chemistry - A European Journal, 2019, 25, .	1.7	0

#	Article	IF	Citations
231	Modification of CSF findings in multiple sclerosis in the era of rapidly expanding treatment options. Expert Review of Neurotherapeutics, 2019, 19, 277-283.	1.4	1
232	Instead of tweaking the diagnostic criteria for MS in those with CIS, we should develop diagnostic criteria that distinguish MS from other conditions â€“ Yes. Multiple Sclerosis Journal, 2019, 25, 766-768.	1.4	4
233	Framing multiple sclerosis under a polysomnographic perspective. Sleep, 2019, 43, .	0.6	6
234	Effect of omega-3 fatty acids and fish oil supplementation on multiple sclerosis: a systematic review. Nutritional Neuroscience, 2021, 24, 569-579.	1.5	54
235	Human immunodeficiency virus and multiple sclerosis: a review of the literature. Neurological Research and Practice, 2019, 1, 24.	1.0	9
236	Localised grey matter atrophy in multiple sclerosis is network-based: aÂcoordinate-based meta-analysis. Clinical Radiology, 2019, 74, 816.e19-816.e28.	0.5	13
237	GDF-15, a mitochondrial disease biomarker, is associated with the severity of multiple sclerosis. Journal of the Neurological Sciences, 2019, 405, 116429.	0.3	14
238	Characterization of the human myelin oligodendrocyte glycoprotein antibody response in demyelination. Acta Neuropathologica Communications, 2019, 7, 145.	2.4	71
239	The spectrum of immune-mediated and inflammatory lesions of the brainstem. Neurology, 2019, 93, 390-405.	1.5	22
240	The accuracy of flow cytometric cell-based assay to detect anti-myelin oligodendrocyte glycoprotein (MOG) antibodies determining the optimal method for positivity judgement. Journal of Neuroimmunology, 2019, 336, 577021.	1.1	20
241	Spinal cord lesions are frequently asymptomatic in relapsingâ€“remitting multiple sclerosis: a retrospective MRI survey. Journal of Neurology, 2019, 266, 3031-3037.	1.8	17
242	Long-term use of interferon-Î² in multiple sclerosis increases VÎ´1â^'VÎ´2â^'VÎ³9â^' Î³Î´ T cells that are associated with a better outcome. Journal of Neuroinflammation, 2019, 16, 179.	3.1	6
243	MRI features associated with high likelihood of conversion of radiologically isolated syndrome to multiple sclerosis. Multiple Sclerosis and Related Disorders, 2019, 36, 101381.	0.9	10
244	Longitudinal analysis of white matter and cortical lesions in multiple sclerosis. NeuroImage: Clinical, 2019, 23, 101938.	1.4	25
245	Validation of multiple sclerosis diagnoses in the Swedish National Patient Register. European Journal of Epidemiology, 2019, 34, 1161-1169.	2.5	19
246	Atrophied Brain T2 Lesion Volume at MRI Is Associated with Disability Progression and Conversion to Secondary Progressive Multiple Sclerosis. Radiology, 2019, 293, 424-433.	3.6	36
247	Evaluating the efficacy and safety of ZytuxTM (Rituximab, AryoGen pharmed) in Iranian multiple sclerosis patients: An observational study. Multiple Sclerosis and Related Disorders, 2019, 36, 101419.	0.9	15
248	The Neutrophil-to-Lymphocyte Ratio is Related to Disease Activity in Relapsing Remitting Multiple Sclerosis. Cells, 2019, 8, 1114.	1.8	40

#	Article	IF	Citations
250	Newer Treatment Approaches in Pediatric-Onset Multiple Sclerosis. Current Treatment Options in Neurology, 2019, 21, 50.	0.7	24
251	The natalizumab wearing-off effect. Neurology, 2019, 93, e1579-e1586.	1.5	16
252	Multiple sclerosis associated with pembrolizumab in a patient with non-small cell lung cancer. Journal of Neurology, 2019, 266, 3163-3166.	1.8	9
253	Diagnostic Approach to Intrinsic Abnormality of Spinal Cord Signal Intensity. Radiographics, 2019, 39, 1824-1839.	1.4	23
254	Diagnostic Delay of Multiple Sclerosis in a Portuguese Population. Acta Medica Portuguesa, 2019, 32, 289-294.	0.2	22
255	Homocysteine, vitamin B12, and folate levels in patients with multiple sclerosis in Chinese population: A case-control study and meta-analysis. Multiple Sclerosis and Related Disorders, 2019, 36, 101395.	0.9	14
256	Uncovering convolutional neural network decisions for diagnosing multiple sclerosis on conventional MRI using layer-wise relevance propagation. NeuroImage: Clinical, 2019, 24, 102003.	1.4	93
257	Jacqueline du PrÃ© and her alternative diagnosis. Medical Hypotheses, 2019, 133, 109401.	0.8	0
258	Global, regional, and national burden of multiple sclerosis 1990â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurology, The, 2019, 18, 269-285.	4.9	716
259	Sleep-related disorders and their relationship with MRI findings in multiple sclerosis. Sleep Medicine, 2019, 56, 90-97.	0.8	51
260	High performance of cerebrospinal fluid immunoglobulin G analysis for diagnosis of multiple sclerosis. Journal of Neurology, 2019, 266, 902-909.	1.8	2
261	The Diversity of Encephalitogenic CD4+ T Cells in Multiple Sclerosis and Its Animal Models. Journal of Clinical Medicine, 2019, 8, 120.	1.0	38
262	Optical coherence tomography for diagnosing optic neuritis. Neurology, 2019, 92, 253-254.	1.5	15
263	Optical coherence tomography is highly sensitive in detecting prior optic neuritis. Neurology, 2019, 92, e527-e535.	1.5	56
264	Predictors of Evolution Into Multiple Sclerosis After a First Acute Demyelinating Syndrome in Children and Adolescents. Frontiers in Neurology, 2019, 9, 1156.	1.1	12
265	Evidence for a white matter lesion size threshold to support the diagnosis of relapsing remitting multiple sclerosis. Multiple Sclerosis and Related Disorders, 2019, 29, 124-129.	0.9	6
266	Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders. Lancet Neurology, The, 2019, 18, 185-197.	4.9	110
267	2017 McDonald criteria for multiple sclerosis: Earlier diagnosis with reduced specificity?. Multiple Sclerosis and Related Disorders, 2019, 29, 23-25.	0.9	24

#	Article	IF	Citations
268	Long-term outcomes with teriflunomide in patients with clinically isolated syndrome: Results of the TOPIC extension studyâ˜…â˜…. Multiple Sclerosis and Related Disorders, 2019, 33, 131-138.	0.9	15
269	Caesarean section and infant formula feeding are associated with an earlier age of onset of multiple sclerosis. Multiple Sclerosis and Related Disorders, 2019, 33, 75-77.	0.9	13
270	Cerebrospinal fluid neurofilament light chain in multiple sclerosis and its subtypes: a meta-analysis of caseâ€“control studies. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 1059-1067.	0.9	53
271	Neurofilament levels in patients with neurological diseases: A comparison of neurofilament light and heavy chain levels. Journal of Clinical Laboratory Analysis, 2019, 33, e22948.	0.9	21
272	Follow-up MRI in multiple sclerosis patients: automated co-registration and lesion color-coding improves diagnostic accuracy and reduces reading time. European Radiology, 2019, 29, 7047-7054.	2.3	11
273	Incidence of pediatric neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody-associated disease in Denmark 2008â€’2018: A nationwide, population-based cohort study. Multiple Sclerosis and Related Disorders, 2019, 33, 162-167.	0.9	35
274	Cognitive but Not Affective Theory of Mind Deficits in Progressive MS. Journal of the International Neuropsychological Society, 2019, 25, 896-900.	1.2	4
275	For Massachusetts Eye and Ear Special Issue: Updates on Therapies for Multiple Sclerosis for the Ophthalmologist. Seminars in Ophthalmology, 2019, 34, 270-278.	0.8	3
276	Assessment of lesions on magnetic resonance imaging in multiple sclerosis: practical guidelines. Brain, 2019, 142, 1858-1875.	3.7	303
277	CD28 Autonomous Signaling Up-Regulates C-Myc Expression and Promotes Glycolysis Enabling Inflammatory T Cell Responses in Multiple Sclerosis. Cells, 2019, 8, 575.	1.8	30
278	Critical review: Typical and atypical optic neuritis. Survey of Ophthalmology, 2019, 64, 770-779.	1.7	76
279	White matter plasticity and maturation in human cognition. Glia, 2019, 67, 2020-2037.	2.5	31
280	A Review of Available Treatments, Clinical Evidence, and Guidelines for Diagnosis and Treatment of Pediatric Multiple Sclerosis in the United States. Journal of Child Neurology, 2019, 34, 612-620.	0.7	10
281	Conversion of clinically isolated syndrome to multiple sclerosis: a prospective multi-center study in Eastern India. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2019, 5, 205521731984972.	0.5	6
282	Multiple sclerosis and stroke: a systematic review and meta-analysis. BMC Neurology, 2019, 19, 139.	0.8	45
283	Comparison of multiple sclerosis patients with and without oligoclonal IgG bands in South China. Journal of Clinical Neuroscience, 2019, 66, 51-55.	0.8	14
284	Investigation of Oligoclonal IgG Bands in Tear Fluid of Multiple Sclerosis Patients. Frontiers in Immunology, 2019, 10, 1110.	2.2	16
285	Cerebrospinal Fluid Analysis in Multiple Sclerosis Diagnosis: An Update. Medicina (Lithuania), 2019, 55, 245.	0.8	31

#	Article	IF	Citations
286	Elephant in the Room vs. Red Herring. In Clinical Practice, 2019, , 81-89.	0.1	0
287	Pain in the Face. In Clinical Practice, 2019, , 7-12.	0.1	0
288	Clinical Cases in Neurology. In Clinical Practice, 2019, , .	0.1	0
289	Women who contributed to past research in multiple sclerosis. Multiple Sclerosis Journal, 2019, 25, 1440-1443.	1.4	1
290	Structural and functional MRI correlates of T2 hyperintensities of brain white matter in young neurologically asymptomatic adults. European Radiology, 2019, 29, 7027-7036.	2.3	8
291	MOG antibody-associated demyelinating disease mimicking typical multiple sclerosis: A case for expanding anti-MOG testing?. Multiple Sclerosis and Related Disorders, 2019, 33, 67-69.	0.9	10
293	Improving Outcomes in Pediatric Multiple Sclerosis: Current and Emerging Treatments. Paediatric Drugs, 2019, 21, 137-152.	1.3	5
294	Visual but not verbal working memory interferes with balance in patients after optic neuritis suggestive of multiple sclerosis. Neuroscience Letters, 2019, 707, 134288.	1.0	2
295	Type 2 Inflammatory Responses in Autoimmune Demyelination of the Central Nervous System: Recent Advances. Journal of Immunology Research, 2019, 2019, 1-10.	0.9	7
296	The potential of visual physiology: An instrument with a place in MS translation. Clinical Neurophysiology Practice, 2019, 4, 112-113.	0.6	1
297	Multiple sclerosis and sarcoidosis. Neurology: Clinical Practice, 2019, 9, 218-227.	0.8	12
298	Serum-based differentiation between multiple sclerosis and amyotrophic lateral sclerosis by Random Forest classification of FTIR spectra. Analyst, The, 2019, 144, 4647-4652.	1.7	20
299	Clinical Features of Diffuse Leptomeningeal Glioneuronal Tumor with Rapid Blindness Misdiagnosed as NMOSD and Literature Review. SN Comprehensive Clinical Medicine, 2019, 1, 434-441.	0.3	4
300	Adherence to Clinical Trial Supported Evaluation of Optic Neuritis. Ophthalmic Epidemiology, 2019, 26, 321-328.	0.8	2
301	Gut dysbiosis and lack of short chain fatty acids in a Chinese cohort of patients with multiple sclerosis. Neurochemistry International, 2019, 129, 104468.	1.9	96
302	Distinct serum and cerebrospinal fluid cytokine and chemokine profiles in autoantibody-associated demyelinating diseases. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2019, 5, 205521731984846.	0.5	10
303	The Argentinean multiple sclerosis registry (RelevarEM): Methodological aspects and directions. Multiple Sclerosis and Related Disorders, 2019, 32, 133-137.	0.9	24
304	Spatial Characterisation of Fibre Response Functions for Spherical Deconvolution in Multiple Sclerosis. Mathematics and Visualization, 2019, , 265-279.	0.4	0

#	Article	IF	Citations
305	Three-dimensional MRI sequences in MS diagnosis and research. Multiple Sclerosis Journal, 2019, 25, 1700-1709.	1.4	9
306	Swept source optical coherence tomography to early detect multiple sclerosis disease. The use of machine learning techniques. PLoS ONE, 2019, 14, e0216410.	1.1	43
307	Myelin in the Central Nervous System: Structure, Function, and Pathology. Physiological Reviews, 2019, 99, 1381-1431.	13.1	336
308	Cognitive Impairment in Multiple Sclerosis Is Reflected by Increased Susceptibility to the Sound-Induced Flash Illusion. Frontiers in Neurology, 2019, 10, 373.	1.1	4
309	Oligoclonal bands do not represent dissemination in time in the 2017 revisions to the McDonald criteria. Multiple Sclerosis Journal, 2019, 25, 1690-1691.	1.4	7
310	The electrophysiological assessment of visual function in Multiple Sclerosis. Clinical Neurophysiology Practice, 2019, 4, 90-96.	0.6	30
311	Natalizumab induced cutaneous sarcoidosis-like reaction. Journal of Neuroimmunology, 2019, 333, 476955.	1.1	7
312	Persistence of intrathecal oligoclonal B cells and IgG in multiple sclerosis. Journal of Neuroimmunology, 2019, 333, 576966.	1.1	16
313	Automated segmentation of changes in FLAIR-hyperintense white matter lesions in multiple sclerosis on serial magnetic resonance imaging. NeuroImage: Clinical, 2019, 23, 101849.	1.4	60
314	Clinical trials in multiple sclerosis: potential future trial designs. Therapeutic Advances in Neurological Disorders, 2019, 12, 175628641984709.	1.5	10
315	Primary progressive multiple sclerosis to be treated with ocrelizumab: a mistaken case of cobalamin deficiency. BMJ Case Reports, 2019, 12, e229080.	0.2	2
316	Immune Cell Profiling of the Cerebrospinal Fluid Provides Pathogenetic Insights Into Inflammatory Neuropathies. Frontiers in Immunology, 2019, 10, 515.	2.2	26
317	Familial multiple sclerosis patients have a shorter delay in diagnosis than sporadic cases. Multiple Sclerosis and Related Disorders, 2019, 32, 97-102.	0.9	17
318	Implementing the 2017 McDonald criteria for the diagnosis of multiple sclerosis. Nature Reviews Neurology, 2019, 15, 441-445.	4.9	18
319	Glial cells as therapeutic targets in progressive multiple sclerosis. Expert Review of Neurotherapeutics, 2019, 19, 481-494.	1.4	10
320	Molecular imaging of multiple sclerosis: from the clinical demand to novel radiotracers. EJNMMI Radiopharmacy and Chemistry, 2019, 4, 6.	1.8	29
321	Magnetic resonance imaging in myelopathy: a pictorial review. Clinical Imaging, 2019, 57, 56-68.	0.8	10
322	Callosal lesions on magnetic resonance imaging with multiple sclerosis, neuromyelitis optica spectrum disorder and acute disseminated encephalomyelitis. Multiple Sclerosis and Related Disorders, 2019, 32, 41-45.	0.9	15

#	Article	IF	Citations
323	K Index is a Reliable Marker of Intrathecal Synthesis, and an Alternative to IgG Index in Multiple Sclerosis Diagnostic Work-Up. Journal of Clinical Medicine, 2019, 8, 446.	1.0	27
324	Epidemiology and treatment of multiple sclerosis in elderly populations. Nature Reviews Neurology, 2019, 15, 329-342.	4.9	185
325	The Central Vein Sign in Radiologically Isolated Syndrome. American Journal of Neuroradiology, 2019, 40, 776-783.	1.2	41
326	A SCA7 premutation may be a novel Mendelian modifier of MS course: A case report. Multiple Sclerosis and Related Disorders, 2019, 31, 148-150.	0.9	1
327	The relationship between cognitive function and body mass index in multiple sclerosis patients. Multiple Sclerosis and Related Disorders, 2019, 32, 37-40.	0.9	15
328	Differential diagnosis of multiple sclerosis. Neurology, 2019, 92, 1037-1038.	1.5	4
329	â€œBetter explanationsâ€•in multiple sclerosis diagnostic workup. Neurology, 2019, 92, e2527-e2537.	1.5	44
330	Computational Diffusion MRI. Mathematics and Visualization, 2019, , .	0.4	4
331	Clinical trials of disease-modifying agents in pediatric MS. Neurology, 2019, 92, e2538-e2549.	1.5	62
332	Advances in spinal cord imaging in multiple sclerosis. Therapeutic Advances in Neurological Disorders, 2019, 12, 175628641984059.	1.5	69
333	Association of Intrathecal Immunoglobulin G Synthesis With Disability Worsening in Multiple Sclerosis. JAMA Neurology, 2019, 76, 841.	4.5	48
334	A cell type-specific transcriptomic approach to map B cell and monocyte type I interferon-linked pathogenic signatures in Multiple Sclerosis. Journal of Autoimmunity, 2019, 101, 1-16.	3.0	12
335	The prevalence of multiple sclerosis continues to increase in Kuwait. Multiple Sclerosis and Related Disorders, 2019, 32, 74-76.	0.9	16
336	Standardization of T1w/T2w Ratio Improves Detection of Tissue Damage in Multiple Sclerosis. Frontiers in Neurology, 2019, 10, 334.	1.1	31
337	Novel Multiple Sclerosis Drugs in the Pipeline. Clinical Pharmacology and Therapeutics, 2019, 105, 1082-1090.	2.3	3
338	The clinical significance of single or double bands in cerebrospinal fluid isoelectric focusing. A retrospective study and systematic review. PLoS ONE, 2019, 14, e0215410.	1.1	23
339	CSF Free Light Chains as a Marker of Intrathecal Immunoglobulin Synthesis in Multiple Sclerosis: A Blood-CSF Barrier Related Evaluation in a Large Cohort. Frontiers in Immunology, 2019, 10, 641.	2.2	34
340	The Cerebrospinal Fluid in Multiple Sclerosis. Frontiers in Immunology, 2019, 10, 726.	2.2	107

#	Article	IF	Citations
341	Case report of recalcitrant allergic contact eczema successfully treated with teriflunomide. Dermatologic Therapy, 2019, 32, e12947.	0.8	0
342	Multiple Sclerosis Misdiagnosis: A Persistent Problem to Solve. Frontiers in Neurology, 2019, 10, 466.	1.1	17
343	Pediatric Multiple Sclerosis. Advances in Pediatrics, 2019, 66, 209-229.	0.5	21
344	CSI: Multiple sclerosis. Tracing optic nerve involvement by standardized optical coherence tomography. Annals of Neurology, 2019, 85, 615-617.	2.8	3
345	Diagnostic Value of Oligoclonal Bands in Children: A Nationwide Population-Based Cohort Study. Pediatric Neurology, 2019, 97, 56-63.	1.0	11
346	Established and Emerging Immunological Complications of Biological Therapeutics in Multiple Sclerosis. Drug Safety, 2019, 42, 941-956.	1.4	12
347	Fingolimod Alters Tissue Distribution and Cytokine Production of Human and Murine Innate Lymphoid Cells. Frontiers in Immunology, 2019, 10, 217.	2.2	28
348	Time Is Brain and Spine. JAMA Neurology, 2019, 76, 623.	4.5	0
349	Evolution of clinical trials in multiple sclerosis. Therapeutic Advances in Neurological Disorders, 2019, 12, 175628641982654.	1.5	37
350	Optical coherence tomography: a window to the optic nerve in clinically isolated syndrome. Brain, 2019, 142, 903-915.	3.7	33
351	Gadolinium-Enhanced Susceptibility-Weighted Imaging in Multiple Sclerosis: Optimizing the Recognition of Active Plaques for Different MR Imaging Sequences. American Journal of Neuroradiology, 2019, 40, 614-619.	1.2	12
352	MSJ 2019 - Editorial comment. Multiple Sclerosis Journal, 2019, 25, 4-5.	1.4	0
353	Myelinoclastic diffuse sclerosis (Schilderâ€™s disease) is immunologically distinct from multiple sclerosis: results from retrospective analysis of 92 lumbar punctures. Journal of Neuroinflammation, 2019, 16, 51.	3.1	16
354	Oligoclonal bands increase the specificity of MRI criteria to predict multiple sclerosis in children with radiologically isolated syndrome. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2019, 5, 205521731983666.	0.5	23
355	Optimal intereye difference thresholds by optical coherence tomography in multiple sclerosis: An international study. Annals of Neurology, 2019, 85, 618-629.	2.8	104
356	How much do periventricular lesions assist in distinguishing migraine with aura from CIS?. Neurology, 2019, 92, e1739-e1744.	1.5	15
357	A Woman in Her 40s With Transient Neurological Symptoms, Migraine Headaches, and Hearing Loss. JAMA Neurology, 2019, 76, 504.	4.5	0
358	Accuracy of Unenhanced MRI in the Detection of New Brain Lesions in Multiple Sclerosis. Radiology, 2019, 291, 429-435.	3.6	46

#	Article	IF	Citations
359	Predictors for Therapy Response to Intrathecal Corticosteroid Therapy in Multiple Sclerosis. Frontiers in Neurology, 2019, 10, 132.	1.1	2
360	Time Is Brain and Spineâ€"Reply. JAMA Neurology, 2019, 76, 623.	4.5	0
361	Cerebrospinal fluid biomarkers for predicting development of multiple sclerosis in acute optic neuritis: a population-based prospective cohort study. Journal of Neuroinflammation, 2019, 16, 59.	3.1	39
362	The role of vitamin D and P2X7R in multiple sclerosis. Journal of Neuroimmunology, 2019, 330, 159-169.	1.1	6
363	Magnetic resonance imaging diagnosis of demyelinating diseases: An update. Clinical and Experimental Neuroimmunology, 2019, 10, 32-48.	0.5	12
364	Bowel symptoms predate the diagnosis among many patients with multiple sclerosis: A 14â€year cohort study. Neurogastroenterology and Motility, 2019, 31, e13592.	1.6	20
365	Cortical Lesions on 7-T MRI in Multiple Sclerosis: A Window into Pathogenetic Mechanisms?. Radiology, 2019, 291, 750-751.	3.6	4
366	Glial Activation Markers in CSF and Serum From Patients With Primary Progressive Multiple Sclerosis: Potential of Serum GFAP as Disease Severity Marker?. Frontiers in Neurology, 2019, 10, 280.	1.1	87
367	Illuminating an Invisible Epidemic: A Systemic Review of the Clinical and Economic Benefits of Early Diagnosis and Treatment in Inflammatory Disease and Related Syndromes. Journal of Clinical Medicine, 2019, 8, 493.	1.0	13
368	Impact of the McDonald Criteria 2017 on Early Diagnosis of Relapsing-Remitting Multiple Sclerosis. Frontiers in Neurology, 2019, 10, 188.	1.1	52
369	Characterization of gray-matter multiple sclerosis lesions using double inversion recovery, diffusion, contrast-enhanced, and volumetric MRI. Multiple Sclerosis and Related Disorders, 2019, 31, 74-81.	0.9	6
370	White matter lesion loads associated with dynamic functional connectivity within attention network in patients with relapsing-remitting multiple sclerosis. Journal of Clinical Neuroscience, 2019, 65, 59-65.	0.8	17
371	Myalgic encephalomyelitis and chronic fatigue syndrome case definitions: effects of requiring a substantial reduction in functioning. Fatigue: Biomedicine, Health and Behavior, 2019, 7, 59-68.	1.2	1
372	Paediatric multiple sclerosis: a new era in diagnosis and treatment. Developmental Medicine and Child Neurology, 2019, 61, 1039-1049.	1.1	30
373	Prediction of conversion to multiple sclerosis using the 2017 McDonald and 2016 MAGNIMS criteria in patients with clinically isolated syndrome: a retrospective single-centre study. Therapeutic Advances in Neurological Disorders, 2019, 12, 175628641983565.	1.5	3
374	Acute effects of aerobic intensities on the cytokine response in women with mild multiple sclerosis. Multiple Sclerosis and Related Disorders, 2019, 31, 82-86.	0.9	10
375	Reaching an evidence-based prognosis for personalized treatment of multiple sclerosis. Nature Reviews Neurology, 2019, 15, 287-300.	4.9	167
376	Are children with multiple sclerosis really â€œoldâ€•adults. Multiple Sclerosis Journal, 2019, 25, 888-890.	1.4	2

#	Article	IF	Citations
377	A computer-aided diagnosis of multiple sclerosis based on mfVEP recordings. PLoS ONE, 2019, 14, e0214662.	1.1	9
378	Demyelinating Diseases. , 2019, , 25-34.		0
379	Diagnostic utility of kappa free light chains in multiple sclerosis. Expert Review of Molecular Diagnostics, 2019, 19, 277-279.	1.5	10
381	Misdiagnoses and delay of diagnoses in Moyamoya angiopathyâ€"a large Caucasian case series. Journal of Neurology, 2019, 266, 1153-1159.	1.8	28
382	Kappa free light chains could predict early disease course in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2019, 30, 81-84.	0.9	23
383	Neurofilament light chain. Neurology, 2019, 92, 451-452.	1.5	16
384	Radiomics in multiple sclerosis and neuromyelitis optica spectrum disorder. European Radiology, 2019, 29, 4670-4677.	2.3	25
385	Iatrogenic CNS demyelination in the era of modern biologics. Multiple Sclerosis Journal, 2019, 25, 1079-1085.	1.4	40
386	Incidence of multiple sclerosis misdiagnosis in referrals to two academic centers. Multiple Sclerosis and Related Disorders, 2019, 30, 51-56.	0.9	92
387	The features of cerebral permeability and perfusion detected by dynamic contrast-enhanced magnetic resonance imaging with Patlak model in relapsing–remitting multiple sclerosis . Therapeutics and Clinical Risk Management, 2019, Volume 15, 233-240.	0.9	8
388	Emotions towards magnetic resonance imaging in people with multiple sclerosis. Acta Neurologica Scandinavica, 2019, 139, 497-504.	1.0	12
389	Tablet App Based Dexterity Training in Multiple Sclerosis (TAD-MS): Research Protocol of a Randomized Controlled Trial. Frontiers in Neurology, 2019, 10, 61.	1.1	10
390	Enduring Clinical Value of CopaxoneÂ® (Glatiramer Acetate) in Multiple Sclerosis after 20 Years of Use. Multiple Sclerosis International, 2019, 2019, 1-19.	0.4	11
391	Serum neurofilaments increase at progressive multifocal leukoencephalopathy onset in natalizumabâ€treated multiple sclerosis patients. Annals of Neurology, 2019, 85, 606-610.	2.8	30
392	Early adaptive immune activation detected in monozygotic twins with prodromal multiple sclerosis. Journal of Clinical Investigation, 2019, 129, 4758-4768.	3.9	81
393	Tolerogenic dendritic cell-based treatment for multiple sclerosis (MS): a harmonised study protocol for two phase I clinical trials comparing intradermal and intranodal cell administration. BMJ Open, 2019, 9, e030309.	0.8	63
394	Earnings among people with multiple sclerosis compared to references, in total and by educational level and type of occupation: a population-based cohort study at different points in time. BMJ Open, 2019, 9, e024836.	0.8	15
395	Identifying people with multiple sclerosis in the Canadian Primary Care Sentinel Surveillance Network. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2019, 5, 205521731989436.	0.5	2

#	Article	IF	Citations
396	Evaluating the relationship between psychometric intelligence and cognitive functions in paediatric multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2019, 5, 205521731989436.	0.5	7
397	The Influence of Contrast-to-Noise Ratio on the Discrimination Between Cortical and Juxtacortical Lesions in Multiple Sclerosis. Journal of Computer Assisted Tomography, 2019, 43, 958-962.	0.5	3
398	Follow up of the Multiple Sclerosis Lesion's Evolution in Brain MRI by Automated Registration Approach. , 2019, , .		1
399	Joven de 25 aÃ±os con alteraciÃ³n de la marcha. Medicine, 2019, 12, 4649-4649.e8.	0.0	0
401	Understanding Childhood Neuroimmune Diseases of the Central Nervous System. Frontiers in Pediatrics, 2019, 7, 511.	0.9	23
402	Intrathecal B-cell accumulation and axonal damage distinguish MRI-based benign from aggressive onset in MS. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, e595.	3.1	15
403	German translation, cultural adaption and validation of the unidimensional self-efficacy scale for multiple sclerosis: a study protocol. BMJ Open, 2019, 9, e029565.	0.8	3
404	Diagnostic value ofÂalternative techniques to gadolinium-based contrast agents in MR neuroimagingâ€"a comprehensive overview. Insights Into Imaging, 2019, 10, 84.	1.6	44
405	Dimethyl fumarate decreases neurofilament light chain in CSF and blood of treatment naÃ¯ve relapsing MS patients. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, jnnp-2019-321321.	0.9	66
406	Diagnosis of Multiple Sclerosis. , 0, , .		0
407	Percutaneous transluminal angioplasty for treatment of chronic cerebrospinal venous insufficiency (CCSVI) in people with multiple sclerosis. The Cochrane Library, 2019, 5, CD009903.	1.5	7
408	A Framework for Estimating the Burden of Chronic Diseases: Design and Application in the Context of Multiple Sclerosis. Frontiers in Neurology, 2019, 10, 953.	1.1	17
409	Palliative care interventions for people with multiple sclerosis. The Cochrane Library, 2019, 2019, CD012936.	1.5	8
410	Visual Outcomes of Plasma Exchange Treatment of Steroid-Refractory Optic Neuritis: A Retrospective Monocentric Analysis. Transfusion Medicine and Hemotherapy, 2019, 46, 417-422.	0.7	10
411	Relevance of cerebrospinal fluid findings in patients with multiple sclerosis and seizures. Journal of the Neurological Sciences, 2019, 406, 116482.	0.3	0
412	Reasons to switch: a noninterventional study evaluating immunotherapy switches in a large German multicentre cohort of patients with relapsing-remitting multiple sclerosis. Therapeutic Advances in Neurological Disorders, 2019, 12, 175628641989207.	1.5	15
413	Actualisation des aspects cliniques et des critÃ¨res diagnostiques de la sclÃ©rose en plaques. Pratique Neurologique - FMC, 2019, 10, 118-125.	0.1	0
414	Multiple Sclerosis in the Emirati Population: Onset Disease Characterization by MR Imaging. Multiple Sclerosis International, 2019, 2019, 1-6.	0.4	1

#	Article	IF	Citations
415	Free Light Chains as a Novel Diagnostic Biomarker of Immune System Abnormalities in Multiple Sclerosis and HIV Infection. BioMed Research International, 2019, 2019, 1-7.	0.9	8
416	Biological characteristics of transcription factor RelB in different immune cell types: implications for the treatment of multiple sclerosis. Molecular Brain, 2019, 12, 115.	1.3	17
417	Long segment 3D double inversion recovery (DIR) hypersignal on MRI in glaucomatous optic neuropathy. BMC Ophthalmology, 2019, 19, 258.	0.6	5
419	Cranial Nerve Enhancement in Multiple Sclerosis Is Associated With Younger Age at Onset and More Severe Disease. Frontiers in Neurology, 2019, 10, 1085.	1.1	7
420	Unilateral motor progression in MS. Neurology, 2019, 93, e628-e634.	1.5	22
421	Atypical Pediatric Demyelinating Diseases of the Central Nervous System. Current Neurology and Neuroscience Reports, 2019, 19, 95.	2.0	11
423	Functional Magnetic Resonance Imaging Correlations Between Fatigue and Cognitive Performance in Patients With Relapsing Remitting Multiple Sclerosis. Frontiers in Psychiatry, 2019, 10, 754.	1.3	9
424	Multiple Sclerosis. Advances in Experimental Medicine and Biology, 2019, 1190, 217-247.	0.8	16
425	Visualization of Myelin for the Diagnosis and Treatment Monitoring of Multiple Sclerosis. Advances in Experimental Medicine and Biology, 2019, 1190, 249-256.	0.8	2
426	Automated Detection and Segmentation of Multiple Sclerosis Lesions Using Ultraâ€“High-Field MP2RAGE. Investigative Radiology, 2019, 54, 356-364.	3.5	34
427	Real-World Effectiveness and Safety of Fingolimod in Patients With Relapsing Remitting Multiple Sclerosis: A Prospective Analysis in Buenos Aires, Argentina. Clinical Neuropharmacology, 2019, 42, 163-166.	0.2	6
429	Amide Proton Transfer Weighted Imaging Shows Differences in Multiple Sclerosis Lesions and White Matter Hyperintensities of Presumed Vascular Origin. Frontiers in Neurology, 2019, 10, 1307.	1.1	16
431	The (Un)Resolved Case: Blurry vision, left foot drop and brain cysts. Clinical and Translational Neuroscience, 2019, 3, 2514183X1986609.	0.4	0
432	The history of neuromyelitis optica. Part 2: â€˜Spinal amaurosisâ€™, or how it all began. Journal of Neuroinflammation, 2019, 16, 280.	3.1	32
433	Molecular biomarkers in multiple sclerosis. Journal of Neuroinflammation, 2019, 16, 272.	3.1	158
434	Association of CD58 polymorphism and multiple sclerosis in Malaysia: a pilot study. Autoimmunity Highlights, 2019, 10, 13.	3.9	3
437	Clinical and radiologic approach to â€˜typicalâ€™ versus antibody-related optic neuritis. Current Opinion in Ophthalmology, 2019, 30, 412-417.	1.3	11
439	The Effects of Concurrent Resistance and Aerobic Exercise Training on Functional Status in Patients with Multiple Sclerosis. Current Sports Medicine Reports, 2019, 18, 452-457.	0.5	30

#	Article	IF	Citations
440	Retinal correlates of neurological disorders. Therapeutic Advances in Chronic Disease, 2019, 10, 204062231988220.	1.1	36
441	Computer-Aided Diagnosis of Multiple Sclerosis Using a Support Vector Machine and Optical Coherence Tomography Features. Sensors, 2019, 19, 5323.	2.1	44
442	Acceleration of Double Inversion Recovery Sequences in Multiple Sclerosis With Compressed Sensing. Investigative Radiology, 2019, 54, 319-324.	3.5	28
443	Biopsychosocial model of resilience in young adults with multiple sclerosis (BPS-ARMS): an observational study protocol exploring psychological reactions early after diagnosis. BMJ Open, 2019, 9, e030469.	0.8	10
444	Update on pediatric optic neuritis. Current Opinion in Ophthalmology, 2019, 30, 418-425.	1.3	23
445	Diagnosis of multiple sclerosis: revisions of the McDonald criteria 2017 â€“ continuity and change. Current Opinion in Neurology, 2019, 32, 327-337.	1.8	32
446	Detecting neurodegenerative pathology in multiple sclerosis before irreversible brain tissue loss sets in. Translational Neurodegeneration, 2019, 8, 37.	3.6	23
447	Autologous haematopoietic stem cell therapy for multiple sclerosis: a review for supportive care clinicians on behalf of the Autoimmune Diseases Working Party of the European Society for Blood and Marrow Transplantation. Current Opinion in Supportive and Palliative Care, 2019, 13, 394-401.	0.5	10
448	Protocolo diagnÃ³stico del paciente con sospecha de enfermedad desmielinizante. Medicine, 2019, 12, 4634-4638.	0.0	0
449	Entropy of human leukocyte antigen and killer-cell immunoglobulin-like receptor systems in immune-mediated disorders: A pilot study on multiple sclerosis. PLoS ONE, 2019, 14, e0226615.	1.1	6
450	Imaging of meningeal inflammation should become part of the routine MRI protocol â€“ Yes. Multiple Sclerosis Journal, 2019, 25, 330-331.	1.4	4
451	X linked Charcot-Marie-Tooth disease and multiple sclerosis: emerging evidence for an association. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 187-194.	0.9	8
452	Multiple sclerosis with atypical MRI presentation: Results of a nationwide multicenter study in 57 consecutive cases. Multiple Sclerosis and Related Disorders, 2019, 28, 109-116.	0.9	9
453	Exploring the relationship between Endothelin-1 and peripheral inflammation in multiple sclerosis. Journal of Neuroimmunology, 2019, 326, 45-48.	1.1	11
454	Myelin oligodendrocyte glycoprotein antibodies in neurological disease. Nature Reviews Neurology, 2019, 15, 89-102.	4.9	439
455	Novel uses of retinal imaging with optical coherence tomography in multiple sclerosis. Expert Review of Neurotherapeutics, 2019, 19, 31-43.	1.4	44
456	Neurological update: MOG antibodyÂdisease. Journal of Neurology, 2019, 266, 1280-1286.	1.8	171
457	The combined effect of IL-17F and CCL20 gene polymorphism in susceptibility to multiple sclerosis in Egypt. Gene, 2019, 685, 164-169.	1.0	11

#	Article	IF	Citations
458	Multiple Sclerosis Incidence and Prevalence Trends in the Province of Padua, Northeast Italy, 1965â€“2018. Neuroepidemiology, 2019, 52, 41-46.	1.1	13
460	Asymmetry of Brain Excitability: A New Biomarker that Predicts Objective and Subjective Symptoms in Multiple Sclerosis. Behavioural Brain Research, 2019, 359, 281-291.	1.2	33
461	Effect of glatiramer acetate on cerebral grey matter pathology in patients with relapsing-remitting multiple sclerosis. Multiple Sclerosis and Related Disorders, 2019, 27, 305-311.	0.9	7
462	Detecting optic nerve lesions in clinically isolated syndrome and multiple sclerosis: double-inversion recovery magnetic resonance imaging in comparison with visually evoked potentials. Journal of Neurology, 2019, 266, 148-156.	1.8	19
463	Multivariate prediction of multiple sclerosis using robust quantitative MR-based image metrics. Zeitschrift Fur Medizinische Physik, 2019, 29, 262-271.	0.6	11
464	Validation and meta-analysis of kappa index biomarker in multiple sclerosis diagnosis. Autoimmunity Reviews, 2019, 18, 43-49.	2.5	22
465	The Italian multiple sclerosis register. Neurological Sciences, 2019, 40, 155-165.	0.9	59
466	Exploring cannabis use by patients with multiple sclerosis in a state where cannabis is legal. Multiple Sclerosis and Related Disorders, 2019, 27, 383-390.	0.9	19
467	Real-world validation of the 2017 McDonald criteria for pediatric MS. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, e528.	3.1	37
468	Multiple sclerosis â€“ the remarkable story of a baffling disease. Reviews in the Neurosciences, 2019, 30, 511-526.	1.4	13
469	Association between pathological and MRI findings in multiple sclerosis. Lancet Neurology, The, 2019, 18, 198-210.	4.9	163
470	Brain and cord imaging features in neuromyelitis optica spectrum disorders. Annals of Neurology, 2019, 85, 371-384.	2.8	66
471	Millsâ€™ syndrome revisited. Journal of Neurology, 2019, 266, 667-679.	1.8	15
472	Autonomic symptom burden can predict disease activity in early multiple sclerosis. Multiple Sclerosis and Related Disorders, 2019, 28, 250-255.	0.9	28
473	Instead of tweaking the diagnostic criteria for MS in those with CIS, we should develop diagnostic criteria that distinguish MS from other conditions â€“ No. Multiple Sclerosis Journal, 2019, 25, 768-770.	1.4	2
474	Instead of tweaking the diagnostic criteria for MS in those with CIS, we should develop diagnostic criteria that distinguish MS from other conditions â€“ Commentary. Multiple Sclerosis Journal, 2019, 25, 770-771.	1.4	2
475	Prognostic value of serum neurofilaments in patients with clinically isolated syndromes. Neurology, 2019, 92, e733-e741.	1.5	57
476	Can We Design a Nogo Receptor-Dependent Cellular Therapy to Target MS?. Cells, 2019, 8, 1.	1.8	170

#	Article	IF	Citations
477	Clinical 7 T MRI: Are we there yet? A review about magnetic resonance imaging at ultra-high field. British Journal of Radiology, 2019, 92, 20180492.	1.0	66
478	Coexistence of Multiple Sclerosis and Alzheimer's disease: A review. Multiple Sclerosis and Related Disorders, 2019, 27, 232-238.	0.9	32
479	Clinical spectrum of inflammatory central nervous system demyelinating disorders associated with antibodies against myelin oligodendrocyte glycoprotein. Neurochemistry International, 2019, 130, 104319.	1.9	35
480	Diagnostic value of the 2017 McDonald criteria in patients with a first demyelinating event suggestive of relapsingâ€“remitting multiple sclerosis. European Journal of Neurology, 2019, 26, 540-545.	1.7	27
481	International consensus on quality standards for brain health-focused care in multiple sclerosis. Multiple Sclerosis Journal, 2019, 25, 1809-1818.	1.4	55
482	Misdiagnosis of multiple sclerosis. Neurology, 2019, 92, 26-33.	1.5	123
483	Misdiagnosis of multiple sclerosis. Neurology, 2019, 92, 15-16.	1.5	109
484	No evidence of disease activity status over 3 years in a real-world cohort of relapsing remitting MS patients in Germany. Multiple Sclerosis and Related Disorders, 2019, 27, 133-138.	0.9	11
485	Validation of CSF free light chain in diagnosis and prognosis of multiple sclerosis and clinically isolated syndrome: prospective cohort study in Buenos Aires. Journal of Neurology, 2019, 266, 112-118.	1.8	12
486	The contribution of the instrumented Timed-Up-and-Go test to detect falls and fear of falling in people with multiple sclerosis. Multiple Sclerosis and Related Disorders, 2019, 27, 226-231.	0.9	9
487	Moyamoya masquerading as relapsing remitting multiple sclerosis. Neurological Sciences, 2019, 40, 635-637.	0.9	2
488	CNS phenotype in X linked Charcot- Marie-Tooth disease. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 1068.1-1068.	0.9	7
489	Multiple Sclerosis and Autoimmune Neurology of the Central Nervous System. Medical Clinics of North America, 2019, 103, 325-336.	1.1	27
490	Common Symptoms in the Neurology Clinic. , 2019, , 377-472.		0
491	The prevalence and prognostic value of myelin oligodendrocyte glycoprotein antibody in adult optic neuritis. Journal of the Neurological Sciences, 2019, 396, 225-231.	0.3	49
492	Optic nerve double inversion recovery hypersignal in patients with clinically isolated syndrome is associated with asymptomatic gadolinium-enhanced lesion. Multiple Sclerosis Journal, 2019, 25, 1888-1895.	1.4	12
493	Clinical utility of a molecular signature in inflammatory demyelinating disease. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, e520.	3.1	16
495	Concurrence of juvenile idiopathic arthritis and primary demyelinating disease in a young child. Multiple Sclerosis and Related Disorders, 2019, 27, 20-22.	0.9	4

#	Article	IF	Citations
496	Multiple sclerosis â€“ a review. European Journal of Neurology, 2019, 26, 27-40.	1.7	1,057
497	Automatic segmentation of the spinal cord and intramedullary multiple sclerosis lesions with convolutional neural networks. NeuroImage, 2019, 184, 901-915.	2.1	163
498	Decision-making on radiologically isolated syndrome among Argentinean neurologists: A survey based on clinical experience. Multiple Sclerosis and Related Disorders, 2019, 27, 61-64.	0.9	6
499	Repeatability and reproducibility of FreeSurfer, FSL-SIENAX and SPM brain volumetric measurements and the effect of lesion filling in multiple sclerosis. European Radiology, 2019, 29, 1355-1364.	2.3	93
500	Multiple sclerosis relapse: Qualitative findings from clinician and patient interviews. Multiple Sclerosis and Related Disorders, 2019, 27, 139-146.	0.9	15
501	Restriction spectrum imaging of white matter and its relation to neurological disability in multiple sclerosis. Multiple Sclerosis Journal, 2019, 25, 687-698.	1.4	8
502	New versus old: Implications of evolving diagnostic criteria for relapsingâ€“remitting multiple sclerosis. Multiple Sclerosis Journal, 2019, 25, 867-870.	1.4	26
503	Long-term follow-up of multiple sclerosis studies and outcomes from early treatment of clinically isolated syndrome in the BENEFIT 11 study. Journal of Neurology, 2020, 267, 308-316.	1.8	12
504	Kappa free light chains is a valid tool in the diagnostics of MS: A large multicenter study. Multiple Sclerosis Journal, 2020, 26, 912-923.	1.4	52
505	Pediatric onset multiple sclerosis. Revue Neurologique, 2020, 176, 30-36.	0.6	18
506	How do patients enter the healthcare system after the first onset of multiple sclerosis symptoms? The influence of setting and physician specialty on speed of diagnosis. Multiple Sclerosis Journal, 2020, 26, 489-500.	1.4	15
507	Dissociable cognitive patterns related to depression and anxiety in multiple sclerosis. Multiple Sclerosis Journal, 2020, 26, 1247-1255.	1.4	35
508	Brain and spinal MRI features distinguishing MS from different AQP4 antibody serostatus NMOSD at disease onset in a cohort of Latin American patients. Multiple Sclerosis Journal, 2020, 26, 945-954.	1.4	11
509	Comparative efficacy and acceptability of disease-modifying therapies in patients with relapsingâ€“remitting multiple sclerosis: a systematic review and network meta-analysis. Journal of Neurology, 2020, 267, 3489-3498.	1.8	82
510	Does Resetting the Immune System Fix Multiple Sclerosis?. Canadian Journal of Neurological Sciences, 2020, 47, 1-10.	0.3	7
511	The â€œcentral vein signâ€•in patients with diagnostic â€œred flagsâ€•for multiple sclerosis: A prospective multicenter 3T study. Multiple Sclerosis Journal, 2020, 26, 421-432.	1.4	44
512	Treatment of multiple sclerosis with rituximab: A multicentric Italianâ€“Swiss experience. Multiple Sclerosis Journal, 2020, 26, 1519-1531.	1.4	38
513	CNS Inflammatory Demyelinating Disorders: MS, NMOSD and MOG Antibody Associated Disease. Journal of Investigative Medicine, 2020, 68, 321-330.	0.7	36

#	Article	IF	Citations
514	Monitoring diffuse injury during disease progression in experimental autoimmune encephalomyelitis with on resonance variable delay multiple pulse (onVDMP) CEST MRI. NeuroImage, 2020, 204, 116245.	2.1	10
515	Cortical quantitative MRI parameters are related to the cognitive status in patients with relapsing-remitting multiple sclerosis. European Radiology, 2020, 30, 1045-1053.	2.3	10
516	Differential diagnosis of multiple sclerosis and other inflammatory CNS diseases. Multiple Sclerosis and Related Disorders, 2020, 37, 101452.	0.9	57
517	The multiple sclerosis gut microbiota: A systematic review. Multiple Sclerosis and Related Disorders, 2020, 37, 101427.	0.9	102
518	Radiologically isolated syndrome with oligoclonal bands in CSF (RIS + OCB) can be classified as high MS risk group. Multiple Sclerosis Journal, 2020, 26, 869-870.	1.4	7
519	Infratentorial and spinal cord lesions: Cumulative predictors of long-term disability?. Multiple Sclerosis Journal, 2020, 26, 1381-1391.	1.4	22
521	Improved performance of the 2017 McDonald criteria for diagnosis of multiple sclerosis in children in a real-life cohort. Multiple Sclerosis Journal, 2020, 26, 1372-1380.	1.4	28
522	Single-subject structural cortical networks in clinically isolated syndrome. Multiple Sclerosis Journal, 2020, 26, 1392-1401.	1.4	10
523	Change in multiple sclerosis prevalence over time in Australia 2010â€“2017 utilising disease-modifying therapy prescription data. Multiple Sclerosis Journal, 2020, 26, 1315-1328.	1.4	30
524	Intrathecal immunoglobulins and neurofilament light after autologous haematopoietic stem cell transplantation for multiple sclerosis. Multiple Sclerosis Journal, 2020, 26, 1351-1359.	1.4	17
525	Optical coherence tomography and multiple sclerosis: Update on clinical application and role in clinical trials. Multiple Sclerosis Journal, 2020, 26, 624-639.	1.4	27
526	Extending the Interval of Natalizumab Dosing: Is Efficacy Preserved?. Neurotherapeutics, 2020, 17, 200-207.	2.1	39
527	Progressive Multifocal Myelopathy or Multiple Sclerosis?. Multiple Sclerosis and Related Disorders, 2020, 37, 101373.	0.9	2
528	Exit strategies for â€œneedle fatigueâ€•in multiple sclerosis: a propensity score-matched comparison study. Journal of Neurology, 2020, 267, 694-702.	1.8	6
529	Cerebrospinal fluid kappa and lambda free light chains in oligoclonal bandâ€•negative patients with suspected multiple sclerosis. European Journal of Neurology, 2020, 27, 461-467.	1.7	26
530	Canadian Multiple Sclerosis Pregnancy Study (CANPREG-MS): Rationale and Methodology. Canadian Journal of Neurological Sciences, 2020, 47, 109-114.	0.3	4
531	Current Concepts in Ophthalmology. , 2020, , .		1
532	Cerebrospinal fluid free light chains compared to oligoclonal bands as biomarkers in multiple sclerosis. Journal of Neuroimmunology, 2020, 339, 577108.	1.1	31

#	Article	IF	Citations
533	Do people with multiple sclerosis want to discuss their long-term prognosis? A nationwide study in Argentina. Multiple Sclerosis and Related Disorders, 2020, 37, 101445.	0.9	8
534	Diagnosis of multiple sclerosis: what is changing?. Expert Review of Neurotherapeutics, 2020, 20, 743-746.	1.4	3
535	The P2X7 receptor tracer [11C]SMW139 as an in vivo marker of neuroinflammation in multiple sclerosis: a first-in man study. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 379-389.	3.3	44
536	Measurement of mucociliary clearance in the patients with multiple sclerosis. European Archives of Oto-Rhino-Laryngology, 2020, 277, 469-473.	0.8	5
537	Single Test to ARrive at Multiple Sclerosis (STAR-MS) diagnosis: A prospective pilot study assessing the accuracy of the central vein sign in predicting multiple sclerosis in cases of diagnostic uncertainty. Multiple Sclerosis Journal, 2020, 26, 433-441.	1.4	23
538	Voxelâ€wise lesion mapping of selfâ€reported urinary incontinence in multiple sclerosis. Neurourology and Urodynamics, 2020, 39, 295-302.	0.8	3
539	7T MRI cerebral leptomeningeal enhancement is common in relapsing-remitting multiple sclerosis and is associated with cortical and thalamic lesions. Multiple Sclerosis Journal, 2020, 26, 177-187.	1.4	49
540	Role of NR3C1 and GAS5 genes polymorphisms in multiple sclerosis. International Journal of Neuroscience, 2020, 130, 407-412.	0.8	14
541	Clinical, imaging and followâ€up study of optic neuritis associated with myelin oligodendrocyte glycoprotein antibody: a multicentre study of 62 adult patients. European Journal of Neurology, 2020, 27, 384-391.	1.7	19
542	Evoked potentials can predict future disability in people with clinically isolated syndrome. European Journal of Neurology, 2020, 27, 437-444.	1.7	9
543	3D PSIR MRI at 3ÂTesla improves detection of spinal cord lesions in multiple sclerosis. Journal of Neurology, 2020, 267, 406-414.	1.8	17
544	Acute effects of whole-body vibration training on neuromuscular performance and mobility in hypoxia and normoxia in persons with multiple sclerosis: A crossover study. Multiple Sclerosis and Related Disorders, 2020, 37, 101454.	0.9	4
545	Consensus recommendations for the diagnosis and treatment of multiple sclerosis: 2019 revisions to the MENACTRIMS guidelines. Multiple Sclerosis and Related Disorders, 2020, 37, 101459.	0.9	56
546	Empirical Mode Decomposition-Based Filter Applied to Multifocal Electroretinograms in Multiple Sclerosis Diagnosis. Sensors, 2020, 20, 7.	2.1	11
547	Pediatric multiple sclerosis: from clinical basis to imaging spectrum and differential diagnosis. Pediatric Radiology, 2020, 50, 776-792.	1.1	17
548	Do patients with multiple sclerosis benefit from semi-immersive virtual reality? A randomized clinical trial on cognitive and motor outcomes. Applied Neuropsychology Adult, 2022, 29, 59-65.	0.7	28
549	Diagnosis and management of central nervous system SjÃ¶gren's syndrome. , 2020, , 189-209.		0
550	Microglial NLRP3 inflammasome activation in multiple sclerosis. Advances in Protein Chemistry and Structural Biology, 2020, 119, 247-308.	1.0	48

#	Article	IF	Citations
551	â€œNo evidence of disease activityâ€: Is it an aspirational therapeutic goal in multiple sclerosis?. Multiple Sclerosis and Related Disorders, 2020, 40, 101935.	0.9	17
552	Deciphering anti-MOG IgG antibodies: Clinical and radiological spectrum, and comparison of antibody detection assays. Journal of the Neurological Sciences, 2020, 410, 116673.	0.3	12
553	Can semantic fluency be used as an alternative or additional measure in the abbreviated Minimal Assessment of Cognitive Function in Multiple Sclerosis (aMACFIMS)?. Journal of the Neurological Sciences, 2020, 410, 116640.	0.3	7
554	The differential expression of natural killer cells in NMOSD and MS. Journal of Clinical Neuroscience, 2020, 71, 9-14.	0.8	15
555	The impact of modifiable risk factors on lesion burden in patients with early multiple sclerosis. Multiple Sclerosis and Related Disorders, 2020, 39, 101886.	0.9	3
556	No evidence of disease activity status in patients treated with early vs. delayed subcutaneous interferon Î²-1a. Multiple Sclerosis and Related Disorders, 2020, 39, 101891.	0.9	4
557	To treat or not to treat: Sequential individualized treatment evaluation in relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders, 2020, 39, 101908.	0.9	29
558	Pediatric optic neuritis and anti MOG antibodies: a cohort of Italian patients. Multiple Sclerosis and Related Disorders, 2020, 39, 101917.	0.9	13
559	Pathological findings in central nervous system demyelination associated with infliximab. Multiple Sclerosis Journal, 2020, 26, 1124-1129.	1.4	11
560	Trigeminal neuralgia associated with a solitary pontine lesion: clinical and neuroimaging definition of a new syndrome. Pain, 2020, 161, 916-925.	2.0	23
561	Deep Learning for Predicting Enhancing Lesions in Multiple Sclerosis from Noncontrast MRI. Radiology, 2020, 294, 398-404.	3.6	67
562	Bad Tests Die Slowly: The Myelin Basic Protein Example. journal of applied laboratory medicine, The, 2020, 5, 136-141.	0.6	0
563	Thalamo-cortical dysfunction contributes to fatigability in multiple sclerosis patients: A neurophysiological study. Multiple Sclerosis and Related Disorders, 2020, 39, 101897.	0.9	12
564	Population-based Incidence of Pediatric and Adult Optic Neuritis and the Risk of Multiple Sclerosis. Ophthalmology, 2020, 127, 417-425.	2.5	34
565	Scientific impact of multiple sclerosis and neuromyelitis optica spectrum disorder research from Southeast Asia: A bibliometric analysis. Multiple Sclerosis and Related Disorders, 2020, 38, 101862.	0.9	17
566	Word-finding difficulty is a prevalent disease-related deficit in early multiple sclerosis. Multiple Sclerosis Journal, 2020, 26, 1752-1764.	1.4	34
567	Efficacy and Safety of Oral Therapies for Relapsing-Remitting Multiple Sclerosis. CNS Drugs, 2020, 34, 65-92.	2.7	13
568	Ketogenic diet and fasting diet as Nutritional Approaches in Multiple Sclerosis (NAMS): protocol of a randomized controlled study. Trials, 2020, 21, 3.	0.7	55

#	Article	IF	Citations
569	Consensus Recommendations of the Multiple Sclerosis Study Group and the Portuguese Neuroradiological Society for the Use of Magnetic Resonance Imaging in Multiple Sclerosis in Clinical Practice: Part 2.. Acta Medica Portuguesa, 2020, 33, 66-75.	0.2	1
570	The role of melatonin in Multiple Sclerosis. Neurological Sciences, 2020, 41, 769-781.	0.9	26
571	Male microchimerism in peripheral blood from women with multiple sclerosis in Isfahan Province. International Journal of Immunogenetics, 2020, 47, 175-179.	0.8	6
572	Dissecting task-specific plasticity capacity in patients with multiple sclerosis with transcranial magnetic stimulation. Clinical Neurophysiology, 2020, 131, 472-473.	0.7	2
573	Neurofibromatosis type 2 and multiple sclerosis. Multiple Sclerosis and Related Disorders, 2020, 39, 101890.	0.9	0
574	NLRP3 level in cerebrospinal fluid of patients with neuromyelitis optica spectrum disorders: Increased levels and association with disease severity. Multiple Sclerosis and Related Disorders, 2020, 39, 101888.	0.9	10
575	What do we currently know about the clinically isolated syndrome suggestive of multiple sclerosis? An update. Reviews in the Neurosciences, 2020, 31, 335-349.	1.4	4
576	Special Issue CCA for the proceedings of the 2nd symposium of the Society of CSF analysis and Clinical Neurochemistry. Clinica Chimica Acta, 2020, 502, 199-200.	0.5	0
577	Short term real-world Fingolimod efficacy and safety in Emirati patients with multiple sclerosis. Journal of Clinical Neuroscience, 2020, 71, 39-42.	0.8	3
578	Kappa free light chains index in the differential diagnosis of Multiple Sclerosis from Neuromyelitis optica spectrum disorders and other immune-mediated central nervous system disorders. Journal of Neuroimmunology, 2020, 339, 577122.	1.1	19
579	The efficacy of interferon-beta therapy in multiple sclerosis patients: investigation of the RORA gene as a predictive biomarker. Pharmacogenomics Journal, 2020, 20, 271-276.	0.9	7
580	Klotho and vitamin D in multiple sclerosis: an Italian study. Archives of Medical Science, 2020, 16, 842-847.	0.4	12
581	Dalfampridine to Improve Balance in Multiple Sclerosis: Substudy from a Randomized Placebo-Controlled Trial. Neurotherapeutics, 2020, 17, 704-709.	2.1	5
582	The accuracy of standard multiple sclerosis MRI brain sequences for the diagnosis of optic neuropathy. Multiple Sclerosis and Related Disorders, 2020, 38, 101521.	0.9	4
583	Trigeminal neuralgia associated with multiple sclerosis: A multimodal assessment of brainstem plaques and response to Gamma Knife radiosurgery. Multiple Sclerosis Journal, 2020, 26, 1877-1888.	1.4	9
584	The impact of diagnostic criteria and treatments on the 20-year costs for treating relapsing-remitting multiple sclerosis. Multiple Sclerosis and Related Disorders, 2020, 38, 101514.	0.9	9
585	Consensus recommendations on the management of multiple sclerosis patients in Argentina. Journal of the Neurological Sciences, 2020, 409, 116609.	0.3	11
586	Social phobia in immune-mediated inflammatory diseases. Journal of Psychosomatic Research, 2020, 128, 109890.	1.2	6

#	Article	IF	Citations
587	Limited One-time Sampling Irregularity Map (LOTS-IM) for Automatic Unsupervised Assessment of White Matter Hyperintensities and Multiple Sclerosis Lesions in Structural Brain Magnetic Resonance Images. Computerized Medical Imaging and Graphics, 2020, 79, 101685.	3.5	12
588	Comparing Plasma Exchange to Escalated Methyl Prednisolone in Refractory Multiple Sclerosis Relapses. Journal of Clinical Medicine, 2020, 9, 35.	1.0	13
589	Automated volumetric assessment with artificial neural networks might enable a more accurate assessment of disease burden in patients with multiple sclerosis. European Radiology, 2020, 30, 2356-2364.	2.3	16
590	Selective Cerebellar Atrophy Associates with Depression and Fatigue in the Early Phases of Relapse-Onset Multiple Sclerosis. Cerebellum, 2020, 19, 192-200.	1.4	17
591	Nursing interventions in autologous stem cell transplantation for autoimmune diseases. Journal of Advanced Nursing, 2020, 76, 3473-3482.	1.5	0
592	Single-Arm, Non-randomized, Time Series, Single-Subject Study of Fecal Microbiota Transplantation in Multiple Sclerosis. Frontiers in Neurology, 2020, 11, 978.	1.1	48
593	Social norms in patients with relapsing-remitting multiple sclerosis: Impairment of the moral/conventional distinction?. Social Neuroscience, 2020, 15, 630-640.	0.7	2
594	The impairment of the functional system and fatigue at the onset of the disease predict reaching disability milestones in relapsingâ€“remitting multiple sclerosis differently in female and male patients. Acta Neurologica Belgica, 2021, 121, 1699-1706.	0.5	3
595	Multiple sclerosis in a young woman with sickle cell disease. Multiple Sclerosis and Related Disorders, 2020, 45, 102427.	0.9	1
596	Differential diagnosis in acute inflammatory myelitis. Multiple Sclerosis and Related Disorders, 2020, 46, 102481.	0.9	4
597	Multiple sclerosis and COVIDâ€19: How many are at risk?. European Journal of Neurology, 2021, 28, 3369-3374.	1.7	37
598	Cerebrospinal fluid oligoclonal bands in Neuroborreliosis are specific for Borrelia burgdorferi. PLoS ONE, 2020, 15, e0239453.	1.1	7
599	Research on Cognition Disorders. , 2020, , .		0
600	Revisiting the Pathoetiology of Multiple Sclerosis: Has the Tail Been Wagging the Mouse?. Frontiers in Immunology, 2020, 11, 572186.	2.2	33
601	ExposiciÃ³n a fÃ¡rmacos modificadores de la enfermedad durante el embarazo en esclerosis mÃºltiple: estudio prospectivo. Medicina ClÃnica, 2020, 154, 214-217.	0.3	2
602	Frequency and etiology of acute transverse myelitis in Southern Finland. Multiple Sclerosis and Related Disorders, 2020, 46, 102562.	0.9	5
603	The Administrative Prevalence of Multiple Sclerosis in Greece on the Basis of a Nationwide Prescription Database. Frontiers in Neurology, 2020, 11, 1012.	1.1	14
604	Interval Timing in Pediatric Multiple Sclerosis: Impaired in the Subsecond Range but Unimpaired in the One-Second Range. Frontiers in Neurology, 2020, 11, 575780.	1.1	1

#	Article	IF	Citations
605	Paediatric onset of multiple sclerosis: Analysis of chemokine and cytokine levels in the context of the early clinical course. Multiple Sclerosis and Related Disorders, 2020, 46, 102467.	0.9	5
606	Diverse Applications of Artificial Intelligence in Neuroradiology. Neuroimaging Clinics of North America, 2020, 30, 505-516.	0.5	16
607	Association of multiple sclerosis with vitiligo: a systematic review and meta-analysis. Scientific Reports, 2020, 10, 17792.	1.6	3
608	HLA-DR15 Molecules Jointly Shape an Autoreactive T Cell Repertoire in Multiple Sclerosis. Cell, 2020, 183, 1264-1281.e20.	13.5	133
609	Smell as a clinical-marker for functional limitations in multiple sclerosis: A pilot study. Multiple Sclerosis and Related Disorders, 2020, 46, 102508.	0.9	10
610	Selective modulation of trans-endothelial migration of lymphocyte subsets in multiple sclerosis patients under fingolimod treatment. Journal of Neuroimmunology, 2020, 349, 577392.	1.1	13
611	MS Spasticity: Take Control (STC) for ambulatory adults: protocol for a randomized controlled trial. BMC Neurology, 2020, 20, 368.	0.8	1
612	The weak association between neurofilament levels at multiple sclerosis onset and cognitive performance after 9 years. Multiple Sclerosis and Related Disorders, 2020, 46, 102534.	0.9	14
613	Demographic and clinical characterization of multiple sclerosis in Mexico: The REMEMBer study. Multiple Sclerosis and Related Disorders, 2020, 46, 102575.	0.9	6
614	Blunted neural and psychological stress processing predicts future grey matter atrophy in multiple sclerosis. Neurobiology of Stress, 2020, 13, 100244.	1.9	10
615	Sensitive Detection of Infratentorial and Upper Cervical Cord Lesions in Multiple Sclerosis with Combined 3D FLAIR and T2-Weighted (FLAIR3) Imaging. American Journal of Neuroradiology, 2020, 41, 2062-2067.	1.2	2
616	Accelerating Brain 3D T1-Weighted Turbo Field Echo MRI Using Compressed Sensing-Sensitivity Encoding (CS-SENSE). European Journal of Radiology, 2020, 131, 109255.	1.2	14
617	Expression of Akt1 and p-Akt1 in peripheral T cell subsets of multiple sclerosis patients. Acta Neurologica Belgica, 2020, 121, 1777-1782.	0.5	5
618	Corneal epithelial dendritic cells in patients with multiple sclerosis: An in vivo confocal microscopy study. Journal of Clinical Neuroscience, 2020, 81, 139-143.	0.8	10
619	Prevalence of comorbidities in Multiple Sclerosis and impact on physical disability according to disease phenotypes. Multiple Sclerosis and Related Disorders, 2020, 46, 102565.	0.9	7
620	Early changes in ILâ€21, ILâ€22, CCL2, and CCL4 serum cytokines after outpatient autologous transplantation for multiple sclerosis: A proof of concept study. Clinical Transplantation, 2020, 34, e14114.	0.8	10
622	Multiple sclerosis lesion activity segmentation with attention-guided two-path CNNs. Computerized Medical Imaging and Graphics, 2020, 84, 101772.	3.5	36
623	Could the performance of oral glucose tolerance test contribute to the brain health-focused care in multiple sclerosis?. Multiple Sclerosis and Related Disorders, 2020, 46, 102536.	0.9	3

#	Article	IF	Citations
624	Association of Pregnancy With the Onset of Clinically Isolated Syndrome. JAMA Neurology, 2020, 77, 1496.	4.5	21
625	New concepts about the role of magnetic resonance imaging in the diagnosis and follow-up of multiple sclerosis. Radiologia, 2020, 62, 349-359.	0.3	0
626	Multiple sclerosis attack case presenting with pseudo-vestibular neuritis. International Journal of Neuroscience, 2020, , 1-5.	0.8	1
627	Brain TSPO-PET predicts later disease progression independent of relapses in multiple sclerosis. Brain, 2020, 143, 3318-3330.	3.7	71
628	Urologic, neurologic, and general practice implications of the Time to be Ready to Void Test. Annals of Physical and Rehabilitation Medicine, 2020, 64, 101372.	1.1	1
629	White Matter Lesions in Adults â€“ a Differential Diagnostic Approach. RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren, 2020, 192, 1154-1173.	0.7	5
630	Population-Based Incidence of Optic Neuritis in the Era of Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein Antibodies. American Journal of Ophthalmology, 2020, 220, 110-114.	1.7	48
631	Ultra-high field 7â€ŠT imaging in multiple sclerosis. Current Opinion in Neurology, 2020, 33, 422-429.	1.8	9
632	AvanÃ§os no tratamento da esclerose mÃºltipla atravÃ©s do anticorpo monoclonal Ocrelizumabe. Medicina, 2020, 53, 35-41.	0.0	1
633	Short-term outcomes of pediatric multiple sclerosis patients treated with alemtuzumab at a Canadian University multiple sclerosis clinic. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2020, 6, 205521732092661.	0.5	5
634	Clinical and laboratory features distinguishing MOG antibody disease from multiple sclerosis and AQP4 antibody-positive neuromyelitis optica. Multiple Sclerosis and Related Disorders, 2020, 45, 102399.	0.9	33
635	Multiple sclerosis cortical and WM lesion segmentation at 3T MRI: a deep learning method based on FLAIR and MP2RAGE. NeuroImage: Clinical, 2020, 27, 102335.	1.4	54
636	A Score Based on NfL and Glial Markers May Differentiate Between Relapsingâ€“Remitting and Progressive MS Course. Frontiers in Neurology, 2020, 11, 608.	1.1	25
637	Co-incident primary progressive multiple sclerosis and hereditary spastic paraplegia (SPG4) â€“ a case report. Multiple Sclerosis and Related Disorders, 2020, 44, 102375.	0.9	3
638	Measurements of the corpus callosum index and fractional anisotropy of the corpus callosum and their cutoff values are useful to assess global brain volume loss in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2020, 45, 102388.	0.9	13
639	Multiplex assessment of cerebrospinal fluid biomarkers in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2020, 45, 102391.	0.9	11
640	Coexistence of emotional reactions and atrophic brain changes in patients with clinically isolated syndrome of multiple sclerosis. Postepy Psychiatrii I Neurologii, 2020, 29, 3-10.	0.2	0
641	CSF oligoclonal band frequency in a Cuban cohort of patients with multiple sclerosis. comparison with Latin American countries and association with latitude. Multiple Sclerosis and Related Disorders, 2020, 45, 102412.	0.9	2

#	Article	IF	Citations
642	Impact of intrathecal IgG synthesis on neurological disability in patients with multiple sclerosis. Multiple Sclerosis and Related Disorders, 2020, 45, 102382.	0.9	7
643	State of the Art and Future Challenges in Multiple Sclerosis Research and Medical Management: An Insight into the 5th International Porto Congress of Multiple Sclerosis. Neurology and Therapy, 2020, 9, 281-300.	1.4	3
644	Treatment of Multiple Sclerosis: A Review. American Journal of Medicine, 2020, 133, 1380-1390.e2.	0.6	374
645	AI in Radiology: Where are we today in Multiple Sclerosis Imaging?. RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren, 2020, 192, 847-853.	0.7	6
646	Structural correlates of atypical visual and motor cortical oscillations in pediatricâ€onset multiple sclerosis. Human Brain Mapping, 2020, 41, 4299-4313.	1.9	6
647	Importance of Not MSing Cerebral White Matter Disease in Patients with Inflammatory Bowel Disease. Digestive Diseases and Sciences, 2020, 65, 2527-2532.	1.1	0
648	A Pilot Study to Explore Patient Satisfaction With a Virtual Rehabilitation Program in Multiple Sclerosis: The RehabVR Study Protocol. Frontiers in Neurology, 2020, 11, 900.	1.1	6
649	Cerebrospinal Fluid IgM Levels in Association With Inflammatory Pathways in Multiple Sclerosis Patients. Frontiers in Cellular Neuroscience, 2020, 14, 569827.	1.8	5
650	Imaging of the Spinal Cord in Multiple Sclerosis: Past, Present, Future. Brain Sciences, 2020, 10, 857.	1.1	10
651	Gut microbiotaâ€“specific IgA ⁺ B cells traffic to the CNS in active multiple sclerosis. Science Immunology, 2020, 5, .	5.6	132
652	Multiple Sclerosis: Shall We Target CD33?. Genes, 2020, 11, 1334.	1.0	9
653	Intrathecal kappa free light chains as markers for multiple sclerosis. Scientific Reports, 2020, 10, 20329.	1.6	29
654	Assessment of mental health, knowledge, and attitude of patients with multiple sclerosis and neuromyelitis optica spectrum disorder in response to 2019 novel coronavirus. Neurological Sciences, 2021, 42, 2891-2901.	0.9	10
655	An electronic, unsupervised patient-reported Expanded Disability Status Scale for multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 1432-1441.	1.4	9
656	Magnetic resonance imaging at baseline and follow-up to differentiate between pediatric monophasic acquired CNS demyelination and MS. Multiple Sclerosis and Related Disorders, 2020, 46, 102590.	0.9	4
657	Slowing of brain atrophy with teriflunomide and delayed conversion to clinically definite MS. Therapeutic Advances in Neurological Disorders, 2020, 13, 175628642097075.	1.5	7
658	Vestibular rehabilitation in multiple sclerosis: study protocol for a randomised controlled trial and cost-effectiveness analysis comparing customised with booklet based vestibular rehabilitation for vestibulopathy and a 12â€‰month observational cohort study of the symptom reduction and recurrence rate following treatment for benign paroxysmal positional vertigo. BMC Neurology, 2020, 20, 430.	0.8	3
659	Adding brain volume measures into response criteria in multiple sclerosis: the RÃo-4 score. Neuroradiology, 2021, 63, 1031-1041.	1.1	2

#	Article	IF	Citations
660	Lipid profile: causal relationship on cognitive performance in multiple sclerosis?. Molecular Biology Reports, 2020, 47, 9667-9676.	1.0	10
661	The Development of Cladribine Tablets for the Treatment of Multiple Sclerosis: A Comprehensive Review. Drugs, 2020, 80, 1901-1928.	4.9	42
662	Cerebrospinal Fluid Biomarkers in Relation to MRZ Reaction Status in Primary Progressive Multiple Sclerosis. Cells, 2020, 9, 2543.	1.8	8
663	Pain Characteristics and Associations with Quality of Life in Patients with Multiple Sclerosis in Lithuania. Medicina (Lithuania), 2020, 56, 596.	0.8	8
664	A cross-sectional comparison of performance, neurophysiological and MRI outcomes of responders and non-responders to fampridine treatment in multiple sclerosis â€“ An explorative study. Journal of Clinical Neuroscience, 2020, 82, 179-185.	0.8	6
665	Utility of shape evolution and displacement in the classification of chronic multiple sclerosis lesions. Scientific Reports, 2020, 10, 19560.	1.6	10
666	The effect of tonsillectomy on John Cunningham virus serological status in multiple sclerosis patients: A retrospective caseâ€“control study. Multiple Sclerosis Journal, 2021, 27, 1297-1300.	1.4	0
667	The Use of the Central Vein Sign in the Diagnosis of Multiple Sclerosis: A Systematic Review and Meta-analysis. Diagnostics, 2020, 10, 1025.	1.3	30
668	Orexin and Psychoneurobiology: A Hidden Treasure. , 2020, , .		0
669	Evolving relationship between respiratory functions & impairment in sleep and cognition in patients with multiple sclerosis. Multiple Sclerosis and Related Disorders, 2020, 46, 102514.	0.9	6
670	SÃndrome de SjÃ¶gren neuropsiquiÃ¡trico. Revista Colombiana De ReumatologÃa, 2020, 27, 125-139.	0.0	0
671	Progress in the Management of Paediatric-Onset Multiple Sclerosis. Children, 2020, 7, 222.	0.6	4
672	Synthetic <scp>MRI</scp>: Technologies and Applications in Neuroradiology. Journal of Magnetic Resonance Imaging, 2022, 55, 1013-1025.	1.9	40
673	Clinical Immunological Correlations in Patients with Multiple Sclerosis Treated with Natalizumab. Brain Sciences, 2020, 10, 802.	1.1	2
675	ASPIRE trial: study protocol for a double-blind randomised controlled trial of aspirin for overheating during exercise in multiple sclerosis. BMJ Open, 2020, 10, e039691.	0.8	2
676	A preliminary study of the concentration of metallic elements in the blood of patients with multiple sclerosis as measured by ICP-MS. Scientific Reports, 2020, 10, 13112.	1.6	15
677	Retinal and brain damage during multiple sclerosis course: inflammatory activity is a key factor in the first 5 years. Scientific Reports, 2020, 10, 13333.	1.6	20
678	Is there a correlation between dyslipidemia and cognitive impairment in patients with multiple sclerosis?. International Journal of Neuroscience, 2022, 132, 201-206.	0.8	7

#	Article	IF	Citations
679	The role of contrast-enhanced and non-contrast-enhanced MRI in the follow-up of multiple sclerosis. Acta Radiologica, 2021, 62, 916-921.	0.5	4
680	Autoimmune and demyelinating optic neuritis. Archivos De La Sociedad Espanola De Oftalmologia, 2020, 95, 386-395.	0.1	0
681	Seasonal variation in relapse of neuromyelitis optica spectrum disorders: A retrospective study in China. Journal of Neuroimmunology, 2020, 347, 577351.	1.1	4
682	Reactive increase of cerebrospinal fluid white blood cell count after lumbar puncture: Fact or fiction?. Journal of the Neurological Sciences, 2020, 414, 116876.	0.3	2
683	Combined exercise training improves cognitive functions in multiple sclerosis patients with cognitive impairment: A single-blinded randomized controlled trial. Multiple Sclerosis and Related Disorders, 2020, 45, 102419.	0.9	28
684	12 Diffuse White Matter Hyperintensities. , 2020, , .		0
685	Pediatric Multiple Sclerosis Severity Score in a large US cohort. Neurology, 2020, 95, e1844-e1853.	1.5	11
686	Personalized extended interval dosing of natalizumab in MS. Neurology, 2020, 95, e745-e754.	1.5	36
687	Contralateral Strength Training as Preparation for Direct Strength Training in a Patient With Unilateral Foot-Drop Because of Multiple Sclerosis: A Case Report. Physical Therapy, 2020, 100, 1816-1824.	1.1	1
688	Validation of Quantitative Scores Derived From Motor Evoked Potentials in the Assessment of Primary Progressive Multiple Sclerosis: A Longitudinal Study. Frontiers in Neurology, 2020, 11, 735.	1.1	9
689	A Multiple N-Glucosylated Peptide Epitope Efficiently Detecting Antibodies in Multiple Sclerosis. Brain Sciences, 2020, 10, 453.	1.1	5
690	Lower extremity muscle strength across the adult lifespan in multiple sclerosis: Implications for walking and stair climbing capacity. Experimental Gerontology, 2020, 139, 111025.	1.2	18
691	Differential effects of disease modifying drugs on peripheral blood B cell subsets: A cross sectional study in multiple sclerosis patients treated with interferon-Î², glatiramer acetate, dimethyl fumarate, fingolimod or natalizumab. PLoS ONE, 2020, 15, e0235449.	1.1	20
692	Incidence and prevalence of multiple sclerosis in Hungary based on record linkage of nationwide multiple healthcare administrative data. PLoS ONE, 2020, 15, e0236432.	1.1	9
693	Effect of remote ischaemic preconditioning on walking in people with multiple sclerosis: double-blind randomised controlled trial. BMJ Neurology Open, 2020, 2, e000022.	0.7	10
694	Mitochondrial Oxidative Damage Underlies Regulatory T Cell Defects in Autoimmunity. Cell Metabolism, 2020, 32, 591-604.e7.	7.2	79
695	Latin American consensus recommendations for management and treatment of neuromyelitis optica spectrum disorders in clinical practice. Multiple Sclerosis and Related Disorders, 2020, 45, 102428.	0.9	42
696	Understanding Pediatric Neuroimmune Disorder Conflicts: A Neuroradiologic Approach in the Molecular Era. Radiographics, 2020, 40, 1395-1411.	1.4	8

#	Article	IF	Citations
697	The Effect of Coffee and Caffeine Consumption on Patients with Multiple Sclerosis-Related Fatigue. Nutrients, 2020, 12, 2262.	1.7	12
698	Validation of inter-eye difference thresholds in optical coherence tomography for identification of optic neuritis in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2020, 45, 102403.	0.9	22
699	Optical coherence tomography for detection of asymptomatic optic nerve lesions in clinically isolated syndrome. Neurology, 2020, 95, e733-e744.	1.5	29
700	Optical coherence tomography: A useful tool for identifying subclinical optic neuropathy in diagnosing multiple sclerosis. Neurology, 2020, 95, 239-240.	1.5	7
701	Is Fertility Affected in Women of Childbearing Age with Multiple Sclerosis or Neuromyelitis Optica Spectrum Disorder?. Journal of Molecular Neuroscience, 2020, 70, 1829-1835.	1.1	6
702	Paroxysmal dysarthria-ataxia syndrome: Literature review on MRI findings and report of a peculiar case with clinically isolated syndrome coexisting with anti-N-methyl-d-aspartate receptor antibodies. Journal of Neuroimmunology, 2020, 347, 577327.	1.1	2
703	Large check size pattern reversal visual evoked potentials â€“ Full and sectorial field stimulation in multiple sclerosis and controls. Journal of Clinical Neuroscience, 2020, 75, 181-187.	0.8	0
704	Valid or not: A critique of Graver and Green. Applied Neuropsychology Adult, 2022, 29, 639-642.	0.7	5
705	Recent developments in MOG-IgG associated neurological disorders. Therapeutic Advances in Neurological Disorders, 2020, 13, 175628642094513.	1.5	45
706	Understanding the application of diagnostic criteria for multiple sclerosis helps prevent misdiagnosis. Cmaj, 2020, 192, E894-E894.	0.9	2
707	Gonadal Steroids and Sperm Quality in a Cohort of Relapsing Remitting Multiple Sclerosis: A Case-Control Study. Frontiers in Neurology, 2020, 11, 756.	1.1	6
708	Changes in Amino Acid and Acylcarnitine Plasma Profiles for Distinguishing Patients with Multiple Sclerosis from Healthy Controls. Multiple Sclerosis International, 2020, 2020, 1-10.	0.4	4
709	Regional differences in the association of cytomegalovirus seropositivity and multiple sclerosis: A systematic review and meta-analysis. Multiple Sclerosis and Related Disorders, 2020, 45, 102393.	0.9	13
710	A blood-based metabolomics test to distinguish relapsingâ€“remitting and secondary progressive multiple sclerosis: addressing practical considerations for clinical application. Scientific Reports, 2020, 10, 12381.	1.6	8
711	The apparently milder course of multiple sclerosis: changes in the diagnostic criteria, therapy and natural history. Brain, 2020, 143, 2637-2652.	3.7	56
712	Pregnancy exposure to disease-modifying drugs in multiple sclerosis: a prospective study. Medicina ClÃnica (English Edition), 2020, 154, 214-217.	0.1	2
714	Investigation of the â€œcentral vein signâ€•in infratentorial multiple sclerosis lesions. Multiple Sclerosis and Related Disorders, 2020, 45, 102409.	0.9	8
715	The effect of a telerehabilitation virtual reality intervention on functional upper limb activities in people with multiple sclerosis: a study protocol for the TEAMS pilot randomized controlled trial. Trials, 2020, 21, 713.	0.7	14

#	Article	IF	Citations
716	Prognostic value of kappa free light chains determination in first-ever multiple sclerosis relapse. Journal of Neuroimmunology, 2020, 347, 577355.	1.1	13
717	Serum neurofilament-light concentration and real-world outcome in MS. Journal of the Neurological Sciences, 2020, 417, 117079.	0.3	10
718	Fatigue in multiple sclerosis patients with different clinical phenotypes: a clinical and magnetic resonance imaging study. European Journal of Neurology, 2020, 27, 2549-2560.	1.7	30
719	On the STAIR-Way to Imaging Myelin with Clinical MRI. Radiology, 2020, 297, 405-406.	3.6	2
720	Radiologically Isolated Syndrome: A Review for Neuroradiologists. American Journal of Neuroradiology, 2020, 41, 1542-1549.	1.2	17
721	Movement Velocity as A Measure of Exercise Intensity in Persons with Multiple Sclerosis: A Validity Study. Journal of Clinical Medicine, 2020, 9, 2458.	1.0	2
722	Paramagnetic Rim Lesions are Specific to Multiple Sclerosis: An International Multicenter 3T MRI Study. Annals of Neurology, 2020, 88, 1034-1042.	2.8	89
723	Serum level of IL-1Î² in patients with inflammatory demyelinating disease: Marked upregulation in the early acute phase of MOG antibody associated disease (MOGAD). Journal of Neuroimmunology, 2020, 348, 577361.	1.1	14
724	Advanced MRI features in relapsing multiple sclerosis patients with and without CSF oligoclonal IgG bands. Scientific Reports, 2020, 10, 13703.	1.6	6
725	Blood platelet RNA enables the detection of multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2020, 6, 205521732094678.	0.5	14
726	Pediatric Demyelinating Disease: Emerging Patterns from Multiple Sclerosis to Anti-Myelin Oligodendrocyte Glycoproteinâ€Associated Encephalomyelitis. Neurographics, 2020, 10, 139-151.	0.0	3
727	Nuevos conceptos sobre el papel de la resonancia magnÃ©tica en el diagnÃ³stico y seguimiento de la esclerosis mÃºltiple. Radiologia, 2020, 62, 349-359.	0.3	2
728	Kappa Index versus CSF Oligoclonal Bands in Predicting Multiple Sclerosis and Infectious/Inflammatory CNS Disorders. Diagnostics, 2020, 10, 856.	1.3	19
729	Dietary supplementation with L-carnosine improves patient-reported outcomes, autonomic nervous system performance, and brain metabolism in 3 adult patients with multiple sclerosis. Nutrition Research, 2020, 84, 63-69.	1.3	6
730	Acceptability and outcomes of an individualized exergaming telePT program for veterans with multiple sclerosis: a pilot study. Archives of Physiotherapy, 2020, 10, 18.	0.7	12
731	CSF and Blood Biomarkers in Neuroinflammatory and Neurodegenerative Diseases: Implications for Treatment. Trends in Pharmacological Sciences, 2020, 41, 1023-1037.	4.0	48
732	Cerebrospinal fluid lipidomic biomarker signatures of demyelination for multiple sclerosis and Guillainâ€“BarrÃ© syndrome. Scientific Reports, 2020, 10, 18380.	1.6	13
733	Local functional connectivity of patients with acute and remitting multiple sclerosis. Medicine (United States), 2020, 99, e22860.	0.4	10

#	Article	IF	Citations
734	A comparative study of tolerability and effects on immunoglobulin levels and CD19 cell counts with ocrelizumab vs low dose of rituximab in multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2020, 6, 205521732096450.	0.5	13
735	Gadolinium-Enhanced 3D T1-Weighted Black-Blood MR Imaging for the Detection of Acute Optic Neuritis. American Journal of Neuroradiology, 2020, 41, 2333-2338.	1.2	4
736	Concentrations of plasma-borne extracellular particles differ between multiple sclerosis disease courses and compared to healthy controls. Multiple Sclerosis and Related Disorders, 2020, 45, 102446.	0.9	8
737	Structured Reporting in Multiple Sclerosis Reduces Interpretation Time. Academic Radiology, 2021, 28, 1733-1738.	1.3	4
738	African Americans experience disproportionate neurodegenerative changes in the medulla and upper cervical spinal cord in early multiple sclerosis. Multiple Sclerosis and Related Disorders, 2020, 45, 102429.	0.9	20
739	Multiple sclerosis and nutrition: back to the future?. Therapeutic Advances in Neurological Disorders, 2020, 13, 175628642093616.	1.5	2
740	Serum levels of cell adhesion molecules in patients with neuromyelitis optica spectrum disorder. Annals of Clinical and Translational Neurology, 2020, 7, 1854-1861.	1.7	2
741	Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 1:ÂResults from 163 lumbar punctures in 100 adult patients. Journal of Neuroinflammation, 2020, 17, 261.	3.1	84
742	Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 2: Results from 108 lumbar punctures in 80 pediatric patients. Journal of Neuroinflammation, 2020, 17, 262.	3.1	44
743	Histopathology-validated recommendations for cortical lesion imaging in multiple sclerosis. Brain, 2020, 143, 2988-2997.	3.7	24
744	IgG Index Revisited: Diagnostic Utility and Prognostic Value in Multiple Sclerosis. Frontiers in Immunology, 2020, 11, 1799.	2.2	26
745	The Agony of Choice? Preserved Affective Decision Making in Early Multiple Sclerosis. Frontiers in Neurology, 2020, 11, 914.	1.1	1
746	Genomic, proteomic, and systems biology approaches in biomarker discovery for multiple sclerosis. Cellular Immunology, 2020, 358, 104219.	1.4	12
747	The current status and challenges in multiple sclerosis management in the Philippines. Multiple Sclerosis and Related Disorders, 2020, 46, 102510.	0.9	16
748	7 T imaging reveals a gradient in spinal cord lesion distribution in multiple sclerosis. Brain, 2020, 143, 2973-2987.	3.7	22
749	Free light chains kappa can differentiate between myelitis and noninflammatory myelopathy. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	3.1	17
750	Cortical Thinning and Ventricle Enlargement in Neuromyelitis Optica Spectrum Disorders. Frontiers in Neurology, 2020, 11, 872.	1.1	7
751	Clinical and demographic characteristics of primary progressive multiple sclerosis in Argentina: Argentinean registry cohort study (RelevarEM). Neurological Sciences, 2020, 41, 3329-3335.	0.9	4

#	Article	IF	Citations
752	A pathogenic and clonally expanded B cell transcriptome in active multiple sclerosis. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 22932-22943.	3.3	119
753	Probable Autoimmune Depression in a Patient With Multiple Sclerosis and Antineuronal Antibodies. Frontiers in Psychiatry, 2020, 11, 745.	1.3	3
755	Creatine and multiple sclerosis. Nutritional Neuroscience, 2022, 25, 912-919.	1.5	7
756	Prevalence of multiple sclerosis in rural and urban districts in Telemark county, Norway. Multiple Sclerosis and Related Disorders, 2020, 45, 102352.	0.9	8
757	Multiple Sclerosis as a Syndromeâ€"Implications for Future Management. Frontiers in Neurology, 2020, 11, 784.	1.1	3
758	Safety and Tolerability of Plasma Exchange and Immunoadsorption in Neuroinflammatory Diseases. Journal of Clinical Medicine, 2020, 9, 2874.	1.0	11
759	Progressive patterns of neurological disability in multiple sclerosis and neuromyelitis optica spectrum disorders. Scientific Reports, 2020, 10, 13890.	1.6	42
760	Improved relapse recovery in paediatric compared to adult multiple sclerosis. Brain, 2020, 143, 2733-2741.	3.7	45
761	Biologic Therapy in Refractory Non-Multiple Sclerosis Optic Neuritis Isolated or Associated to Immune-Mediated Inflammatory Diseases. A Multicenter Study. Journal of Clinical Medicine, 2020, 9, 2608.	1.0	3
763	Immune signatures of prodromal multiple sclerosis in monozygotic twins. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 21546-21556.	3.3	36
764	Different Effects of Transcranial Direct Current Stimulation on Leg Muscle Glucose Uptake Asymmetry in Two Women with Multiple Sclerosis. Brain Sciences, 2020, 10, 549.	1.1	5
765	Objective evaluation of Nintendo Wii Fit Plus balance program training on postural stability in Multiple Sclerosis patients: a pilot study. International Journal of Rehabilitation Research, 2020, 43, 199-205.	0.7	6
766	Alterations of the gut ecological and functional microenvironment in different stages of multiple sclerosis. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 22402-22412.	3.3	103
767	Extensive Healthy Donor Age/Gender Adjustments and Propensity Score Matching Reveal Physiology of Multiple Sclerosis Through Immunophenotyping. Frontiers in Neurology, 2020, 11, 565957.	1.1	3
768	The Relationship of the Mechanisms of the Pathogenesis of Multiple Sclerosis and the Expression of Endogenous Retroviruses. Biology, 2020, 9, 464.	1.3	5
769	Cerebrospinal fluid inflammatory biomarkers predicting interferon-beta response in MS patients. Therapeutic Advances in Neurological Disorders, 2020, 13, 175628642097083.	1.5	5
770	Rehabilitation Before and After Autologous Haematopoietic Stem Cell Transplantation (AHSCT) for Patients With Multiple Sclerosis (MS): Consensus Guidelines and Recommendations for Best Clinical Practice on Behalf of the Autoimmune Diseases Working Party, Nurses Group, and Patient Advocacy Committee of the European Society for Blood and Marrow Transplantation (EBMT). Frontiers in Neurology, 2020, 11, 556141.	1.1	8
771	Low Contrast Visual Acuity Might Help to Detect Previous Optic Neuritis. Frontiers in Neurology, 2020, 11, 602193.	1.1	7

#	Article	IF	Citations
772	Investigation of Deep-Learning-Driven Identification of Multiple Sclerosis Patients Based on Susceptibility-Weighted Images Using Relevance Analysis. Frontiers in Neuroscience, 2020, 14, 609468.	1.4	21
773	The Roles of Matrix Metalloproteinases and Their Inhibitors in Human Diseases. International Journal of Molecular Sciences, 2020, 21, 9739.	1.8	585
774	Prevalence of SARS-CoV-2 Antibodies in Multiple Sclerosis: The Hidden Part of the Iceberg. Journal of Clinical Medicine, 2020, 9, 4066.	1.0	19
775	Elevated Concentrations of Soluble Fas and FasL in Multiple Sclerosis Patients with Antinuclear Antibodies. Journal of Clinical Medicine, 2020, 9, 3845.	1.0	1
776	Increased socioeconomic burden in patients with primary progressive multiple sclerosis: A Danish nationwide population-based study. Multiple Sclerosis and Related Disorders, 2020, 46, 102567.	0.9	6
777	Spatial constraints and cognitive fatigue affect motor imagery of walking in people with multiple sclerosis. Scientific Reports, 2020, 10, 21938.	1.6	4
778	Central Nervous System Demyelination Associated With Immune Checkpoint Inhibitors: Review of the Literature. Frontiers in Neurology, 2020, 11, 538695.	1.1	37
779	3D Compressed Convolutional Neural Network Differentiates Neuromyelitis Optical Spectrum Disorders From Multiple Sclerosis Using Automated White Matter Hyperintensities Segmentations. Frontiers in Physiology, 2020, 11, 612928.	1.3	8
780	Depression and anxiety in patients with multiple sclerosis treated with interferon-beta or fingolimod: Role of indoleamine 2,3-dioxygenase and pro-inflammatory cytokines. Brain, Behavior, & Immunity - Health, 2020, 9, 100162.	1.3	3
781	Fulminant inflammatory demyelination presenting as strokeâ€inâ€evolution in an elderly subject. Brain and Behavior, 2021, 11, e01967.	1.0	2
782	Validation of the Italian version of the Multiple Sclerosis Intimacy and Sexuality Questionnaire-19. Neurological Sciences, 2020, 42, 2903-2910.	0.9	8
783	The impact of lymphocytosis and CD4/CD8 ratio on the anti-JCV antibody index and clinical data in patients treated with natalizumab. Neurological Sciences, 2021, 42, 2847-2853.	0.9	2
784	Adherence to a healthy lifestyle and multiple sclerosis: a caseâ€“control study from the UK Biobank. Nutritional Neuroscience, 2020, , 1-9.	1.5	4
785	Short report: assessment of coping strategies in patients with neuromyelitis optica spectrum disorder (NMOSD) and multiple sclerosis. Psychology, Health and Medicine, 2022, 27, 1234-1244.	1.3	2
786	Development, Spanish Normative Data, and Validation of a Social Cognition Battery in Prodromal Alzheimerâ€™s Disease and Multiple Sclerosis. Archives of Clinical Neuropsychology, 2021, 36, 711-722.	0.3	5
787	Identification of regulatory T cell molecules associated with severity of multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 1695-1705.	1.4	13
788	Clinical significance of a single cerebrospinal fluid immunoglobulin band: A retrospective study. Multiple Sclerosis Journal, 2020, 27, 135245852097822.	1.4	3
789	Assessing the effect of an evidence-based patient online educational tool for people with multiple sclerosis called UMIMSâ€”understanding magnetic resonance imaging in multiple sclerosis: study protocol for a double-blind, randomized controlled trial. Trials, 2020, 21, 1008.	0.7	2

#	Article	IF	Citations
790	Gray Matter Matters: A Longitudinal Magnetic Resonance Voxel-Based Morphometry Study of Primary Progressive Multiple Sclerosis. Frontiers in Neurology, 2020, 11, 581537.	1.1	9
791	The STING-IFN-Î²-Dependent Axis Is Markedly Low in Patients with Relapsing-Remitting Multiple Sclerosis. International Journal of Molecular Sciences, 2020, 21, 9249.	1.8	11
792	Altered PPARÎ³ Expression Promotes Myelin-Induced Foam Cell Formation in Macrophages in Multiple Sclerosis. International Journal of Molecular Sciences, 2020, 21, 9329.	1.8	16
793	Double Filtration Plasmapheresis Treatment of Refractory Multiple Sclerosis Relapsed on Fingolimod: A Case Report. Applied Sciences (Switzerland), 2020, 10, 7404.	1.3	3
794	Neurite Orientation Dispersion and Density Imaging for Assessing Acute Inflammation and Lesion Evolution in MS. American Journal of Neuroradiology, 2020, 41, 2219-2226.	1.2	14
795	Intrathecal Inflammation in Progressive Multiple Sclerosis. International Journal of Molecular Sciences, 2020, 21, 8217.	1.8	36
796	Real-world keystroke dynamics are a potentially valid biomarker for clinical disability in multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 1421-1431.	1.4	29
797	A Single Session of Anodal Cerebellar Transcranial Direct Current Stimulation Does Not Induce Facilitation of Locomotor Consolidation in Patients With Multiple Sclerosis. Frontiers in Human Neuroscience, 2020, 14, 588671.	1.0	10
798	Effects of Transcranial Direct Current Stimulation on Information Processing Speed, Working Memory, Attention, and Social Cognition in Multiple Sclerosis. Frontiers in Neurology, 2020, 11, 545377.	1.1	6
799	Blood neurofilament light: a critical review of its application to neurologic disease. Annals of Clinical and Translational Neurology, 2020, 7, 2508-2523.	1.7	132
800	Seasonal variation of onset in patients with anti-aquaporin-4 antibodies and anti-myelin oligodendrocyte glycoprotein antibody. Journal of Neuroimmunology, 2020, 349, 577431.	1.1	9
801	LHON-MS - The overlaps in clinical and molecular features of both LHON and MS. Multiple Sclerosis and Related Disorders, 2020, 45, 102322.	0.9	1
802	Clinical manifestations and imaging features of white matter demyelination in older patients. Journal of International Medical Research, 2020, 48, 030006052096680.	0.4	1
803	Treatment Patterns and Relapses Among Newly Treated Multiple Sclerosis Patients From a Retrospective Claims Analysis. Clinical Therapeutics, 2020, 42, 2136-2147.e3.	1.1	5
804	The Danger of Walking with Socks: Evidence from Kinematic Analysis in People with Progressive Multiple Sclerosis. Sensors, 2020, 20, 6160.	2.1	3
805	Associations Between Findings From Myelin Water Imaging and Cognitive Performance Among Individuals With Multiple Sclerosis. JAMA Network Open, 2020, 3, e2014220.	2.8	18
806	Caffeic Acid Phenethyl Ester Protects against Experimental Autoimmune Encephalomyelitis by Regulating T Cell Activities. Oxidative Medicine and Cellular Longevity, 2020, 2020, 1-13.	1.9	7
807	Multiple Sklerose: Neuroinflammation und -degeneration Hand in Hand. Karger Kompass Autoimmun, 2020, 2, 147-150.	0.0	0

#	Article	IF	Citations
808	Peak width of skeletonized mean diffusivity (PSMD) and cognitive functions in relapsing-remitting multiple sclerosis. Brain Imaging and Behavior, 2021, 15, 2228-2233.	1.1	6
809	Acute vestibular syndrome and hearing loss mimicking labyrinthitis as initial presentation of multiple sclerosis. International Journal of Pediatric Otorhinolaryngology, 2020, 134, 110048.	0.4	5
810	Clinical predictivity of thalamic sub-regional connectivity in clinically isolated syndrome: a 7-year study. Molecular Psychiatry, 2021, 26, 2163-2174.	4.1	11
811	Deep-Learning Generated Synthetic Double Inversion Recovery Images Improve Multiple Sclerosis Lesion Detection. Investigative Radiology, 2020, 55, 318-323.	3.5	38
812	RadioGraphics Update: White Matter Diseases with Radiologic-Pathologic Correlation. Radiographics, 2020, 40, E4-E7.	1.4	5
813	Risk of MS relapse after yellow fever vaccination. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, e726.	3.1	25
814	Rituximab, MS, and pregnancy. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	3.1	59
815	Sensitivity of the Inhomogeneous Magnetization Transfer Imaging Technique to Spinal Cord Damage in Multiple Sclerosis. American Journal of Neuroradiology, 2020, 41, 929-937.	1.2	16
816	Clinical Characteristics and Disability Progression of Early- and Late-Onset Multiple Sclerosis Compared to Adult-Onset Multiple Sclerosis. Journal of Clinical Medicine, 2020, 9, 1326.	1.0	55
817	Aggressive multiple sclerosis: a singleâ€centre, realâ€world treatment experience with autologous haematopoietic stem cell transplantation and alemtuzumab. European Journal of Neurology, 2020, 27, 2047-2055.	1.7	18
818	Association Between Tumor Necrosis Factor Inhibitor Exposure and Inflammatory Central Nervous System Events. JAMA Neurology, 2020, 77, 937.	4.5	78
819	Navigating the TOR of Multiple Sclerosis. Canadian Journal of Neurological Sciences, 2020, 47, 435-436.	0.3	0
820	Clinically reliable cognitive decline in relapsing remitting multiple sclerosis: Is it the tip of the iceberg?. Neurological Research, 2020, 42, 575-586.	0.6	7
821	Innate Immune System and Multiple Sclerosis. Granulocyte Numbers Are Reduced in Patients Affected by Relapsing-Remitting Multiple Sclerosis during the Remission Phase. Journal of Clinical Medicine, 2020, 9, 1468.	1.0	4
822	Dietary interventions for multiple sclerosis-related outcomes. The Cochrane Library, 2020, 2020, CD004192.	1.5	35
823	Longitudinal Development of Peripapillary Hyperâ€Reflective Ovoid Masslike Structures Suggests a Novel Pathological Pathway in <scp>Multiple Sclerosis</scp>. Annals of Neurology, 2020, 88, 309-319.	2.8	21
824	TAPAS: A Thresholding Approach for Probability Map Automatic Segmentation in Multiple Sclerosis. NeuroImage: Clinical, 2020, 27, 102256.	1.4	5
825	Comparison of brain atrophy in patients with multiple sclerosis treated with firstâ€versus secondâ€generation disease modifying therapy without clinical relapse. European Journal of Neurology, 2020, 27, 2056-2061.	1.7	4

#	Article	IF	Citations
826	The epidemiology of multiple sclerosis in the entre Douro e Vouga region of northern Portugal: a multisource population-based study. BMC Neurology, 2020, 20, 195.	0.8	10
827	Treatment Optimization in Multiple Sclerosis: Canadian MS Working Group Recommendations. Canadian Journal of Neurological Sciences, 2020, 47, 437-455.	0.3	63
828	FCRL3 promotes ILâ€10 expression in B cells through the SHPâ€1 and p38 MAPK signaling pathways. Cell Biology International, 2020, 44, 1811-1819.	1.4	6
829	Neuroprotective effects of exercise in people with progressive multiple sclerosis (Exercise PRO-MS): study protocol of a phase II trial. BMC Neurology, 2020, 20, 177.	0.8	10
830	Single-cell RNA-seq analysis of human CSF microglia and myeloid cells in neuroinflammation. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	3.1	65
831	High incidence and prevalence of MS in MÃ¸re and Romsdal County, Norway, 1950â€“2018. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	3.1	14
832	The contribution of enhancing lesions in monitoring multiple sclerosis treatment: is gadolinium always necessary?. Journal of Neurology, 2020, 267, 2642-2647.	1.8	5
833	Changes in oxygen saturation and the retinal nerve fibre layer in patients with optic neuritis associated with multiple sclerosis in a 6â€month followâ€up. Acta Ophthalmologica, 2020, 98, 841-847.	0.6	5
834	The 2013 clinical course descriptors for multiple sclerosis. Neurology, 2020, 94, 1088-1092.	1.5	73
835	Clinical implications of serum neurofilament in newly diagnosed MS patients: A longitudinal multicentre cohort study. EBioMedicine, 2020, 56, 102807.	2.7	67
836	Functional representation of the symbol digit modalities test in relapsing remitting multiple sclerosis. Multiple Sclerosis and Related Disorders, 2020, 43, 102159.	0.9	6
837	Validity of the McDonald criteria in predicting second events in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2020, 43, 102223.	0.9	3
838	Neurophysiological impairments in multiple sclerosisâ€"Central and peripheral motor pathways. Acta Neurologica Scandinavica, 2020, 142, 401-417.	1.0	25
839	Incidence, prevalence and characteristics of MS in SÃ£o Miguel, an island in the Atlantic. Multiple Sclerosis and Related Disorders, 2020, 44, 102254.	0.9	2
840	Analysis of soluble interleukin-2 receptor as CSF biomarker for neurosarcoidosis. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	3.1	19
841	Association of Individual-Level Factors With Visual Outcomes in Optic Neuritis. JAMA Network Open, 2020, 3, e204339.	2.8	10
842	From BalÃ³â€™s concentric sclerosis to multiple sclerosis: a series of 6 patients. Multiple Sclerosis and Related Disorders, 2020, 42, 102078.	0.9	5
843	Cognitive reserve is a determinant of social and occupational attainment in patients with pediatric and adult onset multiple sclerosis. Multiple Sclerosis and Related Disorders, 2020, 42, 102145.	0.9	6

#	Article	IF	Citations
844	Epidemiology of multiple sclerosis in Santiago de Compostela (Spain). Acta Neurologica Scandinavica, 2020, 142, 267-274.	1.0	7
845	A case of pure bilateral horizontal gaze palsy due to multiple sclerosis. Neurology and Clinical Neuroscience, 2020, 8, 215-217.	0.2	0
846	The relationship between ANT1 and NFL with autophagy and mitophagy markers in patients with multiple sclerosis. Journal of Clinical Neuroscience, 2020, 78, 307-312.	0.8	19
847	Teriflunomide vs injectable disease modifying therapies for relapsing forms of MS. Multiple Sclerosis and Related Disorders, 2020, 43, 102158.	0.9	8
848	An overview of lipidomic analysis in different human matrices of multiple sclerosis. Multiple Sclerosis and Related Disorders, 2020, 44, 102189.	0.9	22
849	Effect of hippotherapy on walking performance and gait parameters in people with multiple sclerosis. Multiple Sclerosis and Related Disorders, 2020, 43, 102203.	0.9	11
850	Inflammation-related plasma and CSF biomarkers for multiple sclerosis. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 12952-12960.	3.3	102
851	Pharmacological treatment for chronic central neuropathic pain in people with multiple sclerosis. The Cochrane Library, 2020, , .	1.5	1
852	Diagnosis and management of multiple sclerosis: MRI in clinical practice. Journal of Neurology, 2020, 267, 2917-2925.	1.8	19
853	Non-inflammatory causes of emergency consultation in patients with multiple sclerosis. NeurologÃa (English Edition), 2020, 36, 403-411.	0.2	2
854	Myelin oligodendrocyte glycoprotein-associated disorders are associated with HLA subtypes in a Chinese paediatric-onset cohort. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 733-739.	0.9	17
855	Plasma neurofilament light levels are associated with risk of disability in multiple sclerosis. Neurology, 2020, 94, e2457-e2467.	1.5	61
856	The IN-DEEP project â€œINtegrating and Deriving Evidence, Experiences, Preferencesâ€• a web information model on magnetic resonance imaging for people with multiple sclerosis. Journal of Neurology, 2020, 267, 2421-2431.	1.8	1
857	BOLD signal within and around white matter lesions distinguishes multiple sclerosis and non-specific white matter disease: a three-dimensional approach. Journal of Neurology, 2020, 267, 2888-2896.	1.8	8
858	Decreased second to fourth digit ratios in female multiple sclerosis patients. Early Human Development, 2020, 144, 105039.	0.8	3
859	Promises and Limitations of Neural Stem Cell Therapies for Progressive Multiple Sclerosis. Trends in Molecular Medicine, 2020, 26, 898-912.	3.5	42
860	Machine Learning and Multiparametric Brain MRI to Differentiate Hereditary Diffuse Leukodystrophy with Spheroids from Multiple Sclerosis. Journal of Neuroimaging, 2020, 30, 674-682.	1.0	12
861	Different Exosomal microRNA Profile in Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorders. Frontiers in Immunology, 2020, 11, 1064.	2.2	8

#	Article	IF	Citations
862	Spinal Cord Involvement in MS and Other Demyelinating Diseases. Biomedicines, 2020, 8, 130.	1.4	9
863	Plasma Exchange or Immunoadsorption in Demyelinating Diseases: A Meta-Analysis. Journal of Clinical Medicine, 2020, 9, 1597.	1.0	22
864	Changes in multiple sclerosis epidemiology in Finland over five decades. Acta Neurologica Scandinavica, 2020, 142, 200-209.	1.0	11
865	Diagnostic accuracy of intrathecal kappa free light chains compared with OCBs in MS. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, e775.	3.1	16
866	Siponimod for multiple sclerosis. The Cochrane Library, 2020, , .	1.5	4
867	Cerebrospinal fluid oligoclonal IgM test in routine practice: Comparison with quantitative assessment of intrathecal IgM synthesis. Clinica Chimica Acta, 2020, 508, 137-145.	0.5	7
868	Do you believe in Gad?. Multiple Sclerosis and Related Disorders, 2020, 44, 102299.	0.9	2
869	Molecular Biomarkers in the Cerebrospinal Fluid in Multiple Sclerosis. Neuroscience and Behavioral Physiology, 2020, 50, 527-533.	0.2	1
870	Unilateral Optic Neuritis in Children: Experience of a Tertiary Centre. European Neurology, 2020, 83, 251-258.	0.6	2
871	Free light chain kappa and the polyspecific immune response in MS and CIS â€“ Application of the hyperbolic reference range for most reliable data interpretation. Journal of Neuroimmunology, 2020, 346, 577287.	1.1	16
872	Multiple sclerosis lesions in motor tracts from brain to cervical cord: spatial distribution and correlation with disability. Brain, 2020, 143, 2089-2105.	3.7	34
873	Clinical Relevance of Multiparametric MRI Assessment of Cervical Cord Damage in Multiple Sclerosis. Radiology, 2020, 296, 605-615.	3.6	25
874	An investigation of knee position sense, balance, and dual task performance in different phases of menstrual cycle in females with multiple sclerosis: a pilot study. Multiple Sclerosis and Related Disorders, 2020, 44, 102235.	0.9	3
875	Optic neuropathy: A 15-year retrospective observational study. Multiple Sclerosis and Related Disorders, 2020, 44, 102337.	0.9	4
876	Epidemiology of pediatric multiple sclerosis: A systematic literature review and meta-analysis. Multiple Sclerosis and Related Disorders, 2020, 44, 102260.	0.9	35
877	Conversion of clinically isolated syndrome to multiple sclerosis: a prospective study. Multiple Sclerosis and Related Disorders, 2020, 44, 102262.	0.9	15
878	Clinical implication of serum biomarkers and patient age in inflammatory demyelinating diseases. Annals of Clinical and Translational Neurology, 2020, 7, 992-1001.	1.7	25
879	Analysis of MRI Data in Diagnostic Neuroradiology. Annual Review of Biomedical Data Science, 2020, 3, 365-390.	2.8	5

#	Article	IF	Citations
880	Multiple sclerosis 2017 McDonald criteria are also relevant for Tunisians. Multiple Sclerosis and Related Disorders, 2020, 43, 102161.	0.9	3
881	A Scope of the Social Brain in Multiple Sclerosis: Insights From Neuroimaging Studies. Cognitive and Behavioral Neurology, 2020, 33, 90-102.	0.5	8
882	Gadolinium should always be used to assess disease activity in MS â€“ Yes. Multiple Sclerosis Journal, 2020, 26, 765-766.	1.4	9
883	Stress cardiomyopathy associated with the first manifestation of multiple sclerosis: a case report. BMC Neurology, 2020, 20, 227.	0.8	6
884	Early diagnosis of secondary progressive multiple sclerosis: focus on fluid and neurophysiological biomarkers. Journal of Neurology, 2021, 268, 3626-3645.	1.8	16
885	Cognitive Fatigability is Independent of Subjective Cognitive Fatigue and Mood in Multiple Sclerosis. Cognitive and Behavioral Neurology, 2020, 33, 113-121.	0.5	7
886	Influence of physical activity on serum vitamin D levels in people with multiple sclerosis. PLoS ONE, 2020, 15, e0234333.	1.1	2
887	Visualizing the Central Nervous System: Imaging Tools for Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders. Frontiers in Neurology, 2020, 11, 450.	1.1	29
888	Potential COVID-19 infection in patients with severe multiple sclerosis treated with alemtuzumab. Multiple Sclerosis and Related Disorders, 2020, 44, 102297.	0.9	25
889	Real world application of ocrelizumab in multiple sclerosis: Single-center experience of 128 patients. Journal of the Neurological Sciences, 2020, 415, 116973.	0.3	17
890	Eligibility and implementation of disease-modifying therapy for primary progressive multiple sclerosis in a UK cohort. Multiple Sclerosis and Related Disorders, 2020, 42, 102056.	0.9	0
891	The CSF Levels of Neutrophilâ€Related Chemokines in Patients with Neuromyelitis Optica. Annals of Clinical and Translational Neurology, 2020, 7, 1245-1251.	1.7	11
892	CSF microRNAs discriminate MS activity and share similarity to other neuroinflammatory disorders. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	3.1	23
893	Erythrocyte microRNAs show biomarker potential and implicate multiple sclerosis susceptibility genes. Clinical and Translational Medicine, 2020, 10, 74-90.	1.7	7
894	An Overground Robotic Gait Training Program for People With Multiple Sclerosis: A Protocol for a Randomized Clinical Trial. Frontiers in Medicine, 2020, 7, 238.	1.2	4
895	Prognostic models for predicting clinical disease progression, worsening and activity in people with multiple sclerosis. The Cochrane Library, 0, , .	1.5	3
896	Texture analysis in susceptibility-weighted imaging may be useful to differentiate acute from chronic multiple sclerosis lesions. European Radiology, 2020, 30, 6348-6356.	2.3	16
897	Impaired cognition is related to microstructural integrity in relapsing remitting multiple sclerosis. Annals of Clinical and Translational Neurology, 2020, 7, 1193-1203.	1.7	8

#	Article	IF	Citations
898	First case of SARS-COV-2 sequencing in cerebrospinal fluid of a patient with suspected demyelinating disease. Journal of Neurology, 2020, 267, 3154-3156.	1.8	104
899	Acoustic Speech Analytics Are Predictive of Cerebellar Dysfunction in Multiple Sclerosis. Cerebellum, 2020, 19, 691-700.	1.4	22
900	Anxiety in Argentinian patients with multiple sclerosis: Prevalence and associated factors. Multiple Sclerosis and Related Disorders, 2020, 41, 102042.	0.9	7
901	Evaluating the feasibility and preliminary efficacy of a Cognitive Occupation-Based programme for people with Multiple Sclerosis (COB-MS): protocol for a feasibility cluster-randomised controlled trial. Trials, 2020, 21, 269.	0.7	10
902	The GPR17 Receptorâ€"A Promising Goal for Therapy and a Potential Marker of the Neurodegenerative Process in Multiple Sclerosis. International Journal of Molecular Sciences, 2020, 21, 1852.	1.8	16
903	Corticospinal inhibition and alexithymia in multiple sclerosis patientsâ€"An exploratory study. Multiple Sclerosis and Related Disorders, 2020, 41, 102039.	0.9	2
904	Detection of central vein should be part of MS diagnostic criteria â€" No. Multiple Sclerosis Journal, 2020, 26, 407-408.	1.4	1
905	Degree of microstructural changes within T1-SE versus T1-GE hypointense lesions in multiple sclerosis: relevance for the definition of â€œblack holesâ€. European Radiology, 2020, 30, 3843-3851.	2.3	4
906	Intrathecal IgM as a Prognostic Marker in Multiple Sclerosis. Molecular Diagnosis and Therapy, 2020, 24, 263-277.	1.6	11
907	What role should spinal cord MRI take in the future of multiple sclerosis surveillance?. Expert Review of Neurotherapeutics, 2020, 20, 783-797.	1.4	14
908	Detection of central vein should be part of MS diagnostic criteria â€" Commentary. Multiple Sclerosis Journal, 2020, 26, 409-410.	1.4	1
909	Primary progressive multiple sclerosis presenting under the age of 18 years: Fact or fiction?. Multiple Sclerosis Journal, 2021, 27, 309-314.	1.4	5
910	Central vein sign for multiple sclerosis: A systematic review and meta-analysis. Clinical Radiology, 2020, 75, 479.e9-479.e15.	0.5	11
911	Generation of a Model to Predict Differentiation and Migration of Lymphocyte Subsets under Homeostatic and CNS Autoinflammatory Conditions. International Journal of Molecular Sciences, 2020, 21, 2046.	1.8	5
912	Epidemiology of multiple sclerosis in Central Europe, update from Hungary. Brain and Behavior, 2020, 10, e01598.	1.0	13
913	Targeted resequencing reveals rare variants enrichment in multiple sclerosis susceptibility genes. Human Mutation, 2020, 41, 1308-1320.	1.1	1
914	Deciphering the neural underpinnings of alexithymia in multiple sclerosis. Neuroscience Letters, 2020, 725, 134894.	1.0	8
915	Wide Cytokine Analysis in Cerebrospinal Fluid at Diagnosis Identified CCL-3 as a Possible Prognostic Factor for Multiple Sclerosis. Frontiers in Immunology, 2020, 11, 174.	2.2	11

#	Article	IF	Citations
916	Brain magnetic resonance imaging features in multiple sclerosis and neuromyelitis optica spectrum disorders patients with or without aquaporin-4 antibody in a Latin American population. Multiple Sclerosis and Related Disorders, 2020, 42, 102049.	0.9	4
917	Effects of Transcranial Direct Current Stimulation on Hand Dexterity in Multiple Sclerosis: A Design for a Randomized Controlled Trial. Brain Sciences, 2020, 10, 185.	1.1	3
918	A validated UHPLC-MS method for tryptophan metabolites: Application in the diagnosis of multiple sclerosis. Journal of Pharmaceutical and Biomedical Analysis, 2020, 185, 113246.	1.4	32
919	First therapy choice in newly diagnosed Multiple Sclerosis patients: A multicenter Italian study. Multiple Sclerosis and Related Disorders, 2020, 42, 102059.	0.9	4
920	Multi-Platform Characterization of Cerebrospinal Fluid and Serum Metabolome of Patients Affected by Relapsingâ€“Remitting and Primary Progressive Multiple Sclerosis. Journal of Clinical Medicine, 2020, 9, 863.	1.0	22
921	Primary lateral sclerosis: diagnosis and management. Practical Neurology, 2020, 20, 262-269.	0.5	19
922	Serum levels of Homocysteine, Vitamin B12 and Folate in Patients with Multiple Sclerosis: an Updated Meta-Analysis. International Journal of Medical Sciences, 2020, 17, 751-761.	1.1	21
923	Race, ethnicity, and cognition in persons newly diagnosed with multiple sclerosis. Neurology, 2020, 94, e1548-e1556.	1.5	20
924	Recent Advances in Smart Biomaterials for the Detection and Treatment of Autoimmune Diseases. Advanced Functional Materials, 2020, 30, 1909556.	7.8	16
925	Bifrontal transcranial direct current stimulation modulates fatigue in multiple sclerosis: a randomized sham-controlled study. Journal of Neural Transmission, 2020, 127, 953-961.	1.4	23
926	Acute Disseminated Encephalomyelitis followed by Optic Neuritis: A Rare Syndrome of Uncertain Treatment and Prognosis. Neuropediatrics, 2020, 51, 286-291.	0.3	4
927	Challenges in multiple sclerosis diagnosis: Misunderstanding and misapplication of the McDonald criteria. Multiple Sclerosis Journal, 2021, 27, 250-258.	1.4	32
928	Refractory case of myelin oligodendrocyte glycoprotein antibodyâ€associated encephalomyelitis with lumbosacral radiculitis. Clinical and Experimental Neuroimmunology, 2020, 11, 126-130.	0.5	5
929	Resting-State Functional Correlates of Social Cognition in Multiple Sclerosis: An Explorative Study. Frontiers in Behavioral Neuroscience, 2020, 13, 276.	1.0	15
930	CVSnet: A machine learning approach for automated central vein sign assessment in multiple sclerosis. NMR in Biomedicine, 2020, 33, e4283.	1.6	31
931	Cost-Effectiveness Analysis of Cannabinoid Oromucosal Spray Use for the Management of Spasticity in Subjects with Multiple Sclerosis. Clinical Drug Investigation, 2020, 40, 319-326.	1.1	5
932	Risk HLA-DRB1 alleles differentially influence brain and lesion volumes in Japanese patients with multiple sclerosis. Journal of the Neurological Sciences, 2020, 413, 116768.	0.3	0
933	IL-6 in the Cerebrospinal Fluid Signals Disease Activity in Multiple Sclerosis. Frontiers in Cellular Neuroscience, 2020, 14, 120.	1.8	32

#	Article	IF	Citations
934	Effects of Teriflunomide on B Cell Subsets in MuSK-Induced Experimental Autoimmune Myasthenia Gravis and Multiple Sclerosis. Immunological Investigations, 2021, 50, 671-684.	1.0	11
935	Low Seroprevalence of Lyme Disease Among Multiple Sclerosis Patients in New Brunswick. Canadian Journal of Neurological Sciences, 2020, 47, 842-844.	0.3	1
936	Optical coherence tomography measures correlate with brain and spinal cord atrophy and multiple sclerosis diseaseâ€related disability. European Journal of Neurology, 2020, 27, 2225-2232.	1.7	20
937	Comparative Analysis of T-Cell Responses to Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein in Inflammatory Demyelinating Central Nervous System Diseases. Frontiers in Immunology, 2020, 11, 1188.	2.2	16
938	A Comprehensive Approach to Disentangle the Effect of Cerebellar Damage on Physical Disability in Multiple Sclerosis. Frontiers in Neurology, 2020, 11, 529.	1.1	11
939	Peripapillary Vessel Density as Early Biomarker in Multiple Sclerosis. Frontiers in Neurology, 2020, 11, 542.	1.1	35
940	Patients' perspective and usability of innovation technology in a new rehabilitation pathway: An exploratory study in patients with multiple sclerosis. Multiple Sclerosis and Related Disorders, 2020, 44, 102312.	0.9	33
941	Real-World Results of Ocrelizumab Treatment for Primary Progressive Multiple Sclerosis. Multiple Sclerosis International, 2020, 2020, 1-6.	0.4	10
942	Support vectors machine-based model for diagnosis of multiple sclerosis using the plasma levels of selenium, vitamin B12, and vitamin D3. Informatics in Medicine Unlocked, 2020, 20, 100382.	1.9	8
943	Highly sensitive quantification of optic neuritis intrathecal biomarker CXCL13. Multiple Sclerosis and Related Disorders, 2020, 44, 102281.	0.9	3
944	Relapsing Demyelinating Syndromes in Children: A Practical Review of Neuroradiological Mimics. Frontiers in Neurology, 2020, 11, 627.	1.1	9
945	Metabolic syndrome components and disease disability in egyptian multiple sclerosis patients. Multiple Sclerosis and Related Disorders, 2020, 44, 102336.	0.9	7
946	The retirement rate due to multiple sclerosis has decreased since 1995â€“ A retrospective study in a Finnish central hospital. Multiple Sclerosis and Related Disorders, 2020, 45, 102360.	0.9	8
948	Impact of multiple sclerosis risk loci in postinfectious neurological syndromes. Multiple Sclerosis and Related Disorders, 2020, 44, 102326.	0.9	2
949	Saliva immunoglobulin free light chain analysis for monitoring disease activity and response to treatment in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2020, 44, 102339.	0.9	8
950	Kappa Free Light Chains and IgG Combined in a Novel Algorithm for the Detection of Multiple Sclerosis. Brain Sciences, 2020, 10, 324.	1.1	18
951	The Impact of Reproductive Issues on Preferences of Women with Relapsing Multiple Sclerosis for Disease-Modifying Treatments. Patient, 2020, 13, 583-597.	1.1	5
952	Thalamic atrophy correlates with dysfunctional impulsivity in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2020, 44, 102374.	0.9	4

#	Article	IF	Citations
953	Cerebrospinal Fluid Testing for Multiple Sclerosis. Clinics in Laboratory Medicine, 2020, 40, 369-377.	0.7	5
954	Serum GFAP in multiple sclerosis: correlation with disease type and MRI markers of disease severity. Scientific Reports, 2020, 10, 10923.	1.6	66
955	A new paraplegin mutation in a patient with primary progressive multiple sclerosis. Multiple Sclerosis and Related Disorders, 2020, 44, 102302.	0.9	3
956	Image Domain Transfer by Deep Learning is Feasible in Multiple Sclerosis Clinical Practice. Investigative Radiology, 2020, 55, 324-325.	3.5	3
957	Cell-based assays for the detection of MOG antibodies: a comparative study. Journal of Neurology, 2020, 267, 3555-3564.	1.8	44
958	Multiple sclerosis with intractable vomiting and atypical area postrema lesion. Multiple Sclerosis and Related Disorders, 2020, 45, 102348.	0.9	6
959	Unsuspected Alzheimer disease in a patient with Multiple sclerosis and progressive aphasia. Multiple Sclerosis and Related Disorders, 2020, 45, 102349.	0.9	0
960	Immunoadsorption and Plasma Exchange in Seropositive and Seronegative Immune-Mediated Neuropathies. Journal of Clinical Medicine, 2020, 9, 2025.	1.0	22
961	Lymphocytic colitis in the setting of teriflunomide use for relapsing multiple sclerosis. Multiple Sclerosis Journal, 2020, 26, 1801-1803.	1.4	8
962	The diagnostic value of IgG index versus oligoclonal bands in cerebrospinal fluid of patients with multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2020, 6, 205521731990129.	0.5	18
963	Oligoclonal IgG antibodies in multiple sclerosis target patient-specific peptides. PLoS ONE, 2020, 15, e0228883.	1.1	33
964	Family planning is the second most relevant factor for treatment decisions after disease activity â€“ Yes. Multiple Sclerosis Journal, 2020, 26, 640-641.	1.4	2
965	Prognostic role of intrathecal IgM synthesis in multiple sclerosis: Results from a clinical series. Multiple Sclerosis Journal, 2021, 27, 198-207.	1.4	10
966	MAGNIMS consensus recommendations on the use of brain and spinal cord atrophy measures in clinical practice. Nature Reviews Neurology, 2020, 16, 171-182.	4.9	150
967	T Helper Cells: The Modulators of Inflammation in Multiple Sclerosis. Cells, 2020, 9, 482.	1.8	134
968	Cladribine for people with multiple sclerosis. The Cochrane Library, 2020, , .	1.5	0
969	Disrupted principal network organisation in multiple sclerosis relates to disability. Scientific Reports, 2020, 10, 3620.	1.6	2
970	MRI features associated with rapid disease activity in clinically isolated syndrome patients at high risk for multiple sclerosis. Multiple Sclerosis and Related Disorders, 2020, 41, 101985.	0.9	2

#	Article	IF	Citations
971	Position Sense Deficits at the Lower Limbs in Early Multiple Sclerosis: Clinical and Neural Correlates. Neurorehabilitation and Neural Repair, 2020, 34, 260-270.	1.4	9
972	Non-compliance with disease modifying therapies in patients with Multiple Sclerosis: A qualitative analysis. Multiple Sclerosis and Related Disorders, 2020, 41, 102016.	0.9	4
973	Multiple sclerosis prevalence in Santa Fe province, Argentina. Multiple Sclerosis and Related Disorders, 2020, 41, 102006.	0.9	3
974	Generalized chorea associated with subcortical leukoaraiosis of Binswanger type: aÂcase report. Neurodegenerative Disease Management, 2020, 10, 9-13.	1.2	0
975	Toward an automatic tool for oligoclonal band detection in cerebrospinal fluid and tears for multiple sclerosis diagnosis: lane segmentation based on a ribbon univariate open active contour. Medical and Biological Engineering and Computing, 2020, 58, 967-976.	1.6	1
976	Understanding the Radiologist's Role in Evaluating Multiple Sclerosis: A Review of the Tip of the Iceberg. Seminars in Ultrasound, CT and MRI, 2020, 41, 275-283.	0.7	0
977	Natural killer cells in multiple sclerosis: A review. Immunology Letters, 2020, 222, 1-11.	1.1	34
979	Associations of paediatric demyelinating and encephalitic syndromes with myelin oligodendrocyte glycoprotein antibodies: a multicentre observational study. Lancet Neurology, The, 2020, 19, 234-246.	4.9	207
980	Does the multiple sclerosis (MS) map need to change again? An update of MS prevalence in Mazandaran province of Iran in 2018. BMC Neurology, 2020, 20, 52.	0.8	7
981	SWAN-Venule: An Optimized MRI Technique to Detect the Central Vein Sign in MS Plaques. American Journal of Neuroradiology, 2020, 41, 456-460.	1.2	11
983	MOG encephalomyelitis: distinct clinical, MRI and CSF features in patients with longitudinal extensive transverse myelitis as first clinical presentation. Journal of Neurology, 2020, 267, 1632-1642.	1.8	24
984	Multiple Sclerosis Presenting as an Anterior Semicircular Canal Benign Paroxysmal Positional Vertigo: Case Report. Ear, Nose and Throat Journal, 2021, 100, 636S-640S.	0.4	3
985	Polypharmacy among patients with multiple sclerosis: a qualitative systematic review. Expert Opinion on Drug Safety, 2020, 19, 139-145.	1.0	32
986	Imaging Biomarkers of Alzheimer Disease in Multiple Sclerosis. Annals of Neurology, 2020, 87, 556-567.	2.8	17
987	Nanoimmunosensor based on atomic force spectroscopy to detect anti-myelin basic protein related to early-stage multiple sclerosis. Ultramicroscopy, 2020, 211, 112946.	0.8	3
988	Antibody signatures in patients with histopathologically defined multiple sclerosis patterns. Acta Neuropathologica, 2020, 139, 547-564.	3.9	11
989	Integrated single cell analysis of blood and cerebrospinal fluid leukocytes in multiple sclerosis. Nature Communications, 2020, 11, 247.	5.8	242
990	Clinical Use of Îº Free Light Chains Index as a Screening Test for Multiple Sclerosis. Laboratory Medicine, 2020, 51, 402-407.	0.8	19

#	Article	IF	Citations
991	New MRI lesions and topography at 6 months of treatment initiation and disease activity during follow up in relapsing remitting multiple sclerosis patients. Neurological Research, 2020, 42, 148-152.	0.6	5
992	Anti-CD20 Monoclonal Antibodies for Relapsing and Progressive Multiple Sclerosis. CNS Drugs, 2020, 34, 269-280.	2.7	49
993	Minimal evidence of disease activity (MEDA) in relapsing-remitting multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 271-277.	0.9	29
994	Relationship between sensory processing patterns, trait anxiety, and health-related quality of life in multiple sclerosis. Journal of Health Psychology, 2020, 26, 135910531990131.	1.3	6
995	Associations of serum 25(OH) vitamin D levels with clinical and radiological outcomes in multiple sclerosis, a systematic review and meta-analysis. Journal of the Neurological Sciences, 2020, 411, 116668.	0.3	26
996	Differential white and gray matter damage in highly active multiple sclerosis: A prospective cohort study. Journal of Clinical Neuroscience, 2020, 74, 65-68.	0.8	0
997	Multiple sclerosis and neuromyelitis optica spectrum disorders in Argentina: comparing baseline data from the Argentinean MS Registry (RelevarEM). Neurological Sciences, 2020, 41, 1513-1519.	0.9	16
998	Why do multiple sclerosis and migraine coexist?. Multiple Sclerosis and Related Disorders, 2020, 40, 101946.	0.9	5
999	Clinically isolated syndrome, oligoclonal bands and multiple sclerosis. Clinical and Experimental Neuroimmunology, 2020, 11, 33-39.	0.5	9
1000	New imaging approaches for precision diagnosis and disease staging of MS?. Multiple Sclerosis Journal, 2020, 26, 568-575.	1.4	9
1001	Metabolomics in multiple sclerosis disease course and progression. Multiple Sclerosis Journal, 2020, 26, 591-598.	1.4	36
1002	PPMS onset upon adalimumab treatment extends the spectrum of anti-TNF-Î± therapy-associated demyelinating disorders. Therapeutic Advances in Neurological Disorders, 2020, 13, 175628641989515.	1.5	12
1003	CHIT1 at Diagnosis Reflects Longâ€Term Multiple Sclerosis Disease Activity. Annals of Neurology, 2020, 87, 633-645.	2.8	22
1004	Multiple sclerosis as differential diagnosis of radionecrosis for post-irradiation brain lesions: A case report. Clinical and Translational Radiation Oncology, 2020, 21, 44-48.	0.9	2
1005	Application of the 2017 McDonald criteria in a Chinese population with clinically isolated syndrome. Therapeutic Advances in Neurological Disorders, 2020, 13, 175628641989808.	1.5	8
1006	Short segment myelitis as the initial and only manifestation of aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorders. Therapeutic Advances in Neurological Disorders, 2020, 13, 175628641989859.	1.5	8
1007	Autoantibody Diagnostics in Neuroimmunology: Experience From the 2018 Italian Neuroimmunology Association External Quality Assessment Program. Frontiers in Neurology, 2019, 10, 1385.	1.1	26
1008	Optimization of spectral domain optical coherence tomography and visual evoked potentials to identify unilateral optic neuritis. Multiple Sclerosis and Related Disorders, 2020, 41, 101988.	0.9	13

#	Article	IF	Citations
1009	New OFSEP recommendations for MRI assessment of multiple sclerosis patients: Special consideration for gadolinium deposition and frequent acquisitions. Journal of Neuroradiology, 2020, 47, 250-258.	0.6	46
1010	RIC3, the cholinergic anti-inflammatory pathway, and neuroinflammation. International Immunopharmacology, 2020, 83, 106381.	1.7	9
1011	Finding the right balance with participation in exercise and sport for individuals with multiple sclerosis: protocol for a pre and post intervention feasibility study. BMJ Open, 2020, 10, e035378.	0.8	3
1012	Expansion of Neutrophils and Classical and Nonclassical Monocytes as a Hallmark in Relapsing-Remitting Multiple Sclerosis. Frontiers in Immunology, 2020, 11, 594.	2.2	33
1013	Association Between Fatigue and Motor Exertion in Patients With Multiple Sclerosisâ€"a Prospective Study. Frontiers in Neurology, 2020, 11, 208.	1.1	18
1014	Diagnostic value of kappa free light chains in patients with one isolated band in isoelectric focusing. Clinica Chimica Acta, 2020, 507, 205-209.	0.5	11
1015	Evidence of retinal anterograde neurodegeneration in the very early stages of multiple sclerosis: a longitudinal OCT study. Neurological Sciences, 2020, 41, 3175-3183.	0.9	16
1016	A novel neurodegenerative spectrum disorder in patients with MLKL deficiency. Cell Death and Disease, 2020, 11, 303.	2.7	16
1017	Current Advances in Pediatric Onset Multiple Sclerosis. Biomedicines, 2020, 8, 71.	1.4	26
1018	Possible clinical role of MOG antibody testing in children presenting with acute neurological symptoms. Neurological Sciences, 2020, 41, 2553-2559.	0.9	2
1019	Dietary influence on central nervous system myelin production, injury, and regeneration. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2020, 1866, 165779.	1.8	13
1020	Should spinal cord MRI be systematically performed for diagnosis and follow-up of multiple sclerosis? No. Revue Neurologique, 2020, 176, 485-486.	0.6	0
1022	Effect of Eccentric Strength Training on Elbow Flexor Spasticity and Muscle Weakness in People With Multiple Sclerosis: Proof-of-Concept Single-System Case Series. Physical Therapy, 2020, 100, 1142-1152.	1.1	9
1023	Activated monocytes and markers of inflammation in newly diagnosed multiple sclerosis. Immunology and Cell Biology, 2020, 98, 549-562.	1.0	10
1024	Reduced Global Efficiency and Random Network Features in Patients with Relapsing-Remitting Multiple Sclerosis with Cognitive Impairment. American Journal of Neuroradiology, 2020, 41, 449-455.	1.2	14
1025	Alemtuzumab for relapsing multiple sclerosis in clinical practice: A four-year retrospective one-center study. International Journal of Risk and Safety in Medicine, 2020, 31, 259-265.	0.3	6
1026	Microbiome in Multiple Sclerosis: Where Are We, What We Know and Do Not Know. Brain Sciences, 2020, 10, 234.	1.1	59
1027	Cerebrospinal Fluid Neurofilament Light Chain Is Associated with Kynurenine Pathway Metabolite Changes in Multiple Sclerosis. International Journal of Molecular Sciences, 2020, 21, 2665.	1.8	24

#	Article	IF	Citations
1028	Is Initial Misdiagnosis Associated with Reaching Disability Milestones in Patients with Multiple Sclerosis?. Medicina (Lithuania), 2020, 56, 170.	0.8	3
1029	Diagnostic and therapeutic issues of inflammatory diseases of the elderly. Revue Neurologique, 2020, 176, 739-749.	0.6	3
1030	Light therapy for multiple sclerosis-associated fatigue: a randomized, controlled phase II trial. Journal of Neurology, 2020, 267, 2319-2327.	1.8	4
1031	Diagnostic revisions in multiple sclerosis. Clinical and Experimental Neuroimmunology, 2020, 11, 171-175.	0.5	1
1032	S1 guidelines â€œlumbar puncture and cerebrospinal fluid analysisâ€•(abridged and translated version). Neurological Research and Practice, 2020, 2, 8.	1.0	23
1033	A unique thymus-derived regulatory T cell subset associated with systemic lupus erythematosus. Arthritis Research and Therapy, 2020, 22, 88.	1.6	14
1034	Glucocorticoid receptor mutations and clinical sensitivity to glucocorticoid in Chinese multiple sclerosis patients. Neurological Sciences, 2020, 41, 2767-2771.	0.9	2
1035	Effectiveness of fingolimod in real-world relapsing-remitting multiple sclerosis Italian patients: the GENIUS study. Neurological Sciences, 2020, 41, 2843-2851.	0.9	7
1036	Determining the effectiveness of early intensive versus escalation approaches for the treatment of relapsing-remitting multiple sclerosis: The DELIVER-MS study protocol. Contemporary Clinical Trials, 2020, 95, 106009.	0.8	31
1037	Successful disease control with alemtuzumab in MOG-IgG-associated demyelinating disease with MS-phenotype. Multiple Sclerosis and Related Disorders, 2020, 42, 102108.	0.9	1
1038	Deep learning with diffusion basis spectrum imaging for classification of multiple sclerosis lesions. Annals of Clinical and Translational Neurology, 2020, 7, 695-706.	1.7	32
1039	Spectrum of anti-myelin oligodendrocyte glycoprotein antibody (MOG-Ab)-associated diseases: an Indian perspective. Acta Neurologica Belgica, 2021, 121, 927-931.	0.5	5
1040	Reliability of gait and dual-task measures in multiple sclerosis. Gait and Posture, 2020, 78, 19-25.	0.6	8
1041	Deep DNA metagenomic sequencing reveals oral microbiome divergence between monozygotic twins discordant for multiple sclerosis severity. Journal of Neuroimmunology, 2020, 343, 577237.	1.1	4
1042	Application of the 2017 McDonald criteria for the diagnosis of multiple sclerosis after a first demyelinating event in patients from Argentina. Multiple Sclerosis and Related Disorders, 2020, 41, 102043.	0.9	5
1043	Multiple Sclerosis in Children: Current and Emerging Concepts. Seminars in Neurology, 2020, 40, 192-200.	0.5	13
1044	MRI biomarkers of disease progression and conversion to secondary-progressive multiple sclerosis. Expert Review of Neurotherapeutics, 2020, 20, 821-834.	1.4	17
1045	Distribution of plaques in the cerebrum in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 901-902.	0.9	1

#	Article	IF	Citations
1046	Progress towards a diagnostic biomarker for MS: Central vein sign. Multiple Sclerosis Journal, 2020, 26, 394-396.	1.4	5
1047	Neurofilament levels are associated with bloodâ€“brain barrier integrity, lymphocyte extravasation, and risk factors following the first demyelinating event in multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 220-231.	1.4	55
1048	Association of intrathecal pleocytosis and IgG synthesis with axonal damage in early MS. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, e679.	3.1	19
1049	Monitoring of radiologic disease activity by serum neurofilaments in MS. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	3.1	24
1050	Number of MRI T1-hypointensity corrected by T2/FLAIR lesion volume indicates clinical severity in patients with multiple sclerosis. PLoS ONE, 2020, 15, e0231225.	1.1	5
1051	The Impact of Immunomodulatory Treatment on Kappa Free Light Chains as Biomarker in Neuroinflammation. Cells, 2020, 9, 842.	1.8	25
1052	Five- and seven-year prognostic value of new effectiveness measures (NEDA, MEDA and six-month) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 414, 116827.	0.3	9
1053	The proportion of myeloid-derived suppressor cells in the spleen is related to the severity of the clinical course and tissue damage extent in a murine model of multiple sclerosis. Neurobiology of Disease, 2020, 140, 104869.	2.1	30
1054	The nervous system in systemic lupus erythematosus. , 2021, , 469-478.		0
1055	Astrocyte metabolism in multiple sclerosis investigated by 1-C-11 acetate PET. Journal of Cerebral Blood Flow and Metabolism, 2021, 41, 369-379.	2.4	15
1056	Diagnostic value of bright spotty lesions on MRI after a first episode of acute myelopathy. Journal of Neuroradiology, 2021, 48, 28-36.	0.6	24
1057	Critical spinal cord lesions associate with secondary progressive motor impairment in long-standing MS: A population-based case-control study. Multiple Sclerosis Journal, 2021, 27, 667-673.	1.4	7
1058	Hippocampal volume is more related to patient-reported memory than objective memory performance in early multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 568-578.	1.4	6
1059	Diagnostic uncertainty during the transition to secondary progressive multiple sclerosis: Multicenter study in Argentina. Multiple Sclerosis Journal, 2021, 27, 579-584.	1.4	8
1060	Predictive value of optical coherence tomography, multifocal visual evoked potentials, and full-field visual evoked potentials of the fellow, non-symptomatic eye for subsequent multiple sclerosis development in patients with acute optic neuritis. Multiple Sclerosis Journal, 2021, 27, 391-400.	1.4	14
1061	Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 755-766.	1.4	11
1062	Ongoing microstructural changes in the cervical cord underpin disability progression in early primary progressive multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 28-38.	1.4	11
1063	Spinal cord and brain MRI should be routinely performed during follow-up in patients with NMOSD â€“ No. Multiple Sclerosis Journal, 2021, 27, 15-16.	1.4	5

#	Article	IF	Citations
1065	Limited Utility of Gadolinium Contrast Administration in Routine Multiple Sclerosis Surveillance. Journal of Neuroimaging, 2021, 31, 103-107.	1.0	4
1066	Classifying multiple sclerosis patients on the basis of SDMT performance using machine learning. Multiple Sclerosis Journal, 2021, 27, 107-116.	1.4	19
1067	Effects of Virtual Reality vs Conventional Balance Training on Balance and Falls in People With Multiple Sclerosis: A Randomized Controlled Trial. Archives of Physical Medicine and Rehabilitation, 2021, 102, 290-299.	0.5	40
1068	The role of pontine lesion location in differentiating multiple sclerosis from vascular risk factor-related small vessel disease. Multiple Sclerosis Journal, 2021, 27, 968-972.	1.4	3
1069	First-ever treatment in multiple sclerosis. Revue Neurologique, 2021, 177, 93-99.	0.6	0
1070	Frequency and characteristics of dysautonomic symptoms in multiple sclerosis: a cross-sectional double-center study with the validated Italian version of the Composite Autonomic Symptom Score-31. Neurological Sciences, 2021, 42, 1395-1403.	0.9	11
1071	Psychological consequences of COVID-19 pandemic in Italian MS patients: signs of resilience?. Journal of Neurology, 2021, 268, 743-750.	1.8	59
1072	Spatial navigation in early multiple sclerosis: a neglected cognitive marker of the disease?. Journal of Neurology, 2021, 268, 77-89.	1.8	5
1073	French validation of the Brief International Cognitive Assessment for Multiple Sclerosis. Revue Neurologique, 2021, 177, 73-79.	0.6	15
1074	Mapping white matter damage distribution in neuromyelitis optica spectrum disorders with a multimodal MRI approach. Multiple Sclerosis Journal, 2021, 27, 841-854.	1.4	20
1075	Onset of progressive motor impairment in patients with critical central nervous system demyelinating lesions. Multiple Sclerosis Journal, 2021, 27, 895-902.	1.4	4
1076	Revised McDonald Criteria, MAGNIMS Consensus and Other Relevant Guidelines for Diagnosis and Follow Up of MS: What Radiologists Need to Know?. Current Problems in Diagnostic Radiology, 2021, 50, 389-400.	0.6	3
1077	Imaging in Pediatric Multiple Sclerosis. Clinical Neuroradiology, 2021, 31, 61-71.	1.0	6
1078	Evaluation of brain and spinal cord lesion distribution criteria at disease onset in distinguishing NMOSD from MS and MOG antibody-associated disorder. Multiple Sclerosis Journal, 2021, 27, 871-882.	1.4	11
1079	Measurement of white matter fiber-bundle cross-section in multiple sclerosis using diffusion-weighted imaging. Multiple Sclerosis Journal, 2021, 27, 818-826.	1.4	14
1080	Imaging Butyrylcholinesterase in Multiple Sclerosis. Molecular Imaging and Biology, 2021, 23, 127-138.	1.3	8
1081	Estimation of Multiple Sclerosis lesion age on magnetic resonance imaging. NeuroImage, 2021, 225, 117451.	2.1	11
1082	Acute and subacute myelopathy. Revue Neurologique, 2021, 177, 557-566.	0.6	2

#	Article	IF	Citations
1083	Speech metrics, general disability, brain imaging and quality of life in multiple sclerosis. European Journal of Neurology, 2021, 28, 259-268.	1.7	19
1084	Elevated IL-38 Serum Levels in Newly Diagnosed Multiple Sclerosis and Systemic Sclerosis Patients. Medical Principles and Practice, 2021, 30, 146-153.	1.1	10
1085	The course of multiple sclerosis rewritten: a Norwegian population-based study on disease demographics and progression. Journal of Neurology, 2021, 268, 1330-1341.	1.8	17
1086	Developmental venous anomalies in patients with multiple sclerosis: is that a coincidence or an ancillary finding?. Neurological Sciences, 2021, 42, 2453-2460.	0.9	4
1087	Prognostic value of spinal cord MRI in multiple sclerosis patients. Revue Neurologique, 2021, 177, 571-581.	0.6	7
1088	Impaired consolidation of visuomotor adaptation in patients with multiple sclerosis. European Journal of Neurology, 2021, 28, 884-892.	1.7	5
1089	â€˜Posture secondâ€™ strategy predicts disability progression in multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 1140-1144.	1.4	0
1090	Productivity Loss and Associated Costs Among Employed Patients Receiving Disease-Modifying Treatment for Multiple Sclerosis. PharmacoEconomics - Open, 2021, 5, 23-34.	0.9	5
1091	Coping strategies used by patients with relapsing multiple sclerosis from Argentina: correlation with quality of life and clinical features. Neurological Research, 2021, 43, 126-132.	0.6	7
1092	Early red nucleus atrophy in relapseâ€onset multiple sclerosis. Human Brain Mapping, 2021, 42, 154-160.	1.9	3
1093	Serum phospholipidomics reveals altered lipid profile and promising biomarkers in multiple sclerosis. Archives of Biochemistry and Biophysics, 2021, 697, 108672.	1.4	31
1094	Exercise-induced changes in gait kinematics in multiple sclerosis with minimal neurological disability. Multiple Sclerosis and Related Disorders, 2021, 47, 102630.	0.9	3
1095	Polymorphisms in proinflammatory cytokines genes and susceptibility to Multiple Sclerosis. Multiple Sclerosis and Related Disorders, 2021, 47, 102654.	0.9	6
1096	Retinal asymmetry in multiple sclerosis. Brain, 2021, 144, 224-235.	3.7	20
1097	Cerebrospinal Fluid Features in Patients With Coronavirus Disease 2019 and Neurological Manifestations: Correlation with Brain Magnetic Resonance Imaging Findings in 58 Patients. Journal of Infectious Diseases, 2021, 223, 600-609.	1.9	47
1098	Current and emerging diseaseâ€modulatory therapies and treatment targets for multiple sclerosis. Journal of Internal Medicine, 2021, 289, 771-791.	2.7	45
1099	Integration of the Extreme Gradient Boosting model with electronic health records to enable the early diagnosis of multiple sclerosis. Multiple Sclerosis and Related Disorders, 2021, 47, 102632.	0.9	6
1100	MRI signs of CNS demyelinating diseases. Multiple Sclerosis and Related Disorders, 2021, 47, 102665.	0.9	13

#	Article	IF	Citations
1101	Quantifying cognition and fatigue to enhance the sensitivity of the EDSS during relapses. Multiple Sclerosis Journal, 2021, 27, 1077-1087.	1.4	18
1102	Overlapping central and peripheral nervous system syndromes in MOG antibodyâ€“associated disorders. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	3.1	58
1103	MR Diffusion Properties of Cervical Spinal Cord as a Predictor of Progression to Multiple Sclerosis in Patients with Clinically Isolated Syndrome. Journal of Neuroimaging, 2021, 31, 108-114.	1.0	2
1104	In Vivo Proton Exchange Rate (k ex) MRI for the Characterization of Multiple Sclerosis Lesions in Patients. Journal of Magnetic Resonance Imaging, 2021, 53, 408-415.	1.9	4
1105	A literature review of biosensors for multiple sclerosis: Towards personalized medicine and point-of-care testing. Multiple Sclerosis and Related Disorders, 2021, 48, 102675.	0.9	6
1106	CD8 + T cell subpopulations and proâ€inflammatory cytokines in neuromyelitis optica spectrum disorder. Annals of Clinical and Translational Neurology, 2021, 8, 43-53.	1.7	15
1107	High birth weight and risk of multiple sclerosis: A multicentre study in Argentina. Multiple Sclerosis and Related Disorders, 2021, 47, 102628.	0.9	6
1108	Cerebrospinal fluid lactate level in aquaporin-4 antibody positive neuromyelitis optica spectrum disorders: a hint on differential diagnosis and possible immunopathogenesis. Multiple Sclerosis and Related Disorders, 2021, 47, 102629.	0.9	0
1109	Living with secondary progressive multiple sclerosis in Europe: perspectives of multiple stakeholders. Neurodegenerative Disease Management, 2021, 11, 9-19.	1.2	3
1110	Is MS affecting the CNS only?. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, e914.	3.1	19
1111	Clinical and transcriptional recovery profiles in pediatric and adult multiple sclerosis patients. Annals of Clinical and Translational Neurology, 2021, 8, 81-94.	1.7	8
1112	Silent New Brain MRI Lesions in Children with MOGâ€Antibody Associated Disease. Annals of Neurology, 2021, 89, 408-413.	2.8	33
1113	Advances in the Treatment of Multiple Sclerosis. Neurologic Clinics, 2021, 39, 21-33.	0.8	33
1114	Sensory and pain modulation profiles of ongoing central neuropathic extremity pain in multiple sclerosis. European Journal of Pain, 2021, 25, 573-594.	1.4	7
1115	Multicentric clinical and epidemiological comparison of neuromyelitis optica spectrum disorder with multiple sclerosis from India. Multiple Sclerosis and Related Disorders, 2021, 47, 102616.	0.9	4
1116	The impact of SARS-CoV2 on the anxiety levels of subjects and on the anxiety and depression levels of their parents. Multiple Sclerosis and Related Disorders, 2021, 47, 102595.	0.9	9
1117	Overground Robotic Program Preserves Gait in Individuals With Multiple Sclerosis and Moderate to Severe Impairments: A Randomized Controlled Trial. Archives of Physical Medicine and Rehabilitation, 2021, 102, 932-939.	0.5	10
1118	A first presentation of multiple sclerosis with concurrent COVID-19 infection. ENeurologicalSci, 2021, 22, 100299.	0.5	38

#	Article	IF	Citations
1119	Does gait bout definition influence the ability to discriminate gait quality between people with and without multiple sclerosis during daily life?. Gait and Posture, 2021, 84, 108-113.	0.6	7
1120	Etiological spectrum, clinico-radiological profile and treatment outcomes of longitudinally extensive transverse myelitis â€“ A prospective study from Northwest India. Journal of Neuroimmunology, 2021, 351, 577456.	1.1	2
1121	High serum neurofilament levels among Chinese patients with aquaporin-4-IgG-seropositive neuromyelitis optica spectrum disorders. Journal of Clinical Neuroscience, 2021, 83, 108-111.	0.8	7
1122	Time interval between disease onset and MS diagnosis during the last decades in Latin America. Multiple Sclerosis and Related Disorders, 2021, 48, 102672.	0.9	2
1123	Defining the course of tumefactive multiple sclerosis: A large retrospective multicentre study. European Journal of Neurology, 2021, 28, 1299-1307.	1.7	12
1124	Structural constraints of functional connectivity drive cognitive impairment in the early stages of multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 559-567.	1.4	20
1125	Alemtuzumab mediates the CD39⁺ Tâ€regulatory cell response via CD23⁺ macrophages. Immunology and Cell Biology, 2021, 99, 521-531.	1.0	3
1126	Fast automatic segmentation of thalamic nuclei from MP2RAGE acquisition at 7 Tesla. Magnetic Resonance in Medicine, 2021, 85, 2781-2790.	1.9	11
1127	Interpretation of Brain Volume Increase in Multiple Sclerosis. Journal of Neuroimaging, 2021, 31, 401-407.	1.0	6
1128	Biomarkers of treatment response in patients with progressive multiple sclerosis treated with highâ€dose pharmaceuticalâ€grade biotin (MD1003). Brain and Behavior, 2021, 11, e01998.	1.0	3
1129	The epidemiology of multiple sclerosis in the Scottish Highlands: Prevalence, incidence and time to confirmed diagnosis and treatment initiation. Multiple Sclerosis and Related Disorders, 2021, 47, 102657.	0.9	1
1130	Teleconsultation will replace most face-to-face interactions in the multiple sclerosis clinic â€“ No. Multiple Sclerosis Journal, 2021, 27, 176-177.	1.4	5
1131	Measuring attack on self: The need for fieldâ€friendly methods development and research on autoimmunity in human biology. American Journal of Human Biology, 2021, 33, .	0.8	6
1132	Interleukin-15 enhances proinflammatory T-cell responses in patients with MS and EAE. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	3.1	13
1133	Preventing multiple sclerosis misdiagnosis using the â€œcentral vein signâ€: A real-world study. Multiple Sclerosis and Related Disorders, 2021, 48, 102671.	0.9	6
1134	Neurological Manifestations of COVID-19 Feature T Cell Exhaustion and Dedifferentiated Monocytes in Cerebrospinal Fluid. Immunity, 2021, 54, 164-175.e6.	6.6	119
1135	Anti-CD20 therapies and pregnancy in neuroimmunologic disorders. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	3.1	43
1136	The sequence of structural, functional and cognitive changes in multiple sclerosis. NeuroImage: Clinical, 2021, 29, 102550.	1.4	21

#	Article	IF	Citations
1137	Epileptic seizures in multiple sclerosis: prevalence, competing causes and diagnostic accuracy. Journal of Neurology, 2021, 268, 1721-1727.	1.8	19
1138	CSF levels of HoxB3 and YKL-40 may predict conversion from clinically isolated syndrome to relapsing remitting multiple sclerosis. Multiple Sclerosis and Related Disorders, 2021, 48, 102697.	0.9	7
1139	Multiple sclerosis identification in brain<scp>MRI</scp>images using wavelet convolutional neural networks. International Journal of Imaging Systems and Technology, 2021, 31, 778-785.	2.7	16
1140	Neuromuscular and Mobility Responses to a Vibration Session in Hypoxia in Multiple Sclerosis. International Journal of Sports Medicine, 2021, 42, 307-313.	0.8	2
1142	Magnetic resonance imaging of BalÃ³â€™s concentric sclerosis: Literature review and presentation of two focused cases. Clinical and Experimental Neuroimmunology, 2021, 12, 54-62.	0.5	0
1144	Regulation of neuroinflammation by B cells and plasma cells. Immunological Reviews, 2021, 299, 45-60.	2.8	19
1145	Testing social cognition in multiple sclerosis: Difference between emotion recognition and theory of mind and its influence on quality of life. Brain and Behavior, 2021, 11, e01925.	1.0	7
1146	A contrast-adaptive method for simultaneous whole-brain and lesion segmentation in multiple sclerosis. NeuroImage, 2021, 225, 117471.	2.1	54
1147	Circulating endothelial progenitor cells during pregnancy in multiple sclerosis. Neurological Sciences, 2021, 42, 1443-1451.	0.9	0
1148	Common genetic variants in PRRC2A are associated with both neuromyelitis optica spectrum disorder and multiple sclerosis in Han Chinese population. Journal of Neurology, 2021, 268, 506-515.	1.8	7
1149	Dimethyl fumarateâ€induced lymphocyte count drop is related to clinical effectiveness in relapsingâ€“remitting multiple sclerosis. European Journal of Neurology, 2021, 28, 269-277.	1.7	1
1150	Should I stop or should I go on? Disease modifying therapy after the first clinical episode of multiple sclerosis. Journal of Neurology, 2021, 268, 1247-1253.	1.8	12
1151	The role of sensory processing difficulties, cognitive impairment, and disease severity in predicting functional behavior among patients with multiple sclerosis. Disability and Rehabilitation, 2021, 43, 1129-1136.	0.9	9
1152	Cytokineâ€“chemokine and cognitive profile of multiple sclerosis patients with predominant optic nerve and spinal cord involvement. Journal of Spinal Cord Medicine, 2021, 44, 411-417.	0.7	5
1153	A focus on secondary progressive multiple sclerosis (SPMS): challenges in diagnosis and definition. Journal of Neurology, 2021, 268, 1210-1221.	1.8	87
1154	The prevalence of epileptic seizures in multiple sclerosis in a large tertiary hospital in Australia. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2021, 7, 205521732198976.	0.5	3
1155	Implications of extreme serum neurofilament light chain levels for the management of patients with relapsing multiple sclerosis. Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642110019.	1.5	2
1156	Multiple Sclerosis and Health-related Quality of Life. , 2021, , 1-2.		0

#	Article	IF	Citations
1157	ZNS-Erkrankungen beim Erwachsenen. , 2021, , 117-128.		0
1158	Standardizing T1-w/T2-w ratio images in trigeminal neuralgia to estimate the degree of demyelination in vivo. NeuroImage: Clinical, 2021, 32, 102798.	1.4	5
1159	Mutual relationship between upper extremity function and core muscle endurance in patients with multiple sclerosis. Clinical and Experimental Health Sciences, 0, , .	0.1	0
1161	Stepwise target controllability identifies dysregulations of macrophage networks in multiple sclerosis. Network Neuroscience, 2021, 5, 337-357.	1.4	1
1162	White Matter Pathology. Neuromethods, 2021, , 29-46.	0.2	1
1163	Imaging in Neuro-Ophthalmology. , 2021, , 1-29.		0
1164	Oligoclonal IgM bands in the cerebrospinal fluid of patients with relapsing MS to inform long-term MS disability. Multiple Sclerosis Journal, 2021, 27, 1706-1716.	1.4	8
1165	Comparison of multi echo T2 relaxation and steady state approaches for myelin imaging in the central nervous system. Scientific Reports, 2021, 11, 1369.	1.6	8
1166	Brenda Banwell. , 2021, , 609-611.		0
1167	Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper). Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642110396.	1.5	86
1168	IL27 T4730C Polymorphism and Serology in Multiple Sclerosis: A Pilot Study. In Vivo, 2021, 35, 2845-2853.	0.6	3
1169	Cognitive impairment in multiple sclerosis: lessons from cerebrospinal fluid biomarkers. Neural Regeneration Research, 2021, 16, 36.	1.6	23
1170	Deep Attention and Graphical Neural Network for Multiple Sclerosis Lesion Segmentation From MR Imaging Sequences. IEEE Journal of Biomedical and Health Informatics, 2022, 26, 1196-1207.	3.9	4
1171	Quantifying the risk of disease reactivation after interferon and glatiramer acetate discontinuation in multiple sclerosis: The VIAADISC score. European Journal of Neurology, 2021, 28, 1609-1616.	1.7	18
1172	Evolution of the Diagnostic Criteria in Multiple Sclerosis. , 2021, , 75-87.		0
1173	Coexistence of autoantibodies and other autoimmune diseases with multiple sclerosis and related disorders â€“ Experience from the Mangalore Demyelinating Disease Registry (MANDDIR). Annals of Indian Academy of Neurology, 2021, 24, 740.	0.2	7
1174	Can white matter lesion burden predict involvement of normal appearing thalami in multiple sclerosis? Study using 3D FLAIR and DTI. Egyptian Journal of Radiology and Nuclear Medicine, 2021, 52, .	0.3	0
1175	A Case of Atypical Multiple Sclerosis Mimicking Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy Syndrome. Cureus, 2021, 13, e12508.	0.2	3

#	Article	IF	Citations
1176	Natural History of Multiple Sclerosis. , 2021, , 89-104.		0
1177	The impact of physical functions on depressive symptoms in people with multiple sclerosis. Arquivos De Neuro-Psiquiatria, 2021, 79, 44-50.	0.3	2
1178	The ILâ€27/ILâ€27R axis is altered in CD4⁺ and CD8⁺ T lymphocytes from multiple sclerosis patients. Clinical and Translational Immunology, 2021, 10, e1262.	1.7	6
1179	Quantitative susceptibility-weighted imaging in predicting disease activity in multiple sclerosis. Neuroradiology, 2021, 63, 1061-1069.	1.1	5
1180	Systemic Sclerosis Revealed by a Primary Progressive Multiple Sclerosis-like Condition: A Case Report. Touch Reviews in Neurology, 2021, 17, 56.	0.1	0
1181	Beyond Lesion-Load: Tractometry-Based Metrics for Characterizing White Matter Lesions within Fibre Pathways. Mathematics and Visualization, 2021, , 227-237.	0.4	4
1183	Evaluating Treatment Patterns, Relapses, Healthcare Resource Utilization, and Costs Associated with Disease-Modifying Treatments for Multiple Sclerosis in DMT-NaÃ¯ve Patients. ClinicoEconomics and Outcomes Research, 2021, Volume 13, 65-75.	0.7	10
1184	Antibiotic Use and Risk of Multiple Sclerosis: A Nested Case-Control Study in Emilia-Romagna Region, Italy. Neuroepidemiology, 2021, 55, 224-231.	1.1	4
1185	Association between cervical disc disease and lesions of multiple sclerosis. Neuroradiology Journal, 2021, 34, 200-204.	0.6	1
1186	Nasolacrimal transition time in patients with multiple sclerosis. European Archives of Oto-Rhino-Laryngology, 2021, 278, 3357-3362.	0.8	0
1187	Rituximab versus mitoxantrone: comparing effectiveness and safety in advanced relapsing multiple sclerosis. Therapeutic Advances in Chronic Disease, 2021, 12, 204062232110243.	1.1	1
1188	Adiponectin in Cerebrospinal Fluid from Patients Affected by Multiple Sclerosis Is Correlated with the Progression and Severity of Disease. Molecular Neurobiology, 2021, 58, 2663-2670.	1.9	7
1189	Systematic Review of Studies on Telomere Length in Patients with Multiple Sclerosis. , 2021, 12, 1272.		18
1190	Should We Use Clinical Tools to Identify Disease Progression?. Frontiers in Neurology, 2020, 11, 628542.	1.1	17
1191	Disruption of brainstem monoaminergic fibre tracts in multiple sclerosis as a putative mechanism for cognitive fatigue: a fixel-based analysis. NeuroImage: Clinical, 2021, 30, 102587.	1.4	26
1192	Multiple sclerosis and subclinical neuropathology in healthy individuals with familial risk: A scoping review of MRI studies. NeuroImage: Clinical, 2021, 31, 102734.	1.4	3
1193	Neuroimaging Modalities in Neuroimmunology. , 2021, , 29-42.		0
1194	Oligoclonal Bands: Isoelectric Focusing and Immunoblotting, and Determination of Îº Free Light Chains in the Cerebrospinal Fluid. Neuromethods, 2021, , 29-54.	0.2	0

#	Article	IF	Citations
1195	¹¹C-PK11195 plasma metabolization has the same rate in multiple sclerosis patients and healthy controls: a cross-sectional study. Neural Regeneration Research, 2021, 16, 2494.	1.6	3
1196	Can powered exoskeletons improve gait and balance in multiple sclerosis? A retrospective study. International Journal of Rehabilitation Research, 2021, 44, 126-130.	0.7	5
1198	FLAIR-only joint volumetric analysis of brain lesions and atrophy in clinically isolated syndrome (CIS) suggestive of multiple sclerosis. NeuroImage: Clinical, 2021, 29, 102542.	1.4	6
1199	Recent advances and future directions on the use of optical coherence tomography in neuro-ophthalmology. Taiwan Journal of Ophthalmology, 2021, 11, 3.	0.3	14
1200	Case Report: Efficacy of Rituximab in a Patient With Familial Mediterranean Fever and Multiple Sclerosis. Frontiers in Neurology, 2020, 11, 591395.	1.1	4
1202	Demyelinating Diseases. , 2021, , 313-351.		1
1203	KIF5A and the contribution of susceptibility genotypes as a predictive biomarker for multiple sclerosis. Journal of Neurology, 2021, 268, 2175-2184.	1.8	5
1204	Neurological disorders of COVID-19 can be explained in terms of both â€œloss and gain of functionâ€• states of a solution for the nervous system. Brain Circulation, 2021, 7, 217.	0.7	2
1205	Comparison of Therapies in MS Patients After the First Demyelinating Event in Real Clinical Practice in the Czech Republic: Data From the National Registry ReMuS. Frontiers in Neurology, 2020, 11, 593527.	1.1	4
1206	Serum neurofilament levels reflect outer retinal layer changes in multiple sclerosis. Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642110034.	1.5	5
1207	The Expanded Disability Status Scale Score and Demographic Indexes Are Correlated with the Severity		

#	Article	IF	Citations
1215	Machine learning-based differentiation between multiple sclerosis and glioma WHO IIÂ°-IVÂ° using O-(2-[18F] fluoroethyl)-L-tyrosine positron emission tomography. Journal of Neuro-Oncology, 2021, 152, 325-332.	1.4	11
1216	A R-Script for Generating Multiple Sclerosis Lesion Pattern Discrimination Plots. Brain Sciences, 2021, 11, 90.	1.1	0
1217	High prevalence of fatigue in contemporary patients with multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2021, 7, 205521732199982.	0.5	18
1218	Ocrelizumab in Multiple Sclerosis: A Real-World Study From Spain. Frontiers in Neurology, 2020, 11, 592304.	1.1	12
1220	Twin studies on the epigenetics of selected neurological disorders and carotid artery disease. , 2021, , 193-211.		0
1221	Identification of hsa-miR-106a-5p as an impact agent on promotion of multiple sclerosis using multi-step data analysis. Neurological Sciences, 2021, 42, 3791-3799.	0.9	9
1222	Clinical Approach to Pediatric Demyelinating Disease. , 2021, , 469-482.		0
1223	Pathogenesis of autoimmune demyelination: from multiple sclerosis to neuromyelitis optica spectrum disorders and myelin oligodendrocyte glycoprotein antibodyâ€associated disease. Clinical and Translational Immunology, 2021, 10, e1316.	1.7	31
1224	Amyotrophic lateral sclerosis patients show increased peripheral and intrathecal T-cell activation. Brain Communications, 2021, 3, fcab157.	1.5	25
1225	The changing landscape of optic neuritis: a narrative review. Journal of Neurology, 2022, 269, 111-124.	1.8	28
1228	Diagnosis of multiple sclerosis in times of MOG and AQP4 autoantibody testing â€“ A monocentric study. Journal of the Neurological Sciences, 2021, 421, 117289.	0.3	0
1229	Deep Learning Corpus Callosum Segmentation as a Neurodegenerative Marker in Multiple Sclerosis. Journal of Neuroimaging, 2021, 31, 493-500.	1.0	13
1230	Immune phenotyping study revealing caveats regarding a switch from fingolimod to cladribine. Multiple Sclerosis and Related Disorders, 2021, 48, 102727.	0.9	5
1231	Defining Benign/Burnt-Out MS and Discontinuing Disease-Modifying Therapies. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	3.1	7
1232	The audiovestibular manifestations as early symptoms of multiple sclerosis: a scoping review of the literature. Irish Journal of Medical Science, 2021, , 1.	0.8	4
1233	A Bio-Psycho-Social Co-created Intervention for Young Adults With Multiple Sclerosis (ESPRIMO): Rationale and Study Protocol for a Feasibility Study. Frontiers in Psychology, 2021, 12, 598726.	1.1	6
1234	Operationalization of a frailty index in patients with multiple sclerosis: A cross-sectional investigation. Multiple Sclerosis Journal, 2021, 27, 1939-1947.	1.4	13
1235	Neuronal and glial CSF biomarkers in multiple sclerosis: a systematic review and meta-analysis. Reviews in the Neurosciences, 2021, 32, 573-595.	1.4	38

#	Article	IF	Citations
1236	Paediatric multiple sclerosis and antibody-associated demyelination: clinical, imaging, and biological considerations for diagnosis and care. Lancet Neurology, The, 2021, 20, 136-149.	4.9	60
1238	Epidemiology and clinical features of demyelinating disorders in India. Neurology and Clinical Neuroscience, 2021, 9, 266-273.	0.2	2
1239	Prevalence and Risk Factors of Dysphagia in Patients with Multiple Sclerosis. Dysphagia, 2022, 37, 21-27.	1.0	7
1240	Amyloidoma mimicking multiple sclerosis. Practical Neurology, 2021, 21, 344-345.	0.5	1
1241	Serum vitamin d inversely correlates with depression scores in people with multiple sclerosis. Multiple Sclerosis and Related Disorders, 2021, 48, 102732.	0.9	10
1242	Ozanimod for relapsing-remitting multiple sclerosis. The Cochrane Library, 0, , .	1.5	0
1244	Classification of multiple sclerosis based on patterns of <scp>CNS</scp> regional atrophy covariance. Human Brain Mapping, 2021, 42, 2399-2415.	1.9	10
1245	An Interview-Based Assessment of the Experience of Cognitive Impairment in Multiple Sclerosis: The Cognitive Assessment Interview (CAI). Frontiers in Neurology, 2021, 12, 637895.	1.1	2
1246	Functional neurological disorder and multiple sclerosis: a systematic review of misdiagnosis and clinical overlap. Journal of Neurology, 2022, 269, 654-663.	1.8	22
1247	Phelan McDermid Syndrome: Multiple Sclerosis as a Rare but Treatable Cause for Regressionâ€"A Case Report. International Journal of Molecular Sciences, 2021, 22, 2311.	1.8	4
1248	Correlation of cortical lesions of multiple sclerosis at double inversion recovery with cognition screening scores. Egyptian Journal of Neurology, Psychiatry and Neurosurgery, 2021, 57, .	0.4	2
1249	Optical Coherence Tomography Angiography of Peripapillary Vessel Density in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder: A Comparative Study. Journal of Clinical Medicine, 2021, 10, 609.	1.0	17
1250	Smartphone-based symbol-digit modalities test reliably captures brain damage in multiple sclerosis. Npj Digital Medicine, 2021, 4, 36.	5.7	28
1251	Neurofibromatosis Type 1 with Highly Active Relapsing-Remitting Multiple Sclerosis (RRMS). European Journal of Case Reports in Internal Medicine, 2019, 8, 002190.	0.2	1
1252	Association of serum levels and receptor genes BsmI, TaqI and FokI polymorphisms of vitamin D with the severity of multiple sclerosis. Journal of Clinical Neuroscience, 2021, 84, 75-81.	0.8	7
1254	Clinical Features of Multiple Sclerosis. , 2021, , 21-36.		0
1255	Interferon beta 1a (RebifÂ®) in relapsing remitting multiple sclerosis. Drug Development Research, 2021, 82, 707-715.	1.4	1
1256	Recent advances in development of nanomedicines for multiple sclerosis diagnosis. Biomedical Materials (Bristol), 2021, 16, 024101.	1.7	6

#	Article	IF	Citations
1257	Patient Satisfaction With the Quality of Counseling Provided by Advanced Practice Nurses Specialized in Multiple Sclerosis: A Quantitative Analysis. Journal of Neuroscience Nursing, 2021, 53, 99-103.	0.7	6
1258	Transient monocular visual impairment as an initial symptom of COVID-19 infection in an individual with multiple sclerosis receiving teriflunomide. Neurological Sciences, 2021, 42, 1661-1664.	0.9	2
1259	Investigating efficient CNN architecture for multiple sclerosis lesion segmentation. Journal of Medical Imaging, 2021, 8, 014504.	0.8	8
1260	Clinical course of central nervous system demyelinating neurological adverse events associated with anti-TNF therapy. Journal of Neurology, 2021, 268, 2895-2899.	1.8	13
1261	In vitro Models of the Bloodâ€“Brain Barrier: Tools in Translational Medicine. Frontiers in Medical Technology, 2020, 2, 623950.	1.3	43
1262	The frequency and characteristics of MS misdiagnosis in patients referred to the multiple sclerosis centre of Catalonia. Multiple Sclerosis Journal, 2021, 27, 913-921.	1.4	20
1263	Memantine for Multiple Sclerosis: A Systematic Review and Meta-Analysis of Randomized Trials. Frontiers in Neurology, 2020, 11, 574748.	1.1	9
1264	Study protocol for a randomised controlled trial of a web-based behavioural lifestyle programme for emPOWERment in early Multiple Sclerosis (POWER@MS1). BMJ Open, 2021, 11, e041720.	0.8	5
1265	Bruchâ€™s membrane opening-minimum rim width: An alternative OCT biomarker study for multiple sclerosis. European Journal of Ophthalmology, 2021, 31, 2141-2149.	0.7	3
1266	A Prospective, Observational, Cohort Study to Assess the Efficacy and Safety of Prolonged-Release Fampridine in Cognition, Fatigue, Depression, and Quality of Life in Multiple Sclerosis Patients: The FAMILY Study. Advances in Therapy, 2021, 38, 1536-1551.	1.3	7
1267	Identifying Early Neuropsychological Indicators of Cognitive Involvement in Multiple Sclerosis. Neuropsychiatric Disease and Treatment, 2021, Volume 17, 323-337.	1.0	7
1268	Development and evaluation of an interactive web-based decision-making programme on relapse management for people with multiple sclerosis (POWER@MS2)â€”study protocol for a randomised controlled trial. Trials, 2021, 22, 139.	0.7	8
1269	High-intensity interval training and energy management education, compared with moderate continuous training and progressive muscle relaxation, for improving health-related quality of life in persons with multiple sclerosis: study protocol of a randomized controlled superiority trial with six monthsâ€™ follow-up. BMC Neurology, 2021, 21, 65.	0.8	12
1270	Risk of Psychiatric Disorders in Multiple Sclerosis: A Nationwide Cohort Study in an Asian Population. Neuropsychiatric Disease and Treatment, 2021, Volume 17, 587-604.	1.0	6
1271	The TGF-Î² superfamily cytokine Activin-A is induced during autoimmune neuroinflammation and drives pathogenic Th17 cell differentiation. Immunity, 2021, 54, 308-323.e6.	6.6	46
1272	Pro-inflammatory adiponectin in pediatric-onset multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 1948-1959.	1.4	9
1273	Rituximab for people with multiple sclerosis. The Cochrane Library, 0, , .	1.5	0
1274	Cerebrospinal fluid proteome shows disrupted neuronal development in multiple sclerosis. Scientific Reports, 2021, 11, 4087.	1.6	10

#	Article	IF	Citations
1275	Real world experience with teriflunomide in multiple sclerosis: the TER-Italy study. Journal of Neurology, 2021, 268, 2922-2932.	1.8	18
1276	Diagnosis and Treatment of Multiple Sclerosis. JAMA - Journal of the American Medical Association, 2021, 325, 765.	3.8	462
1277	Predisposing Factors for Sexual Dysfunction in Multiple Sclerosis. Frontiers in Neurology, 2021, 12, 618370.	1.1	15
1278	Compressive Cervical Myelopathy in Patients With Demyelinating Disease of the Central Nervous System: Improvement After Surgery Despite a Late Diagnosis. Cureus, 2021, 13, e13161.	0.2	3
1279	Early Predictors of 9â€¥ear Disability in Pediatric Multiple Sclerosis. Annals of Neurology, 2021, 89, 1011-1022.	2.8	13
1280	Clinical and radiological features of MS, NMOSD, and MOGAD, and evolution of the diagnostic processes in Thailand. Neurology and Clinical Neuroscience, 2021, 9, 282-291.	0.2	2
1281	Differences in physical, mental, and social functions between males and females in multiple sclerosis: A multicenter cross-sectional study in China. Multiple Sclerosis and Related Disorders, 2021, 48, 102693.	0.9	8
1282	Neuroimaging of Spinal Cord and Cauda Equina Disorders. CONTINUUM Lifelong Learning in Neurology, 2021, 27, 225-263.	0.4	5
1283	COVID-19 in teriflunomide-treated patients with multiple sclerosis: A case report and literature review. Multiple Sclerosis and Related Disorders, 2021, 48, 102734.	0.9	16
1284	Incidence and clinical outcome of Coronavirus disease 2019 in a cohort of 11,560 Brazilian patients with multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 1615-1619.	1.4	16
1285	Clinical and Prognostic Analysis of Autoantibody-Associated CNS Demyelinating Disorders in Children in Southwest China. Frontiers in Neurology, 2021, 12, 642664.	1.1	6
1286	Machine Learning Driven Profiling of Cerebrospinal Fluid Core Biomarkers in Alzheimerâ€™s Disease and Other Neurological Disorders. Frontiers in Neuroscience, 2021, 15, 647783.	1.4	17
1288	Effector T Helper Cells Are Selectively Controlled During Pregnancy and Related to a Postpartum Relapse in Multiple Sclerosis. Frontiers in Immunology, 2021, 12, 642038.	2.2	10
1290	Linear brain atrophy measures in multiple sclerosis and clinically isolated syndromes: a 30-year follow-up. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 839-846.	0.9	9
1291	A pilot study of the impact of an exercise intervention on brain structure, cognition, and psychosocial symptoms in individuals with relapsing-remitting multiple sclerosis. Pilot and Feasibility Studies, 2021, 7, 65.	0.5	5
1292	Pathology-supported genetic testing as a method for disability prevention in multiple sclerosis (MS). Part II. Insights from two MS cases. Metabolic Brain Disease, 2021, 36, 1169-1181.	1.4	4
1293	Clinical predictors to cognitive impairment in multiple sclerosis patients. Egyptian Journal of Neurology, Psychiatry and Neurosurgery, 2021, 57, .	0.4	15
1294	Neurologic Features Associated With SARS-CoV-2 Infection in Children: A Case Series Report. Journal of Child Neurology, 2021, 36, 853-866.	0.7	40

#	Article	IF	Citations
1295	Multiple sclerosis limited to spinal cord lesions. Clinical and Experimental Neuroimmunology, 2021, 12, 111-115.	0.5	1
1296	Treatment of Women with Multiple Sclerosis Planning Pregnancy. Current Treatment Options in Neurology, 2021, 23, 11.	0.7	43
1297	Cerebrospinal Fluid Biomarkers of Myeloid and Glial Cell Activation Are Correlated With Multiple Sclerosis Lesional Inflammatory Activity. Frontiers in Neuroscience, 2021, 15, 649876.	1.4	11
1298	Shear wave elastography evaluation of brachial plexus in multiple sclerosis. Acta Radiologica, 2022, 63, 520-526.	0.5	4
1299	Multiparametric Quantitative MRI in Neurological Diseases. Frontiers in Neurology, 2021, 12, 640239.	1.1	25
1301	Compensatory image of the stability of people with multiple sclerosis and atrial vertigo based on posturography examination. Scientific Reports, 2021, 11, 7027.	1.6	6
1302	Serum level of brain-derived neurotrophic factor in patients with relapsingâ€“remitting multiple sclerosis: a potential biomarker for disease activity. Egyptian Journal of Neurology, Psychiatry and Neurosurgery, 2021, 57, .	0.4	8
1303	Optical coherence tomography angiography helps distinguish multiple sclerosis from AQP4â€IgGâ€seropositive neuromyelitis optica spectrum disorder. Brain and Behavior, 2021, 11, e02125.	1.0	13
1304	Subclinical anterior optic pathway involvement in early multiple sclerosis and clinically isolated syndromes. Brain, 2021, 144, 848-862.	3.7	17
1305	Untreated patients with multiple sclerosis: A study of French expert centers. European Journal of Neurology, 2021, 28, 2026-2036.	1.7	8
1306	Cervical cord myelin abnormality is associated with clinical disability in multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 2191-2198.	1.4	4
1308	Interaction between Neurons and the Oligodendroglial Lineage in Multiple Sclerosis and Its Preclinical Models. Life, 2021, 11, 231.	1.1	0
1309	SÃndrome clÃnico aislado: diagnÃ³stico y riesgo de desarrollar esclerosis mÃºltiple clÃnicamente definida. NeurologÃa, 2021, , .	0.3	1
1310	Validity of the Italian multiple sclerosis neuropsychological screening questionnaire. Neurological Sciences, 2021, 42, 4583-4589.	0.9	2
1311	Magnetic resonance imaging in the diagnosis of non-tumorous multifocal brain lesions mimicking multiple sclerosis. AlÊ¹manah KliniÄeskoj Mediciny, 2021, 49, 89-97.	0.2	0
1312	Isolated Cognitive Decline in Neurologically Stable Patients with Multiple Sclerosis. Diagnostics, 2021, 11, 464.	1.3	9
1313	Genetic Variation in <scp>WNT9B</scp> Increases Relapse Hazard in Multiple Sclerosis. Annals of Neurology, 2021, 89, 884-894.	2.8	12
1314	Cannabidiol and Other Cannabinoids in Demyelinating Diseases. International Journal of Molecular Sciences, 2021, 22, 2992.	1.8	11

#	Article	IF	Citations
1315	Early factors associated with later conversion to multiple sclerosis in patients presenting with isolated myelitis. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 831-838.	0.9	4
1316	Illuminating the in vitro effects of Epstein-Barr virus and vitamin D on immune response in multiple sclerosis patients. Journal of NeuroVirology, 2021, 27, 260-271.	1.0	7
1317	Involvement of cytotoxic Eomes-expressing CD4 ⁺ T cells in secondary progressive multiple sclerosis. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	47
1318	Detection of Optic Neuritis on Routine Brain MRI without and with the Assistance of an Image Postprocessing Algorithm. American Journal of Neuroradiology, 2021, 42, 1130-1135.	1.2	3
1319	Early multiple sclerosis: diagnostic challenges in clinically and radiologically isolated syndrome patients. Current Opinion in Neurology, 2021, 34, 277-285.	1.8	6
1320	Probing the Brainâ€“Body Connection Using Transcranial Magnetic Stimulation (TMS): Validating a Promising Tool to Provide Biomarkers of Neuroplasticity and Central Nervous System Function. Brain Sciences, 2021, 11, 384.	1.1	16
1321	Recomendaciones para la coordinaciÃ³n de los servicios de NeurologÃa y NeurorradiologÃa en la atenciÃ³n a pacientes con esclerosis mÃºltiple. NeurologÃa, 2023, 38, 453-462.	0.3	0
1323	Cerebrospinal fluid findings in patients with psychotic symptomsâ€”a retrospective analysis. Scientific Reports, 2021, 11, 7169.	1.6	13
1324	Diagnosis of Progressive Multiple Sclerosis From the Imaging Perspective. JAMA Neurology, 2021, 78, 351.	4.5	30
1325	Multiple Sclerosis Relapse Presenting as Sensorineural Hearing Loss. Neurology, 2021, 96, 767-768.	1.5	1
1326	Perceived Fatigue Impact and Cognitive Variability in Multiple Sclerosis. Journal of the International Neuropsychological Society, 2021, , 1-11.	1.2	9
1327	Effectiveness of Brainstem Auditory Evoked Potentials Scoring in Evaluating Brainstem Dysfunction and Disability Among Individuals With Multiple Sclerosis. American Journal of Audiology, 2021, 30, 255-265.	0.5	5
1329	Axonal loss in major sensorimotor tracts is associated with impaired motor performance in minimally disabled multiple sclerosis patients. Brain Communications, 2021, 3, fcab032.	1.5	11
1330	Evaluation of Retinal Layer Thickness Parameters as Biomarkers in a Real-World Multiple Sclerosis Cohort. Eye and Brain, 2021, Volume 13, 59-69.	3.8	16
1332	Dedicated 3D-T2-STIR-ZOOMit Imaging Improves Demyelinating Lesion Detection in the Anterior Visual Pathways of Patients with Multiple Sclerosis. American Journal of Neuroradiology, 2021, 42, 1061-1068.	1.2	2
1333	Myelin and axon pathology in multiple sclerosis assessed by myelin water and multi-shell diffusion imaging. Brain, 2021, 144, 1684-1696.	3.7	61
1334	Multiple sclerosis, rituximab, and COVIDâ€19. Annals of Clinical and Translational Neurology, 2021, 8, 938-943.	1.7	29
1335	IgGs-Abzymes from the Sera of Patients with Multiple Sclerosis Recognize and Hydrolyze miRNAs. International Journal of Molecular Sciences, 2021, 22, 2812.	1.8	7

#	Article	IF	Citations
1336	Disease Progression and Obstetric Outcomes of Women with Multiple Sclerosis at a Reference Center in Northeastern Brazil. Revista Brasileira De Ginecologia E Obstetricia, 2021, 43, 165-171.	0.3	0
1337	Latent representation learning in biology and translational medicine. Patterns, 2021, 2, 100198.	3.1	17
1338	Longitudinally Extensive Transverse Myelitis: A Retrospective Study Differentiating Neuromyelitis Optica Spectrum Disorder From Other Etiologies. Cureus, 2021, 13, e13968.	0.2	0
1339	Analysis of Associations of Genetic Predisposition Markers Identified in Genome-Wide Studies with Multiple Sclerosis. Neuroscience and Behavioral Physiology, 2021, 51, 316-321.	0.2	0
1340	Does Extended Interval Dosing Natalizumab Preserve Effectiveness in Multiple Sclerosis? A 7 Year-Retrospective Observational Study. Frontiers in Immunology, 2021, 12, 614715.	2.2	19
1341	Gluten intolerance antibodies in multiple sclerosis and clinically isolated syndrome : Coexistent or coincidental?. Clinical and Experimental Neuroimmunology, 2021, 12, 116-121.	0.5	1
1342	Potential Role of CHI3L1+ Astrocytes in Progression in MS. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	3.1	20
1343	Secondary progressive sclerosis in Russia, medical and social characteristics of patients and urgent tasks of therapy. Medical Alphabet, 2021, , 7-13.	0.0	1
1344	Kinesiophobia in Stroke Patients, Multiple Sclerosis and Parkinsonâ€™s Disesase. Diagnostics, 2021, 11, 796.	1.3	8
1345	3D-Fast Gray Matter Acquisition with Phase Sensitive Inversion Recovery Magnetic Resonance Imaging at 3 Tesla: Application for detection of spinal cord lesions in patients with multiple sclerosis. PLoS ONE, 2021, 16, e0247813.	1.1	3
1346	Demographic features, behavioral measures, and clinical factors as predictors of cognitive function in patients with multiple sclerosis. Multiple Sclerosis and Related Disorders, 2021, 49, 102758.	0.9	3
1347	Maternal multiple sclerosis is not a risk factor for neurodevelopmental disorders in offspring. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2021, 7, 205521732110173.	0.5	2
1348	Lower lymphocyte counts and older age are associated with reduced multiple sclerosis disease activity during dimethyl fumarate treatment. Multiple Sclerosis and Related Disorders, 2021, 49, 102781.	0.9	8
1349	Serum inflammatory markers in patients with multiple sclerosis and their association with clinical manifestations and MRI findings. Acta Neurologica Belgica, 2022, 122, 1187-1193.	0.5	6
1350	Brain microstructural and metabolic alterations detected in vivo at onset of the first demyelinating event. Brain, 2021, 144, 1409-1421.	3.7	24
1351	Differential patterns of parafoveal and peripapillary vessel density in multiple sclerosis and neuromyelitis optica spectrum disorder. Multiple Sclerosis and Related Disorders, 2021, 49, 102780.	0.9	18
1352	Subgroup analysis of clinical and MRI outcomes in participants with a first clinical demyelinating event at risk of multiple sclerosis in the ORACLE-MS study. Multiple Sclerosis and Related Disorders, 2021, 49, 102695.	0.9	5
1353	The effects of supervised versus home Pilates-based core stability training on lower extremity muscle strength and postural sway in people with multiple sclerosis. Multiple Sclerosis Journal, 2022, 28, 269-279.	1.4	11

#	Article	IF	Citations
1354	Early neuropsychological markers of cognitive involvement in multiple sclerosis. Journal of the Neurological Sciences, 2021, 423, 117349.	0.3	3
1355	Pathology-supported genetic testing as a method for disability prevention in multiple sclerosis (MS). Part I. Targeting a metabolic model rather than autoimmunity. Metabolic Brain Disease, 2021, 36, 1151-1167.	1.4	7
1356	Real-world experience of ocrelizumab in multiple sclerosis patients in Latin America. Arquivos De Neuro-Psiquiatria, 2021, 79, 305-309.	0.3	5
1357	Status of Immunotherapy Acceptance in Chinese Patients With Multiple Sclerosis: Analysis of Multiple Sclerosis Patient Survival Report 2018. Frontiers in Neurology, 2021, 12, 651511.	1.1	9
1358	Corneal Subbasal Nerve Plexus Evaluation by in Vivo Confocal Microscopy in Multiple Sclerosis: A Potential New Biomarker. Current Eye Research, 2021, 46, 1452-1459.	0.7	10
1359	Seasonal patterns of relapse and disability in Danish MS patients: A population-based cohort study. Multiple Sclerosis and Related Disorders, 2021, 49, 102739.	0.9	4
1360	Altered distributions in circulating follicular helper and follicular regulatory T cells accountable for imbalanced cytokine production in multiple sclerosis. Clinical and Experimental Immunology, 2021, 205, 75-88.	1.1	8
1361	Longitudinal Imaging of T Cells and Inflammatory Demyelination in a Preclinical Model of Multiple Sclerosis Using ¹⁸F-FAraG PET and MRI. Journal of Nuclear Medicine, 2022, 63, 140-146.	2.8	14
1362	Case Report: Antibodies to the N-Methyl-D-Aspartate Receptor in a Patient With Multiple Sclerosis. Frontiers in Immunology, 2021, 12, 664364.	2.2	4
1363	Thermal Liquid Biopsy (TLB) of Blood Plasma as a Potential Tool to Help in the Early Diagnosis of Multiple Sclerosis. Journal of Personalized Medicine, 2021, 11, 295.	1.1	6
1364	Longitudinal analysis of T1w/T2w ratio in patients with multiple sclerosis from first clinical presentation. Multiple Sclerosis Journal, 2021, 27, 2180-2190.	1.4	12
1365	Dual-Task Cost and Related Clinical Features in Patients With Multiple Sclerosis. Motor Control, 2021, 25, 211-233.	0.3	6
1366	Natalizumab, Fingolimod, and Dimethyl Fumarate Use and Pregnancy-Related Relapse and Disability in Women With Multiple Sclerosis. Neurology, 2021, 96, .	1.5	41
1367	Susceptibility-weighted Imaging: Technical Essentials and Clinical Neurologic Applications. Radiology, 2021, 299, 3-26.	3.6	92
1368	The Evolution of Neurofilament Light Chain in Multiple Sclerosis. Frontiers in Neuroscience, 2021, 15, 642384.	1.4	62
1369	Co-existence of multiple sclerosis and germinoma in an adult male: Case report. , 2021, 12, 177.		0
1370	Magnetoencephalography and High-Density Electroencephalography Study of Acoustic Event Related Potentials in Early Stage of Multiple Sclerosis: A Pilot Study on Cognitive Impairment and Fatigue. Brain Sciences, 2021, 11, 481.	1.1	10
1371	MRI characteristics of Japanese macaque encephalomyelitis: Comparison to human diseases. Journal of Neuroimaging, 2021, 31, 480-492.	1.0	1

#	Article	IF	Citations
1372	A Retrospective Exploratory Analysis on Cardiovascular Risk and Cognitive Dysfunction in Multiple Sclerosis. Brain Sciences, 2021, 11, 502.	1.1	9
1373	Perinatal Depression and Anxiety in Women With Multiple Sclerosis. Neurology, 2021, 96, e2789-e2800.	1.5	14
1374	miR-155 as an Important Regulator of Multiple Sclerosis Pathogenesis. A Review. International Journal of Molecular Sciences, 2021, 22, 4332.	1.8	33
1375	Systematic Assessment of Medical Diagnoses Preceding the First Diagnosis of Multiple Sclerosis. Neurology, 2021, 96, .	1.5	20
1376	A Novel Method to Measure Venular Perivascular Spaces in Patients with MS on 7T MRI. American Journal of Neuroradiology, 2021, 42, 1069-1072.	1.2	9
1377	Exit Strategies in Natalizumab-Treated RRMS at High Risk of Progressive Multifocal Leukoencephalopathy: a Multicentre Comparison Study. Neurotherapeutics, 2021, 18, 1166-1174.	2.1	24
1378	Evaluation of Prolonged Walking in Persons with Multiple Sclerosis: Reliability of the Spatio-Temporal Walking Variables during the 6-Minute Walk Test. Sensors, 2021, 21, 3075.	2.1	7
1379	Assessment of cognitive functions in patients with multiple sclerosis applying the normative values of the Raoâ€™s brief repeatable battery in the Portuguese population. BMC Neurology, 2021, 21, 170.	0.8	4
1380	Disability progression in multiple sclerosis is associated with plasma neuroactive steroid profile. Neurological Sciences, 2021, 42, 5241-5247.	0.9	3
1381	Improving MS patientsâ€™ understanding of treatment risks and benefits in clinical consultations: A randomised crossover trial. Multiple Sclerosis and Related Disorders, 2021, 49, 102737.	0.9	1
1382	Speech Pathology-Specific Questionnaire for Persons with Multiple Sclerosis (SMS): adaptation, validation and preliminary assessment of the diagnostic potential.. Multiple Sclerosis and Related Disorders, 2021, 49, 102796.	0.9	3
1383	Can pulse steroid therapy increase the risk of infection by COVID-19 in patients with multiple sclerosis?. Clinical Neurology and Neurosurgery, 2021, 203, 106563.	0.6	8
1385	A Milestone in Multiple Sclerosis Therapy: Monoclonal Antibodies Against CD20â€”Yet Progress Continues. Neurotherapeutics, 2021, 18, 1602-1622.	2.1	12
1386	Defining the disease course of TNFÎ± blockers-associated Multiple Sclerosis. Journal of Neuroimmunology, 2021, 353, 577525.	1.1	4
1387	Scoring the 10â€year risk of ambulatory disability in multiple sclerosis: the RoAD score. European Journal of Neurology, 2021, 28, 2533-2542.	1.7	16
1388	Subclinical atherosclerosis in patients with relapsing-remitting multiple sclerosis. Wiener Klinische Wochenschrift, 2021, , 1.	1.0	4
1389	Multiple sclerosis: prevalence of the â€˜central veinâ€™ sign in white matter lesions on gadolinium-enhanced susceptibility-weighted images. Neuroradiology Journal, 2021, 34, 1971400921100087.	0.6	4
1390	Current role of evoked potentials in multiple sclerosis diagnostics and monitoring. Neurologie Pro Praxi, 2021, 22, 132-138.	0.0	0

#	Article	IF	Citations
1391	Male fertility in relapsing-remitting multiple sclerosis patients treated with natalizumab and ocrelizumab: A prospective case-control study. Multiple Sclerosis Journal, 2021, 27, 2284-2287.	1.4	8
1392	Switch from sequestering to anti-CD20 depleting treatment: disease activity outcomes during wash-out and in the first 6 months of ocrelizumab therapy. Multiple Sclerosis Journal, 2022, 28, 93-101.	1.4	13
1393	Relapse recovery in multiple sclerosis: Effect of treatment and contribution to long-term disability. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2021, 7, 205521732110155.	0.5	7
1394	Serum ADMA levels were positively correlated with EDSS scores in patients with multiple sclerosis. Journal of Neuroimmunology, 2021, 353, 577497.	1.1	0
1395	Apport du dosage des chaÃ®nes lÃ©gÃ¨res libres kappa et lambda dans le diagnostic de la sclÃ©rose en plaques. Revue Francophone Des Laboratoires, 2021, 2021, 58-64.	0.0	0
1396	Central vein sign and iron rim in multiple sclerosis: ready for clinical use?. Current Opinion in Neurology, 2021, 34, 505-513.	1.8	12
1397	Demyelinating Events Following Initiation of Anti-TNFÎ± Therapy in the British Society for Rheumatology Biologics Registry in Rheumatoid Arthritis. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	3.1	16
1398	Biomarkers in neurological disorders: a fast-growing market. Brain Communications, 2021, 3, fcab086.	1.5	7
1399	Multiple sclerosis: Is there a risk of worsening after yellow fever vaccination?. Multiple Sclerosis Journal, 2021, 27, 2280-2283.	1.4	9
1400	Re-examining the effects of high-dose intravenous methylprednisolone for secondary progressive multiple sclerosis. Neurodegenerative Disease Management, 2021, 11, 177-185.	1.2	0
1401	Effect of nabiximols on Goal Attainment Scale scores in patients with treatment-resistant multiple sclerosis spasticity. Neurodegenerative Disease Management, 2021, 11, 143-153.	1.2	3
1402	Corneal Immune Cells Are Increased in Patients With Multiple Sclerosis. Translational Vision Science and Technology, 2021, 10, 19.	1.1	17
1403	Deciphering Multiple Sclerosis Progression. Frontiers in Neurology, 2021, 12, 608491.	1.1	16
1404	Classification Criteria For Pars Planitis. American Journal of Ophthalmology, 2021, 228, 268-274.	1.7	22
1405	The Prognostic Value of White-Matter Selective Double Inversion Recovery MRI Sequence in Multiple Sclerosis: An Exploratory Study. Diagnostics, 2021, 11, 686.	1.3	1
1406	CSF chitinase 3-like 1 is associated with iron rims in patients with a first demyelinating event. Multiple Sclerosis Journal, 2022, 28, 71-81.	1.4	10
1407	Expression Levels of B Cell Receptor (BCR) Signaling Pathway Factors are Associated with Conversion from Clinically Isolated Syndrome to Multiple Sclerosis. Experimed, 0, , 33-37.	0.0	0
1408	Sexuality and Multiple Sclerosis: Patient and Doctor Perspectives. Journal of Sexual Medicine, 2021, 18, 743-749.	0.3	6

#	Article	IF	Citations
1409	Early diagnosis and treatment of multiple sclerosis. Neurologie Pro Praxi, 2021, 22, 128-131.	0.0	0
1410	Editorial: Challenges in the diagnosis and treatment of multiple sclerosis. Current Opinion in Neurology, 2021, 34, 275-276.	1.8	0
1411	Prevalence and determinants of falls in persons with multiple sclerosis without a clinical disability. Multiple Sclerosis and Related Disorders, 2021, 49, 102771.	0.9	8
1412	Disruption of the Atrophy-based Functional Network in Multiple Sclerosis Is Associated with Clinical Disability: Validation of a Meta-Analytic Model in Resting-State Functional MRI. Radiology, 2021, 299, 159-166.	3.6	5
1413	Reduction in circulating vitamin D binding protein in patients with multiple sclerosis. BMC Neurology, 2021, 21, 168.	0.8	9
1414	Multiple sclerosis in Kenya: Demographic and clinical characteristics of a registry cohort. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2021, 7, 205521732110227.	0.5	3
1415	Gene expression profiles of YAP1, TAZ, CRB3, and VDR in familial and sporadic multiple sclerosis among an Iranian population. Scientific Reports, 2021, 11, 7713.	1.6	5
1416	Classification of neurological diseases using multi-dimensional CSF analysis. Brain, 2021, 144, 2625-2634.	3.7	22
1417	Multiple sclerosis lesion segmentation from brain MRI using U-Net based on wavelet pooling. International Journal of Computer Assisted Radiology and Surgery, 2021, 16, 1459-1467.	1.7	11
1418	Machine learning classifier to identify clinical and radiological features relevant to disability progression in multiple sclerosis. Journal of Neurology, 2021, 268, 4834-4845.	1.8	16
1419	ACR Appropriateness CriteriaÂ® Myelopathy: 2021 Update. Journal of the American College of Radiology, 2021, 18, S73-S82.	0.9	3
1420	Digital Twins for Multiple Sclerosis. Frontiers in Immunology, 2021, 12, 669811.	2.2	108
1421	Multimodal peripheral fluid biomarker analysis in clinically isolated syndrome and early multiple sclerosis. Multiple Sclerosis and Related Disorders, 2021, 50, 102809.	0.9	3
1422	Differentiation between multiple sclerosis and neuromyelitis optica spectrum disorder using optical coherence tomography angiography. Scientific Reports, 2021, 11, 10697.	1.6	19
1423	Quantitative signal properties from standardized MRIs correlate with multiple sclerosis disability. Annals of Clinical and Translational Neurology, 2021, 8, 1096-1109.	1.7	8
1424	MPRAGE to MP2RAGE UNI translation via generative adversarial network improves the automatic tissue and lesion segmentation in multiple sclerosis patients. Computers in Biology and Medicine, 2021, 132, 104297.	3.9	8
1425	Un caso di vertigine a esordio acuto/subacuto in un adolescente. Medico E Bambino Pagine Elettroniche, 2021, 24, 130-137.	0.0	0
1426	In Vivo Induction of Regulatory T Cells Via CTLAâ€4 Signaling Peptide to Control Autoimmune Encephalomyelitis and Prevent Disease Relapse. Advanced Science, 2021, 8, 2004973.	5.6	18

#	Article	IF	Citations
1427	Kappa-Free Light Chains in CSF Predict Early Multiple Sclerosis Disease Activity. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	3.1	26
1428	Can serum glial fibrillary acidic protein (GFAP) solve the longstanding problem of diagnosis and monitoring progressive multiple sclerosis. Multiple Sclerosis and Related Disorders, 2021, 50, 102931.	0.9	2
1429	COVID-19 in a temporal relation to the onset of multiple sclerosis. Multiple Sclerosis and Related Disorders, 2021, 50, 102863.	0.9	14
1430	The relationship of HLA-G 14-bp insertion/deletion genetic polymorphism to the risk of multiple sclerosis and its clinical phenotypes. Egyptian Journal of Neurology, Psychiatry and Neurosurgery, 2021, 57, .	0.4	2
1431	Use of a panel of four microRNAs in CSF as a predicted biomarker for postoperative neoangiogenesis in moyamoya disease. CNS Neuroscience and Therapeutics, 2021, 27, 908-918.	1.9	7
1432	Elucidating distinct clinico-radiologic signatures in the borderland between neuromyelitis optica and multiple sclerosis. Journal of Neurology, 2022, 269, 269-279.	1.8	3
1433	Approaches and challenges in the diagnosis and management of secondary progressive multiple sclerosis: A Central Eastern European perspective from healthcare professionals. Multiple Sclerosis and Related Disorders, 2021, 50, 102778.	0.9	7
1434	The Smartphone App haMSter for Tracking Patient-Reported Outcomes in People With Multiple Sclerosis: Protocol for a Pilot Study. JMIR Research Protocols, 2021, 10, e25011.	0.5	4
1435	Effectiveness and safety of cladribine in MS: Real-world experience from two tertiary centres. Multiple Sclerosis Journal, 2022, 28, 257-268.	1.4	35
1436	Exosomes From Subjects With Multiple Sclerosis Express EBV-Derived Proteins and Activate Monocyte-Derived Macrophages. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, e1004.	3.1	14
1437	Network Damage Predicts Clinical Worsening in Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	3.1	16
1438	Modern Technologies in the Rehabilitation of Patients with Multiple Sclerosis and Their Potential Application in Times of COVID-19. Medicina (Lithuania), 2021, 57, 549.	0.8	21
1439	Assessing brain injury topographically using MR neurite orientation dispersion and density imaging in multiple sclerosis. Journal of Neuroimaging, 2021, 31, 1003-1013.	1.0	2
1440	Interplay Between Cognitive and Bowel/Bladder Function in Multiple Sclerosis. International Neurourology Journal, 2021, 25, 310-318.	0.5	6
1442	Myelopathies in patients older than 50: not to miss inflammatory etiologies.. Multiple Sclerosis and Related Disorders, 2021, 50, 102826.	0.9	0
1443	Association between familial Mediterranean fever and multiple sclerosis: A case series from the JIR cohort and systematic literature review. Multiple Sclerosis and Related Disorders, 2021, 50, 102834.	0.9	6
1444	Sleep disturbance and memory dysfunction in early multiple sclerosis. Annals of Clinical and Translational Neurology, 2021, 8, 1172-1182.	1.7	7
1445	Real-world outcomes for a complete nationwide cohort of more than 3200 teriflunomide-treated multiple sclerosis patients in The Danish Multiple Sclerosis Registry. PLoS ONE, 2021, 16, e0250820.	1.1	12

#	Article	IF	Citations
1446	Sensitivity of T1/T2-weighted ratio in detection of cortical demyelination is similar to magnetization transfer ratio using post-mortem MRI. Multiple Sclerosis Journal, 2022, 28, 198-205.	1.4	18
1447	The Epidemiology of COVID-19 and MS-Related Characteristics in a National Sample of People With MS in China. Frontiers in Neurology, 2021, 12, 682729.	1.1	3
1448	Videoconferencing and Multiple Sclerosis Management: Stopgap or Stay Tuned?. Canadian Journal of Neurological Sciences, 2022, 49, 402-405.	0.3	1
1449	Perturbed Microbiota/Immune Homeostasis in Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, e997.	3.1	15
1450	SIGLEC1 (CD169): a marker of active neuroinflammation in the brain but not in the blood of multiple sclerosis patients. Scientific Reports, 2021, 11, 10299.	1.6	14
1451	OCT Variability Prevents Their Use as Robust Biomarkers in Multiple Sclerosis. Clinical Ophthalmology, 2021, Volume 15, 2025-2036.	0.9	2
1452	False Positive Results in SARS-CoV-2 Serological Tests for Samples From Patients With Chronic Inflammatory Diseases. Frontiers in Immunology, 2021, 12, 666114.	2.2	17
1453	Serum Short-Chain Fatty Acids and Associations With Inflammation in Newly Diagnosed Patients With Multiple Sclerosis and Healthy Controls. Frontiers in Immunology, 2021, 12, 661493.	2.2	43
1454	Insights on the Relationship Between Hippocampal Connectivity and Memory Performances at the Early Stage of Multiple Sclerosis. Frontiers in Neurology, 2021, 12, 667531.	1.1	4
1455	N,N-Dimethylglycine in patients with progressive multiple sclerosis: result of a pilot double-blind, placebo, controlled randomized clinical trial. Neurological Research and Practice, 2021, 3, 29.	1.0	3
1456	Simultaneous T 2 and mapping of multiple sclerosis lesions with radial RAREâ€EPI. Magnetic Resonance in Medicine, 2021, 86, 1383-1402.	1.9	2
1457	MRI activity and extended interval of Natalizumab dosing regimen: a multicentre Italian study. Journal of the Neurological Sciences, 2021, 424, 117385.	0.3	9
1458	Paving the way towards an effective treatment for multiple sclerosis: advances in cell therapy. Cellular and Molecular Immunology, 2021, 18, 1353-1374.	4.8	22
1459	RISCOPâ€“Cognitive profile in a Portuguese cohort of radiological isolated syndrome patients: A case-control study. Multiple Sclerosis and Related Disorders, 2021, 50, 102832.	0.9	0
1460	Identification and diagnosis of Secondary Progressive Multiple Sclerosis during the clinical encounter: Results from a physician survey. Multiple Sclerosis and Related Disorders, 2021, 50, 102858.	0.9	1
1461	Prevalence of neuromyelitis optica spectrum disorder in Belo Horizonte, Southeast Brazil. Multiple Sclerosis and Related Disorders, 2021, 50, 102807.	0.9	21
1462	Fear and anxiety in patients with multiple sclerosis during COVID-19 pandemic; report of an Iranian population. Multiple Sclerosis and Related Disorders, 2021, 50, 102798.	0.9	29
1463	Multiple sclerosis patients have reduced resting and increased activated CD4+CD25+FOXP3+T regulatory cells. Scientific Reports, 2021, 11, 10476.	1.6	30

#	Article	IF	Citations
1464	Cortical activity and gait parameter characteristics in people with multiple sclerosis during unobstructed gait and obstacle avoidance. Gait and Posture, 2021, 86, 226-232.	0.6	9
1465	Longâ€term trajectory of acquired demyelinating syndrome and multiple sclerosis in children. Developmental Medicine and Child Neurology, 2021, 63, 1059-1065.	1.1	3
1466	Pediatric inflammatory demyelinating disorders and mimickers: How to differentiate with MRI?. Autoimmunity Reviews, 2021, 20, 102801.	2.5	9
1467	Cervical spinal degenerative disease in multiple sclerosis. European Journal of Neurology, 2021, 28, 2497-2502.	1.7	5
1468	A matter of atrophy: differential impact of brain and spine damage on disability worsening in multiple sclerosis. Journal of Neurology, 2021, 268, 4698-4706.	1.8	11
1469	Analysis of frequency and severity of relapses in multiple sclerosis patients treated with cladribine tablets or placebo: The CLARITY and CLARITY Extension studies. Multiple Sclerosis Journal, 2022, 28, 111-120.	1.4	15
1470	Monomethyl Fumarate (MMF, Bafiertam) for the Treatment of Relapsing Forms of Multiple Sclerosis (MS). Neurology International, 2021, 13, 207-223.	1.3	20
1471	Early-Onset Alcohol Dependence and Multiple Sclerosis: Diagnostic Challenges. International Journal of Environmental Research and Public Health, 2021, 18, 5588.	1.2	5
1472	Mass Cytometry Identifies Expansion of T-bet+ B Cells and CD206+ Monocytes in Early Multiple Sclerosis. Frontiers in Immunology, 2021, 12, 653577.	2.2	19
1474	Rabies vaccination and multiple sclerosis relapse: A retrospective cohort study. Multiple Sclerosis and Related Disorders, 2021, 51, 102906.	0.9	5
1475	Leg movement activity during sleep in multiple sclerosis with and without RLS. Journal of Clinical Sleep Medicine, 2021, , .	1.4	4
1476	Differential Binding of Autoantibodies to MOG Isoforms in Inflammatory Demyelinating Diseases. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	3.1	16
1477	Skin and gut imprinted helper T cell subsets exhibit distinct functional phenotypes in central nervous system autoimmunity. Nature Immunology, 2021, 22, 880-892.	7.0	34
1478	Update on brain MRI for the diagnosis and follow-up of MS patients. Presse Medicale, 2021, 50, 104067.	0.8	5
1479	Non-standard computer perimetry in the diagnosis of some optic neuropathies. Ophthalmology Journal, 2021, 14, 75-87.	0.1	2
1480	Freiburg Neuropathology Case Conference. Clinical Neuroradiology, 2021, 31, 529-535.	1.0	2
1481	Comparative study of AQP4-NMOSD, MOGAD and seronegative NMOSD: a single-center Belgian cohort. Acta Neurologica Belgica, 2022, 122, 135-144.	0.5	11
1482	Pre-contrast T1-weighted imaging of the spinal cord may be unnecessary in patients with multiple sclerosis. European Radiology, 2021, 31, 9316-9323.	2.3	0

#	Article	IF	Citations
1483	Effect of Whole-Body Cryotherapy on Morphological, Rheological and Biochemical Indices of Blood in People with Multiple Sclerosis. Journal of Clinical Medicine, 2021, 10, 2833.	1.0	5
1484	Cerebrospinal Fluid Findings in 541 Patients With Clinically Isolated Syndrome and Multiple Sclerosis: A Monocentric Study. Frontiers in Immunology, 2021, 12, 675307.	2.2	12
1485	Macular vessel density differs in multiple sclerosis and neuromyelitis optica spectrum disorder: An optical coherence tomography angiography study. PLoS ONE, 2021, 16, e0253417.	1.1	13
1486	Approach to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis. Frontiers in Immunology, 2021, 12, 701752.	2.2	17
1487	The prevalence of antiâ€neurofascinâ€155 antibodies in patients with neuromyelitis optica spectrum disorders. Clinical and Experimental Immunology, 2021, 206, 1-11.	1.1	5
1488	Distinguishing the Diagnosis and Management of Sleep Disturbance and Sleep Disorders in Multiple Sclerosis. Nursing Clinics of North America, 2021, 56, 157-174.	0.7	2
1489	Designing a Self-Perception Cognitive Questionnaire for Italian Multiple Sclerosis Patients (Sclerosi) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 Neurology, 2021, 12, 668933.	1.1	2
1490	Memory B Cells in Multiple Sclerosis: Emerging Players in Disease Pathogenesis. Frontiers in Immunology, 2021, 12, 676686.	2.2	20
1491	Assessment of Macular Function by Multifocal Electroretinogram in Patients with Multiple Sclerosis Treated with Fingolimod. Advances in Therapy, 2021, 38, 3986-3996.	1.3	2
1492	10-Weeks of resistance training improves sleep quality and cardiac autonomic control in persons with multiple sclerosis. Disability and Rehabilitation, 2022, 44, 5241-5249.	0.9	4
1493	Pregnancy-induced effects on memory B-cell development in multiple sclerosis. Scientific Reports, 2021, 11, 12126.	1.6	6
1494	A Pilot Study of 24-h Motor Activity Patterns in Multiple Sclerosis: Pre-Planned Follow-Up at 2 Years. Clocks & Sleep, 2021, 3, 366-376.	0.9	0
1495	Effects of low vs. high frequency local vibration on mild-moderate muscle spasticity: Ultrasonographical and functional evaluation in patients with multiple sclerosis. Multiple Sclerosis and Related Disorders, 2021, 51, 102930.	0.9	6
1496	Nonlesional diffusely abnormal appearing white matter in clinically isolated syndrome: Prevalence, association with clinical and MRI features, and risk for conversion to multiple sclerosis. Journal of Neuroimaging, 2021, 31, 981-994.	1.0	3
1497	Genes and environment in multiple sclerosis: Impact of temporal changes in the sex ratio on recurrence risks. Multiple Sclerosis Journal, 2022, 28, 359-368.	1.4	5
1498	Neutrophil-lymphocyte ratio as a marker for disability and activity in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2021, 51, 102921.	0.9	11
1499	Stressful life events and the risk of primary progressive multiple sclerosis: A population-based case-control study. Multiple Sclerosis and Related Disorders, 2021, 51, 102937.	0.9	2
1500	Prenatal and perinatal factors associated with developing multiple sclerosis later in life: A systematic review and meta-analysis. Autoimmunity Reviews, 2021, 20, 102823.	2.5	2

#	Article	IF	Citations
1501	Resting-State Brain Network Deficits in Multiple Sclerosis Participants: Evidence from Electroencephalography and Graph Theoretical Analysis. Brain Connectivity, 2021, 11, 359-367.	0.8	3
1502	Description and preliminary experience with Virtual Visit Assessment (ViVA) during the COVID-19 pandemic, a structured virtual management protocol for patients with multiple sclerosis. Neurological Sciences, 2022, 43, 1207-1214.	0.9	6
1503	Evaluation of Month of Birth in Neuromyelitis Optica Spectrum Disorders (NMSOD) and Multiple Sclerosis (MS). Multiple Sclerosis International, 2021, 2021, 1-7.	0.4	1
1504	State-of-the-Art Review: Demyelinating Diseases in Indonesia. Multiple Sclerosis International, 2021, 2021, 1-13.	0.4	1
1505	Audio and vestibular analyses in patient with multiple sclerosis: a caseâ€“control study. Hearing, Balance and Communication, 0, , 1-6.	0.1	1
1506	Intrathecal Immunoglobulin M Synthesis is an Independent Biomarker for Higher Disease Activity and Severity in Multiple Sclerosis. Annals of Neurology, 2021, 90, 477-489.	2.8	16
1507	Quantitative magnetic resonance imaging of brain anatomy and in vivo histology. Nature Reviews Physics, 2021, 3, 570-588.	11.9	115
1508	Risk of Persistent Disability in Patients With Pediatric-Onset Multiple Sclerosis. JAMA Neurology, 2021, 78, 726.	4.5	26
1509	Multiple sclerosis projection in Tehran, Iran using Bayesian structural time series. BMC Neurology, 2021, 21, 235.	0.8	10
1512	Serum malondialdehyde as a lipid peroxidation marker in multiple sclerosis patients and its relation to disease characteristics. Multiple Sclerosis and Related Disorders, 2021, 51, 102941.	0.9	19
1513	Chronic White Matter Inflammation and Serum Neurofilament Levels in Multiple Sclerosis. Neurology, 2021, 97, e543-e553.	1.5	54
1514	COVID-19 and the Risk of Relapse in Multiple Sclerosis Patients: A Fight with No Bystander Effect?. Multiple Sclerosis and Related Disorders, 2021, 51, 102915.	0.9	35
1515	The multiple sclerosis prodrome. Nature Reviews Neurology, 2021, 17, 515-521.	4.9	52
1516	Exploring the Connection between Porphyromonas gingivalis and Neurodegenerative Diseases: A Pilot Quantitative Study on the Bacterium Abundance in Oral Cavity and the Amount of Antibodies in Serum. Biomolecules, 2021, 11, 845.	1.8	14
1517	Spectral-Domain Optical Coherence Tomography Assessment in Treatment-NaÃ¯ve Patients with Clinically Isolated Syndrome and Different Multiple Sclerosis Types: Findings and Relationship with the Disability Status. Journal of Clinical Medicine, 2021, 10, 2892.	1.0	5
1518	Neurodegeneration in Multiple Sclerosis: Symptoms of Silent Progression, Biomarkers and Neuroprotective Therapyâ€”Kynurenines Are Important Players. Molecules, 2021, 26, 3423.	1.7	20
1519	Multiple Sclerosis. Annals of Internal Medicine, 2021, 174, ITC81-ITC96.	2.0	43
1520	Characterization of alexithymia in clinically isolated syndrome. Revue Neurologique, 2021, 177, 1145-1150.	0.6	0

#	Article	IF	Citations
1521	Short and long term effects of Nabiximols on balance and walking assessed by 3D-gait analysis in people with Multiple Sclerosis and spasticity.. Multiple Sclerosis and Related Disorders, 2021, 51, 102805.	0.9	15
1522	Multiple sclerosis in a patient with cryopyrin-associated autoinflammatory syndrome: Evidence that autoinflammation is the common link. Clinical Immunology, 2021, 227, 108750.	1.4	3
1523	ApoE4-positive multiple sclerosis patients are more likely to have cognitive impairment: a cross-sectional study. Neurological Sciences, 2022, 43, 1189-1196.	0.9	4
1524	New Prospects for Ultra-High-Field Magnetic Resonance Imaging in Multiple Sclerosis. Investigative Radiology, 2021, 56, 773-784.	3.5	19
1525	Utilization of Multiple Sclerosis Therapies in the Middle East Over a Decade: 2009â€“2018. CNS Drugs, 2021, 35, 1097-1106.	2.7	7
1526	Positive Predictive Value of Myelin Oligodendrocyte Glycoprotein Autoantibody Testing. JAMA Neurology, 2021, 78, 741.	4.5	124
1527	Machine learning in diagnosis and disability prediction of multiple sclerosis using optical coherence tomography. Computers in Biology and Medicine, 2021, 133, 104416.	3.9	34
1528	Pediatric onset multiple sclerosis: Future challenge for early diagnosis and treatment. Presse Medicale, 2021, 50, 104069.	0.8	5
1529	Serum neurofilament light chain and glial fibrillary acidic protein in AQP4â€IgGâ€seropositive neuromyelitis optica spectrum disorders and multiple sclerosis: A cohort study. Journal of Neurochemistry, 2021, 159, 913-922.	2.1	11
1530	Quantitative Magnetic Resonance Imaging Analysis of Early Markers of Upper Cervical Cord Atrophy in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder. Multiple Sclerosis International, 2021, 2021, 1-6.	0.4	0
1531	The Aryl Hydrocarbon Receptorâ€“Dependent TGF-Î±/VEGF-B Ratio Correlates With Disease Subtype and Prognosis in Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	3.1	12
1532	Long-term clinical, MRI, and cognitive follow-up in a large cohort of pathologically confirmed, predominantly tumefactive multiple sclerosis. Multiple Sclerosis Journal, 2022, 28, 441-452.	1.4	8
1533	Identification of the Immunological Changes Appearing in the CSF During the Early Immunosenescence Process Occurring in Multiple Sclerosis. Frontiers in Immunology, 2021, 12, 685139.	2.2	13
1535	Application of deep-learning to the seronegative side of the NMO spectrum. Journal of Neurology, 2022, 269, 1546-1556.	1.8	2
1536	High Level of Serum and Cerebrospinal Fluid of Heparan Sulfate and Hyaluronic Acid Might Be a Biomarker of Severity of Neuromyelitis Optica. Frontiers in Immunology, 2021, 12, 705536.	2.2	3
1537	Association of NLRP3 rs35829419 and rs10754558 Polymorphisms With Risks of Autoimmune Diseases: A Systematic Review and Meta-Analysis. Frontiers in Genetics, 2021, 12, 690860.	1.1	15
1538	Can coronavirus disease 2019 (COVID-19) trigger exacerbation of multiple sclerosis? A retrospective study. Multiple Sclerosis and Related Disorders, 2021, 52, 102947.	0.9	50
1539	Predicting Aggressive Multiple Sclerosis With Intrathecal IgM Synthesis Among Patients With a Clinically Isolated Syndrome. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	3.1	20

#	Article	IF	Citations
1540	The Upper Motor Neuronâ€"Improved Knowledge from ALS and Related Clinical Disorders. Brain Sciences, 2021, 11, 958.	1.1	3
1541	Vertigo. Medical Clinics of North America, 2021, 105, 901-916.	1.1	2
1542	Genetic diseases mimicking multiple sclerosis. Postgraduate Medicine, 2021, 133, 728-749.	0.9	2
1543	Epidemiology of multiple sclerosis in Lebanon: A rising prevalence in the middle east. Multiple Sclerosis and Related Disorders, 2021, 52, 102963.	0.9	8
1544	Secondary cluster headache due to a contralateral demyelinating periaqueductal gray matter lesion. Headache, 2021, 61, 1136-1139.	1.8	2
1545	Progressive myelopathy in myelin oligodendrocyte glycoprotein antibody-associated disease: A new mimicker of progressive multiple sclerosis?. Multiple Sclerosis and Related Disorders, 2021, 52, 102964.	0.9	7
1546	The role of 5-HT2B-receptors in fluoxetine-mediated modulation of Th17- and Th1-cells in multiple sclerosis. Journal of Neuroimmunology, 2021, 356, 577608.	1.1	11
1547	Expression analysis of NF-Î°B-associated long noncoding RNAs in peripheral blood mononuclear cells from relapsing-remitting multiple sclerosis patients. Journal of Neuroimmunology, 2021, 356, 577602.	1.1	6
1548	RNA Sequencing of CD4+ T Cells in Relapsingâ€"Remitting Multiple Sclerosis Patients at Relapse: Deciphering the Involvement of Novel genes and Pathways. Journal of Molecular Neuroscience, 2021, 71, 2628-2645.	1.1	3
1549	18F-florbetapir PET/MRI for quantitatively monitoring myelin loss and recovery in patients with multiple sclerosis: A longitudinal study. EClinicalMedicine, 2021, 37, 100982.	3.2	10
1550	Proteomics of Multiple Sclerosis: Inherent Issues in Defining the Pathoetiology and Identifying (Early) Biomarkers. International Journal of Molecular Sciences, 2021, 22, 7377.	1.8	13
1551	Artificial double inversion recovery images for (juxta)cortical lesion visualization in multiple sclerosis. Multiple Sclerosis Journal, 2021, , 135245852110298.	1.4	11
1552	Clinical characteristics of optic neuritis phenotypes in a 3-year follow-up Chinese cohort. Scientific Reports, 2021, 11, 14603.	1.6	9
1553	Serum Peptide Immunoglobulin G Autoantibody Response in Patients with Different Central Nervous System Inflammatory Demyelinating Disorders. Diagnostics, 2021, 11, 1339.	1.3	4
1554	The road to conception for women with multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2021, 7, 205521732110323.	0.5	2
1555	N6-Methyladenosine RNA modification in cerebrospinal fluid as a novel potential diagnostic biomarker for progressive multiple sclerosis. Journal of Translational Medicine, 2021, 19, 316.	1.8	17
1556	Longitudinal Sodium <scp>MRI</scp> of Multiple Sclerosis Lesions: Is there Added Value of Sodium Inversion Recovery <scp>MRI</scp>. Journal of Magnetic Resonance Imaging, 2022, 55, 140-151.	1.9	6
1557	Sex-Based Differences in Oxygen Cost of Walking and Energy Equivalents in Minimally Disabled Individuals With Multiple Sclerosis and Controls. International Journal of MS Care, 2022, 24, 54-61.	0.4	1

#	Article	IF	Citations
1558	Thalamic nuclei degeneration in multiple sclerosis. Journal of Clinical Neuroscience, 2021, 89, 375-380.	0.8	6
1560	COVID-19 severity and mortality in multiple sclerosis are not associated with immunotherapy: Insights from a nation-wide Austrian registry. PLoS ONE, 2021, 16, e0255316.	1.1	27
1561	Innate immunity impacts social-cognitive functioning in people with multiple sclerosis and healthy individuals: Implications for IL-1ra and urinary immune markers. Brain, Behavior, & Immunity - Health, 2021, 14, 100254.	1.3	4
1562	A patient with probable neuroâ€BehÃ§et's disease presenting a unique linear pontine trigeminal root lesion and a linear subcortical white matter lesion. Clinical and Experimental Neuroimmunology, 2021, 12, 253.	0.5	0
1563	Idiopathic Intracranial Hypertension and Multiple Sclerosis Overlap. Cureus, 2021, 13, e16305.	0.2	2
1565	Modified models to distinguish central nervous system demyelinating diseases with brain lesions. Multiple Sclerosis and Related Disorders, 2021, 52, 102965.	0.9	1
1566	Case 22-2021: A 64-Year-Old Woman with Cognitive Impairment, Headache, and Memory Loss. New England Journal of Medicine, 2021, 385, 358-368.	13.9	1
1567	Does depression in multiple sclerosis mediate effects of cognitive functioning on quality of life?. Quality of Life Research, 2022, 31, 497-506.	1.5	3
1568	Ð•arly diagnosis of multiple sclerosis: experience with the use of class G oligoclonal immunoglobulin. Russian Neurological Journal, 2021, 26, 34-39.	0.1	0
1569	Aggressive multiple sclerosis in Argentina: Data from the nationwide registry RelevarEM. Journal of Clinical Neuroscience, 2021, 89, 360-364.	0.8	1
1570	Neurocognitive performance in relapsing-remitting multiple sclerosis patients is associated with metabolic abnormalities of the thalamus but not the hippocampusâ€“ GABA-edited 1H MRS study. Neurological Research, 2022, 44, 57-64.	0.6	6
1571	Magnetic Resonance Imaging and Clinical Features of the Demyelinating Degeneration of White Matter in Young Patients. International Journal of General Medicine, 2021, Volume 14, 3177-3186.	0.8	2
1572	Effects of Vitamin D and Dexamethasone on Lymphocyte Proportions and Their Associations With Serum Concentrations of 25-Hydroxyvitamin D3In Vitro in Patients With Multiple Sclerosis or Neuromyelitis Optica Spectrum Disorder. Frontiers in Immunology, 2021, 12, 677041.	2.2	3
1573	Cognitive Decline in Multiple Sclerosis Is Related to the Progression of Retinal Atrophy and Presence of Oligoclonal Bands: A 5-Year Follow-Up Study. Frontiers in Neurology, 2021, 12, 678735.	1.1	15
1574	A Greek Validation Study of the Multiple Sclerosis Work Difficulties Questionnaire-23. Healthcare (Switzerland), 2021, 9, 897.	1.0	3
1575	Corneal Parameters in Patients with Multiple Sclerosis: A Pilot Study. Klinische Monatsblatter Fur Augenheilkunde, 2021, , .	0.3	0
1576	Primary diffuse large Bâ€cell lymphoma of the central nervous system with rapidly progressing lesions after dimethyl fumarate treatment, showing relapsing and remitting symptoms: A case report. Clinical and Experimental Neuroimmunology, 0, , .	0.5	0
1577	Beyond McDonald: updated perspectives on MRI diagnosis of multiple sclerosis. Expert Review of Neurotherapeutics, 2021, 21, 895-911.	1.4	7

#	Article	IF	Citations
1579	A real-world single-centre analysis of alemtuzumab and cladribine for multiple sclerosis. Multiple Sclerosis and Related Disorders, 2021, 52, 102945.	0.9	19
1580	Matching-adjusted indirect treatment comparison of ozanimod versus teriflunomide for relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders, 2021, 52, 102972.	0.9	2
1581	CNS demyelination with TNFÎ± inhibitor exposure: A retrospective cohort study. Journal of Neuroimmunology, 2021, 356, 577587.	1.1	10
1582	The nutritional status of relapsing-remitting multiple sclerosis (RRMS) patients compared to that of healthy people: a Turkish hospital-based study. Nutritional Neuroscience, 2022, 25, 2279-2287.	1.5	4
1583	Cerebrospinal fluid oligoclonal immunoglobulin gamma bands and long-term disability progression in multiple sclerosis: a retrospective cohort study. Scientific Reports, 2021, 11, 14987.	1.6	13
1584	Optical coherence tomography angiography indicates subclinical retinal disease in neuromyelitis optica spectrum disorders. Multiple Sclerosis Journal, 2022, 28, 522-531.	1.4	24
1585	Spinal Fluid Myeloid Microvesicles Predict Disease Course in Multiple Sclerosis. Annals of Neurology, 2021, 90, 253-265.	2.8	9
1586	Challenging Mimickers in the Diagnosis of Sarcoidosis: A Case Study. Diagnostics, 2021, 11, 1240.	1.3	9
1587	Focal white matter lesions induce long-lasting axonal degeneration, neuroinflammation and behavioral deficits. Neurobiology of Disease, 2021, 155, 105371.	2.1	4
1588	Comparable Efficacy and Safety of Teriflunomide versus Dimethyl Fumarate for the Treatment of Relapsing-Remitting Multiple Sclerosis. Neurology Research International, 2021, 2021, 1-8.	0.5	3
1589	Exome sequencing reveals novel rare variants in Iranian familial multiple sclerosis: The importance of POLD2 in the disease pathogenesis. Genomics, 2021, 113, 2645-2655.	1.3	5
1590	Evaluation of diagnosis and treatment practices of Brazilian neurologists among patients with multiple sclerosis. Arquivos De Neuro-Psiquiatria, 2021, 79, 598-606.	0.3	1
1591	Wearable Robotic Gait Training in Persons with Multiple Sclerosis: A Satisfaction Study. Sensors, 2021, 21, 4940.	2.1	9
1592	Immunotherapyâ€responsive brainstem lesion accompanied with antiâ€galactocerebroside antibody. Clinical and Experimental Neuroimmunology, 0, , .	0.5	1
1593	Sensory-Motor and Affective-Fatigue Factors are Associated with Symbol Digit Performance in Multiple Sclerosis. Journal of the International Neuropsychological Society, 2022, 28, 362-370.	1.2	9
1594	Comparison of MRI Lesion Evolution in Different Central Nervous System Demyelinating Disorders. Neurology, 2021, 97, e1097-e1109.	1.5	77
1595	Firstâ€line therapies in lateâ€onset multiple sclerosis: An Italian registry study. European Journal of Neurology, 2021, 28, 4117-4123.	1.7	17
1596	Improvement over previous decades in time of diagnosis but not in time of initiating DMD in MS patients in Argentina. Multiple Sclerosis and Related Disorders, 2021, 52, 103007.	0.9	0

#	Article	IF	Citations
1597	Pleiotrophin Serum Level is Increased in Relapsing-Remitting Multiple Sclerosis and Correlates With Sex, BMI and Treatment. Archives of Medical Research, 2022, 53, 59-68.	1.5	1
1598	Walk Your Talk: Real-World Adherence to Guidelines on the Use of MRI in Multiple Sclerosis. Diagnostics, 2021, 11, 1310.	1.3	2
1599	Diagnosis and management of multiple sclerosis and other relapsing demyelinating disease in childhood. Archives of Disease in Childhood, 2022, 107, 216-222.	1.0	2
1600	Review of neurological rehabilitation for Multiple Sclerosis in the British Military. BMJ Military Health, 2021, , bmjmilitary-2021-001852.	0.4	1
1601	Acceptance-based telephone support around the time of transition to secondary progressive multiple sclerosis: A feasibility randomised controlled trial. Journal of Contextual Behavioral Science, 2021, 21, 158-170.	1.3	5
1602	Positivity of oligoclonal bands in the cerebrospinal fluid predisposed to metabolic changes and rearrangement of inhibitory/excitatory neurotransmitters in subcortical brain structures in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2021, 52, 102978.	0.9	5
1603	Identification of differential DNA methylation associated with multiple sclerosis: A family-based study. Journal of Neuroimmunology, 2021, 356, 577600.	1.1	3
1604	Effects of hippotherapy on postural balance, functional mobility, self-perceived fatigue, and quality of life in people with relapsing-remitting multiple sclerosis: Secondary results of an exploratory clinical trial. Multiple Sclerosis and Related Disorders, 2021, 52, 102948.	0.9	8
1605	The association between bladder dysfunction, balance and falls in women with multiple sclerosis: The specific contribution of fear of falling. Gait and Posture, 2021, 88, 252-257.	0.6	1
1606	Sarcotubular Myopathy Due to Novel TRIM32 Mutation in Association with Multiple Sclerosis. Brain Sciences, 2021, 11, 1020.	1.1	2
1607	Persons with suspicious onset of multiple sclerosis but with undetermined diagnosis had persistent lower cognition and reduced quality of life. Multiple Sclerosis and Related Disorders, 2021, 52, 102977.	0.9	2
1608	Postural stability is a valid and meaningful disability metric in progressive MS with potential for use in neuroprotective therapy trials. Multiple Sclerosis and Related Disorders, 2021, 52, 102946.	0.9	4
1609	Optic neuritis classification in 2021. European Journal of Ophthalmology, 2022, 32, 754-766.	0.7	7
1610	Disorders of vision in multiple sclerosis. Australasian journal of optometry, The, 2022, 105, 3-12.	0.6	7
1611	A Phase 3, double-blind, placebo-controlled efficacy and safety study of ADS-5102 (Amantadine) extended-release capsules in people with multiple sclerosis and walking impairment. Multiple Sclerosis Journal, 2022, 28, 817-830.	1.4	2
1612	Complications of COVID-19 Pneumonia and Multiple Sclerosis Exacerbation. Cureus, 2021, 13, e17506.	0.2	4
1613	Myelin basic protein expression in thymoma after methylprednisolone administration for multiple sclerosis. Respirology Case Reports, 2021, 9, e0834.	0.3	0
1614	Explaining the individual challenges of women affected by neuromyelitis optica and multiple sclerosis: A comparative content analysis Study. Clinical Neurology and Neurosurgery, 2021, 207, 106789.	0.6	0

#	Article	IF	Citations
1615	Validating the diagnosis of multiple sclerosis using Swedish administrative data in VÃrmland County. Acta Neurologica Scandinavica, 2021, 144, 680-686.	1.0	4
1616	23Na imaging: Worth its salt for understanding multiple sclerosis. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, e2110799118.	3.3	0
1617	Association of peripapillary hyperâ€reflective ovoid masslike structures and disease duration in primary progressive multiple sclerosis. European Journal of Neurology, 2021, 28, .	1.7	9
1618	Serum neurofilament light is a sensitive biomarker that reflects grey matter volume in Japanese patients with multiple sclerosis. Journal of the Neurological Sciences, 2021, 427, 117528.	0.3	1
1619	Seasonal fluctuations in serum levels of vitamin D in Japanese patients with multiple sclerosis. Journal of Neuroimmunology, 2021, 357, 577624.	1.1	3
1620	Cerebrospinal fluid flow cytometry distinguishes psychosis spectrum disorders from differential diagnoses. Molecular Psychiatry, 2021, 26, 7661-7670.	4.1	18
1621	Trigeminal Neuralgia Associated With a Solitary Pontine Lesion: A Case Report. Neurohospitalist, The, 2022, 12, 143-146.	0.3	1
1622	Nitrosative stress parameters and the level of oxidized DNA bases in patients with multiple sclerosis. Metabolic Brain Disease, 2021, 36, 1935-1941.	1.4	1
1623	Exploring CSF neurofilament light as a biomarker for MS in clinical practice; a retrospective registry-based study. Multiple Sclerosis Journal, 2022, 28, 872-884.	1.4	10
1624	Classification Criteria for Multiple Sclerosis-Associated Intermediate Uveitis. American Journal of Ophthalmology, 2021, 228, 72-79.	1.7	22
1626	Th17-Related Cytokines as Potential Discriminatory Markers between Neuromyelitis Optica (Devicâ€™s) Tj ETQq0 0 0 rgBT /Overlock 10	1.8	16
1627	Muscle architecture and its relationship with lower extremity muscle strength in multiple sclerosis. Acta Neurologica Belgica, 2022, 122, 1521-1528.	0.5	4
1628	Serum levels of leptin and adiponectin in patients with multiple sclerosis. Egyptian Journal of Neurology, Psychiatry and Neurosurgery, 2021, 57, .	0.4	4
1629	Cortical involvement and leptomeningeal inflammation in myelin oligodendrocyte glycoprotein antibody disease: A three-dimensional fluid-attenuated inversion recovery MRI study. Multiple Sclerosis Journal, 2022, 28, 718-729.	1.4	4
1630	Reproducibility and Convergent Validity of the Sitting-Rising Test in People With Multiple Sclerosis. Archives of Physical Medicine and Rehabilitation, 2021, 102, 1541-1546.	0.5	1
1631	Clinical predictors of disease progression in a cohort of progressive Tunisian Multiple Sclerosis. Multiple Sclerosis and Related Disorders, 2021, 56, 103232.	0.9	1
1632	Multiple sclerosis and immune system biomarkers: Novel comparison in glatiramer acetate and interferon beta-1a-treated patient groups. Multiple Sclerosis and Related Disorders, 2021, 53, 103082.	0.9	2
1633	Hemi-paraplegia and hemi-anaesthesia in the inflammatory bowel disease clinic. JRSM Open, 2021, 12, 205427042110359.	0.2	1

#	Article	IF	Citations
1634	Update on Optic Neuritis: An International View. Neuro-Ophthalmology, 2022, 46, 1-18.	0.4	15
1635	Exploratory Radiomic Analysis of Conventional vs. Quantitative Brain MRI: Toward Automatic Diagnosis of Early Multiple Sclerosis. Frontiers in Neuroscience, 2021, 15, 679941.	1.4	7
1636	Energy Expenditure and Oxygen Consumption During Activities of Daily Living in People With Multiple Sclerosis and Healthy Subjects: An Ecological Approach to Estimate Real-Life Fatigue and Fatigability. Archives of Physical Medicine and Rehabilitation, 2021, 102, 1482-1489.	0.5	3
1638	Emerging deep learning techniques using magnetic resonance imaging data applied in multiple sclerosis and clinical isolated syndrome patients (Review). Experimental and Therapeutic Medicine, 2021, 22, 1149.	0.8	5
1639	Impaired motion perception is associated with functional and structural visual pathway damage in multiple sclerosis and neuromyelitis optica spectrum disorders. Multiple Sclerosis Journal, 2022, 28, 757-767.	1.4	3
1640	Clinical observation of the course of COVID-19 in patients with multiple sclerosis during ocrelizumab therapy: two clinical cases. Meditsinskiy Sovet, 2021, , 108-111.	0.1	1
1641	Factors associated with brain ageing - a systematic review. BMC Neurology, 2021, 21, 312.	0.8	47
1642	The role of D2-like dopaminergic receptor in dopamine-mediated modulation of Th17-cells in multiple sclerosis. Current Neuropharmacology, 2021, 19, .	1.4	2
1643	Widespread Disruptions of White Matter in Familial Multiple Sclerosis: DTI and NODDI Study. Frontiers in Neurology, 2021, 12, 678245.	1.1	7
1644	Volume changes of thalamus, hippocampus and cerebellum are associated with specific CSF profile in MS. Multiple Sclerosis Journal, 2022, 28, 550-560.	1.4	7
1645	Proposed Mobility Assessments with Simultaneous Full-Body Inertial Measurement Units and Optical Motion Capture in Healthy Adults and Neurological Patients for Future Validation Studies: Study Protocol. Sensors, 2021, 21, 5833.	2.1	16
1646	Prediction of unenhanced lesion evolution in multiple sclerosis using radiomics-based models: a machine learning approach. Multiple Sclerosis and Related Disorders, 2021, 53, 102989.	0.9	13
1647	The impact of COVID-19 home confinement on neuromuscular performance, functional capacity, and psychological state in Spanish people with Multiple Sclerosis. Multiple Sclerosis and Related Disorders, 2021, 53, 103047.	0.9	9
1648	Demyelinating Disease of the Central Nervous System Concurrent With COVID-19. Cureus, 2021, 13, e17297.	0.2	8
1649	Maternal education has significant influence on progression in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2021, 53, 103052.	0.9	6
1650	A comparison of upper limb function in subjects with multiple sclerosis and healthy controls using an inertial measurement unit. Multiple Sclerosis and Related Disorders, 2021, 53, 103036.	0.9	3
1651	Prevalence and predictors of bowel dysfunction in a large multiple sclerosis outpatient population: an Italian multicenter study. Journal of Neurology, 2022, 269, 1610-1617.	1.8	7
1652	Shear wave elastography in optic neuritis: diagnostic accuracy of the optic nerve and adjacent fat tissue values. Journal of Ultrasonography: Official Publication of Polish Ultrasound Society / Red Nacz Iwona SudoÅ‚-SzopiÅ„ska, 2021, 21, e194-e199.	0.7	1

#	Article	IF	Citations
1653	Tetravalent Influenza Vaccine Is Not Associated With Neuroaxonal Damage in Multiple Sclerosis Patients. Frontiers in Immunology, 2021, 12, 718895.	2.2	3
1654	Multiple sclerosis therapy consensus group (MSTCG): answers to the discussion questions. Neurological Research and Practice, 2021, 3, 44.	1.0	9
1655	Time to diagnosis in multiple sclerosis: Epidemiological data from the German Multiple Sclerosis Registry. Multiple Sclerosis Journal, 2022, 28, 865-871.	1.4	8
1656	Cognition and disease characteristics in adult onset versus late onset multiple sclerosis. Multiple Sclerosis Journal, 2022, 28, 933-941.	1.4	7
1658	Silent progression of brain atrophy in aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 32-40.	0.9	15
1659	Dietary factors and MRI metrics in early Multiple Sclerosis. Multiple Sclerosis and Related Disorders, 2021, 53, 103031.	0.9	13
1660	Increased Serum Neurofilament Light and Thin Ganglion Cellâ€“Inner Plexiform Layer Are Additive Risk Factors for Disease Activity in Early Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	3.1	29
1661	Effect of COVID-19 home confinement on sleep monitorization and cardiac autonomic function in people with multiple sclerosis: A prospective cohort studyâœ°,âœ°âœ°. Physiology and Behavior, 2021, 237, 113392.	1.0	12
1662	MRI of the Entire Spinal Cordâ€”Worth the While or Waste of Time? A Retrospective Study of 74 Patients with Multiple Sclerosis. Diagnostics, 2021, 11, 1424.	1.3	4
1663	Effects of transcranial direct current stimulation on cognitive dysfunction in multiple sclerosis. Neurophysiologie Clinique, 2021, 51, 319-328.	1.0	7
1664	Evaluation of Kappa Index as a Tool in the Diagnosis of Multiple Sclerosis: Implementation in Routine Screening Procedure. Frontiers in Neurology, 2021, 12, 676527.	1.1	19
1665	Outcome measures assisting treatment optimization in multiple sclerosis. Journal of Neurology, 2022, 269, 1282-1297.	1.8	2
1666	Vibrational spectroscopy and multivariate analysis techniques in the clinical immunology laboratory: a review of current applications and requirements for diagnostic use. Applied Spectroscopy Reviews, 2022, 57, 411-440.	3.4	5
1667	Epidemiology of multiple sclerosis in Iraq: retrospective review of 4355 cases and literature review. Neurological Research, 2021, , 1-10.	0.6	7
1668	Clinical risk factors and prognostic model for idiopathic inflammatory demyelinating diseases after haploidentical hematopoietic stem cell transplantation in patients with hematological malignancies. American Journal of Hematology, 2021, 96, 1407-1419.	2.0	5
1669	Epidemiology of multiple sclerosis in the Sultanate of Oman: A hospital based study. Multiple Sclerosis and Related Disorders, 2021, 53, 103034.	0.9	5
1670	Research priorities in multiple sclerosis in Latin America: A multi-stakeholder call to action to improve patients care. Multiple Sclerosis and Related Disorders, 2021, 53, 103038.	0.9	4
1671	Non-ambulatory measures of lower extremity sensorimotor function are associated with walking function in Multiple Sclerosis. Multiple Sclerosis and Related Disorders, 2021, 53, 103051.	0.9	0

#	Article	IF	Citations
1672	Evaluation of Thiol Homeostasis in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders. Frontiers in Neurology, 2021, 12, 716195.	1.1	7
1673	Electroencephalographic evidence of gray matter lesions among multiple sclerosis patients. Medicine (United States), 2021, 100, e27001.	0.4	8
1674	2021 MAGNIMSâ€“CMSCâ€“NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis. Lancet Neurology, The, 2021, 20, 653-670.	4.9	302
1675	Early predictors of conversion to secondary progressive multiple sclerosis. Multiple Sclerosis and Related Disorders, 2021, 54, 103115.	0.9	19
1676	Is computerized screening for processing speed impairment sufficient for identifying MS-related cognitive impairment in a clinical setting?. Multiple Sclerosis and Related Disorders, 2021, 54, 103106.	0.9	4
1677	Multiple sclerosis progression and galanin receptor GALR2: is there evidence for a link?. Meditsinskii Akademicheskii Zhurnal, 2021, 21, 107-111.	0.2	0
1678	Comparison of Phase-Sensitive Inversion Recovery and Conventional Magnetic Resonance Imaging for Detection of Cortical Plaques in MS Patients. Iranian Journal of Radiology, 2021, 18, .	0.1	0
1679	Potent T cellâ€mediated antiâ€inflammatory role of the selective CB2 agonist lenabasum in multiple sclerosis. Neuropathology and Applied Neurobiology, 2022, 48, .	1.8	9
1680	Treatment Options in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders. Current Pharmaceutical Design, 2022, 28, 428-436.	0.9	10
1681	Diagnostic significance of IgG and albumin indices versus oligoclonal band types in demyelinating disorders. Journal of Clinical Pathology, 2023, 76, 166-171.	1.0	2
1682	Vitamin D status, proinflammatory cytokines and bone mineral density in Mexican people with multiple sclerosis. Multiple Sclerosis and Related Disorders, 2021, 56, 103265.	0.9	2
1683	Assessment of cognitive functions in patients with multiple sclerosis. Egyptian Journal of Neurology, Psychiatry and Neurosurgery, 2021, 57, .	0.4	5
1684	Art therapy possibilities in the complex treatment of patients with multiple sclerosis. Nevrologiya, Neiropsikhiatriya, Psikhosomatika, 2021, 13, 45-49.	0.2	0
1685	Pediatric Optic Neuritis: Description of Four Cases and Review of the Literature. Children, 2021, 8, 855.	0.6	1
1686	Multiple Sclerosis and SARS-CoV-2: Has the Interplay Started?. Frontiers in Immunology, 2021, 12, 755333.	2.2	33
1687	Prognostic factors in Tumefactive demyelinating lesions: A retrospective study. Journal of the Neurological Sciences, 2021, 428, 117591.	0.3	4
1688	The multiple sclerosis prodrome is just unspecific symptoms in radiologically isolated syndrome patients â€“ Yes. Multiple Sclerosis Journal, 2021, 27, 1823-1824.	1.4	3
1689	Vascular endothelial dysfunction associated with severity in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2021, 54, 103135.	0.9	10

#	Article	IF	Citations
1690	Myelin content changes in Clinically Isolated Syndrome and Relapsing- Remitting Multiple Sclerosis: Associations with lesion type and severity of visuomotor impairment. Multiple Sclerosis and Related Disorders, 2021, 54, 103108.	0.9	3
1691	Beneficial effects of a nano formulation of pomegranate seed oil, GranaGard, on the cognitive function of multiple sclerosis patients. Multiple Sclerosis and Related Disorders, 2021, 54, 103103.	0.9	11
1692	Cerebrospinal fluid levels of Lâ€glutamate signal central inflammatory neurodegeneration in multiple sclerosis. Journal of Neurochemistry, 2021, 159, 857-866.	2.1	7
1693	Dosage and Effectiveness of Aerobic Training on Cardiorespiratory Fitness, Functional Capacity, Balance, and Fatigue in People With Multiple Sclerosis: A Systematic Review and Meta-Analysis. Archives of Physical Medicine and Rehabilitation, 2021, 102, 1826-1839.	0.5	19
1694	Kv1.3 Channel Up-Regulation in Peripheral Blood T Lymphocytes of Patients With Multiple Sclerosis. Frontiers in Pharmacology, 2021, 12, 714841.	1.6	3
1695	Differential Effects of Fingolimod and Natalizumab on Magnetic Resonance Imaging Measures in Relapsingâ€“Remitting Multiple Sclerosis. Neurotherapeutics, 2021, 18, 2589-2597.	2.1	0
1696	Multiple sclerosis epidemiological trends in Italy highlight the environmental risk factors. Journal of Neurology, 2022, 269, 1817-1824.	1.8	8
1697	Lessons of the month 1: Longitudinal extensive transverse myelitis following AstraZeneca COVID-19 vaccination. Clinical Medicine, 2021, 21, e535-e538.	0.8	34
1698	Disease Reactivation after Fingolimod Discontinuation in Pregnant Multiple Sclerosis Patients. Neurotherapeutics, 2021, 18, 2598-2607.	2.1	12
1699	Autoimmune diseases of the brain, imaging and clinical review. Neuroradiology Journal, 2021, , 197140092110428.	0.6	3
1700	A diagnostic confidence scheme for <scp>CLN3</scp> disease. Journal of Inherited Metabolic Disease, 2021, 44, 1453-1462.	1.7	3
1701	Biomarkers of systemic inflammation, soluble IL-2RÎ± and the multiple sclerosis-associated IL2RA SNP rs2104286 in healthy subjects and multiple sclerosis patients. Multiple Sclerosis and Related Disorders, 2021, 54, 103140.	0.9	5
1702	The Immunological Therapeutic Strategies for Controlling Multiple Sclerosis: Considerations during the COVID-19 Pandemic. Biomolecules, 2021, 11, 1372.	1.8	3
1703	A preliminary study of association of cigarette smoking with risk of neuromyelitis optica spectrum disorder. Medicine (United States), 2021, 100, e27234.	0.4	2
1704	Cognitive impairment and depression in patients with relapsingâ€“remitting multiple sclerosis depending on age and neuroimaging findings. Egyptian Journal of Neurology, Psychiatry and Neurosurgery, 2021, 57, 119.	0.4	1
1705	Electronic pill bottles to monitor and promote medication adherence for people with multiple sclerosis: A randomized, virtual clinical trial. Journal of the Neurological Sciences, 2021, 428, 117612.	0.3	5
1706	Expression and clinical significance of IL7R, NFATc2, and RNF213 in familial and sporadic multiple sclerosis. Scientific Reports, 2021, 11, 19260.	1.6	5
1707	Acute Demyelinating Syndromes: A report of Child neurology department of Sfax University hospital. Multiple Sclerosis and Related Disorders, 2021, 56, 103291.	0.9	0

#	Article	IF	Citations
1708	Chronic Relapsing Inflammatory Optic Neuropathy (CRION). Current Opinion in Ophthalmology, 2021, Publish Ahead of Print, 521-526.	1.3	4
1709	Role of the PDâ€1/PDâ€L1 Signaling in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis: Recent Insights and Future Directions. Molecular Neurobiology, 2021, 58, 6249-6271.	1.9	15
1710	The Dimethyl Fumarate Experience: A Handy Drug With Broad Clinical Utility. Frontiers in Neurology, 2021, 12, 679355.	1.1	2
1711	Effect of Changes in MS Diagnostic Criteria Over 25 Years on Time to Treatment and Prognosis in Patients With Clinically Isolated Syndrome. Neurology, 2021, 97, e1641-e1652.	1.5	35
1713	Automated quantification of deep grey matter structures and white matter lesions using magnetic resonance imaging in relapsing remission multiple sclerosis. Egyptian Journal of Radiology and Nuclear Medicine, 2021, 52, .	0.3	1
1714	Gray matter atrophy in relapsing-remitting multiple sclerosis is associated with white matter lesions in connecting fibers. Multiple Sclerosis Journal, 2022, 28, 900-909.	1.4	4
1715	Rational laboratory testing in uveitis: A Bayesian analysis. Survey of Ophthalmology, 2021, 66, 802-825.	1.7	8
1716	Microstructure-Weighted Connectomics in Multiple Sclerosis. Brain Connectivity, 2022, 12, 6-17.	0.8	4
1717	Accumulative risk of clinical event in high-risk radiologically isolated syndrome in Argentina: data from the nationwide registry RelevarEM. Journal of Neurology, 2022, 269, 2073-2079.	1.8	2
1718	Different neuroinflammatory gene expression profiles in highly active and benign multiple sclerosis. Journal of Neuroimmunology, 2021, 358, 577650.	1.1	3
1719	EBI2-expressing B cells in neuromyelitis optica spectrum disorder with AQP4-IgG: Association with acute attacks and serum cytokines. Journal of Neuroimmunology, 2021, 358, 577637.	1.1	1
1720	Multiple sclerosis epidemiology in Asia and Oceania; A systematic review and meta-analysis. Multiple Sclerosis and Related Disorders, 2021, 54, 103119.	0.9	18
1721	Conus medullaris involvement in demyelinating disorders of the CNS: A comparative study. Multiple Sclerosis and Related Disorders, 2021, 54, 103127.	0.9	8
1722	Apparent changes in the epidemiology and severity of multiple sclerosis. Nature Reviews Neurology, 2021, 17, 676-688.	4.9	69
1723	The blood biomarkers puzzle â€“ A review of protein biomarkers in neurodegenerative diseases. Journal of Neuroscience Methods, 2021, 361, 109281.	1.3	14
1724	Kappa free light chain index as a diagnostic biomarker in multiple sclerosis: A realâ€world investigation. Journal of Neurochemistry, 2021, 159, 618-628.	2.1	26
1726	Irisin levels in the serum and cerebrospinal fluid of patients with multiple sclerosis and the expression and distribution of irisin in experimental autoimmune encephalomyelitis. Clinical and Experimental Immunology, 2021, 206, 208-215.	1.1	5
1727	Anti-severe acute respiratory syndrome coronavirus-2 antibody responses following Pfizer-BioNTech vaccination in a patient with multiple sclerosis treated with ocrelizumab: a case report. Journal of International Medical Research, 2021, 49, 030006052110443.	0.4	2

#	Article	IF	Citations
1729	Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic strategies. Journal of Neuroinflammation, 2021, 18, 208.	3.1	105
1731	MACHINE LEARNING ALGORITHMS IMPLEMENTATION IN THE HEALTHCARE SYSTEM AS A PROSPECTIVE AREA FOR SCIENCE, HEALTHCARE, AND BUSINESS. Medical Science of Ukraine (MSU), 2021, 17, 98-109.	0.0	0
1732	Clinical and epidemiological characteristics of multiple sclerosis in students in the Republic of Bashkortostan. Nevrologiya, Neiropsikhiatriya, Psikhosomatika, 2021, 13, 15-20.	0.2	1
1733	Genome-wide polygenic analysis of multiple sclerosis markers. Nevrologiya, Neiropsikhiatriya, Psikhosomatika, 2021, 13, 31-38.	0.2	1
1734	A pipeline to quantify spinal cord atrophy with deep learning: Application to differentiation of MS and NMOSD patients. Physica Medica, 2021, 89, 51-62.	0.4	2
1735	Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial. Lancet Neurology, The, 2021, 20, 729-738.	4.9	89
1736	MRI Patterns Distinguish AQP4 Antibody Positive Neuromyelitis Optica Spectrum Disorder From Multiple Sclerosis. Frontiers in Neurology, 2021, 12, 722237.	1.1	8
1738	Assessment of Artificial Intelligence Automatic Multiple Sclerosis Lesion Delineation Tool for Clinical Use. Clinical Neuroradiology, 2022, 32, 643-653.	1.0	5
1739	Imaging findings and diagnosis of atypical aggressive demyelinating lesions of the central nervous system. Journal of Radiological Review, 2021, 8, .	0.1	0
1740	Neurological disorders encountered at an out-patient clinic in Ghana's largest medical center: A 16-year review. ENeurologicalSci, 2021, 24, 100361.	0.5	3
1741	Transcranial direct current stimulation (tDCS) for improving fatigue, motor function, and pain in people with multiple sclerosis. The Cochrane Library, 2021, 2021, .	1.5	0
1742	Cognitive recovery in people with relapsing/remitting multiple sclerosis: A randomized clinical trial on virtual reality-based neurorehabilitation. Clinical Neurology and Neurosurgery, 2021, 208, 106828.	0.6	27
1743	An Unusual Case of Isolated Acute Aphasia in Multiple Sclerosis. Cureus, 2021, 13, e18278.	0.2	1
1744	Novel Foveal Features Associated With Vision Impairment in Multiple Sclerosis. , 2021, 62, 27.		1
1745	Progressive multifocal leukoencephalopathy with mild clinical conditions and detection of archetype-like JC virus in cerebrospinal fluid. Journal of NeuroVirology, 2021, , 1.	1.0	1
1746	Prediction in treatment outcomes in multiple sclerosis: challenges and recent advances. Expert Review of Clinical Immunology, 2021, 17, 1187-1198.	1.3	0
1747	<scp>7T MRI</scp> Differentiates Remyelinated from Demyelinated Multiple Sclerosis Lesions. Annals of Neurology, 2021, 90, 612-626.	2.8	37
1748	Consumer experience of a flexible exercise participation program (FEPP) for individuals with multiple sclerosis: A mixedâ€methods study. Physiotherapy Research International, 2021, 26, e1922.	0.7	3

#	Article	IF	Citations
1749	Potential Biomarkers Associated with Multiple Sclerosis Pathology. International Journal of Molecular Sciences, 2021, 22, 10323.	1.8	14
1750	Visual Function and Brief Cognitive Assessment for Multiple Sclerosis in Optic Neuritis Clinically Isolated Syndrome Patients. Journal of Neuro-Ophthalmology, 2022, 42, e22-e31.	0.4	4
1751	Aquaporin-4 Autoantibody Detection by ELISA: A Retrospective Characterization of a Commonly Used Assay. Multiple Sclerosis International, 2021, 2021, 1-6.	0.4	5
1752	Age at Disease Onset Associates With Oxidative Stress, Neuroinflammation, and Impaired Synaptic Plasticity in Relapsing-Remitting Multiple Sclerosis. Frontiers in Aging Neuroscience, 2021, 13, 694651.	1.7	9
1753	Role of BÂcells in the pathogenesis of multiple sclerosis. Clinical and Experimental Neuroimmunology, 2021, 12, 220-227.	0.5	2
1754	Smoldering lesions in MS: if you like it then you should put a rim on it. Neuroradiology, 2022, 64, 703-714.	1.1	8
1755	Elevated levels of serum CD5 antigen-like protein distinguish secondary progressive multiple sclerosis from other disease subtypes. Multiple Sclerosis and Related Disorders, 2021, 56, 103269.	0.9	3
1756	Eosinophilia during natalizumab treatment: Incidence, risk factors and temporal patterns. Journal of Neuroimmunology, 2021, 361, 577729.	1.1	1
1757	Italian translation and psychometric validation of the ABILHAND-26 and its correlation with upper limb objective and subjective measures in multiple sclerosis subjects. Multiple Sclerosis and Related Disorders, 2021, 55, 103160.	0.9	3
1758	Evaluation of ocrelizumab in older progressive multiple sclerosis patients. Multiple Sclerosis and Related Disorders, 2021, 55, 103171.	0.9	5
1759	Missed MS or MIMS not prodromal MS: Expanding the diagnostic MS spectrum. Multiple Sclerosis and Related Disorders, 2021, 55, 103223.	0.9	0
1760	Characterization of humoral response to COVID mRNA vaccines in multiple sclerosis patients on disease modifying therapies. Vaccine, 2021, 39, 6111-6116.	1.7	39
1761	Humoral immune response after COVID-19 in multiple sclerosis: A nation-wide Austrian study. Multiple Sclerosis Journal, 2021, 27, 2209-2218.	1.4	25
1762	Diagnostic approach in multiple sclerosis with MRI: an update. Clinical Imaging, 2021, 78, 276-285.	0.8	7
1763	Therapeutic plasma exchange in MS refractory relapses: Long-term outcome. Multiple Sclerosis and Related Disorders, 2021, 55, 103168.	0.9	3
1764	Outcomes of COVID-19 infection in multiple sclerosis and related conditions: One-year pandemic experience of the multicenter New York COVID-19 Neuroimmunology Consortium (NYCNIC). Multiple Sclerosis and Related Disorders, 2021, 55, 103153.	0.9	16
1765	Radiologically isolated syndrome: A single-center, retrospective cohort study. Multiple Sclerosis and Related Disorders, 2021, 55, 103183.	0.9	6
1766	High-dose biotin for multiple sclerosis: A systematic review and meta-analyses of randomized controlled trials. Multiple Sclerosis and Related Disorders, 2021, 55, 103159.	0.9	6

#	Article	IF	Citations
1767	Severely disabled multiple sclerosis patients can achieve the performance of healthy subjects after expiratory muscle strength training. Multiple Sclerosis and Related Disorders, 2021, 55, 103187.	0.9	4
1768	Prevalence of Multiple Sclerosis in Rosario, Argentina. Multiple Sclerosis and Related Disorders, 2021, 55, 103212.	0.9	5
1769	Multiple sclerosis care units in Latin America: Consensus recommendations about its objectives and functioning implementation. Journal of the Neurological Sciences, 2021, 429, 118072.	0.3	7
1770	Sulfatide in health and disease. The evaluation of sulfatide in cerebrospinal fluid as a possible biomarker for neurodegeneration. Molecular and Cellular Neurosciences, 2021, 116, 103670.	1.0	17
1771	Results from SPECTRUM: A survey of healthcare professionals to understand current diagnosis and management practices for secondary progressive multiple sclerosis in the United Kingdom. Multiple Sclerosis and Related Disorders, 2021, 55, 103174.	0.9	2
1772	Progressive brain microstructural damage in patients with multiple sclerosis but not in patients with neuromyelitis optica spectrum disorder: A cross-sectional and follow-up tract-based spatial statistics study. Multiple Sclerosis and Related Disorders, 2021, 55, 103178.	0.9	6
1773	Multiple sclerosis incidence and prevalence in Poland: Data from administrative health claims. Multiple Sclerosis and Related Disorders, 2021, 55, 103162.	0.9	10
1774	Informed DEcision for cerebrospinal fluid analysis after epiLeptic seizures- the IDEAL-score: A development and validation study. Seizure: the Journal of the British Epilepsy Association, 2021, 91, 228-232.	0.9	1
1775	Five-year visual outcomes after optic neuritis in anti-MOG antibody-associated disease. Multiple Sclerosis and Related Disorders, 2021, 56, 103222.	0.9	14
1776	Disease-modifying therapies and progressive multifocal leukoencephalopathy in multiple sclerosis: A systematic review and meta-analysis. Journal of Neuroimmunology, 2021, 360, 577721.	1.1	21
1777	Dietary risk factors of primary progressive multiple sclerosis: A population-based case-control study. Multiple Sclerosis and Related Disorders, 2021, 56, 103233.	0.9	5
1778	Long-term outcomes in patients presenting with optic neuritis: Analyses of the MSBase registry. Journal of the Neurological Sciences, 2021, 430, 118067.	0.3	9
1779	C3 and C4 complement levels in AQP4-IgG-positive NMOSD and in MOGAD. Journal of Neuroimmunology, 2021, 360, 577699.	1.1	16
1780	In vivo evidence of functional disconnection between brainstem monoaminergic nuclei and brain networks in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2021, 56, 103224.	0.9	4
1781	High titers of myelin oligodendrocyte glycoprotein antibody are only observed close to clinical events in pediatrics. Multiple Sclerosis and Related Disorders, 2021, 56, 103253.	0.9	16
1782	Peripheral nervous system electrodiagnostic abnormalities in predominantly Hispanic Multiple Sclerosis patients. Multiple Sclerosis and Related Disorders, 2021, 56, 103254.	0.9	1
1783	Cerebrospinal Tau levels as a predictor of early disability in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2021, 56, 103231.	0.9	13
1784	Diagnosis of multiple sclerosis using multifocal ERG data feature fusion. Information Fusion, 2021, 76, 157-167.	11.7	5

#	Article	IF	Citations
1785	Multiple sclerosis lesions segmentation from multiple experts: The MICCAI 2016 challenge dataset. NeuroImage, 2021, 244, 118589.	2.1	23
1786	Using advanced analysis of multifocal visual-evoked potentials to evaluate the risk of clinical progression in patients with radiologically isolated syndrome. Scientific Reports, 2021, 11, 2036.	1.6	5
1787	Cognitive Processes Underlying Verbal Fluency in Multiple Sclerosis. Frontiers in Neurology, 2020, 11, 629183.	1.1	17
1788	The Effect of IFN-Î² Treatment on Plasma Levels of BDNF and IL-6 in Relapsing-Remitting Multiple Sclerosis Patients. NeuroImmunoModulation, 2021, 28, 150-157.	0.9	7
1789	In vivo detection of teriflunomide-derived fluorine signal during neuroinflammation using fluorine MR spectroscopy. Theranostics, 2021, 11, 2490-2504.	4.6	10
1790	Radiologically isolated syndrome: from biological bases to practical management. Neurological Sciences, 2021, 42, 1335-1344.	0.9	3
1791	In vivo tensor-valued diffusion MRI of focal demyelination in white and deep grey matter of rodents. NeuroImage: Clinical, 2021, 30, 102675.	1.4	7
1792	Memory, processing of emotional stimuli, and volume of limbic structures in pediatric-onset multiple sclerosis. NeuroImage: Clinical, 2021, 31, 102753.	1.4	4
1793	Therapeutic plasma exchange in steroid-refractory multiple sclerosis relapses. A retrospective two-center study. Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642097564.	1.5	9
1795	3D Quantitative Synthetic MRI in the Evaluation of Multiple Sclerosis Lesions. American Journal of Neuroradiology, 2021, 42, 471-478.	1.2	16
1796	The IL-2 â€“ IL-2 receptor pathway: Key to understanding multiple sclerosis. Journal of Translational Autoimmunity, 2021, 4, 100123.	2.0	11
1797	Neurological manifestations similar to multiple sclerosis in adults after Zika virus infection. , 2021, , 199-207.		1
1798	Patterns of cortical grey matter thickness reduction in multiple sclerosis. Brain and Behavior, 2021, 11, e02050.	1.0	11
1799	Recurrence and Prognostic Value of Asymptomatic Spinal Cord Lesions in Multiple Sclerosis. Journal of Clinical Medicine, 2021, 10, 463.	1.0	6
1801	Usage trend of oral drugs for multiple sclerosis patients in Argentina. Multiple Sclerosis and Related Disorders, 2021, 47, 102664.	0.9	2
1803	Noninvasive Electrophysiology. Neuromethods, 2021, , 251-265.	0.2	0
1805	Positive effects of ocrelizumab in patients with familial mediterranean fever and coexistent multiple sclerosis. Archives of Rheumatology, 2021, 36, 219-226.	0.3	3
1806	Predicting conversion to multiple sclerosis in patients with radiologically isolated syndrome: a retrospective study. Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642110306.	1.5	2

#	Article	IF	Citations
1807	Evaluating the role of HLA DRB1 alleles and oligoclonal bands in influencing clinical course of multiple sclerosis â€“ A study from the Mangalore demyelinating disease registry. Annals of Indian Academy of Neurology, 2021, 24, 356.	0.2	1
1808	Effect of Ocrelizumab in Blood Leukocytes of Patients With Primary Progressive MS. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	3.1	38
1809	Socioeconomic disparity is associated with faster retinal neurodegeneration in multiple sclerosis. Brain, 2021, 144, 3664-3673.	3.7	13
1810	Revealing vascular abnormalities and measuring small vessel density in multiple sclerosis lesions using USPIO. NeuroImage: Clinical, 2021, 29, 102525.	1.4	13
1811	Neutrophil-to-lymphocyte ratio: a marker of neuro-inflammation in multiple sclerosis?. Journal of Neurology, 2021, 268, 717-723.	1.8	19
1812	Neuromyelitis optica is an HLA associated disease different from Multiple Sclerosis: a systematic review with meta-analysis. Scientific Reports, 2021, 11, 152.	1.6	18
1813	Radiomic analysis of the optic nerve at the first episode of acute optic neuritis: an indicator of optic nerve pathology and a predictor of visual recovery?. Radiologia Medica, 2021, 126, 698-706.	4.7	36
1814	Memory rehabilitation for people with multiple sclerosis. The Cochrane Library, 2021, 2021, CD008754.	1.5	19
1815	Realâ€world experience of ocrelizumab in multiple sclerosis in a Spanish population. Annals of Clinical and Translational Neurology, 2021, 8, 385-394.	1.7	23
1816	Systematic Understanding of Bioactive Lipids in Neuro-Immune Interactions: Lessons from an Animal Model of Multiple Sclerosis. Advances in Experimental Medicine and Biology, 2019, 1161, 133-148.	0.8	16
1817	OCT and Multiple Sclerosis. , 2020, , 195-233.		4
1818	EntzÃ¼ndliche Erkrankungen. , 2019, , 51-98.		2
1819	Leukocyte profiles in blood and CSF distinguish neurosarcoidosis from multiple sclerosis. Journal of Neuroimmunology, 2020, 341, 577171.	1.1	17
1820	Choroid plexus changes on magnetic resonance imaging in multiple sclerosis and neuromyelitis optica spectrum disorder. Journal of the Neurological Sciences, 2020, 415, 116904.	0.3	16
1821	Should spinal cord MRI be systematically performed for diagnosis and follow-up of multiple sclerosis? Synthesis. Revue Neurologique, 2020, 176, 490-493.	0.6	1
1822	Impact of communication on first treatment decisions in people with relapsing-remitting multiple sclerosis. Patient Education and Counseling, 2020, 103, 2540-2547.	1.0	8
1823	Translating research findings into clinical practice: a systematic and critical review of neuroimaging-based clinical tools for brain disorders. Translational Psychiatry, 2020, 10, 107.	2.4	29
1824	Epigenetic differences at the HTR2A locus in progressive multiple sclerosis patients. Scientific Reports, 2020, 10, 22217.	1.6	9

#	Article	IF	Citations
1825	Multiple Sclerosis: Epidemiology, Genetics, Symptoms, and Unmet Needs. RSC Drug Discovery Series, 2019, , 1-32.	0.2	6
1826	A current understanding of multiple sclerosis. JAAPA: Official Journal of the American Academy of Physician Assistants, 2020, 33, 19-23.	0.1	5
1827	Deep Learning on Conventional Magnetic Resonance Imaging Improves the Diagnosis of Multiple Sclerosis Mimics. Investigative Radiology, 2021, 56, 252-260.	3.5	20
1828	Diagnostic Error of Neuro-ophthalmologic Conditions: State of the Science. Journal of Neuro-Ophthalmology, 2021, 41, 98-113.	0.4	13
1835	Brainstem and cerebellar involvement in MOG-IgG-associated disorder versus aquaporin-4-IgG and MS. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 384-390.	0.9	55
1836	Transient enlargement of brain ventricles during relapsing-remitting multiple sclerosis and experimental autoimmune encephalomyelitis. JCI Insight, 2020, 5, .	2.3	13
1837	Primary Progressive Multiple Sclerosis Under Anti-TNFÎ± Treatment: A Case Report. Journal of Central Nervous System Disease, 2020, 12, 117957352097382.	0.7	1
1838	Intrathecally produced CXCL13: A predictive biomarker in multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2020, 6, 205521732098139.	0.5	25
1839	18F-florbetapir PET/MRI for quantitatively monitoring demyelination and remyelination in acute disseminated encephalomyelitis. EJNMMI Research, 2019, 9, 96.	1.1	5
1840	Ultra-high-field 7-T MRI in multiple sclerosis and other demyelinating diseases: from pathology to clinical practice. European Radiology Experimental, 2020, 4, 59.	1.7	23
1841	Assessment of the optic nerve and its arterial supply by ultrasound imaging in multiple sclerosis patients. Egyptian Journal of Neurology, Psychiatry and Neurosurgery, 2019, 55, .	0.4	1
1842	Early disability in ambulatory patients with multiple sclerosis: optical coherence tomography versus visual evoked potentials, a comparative study. Egyptian Journal of Neurology, Psychiatry and Neurosurgery, 2020, 56, .	0.4	2
1843	Progressive Multiple Sclerosis. CONTINUUM Lifelong Learning in Neurology, 2019, 25, 736-752.	0.4	15
1844	Diagnosis, Differential Diagnosis, and Misdiagnosis of Multiple Sclerosis. CONTINUUM Lifelong Learning in Neurology, 2019, 25, 611-635.	0.4	15
1845	Clinically Isolated Syndrome and Early Relapsing Multiple Sclerosis. CONTINUUM Lifelong Learning in Neurology, 2019, 25, 670-688.	0.4	5
1846	Management of Multiple Sclerosis Relapses. CONTINUUM Lifelong Learning in Neurology, 2019, 25, 655-669.	0.4	22
1847	Optic Neuritis. CONTINUUM Lifelong Learning in Neurology, 2019, 25, 1236-1264.	0.4	65
1848	Optic Nerve Topography in Multiple Sclerosis Diagnosis. Neurology, 2021, 96, e482-e490.	1.5	32

#	Article	IF	Citations
1849	Atypical Presentation of Acute Disseminated Encephalomyelitis (ADEM) in a Middle-Aged Adult. American Journal of Case Reports, 2019, 20, 361-365.	0.3	2
1850	Emerging small-molecule treatments for multiple sclerosis: focus on B cells. F1000Research, 2019, 8, 245.	0.8	15
1851	An examination of the effects of a patient-designed-and-informed participant information sheet in comparison with a standard, researcher-designed information sheet on recruitment, retention and understanding: Protocol for a study-within-a-trial. HRB Open Research, 2020, 3, 4.	0.3	6
1852	Determination of chitinase 3-like 1 in cerebrospinal fluid in multiple sclerosis and other neurological diseases. PLoS ONE, 2020, 15, e0233519.	1.1	21
1853	The central vein sign in the differential diagnosis of multiple sclerosis. Nevrologiya, Neiropsikhiatriya, Psikhosomatika, 2020, 12, 29-32.	0.2	1
1854	Inter-center agreement in the interpretation of oligoclonal bands. Clinical Chemistry and Laboratory Medicine, 2021, 59, e91-e94.	1.4	4
1855	Management of central nervous system demyelinating diseases during the coronavirus disease 2019 pandemic: a practical approach. Arquivos De Neuro-Psiquiatria, 2020, 78, 430-439.	0.3	7
1862	Paroxysmal dystonia as an initial presentation of multiple sclerosis posing a diagnostic challenge. Journal of King Abdulaziz University, Islamic Economics, 2019, 24, 236-239.	0.5	7
1863	Detection of NUCB2/nesfatin-1 in cerebrospinal fluid of multiple sclerosis patients. Aging, 2020, 12, 24134-24140.	1.4	4
1864	â€œA rose by any other nameâ€¦ does defining extreme phenotypes add to the management of multiple sclerosis?. Annals of Translational Medicine, 2018, 6, 396-396.	0.7	1
1865	Medicinal Chemistry of Multiple Sclerosis: Focus on Cladribine. Mini-Reviews in Medicinal Chemistry, 2020, 20, 269-285.	1.1	6
1866	Early Diagnosis of Multiple Sclerosis Based on Optical and Electrochemical Biosensors: Comprehensive Perspective. Current Analytical Chemistry, 2020, 16, 557-569.	0.6	12
1867	Biomarkers of Multiple Sclerosis. The Open Immunology Journal, 2019, 9, 1-13.	1.5	8
1868	Identification of Factors That Motivate People With Multiple Sclerosis to Participate in Digital Data Collection in Research: Sequential Mixed Methods Study. JMIR Human Factors, 2019, 6, e13295.	1.0	5
1869	Feasibility of Real Time Internet-Based Teleconsultation in Patients With Multiple Sclerosis: Interventional Pilot Study. Journal of Medical Internet Research, 2020, 22, e18178.	2.1	24
1870	Evaluation of More Stamina, a Mobile App for Fatigue Management in Persons with Multiple Sclerosis: Protocol for a Feasibility, Acceptability, and Usability Study. JMIR Research Protocols, 2020, 9, e18196.	0.5	11
1871	Feasibility of a Home-Based Tablet App for Dexterity Training in Multiple Sclerosis: Usability Study. JMIR MHealth and UHealth, 2020, 8, e18204.	1.8	9
1872	Value of 3T Susceptibility-Weighted Imaging in the Diagnosis of Multiple Sclerosis. American Journal of Neuroradiology, 2020, 41, 1001-1008.	1.2	68

#	Article	IF	Citations
1873	Improved Cervical Cord Lesion Detection with 3D-MP2RAGE Sequence in Patients with Multiple Sclerosis. American Journal of Neuroradiology, 2020, 41, 1131-1134.	1.2	7
1874	Amiloride, fluoxetine or riluzole to reduce brain volume loss in secondary progressive multiple sclerosis: the MS-SMART four-arm RCT. Efficacy and Mechanism Evaluation, 2020, 7, 1-72.	0.9	11
1875	Epstein-Barr Virus and Multiple Sclerosis. Frontiers in Immunology, 2020, 11, 587078.	2.2	52
1876	Optical Coherence Tomography and Optical Coherence Tomography Angiography Findings After Optic Neuritis in Multiple Sclerosis. Frontiers in Neurology, 2020, 11, 618879.	1.1	17
1877	Evidence of Oligoclonal Bands Does Not Exclude Non-Inflammatory Neurological Diseases. Diagnostics, 2021, 11, 37.	1.3	19
1878	Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: Current Insights into the Disease Pathophysiology, Diagnosis and Management. International Journal of Molecular Sciences, 2021, 22, 100.	1.8	74
1879	Safety of Newer Disease Modifying Therapies in Multiple Sclerosis. Vaccines, 2021, 9, 12.	2.1	28
1880	Clinical Spectrum of Myelin Oligodendrocyte Glycoprotein-Immunoglobulin G-Associated Disease in		

#	Article	IF	Citations
1891	Clinical presentation and diagnosis of multiple sclerosis. Clinical Medicine, 2020, 20, 380-383.	0.8	57
1892	Multiple sclerosis. Mental Health Clinician, 2019, 9, 349-358.	0.5	12
1893	Assisting the diagnosis of multiple sclerosis using a set of regional brain volumes: A classification model for patients and healthy controls. Informatics in Medicine Unlocked, 2021, 26, 100766.	1.9	2
1894	Imaging cortical multiple sclerosis lesions with ultra-high field MRI. NeuroImage: Clinical, 2021, 32, 102847.	1.4	8
1895	SARS-CoV-2 Serology Among People with Multiple Sclerosis on Disease-Modifying Therapies after BBIBP-CorV (Sinopharm) Inactivated Virus Vaccination: Same Story, Different Vaccine. SSRN Electronic Journal, 0, , .	0.4	1
1896	ALL-Net: Anatomical information lesion-wise loss function integrated into neural network for multiple sclerosis lesion segmentation. NeuroImage: Clinical, 2021, 32, 102854.	1.4	14
1897	A Structured Evaluation of Cryopreservation in Generating Single Cell Transcriptomes From Cerebrospinal Fluid. SSRN Electronic Journal, 0, , .	0.4	0
1898	Experimental autoimmune encephalomyelitis inhibited by huangqi guizhi wuwu decoction via th2 cytokine enhancement. World Journal of Traditional Chinese Medicine, 2021, 7, 467.	0.9	7
1899	Adverse childhood experiences predict reaction to multiple sclerosis diagnosis. Health Psychology Open, 2021, 8, 205510292110528.	0.7	6
1900	Stigma in Multiple Sclerosis: The Important Role of Sense of Coherence and Its Relation to Quality of Life. International Journal of Behavioral Medicine, 2022, 29, 517-523.	0.8	7
1901	Understanding and managing autonomic dysfunction in persons with multiple sclerosis. Expert Review of Neurotherapeutics, 2021, 21, 1409-1417.	1.4	2
1902	Alterations in Leg Muscle Glucose Uptake and Inter-Limb Asymmetry after a Single Session of tDCS in Four People with Multiple Sclerosis. Brain Sciences, 2021, 11, 1363.	1.1	3
1903	Next Generation Sequencing of Cerebrospinal Fluid B Cell Repertoires in Multiple Sclerosis and Other Neuro-Inflammatory Diseasesâ€"A Comprehensive Review. Diagnostics, 2021, 11, 1871.	1.3	2
1904	Biomarkers in Parkinsonâ€™s Disease. Neuromethods, 2022, , 155-180.	0.2	27
1905	K2P18.1 translates T cell receptor signals into thymic regulatory T cell development. Cell Research, 2022, 32, 72-88.	5.7	14
1906	Modelâ€informed assessment of ethnic sensitivity and dosage justification for Asian populations in the global clinical development and use of cladribine tablets. Clinical and Translational Science, 2021, , .	1.5	1
1907	Gut microbiota in forty cases of Egyptian relapsing remitting multiple sclerosis. Iranian Journal of Microbiology, 2021, 13, 632-641.	0.8	4
1908	Multiple sclerosis diagnosis: Knowledge gaps and opportunities for educational intervention in neurologists in the United States. Multiple Sclerosis Journal, 2022, 28, 1248-1256.	1.4	12

#	Article	IF	Citations
1909	Measurement of neurofilaments improves stratification of future disease activity in early multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 2001-2013.	1.4	9
1910	Association of Age at Onset With Gray Matter Volume and White Matter Microstructural Abnormalities in People With Multiple Sclerosis. Neurology, 2021, 97, e2007-e2019.	1.5	7
1911	Myelin imaging measures as predictors of cognitive impairment in MS patients: A hybrid PET-MRI study. Multiple Sclerosis and Related Disorders, 2022, 57, 103331.	0.9	13
1912	Significance of serum VIP and PACAP in multiple sclerosis: an exploratory caseâ€“control study. Neurological Sciences, 2021, , 1.	0.9	3
1913	Clinical, Neurophysiological, and MRI Markers of Fampridine Responsiveness in Multiple Sclerosisâ€”An Explorative Study. Frontiers in Neurology, 2021, 12, 758710.	1.1	1
1914	Evaluation of Natalizumab Pharmacokinetics and Pharmacodynamics: Toward Individualized Doses. Frontiers in Neurology, 2021, 12, 716548.	1.1	10
1915	The Immune Response in Multiple Sclerosis. Annual Review of Pathology: Mechanisms of Disease, 2022, 17, 121-139.	9.6	96
1916	Temporal trends of multiple sclerosis disease activity: Electronic health records indicators. Multiple Sclerosis and Related Disorders, 2022, 57, 103333.	0.9	4
1917	Assessment of the influence of various risk factors on the severity of psycho-emotional disorders in patients with multiple sclerosis. International Neurological Journal, 2021, 17, 31-35.	0.2	0
1918	Linking Microstructural Integrity and Motor Cortex Excitability in Multiple Sclerosis. Frontiers in Immunology, 2021, 12, 748357.	2.2	4
1919	Effects of voice rehabilitation in people with MS: A double-blinded long-term randomized controlled trial. Multiple Sclerosis Journal, 2022, 28, 1081-1090.	1.4	3
1920	Brief International Cognitive Assessment for Multiple Sclerosis scores are associated with the cortical thickness of specific cortical areas in relapsing-remitting patients. Revue Neurologique, 2022, 178, 326-336.	0.6	5
1921	Genetic, Environmental and Lifestyle Determinants of Accelerated Telomere Attrition as Contributors to Risk and Severity of Multiple Sclerosis. Biomolecules, 2021, 11, 1510.	1.8	19
1922	Efficacy of Cladribine Tablets as a Treatment for People With Multiple Sclerosis: Protocol for the CLOBAS Study (Cladribine, a Multicenter, Long-term Efficacy and Biomarker Australian Study). JMIR Research Protocols, 2021, 10, e24969.	0.5	4
1923	Multiple Sclerosis Following SARS-CoV-2 Infection: A Case Report and Literature Review. Cureus, 2021, 13, e19036.	0.2	9
1925	FLAIR2 post-processing: improving MS lesion detection in standard MS imaging protocols. Journal of Neurology, 2021, , 1.	1.8	0
1926	Rebound activity after fingolimod cessation: A case â€“ control study. Multiple Sclerosis and Related Disorders, 2022, 57, 103329.	0.9	6
1927	Product review on MAbs (alemtuzumab and ocrelizumab) for the treatment of multiple sclerosis. Human Vaccines and Immunotherapeutics, 2021, 17, 4345-4362.	1.4	6

#	Article	IF	Citations
1928	Clinical Pathway for the Diagnosis and Management of Patients With Relapsingâ€“Remitting Multiple Sclerosis: A First Proposal for the Peruvian Population. Frontiers in Neurology, 2021, 12, 667398.	1.1	1
1929	Case Report: Multiple Sclerosis Relapses After Vaccination Against SARS-CoV2: A Series of Clinical Cases. Frontiers in Neurology, 2021, 12, 765954.	1.1	42
1930	Prediction of multiple sclerosis outcomes when switching to ocrelizumab. Multiple Sclerosis Journal, 2022, 28, 958-969.	1.4	6
1931	What Can We Learn from Sex Differences in MS?. Journal of Personalized Medicine, 2021, 11, 1006.	1.1	25
1932	Impact of Vitamin D Supplementation on Multiple Sclerosis. Cureus, 2021, 13, e18487.	0.2	6
1933	Acute Response of Stress System in Multiple Sclerosis. Archives of Neuroscience, 2021, 8, .	0.1	0
1934	Objective biomarkers for clinical relapse in multiple sclerosis: a metabolomics approach. Brain Communications, 2021, 3, fcab240.	1.5	9
1935	Comparison of Spinal Cord Magnetic Resonance Imaging Features Among Children With Acquired Demyelinating Syndromes. JAMA Network Open, 2021, 4, e2128871.	2.8	27
1936	A three-year longitudinal study of retinal function and structure in patients with multiple sclerosis. Documenta Ophthalmologica, 2022, 144, 3-16.	1.0	1
1937	Effect of BDNF Val66Met polymorphism on hippocampal subfields in multiple sclerosis patients. Molecular Psychiatry, 2022, 27, 1010-1019.	4.1	10
1938	A deep learning algorithm for white matter hyperintensity lesion detection and segmentation. Neuroradiology, 2022, 64, 727-734.	1.1	9
1939	Incidence of paediatric multiple sclerosis and other acquired demyelinating syndromes: 10â€year followâ€up surveillance study. Developmental Medicine and Child Neurology, 2022, 64, 502-508.	1.1	4
1940	Real-world experience of ocrelizumab in multiple sclerosis in an Arab population. Journal of Drug Assessment, 2021, 10, 106-113.	1.1	4
1941	Project Y: The search for clues explaining phenotype variability in MS. Multiple Sclerosis and Related Disorders, 2022, 57, 103337.	0.9	8
1942	Laboratory biomarkers of Multiple Sclerosis (MS). Clinical Biochemistry, 2022, 99, 1-8.	0.8	10
1943	Automated Diagnosis of Multiple Sclerosis Lesions in Brain MRI Using 3D-FLAIR Acquisition. Lecture Notes in Networks and Systems, 2022, , 1-8.	0.5	0
1944	C-Reactive Protein Levels and Gadolinium-Enhancing Lesions Are Associated With the Degree of Depressive Symptoms in Newly Diagnosed Multiple Sclerosis. Frontiers in Neurology, 2021, 12, 719088.	1.1	2
1945	Impact of Lockdown during COVID-19 Pandemic on Central Activation, Muscle Activity, Contractile Function, and Spasticity in People with Multiple Sclerosis. BioMed Research International, 2021, 2021, 1-8.	0.9	3

#	Article	IF	Citations
1946	Utility of paramagnetic rim lesions on 1.5-T susceptibility phase imaging for the diagnosis of pediatric multiple sclerosis. Pediatric Radiology, 2021, 52, 97.	1.1	7
1947	Reappraisal of CSF-specific oligoclonal bands in Asia. Multiple Sclerosis Journal, 2022, 28, 665-668.	1.4	2
1948	Correlation between the clinical disability and T1 hypointense lesionsâ€™ volume in cerebral magnetic resonance imaging of multiple sclerosis patients: A systematic review and metaâ€analysis. CNS Neuroscience and Therapeutics, 2021, 27, 1268-1280.	1.9	12
1949	Isolated cognitive syndrome is a prodromal presentation of multiple sclerosis. Multiple Sclerosis and Related Disorders, 2021, 56, 103315.	0.9	1
1950	An appraisal of antigen identification and IgG effector functions driving host immune responses in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2021, 56, 103328.	0.9	3
1951	Retinal microvascular and neuronal function in patients with multiple sclerosis: 2-year follow-up. Multiple Sclerosis and Related Disorders, 2021, 56, 103314.	0.9	2
1952	Risk factors for idiopathic myelitis at admission and predictors for late diagnostic change. Journal of Neuroimmunology, 2021, 361, 577747.	1.1	0
1953	Initial clinical manifestation of multiple sclerosis after immunization with the Pfizer-BioNTech COVID-19 vaccine. Journal of Neuroimmunology, 2021, 361, 577755.	1.1	18
1958	Clinically and Radiological isolated syndrome (MS risk). Journal of Radiology and Oncology, 0, , 041-046.	0.2	0
1961	Multifocal Longitudinally Extensive Transverse Myelitis as a Rare Complication of Mumps Infection. Journal of Neurosonology and Neuroimaging, 2018, 10, 37-40.	0.0	0
1962	Novinky v zobrazovÃ¡nÃ: Neurologie Pro Praxi, 2018, 19, 240-242.	0.0	0
1963	Multiple sclerosis: treatment, monitoring, activity and disability. Neurologie Pro Praxi, 2018, 19, 267-270.	0.0	0
1964	Advances in imaging and diagnosing autoimmune and inflammatory diseases. Neurologie Pro Praxi, 2018, 19, 243-250.	0.0	0
1965	Glatiramer acetate in clinically isolated syndrome and its early onset of effect. Neurologie Pro Praxi, 2018, 19, 262-266.	0.0	0
1966	The role of vertebral artery hypoplasia in neurological practice. Aktualnosci Neurologiczne, 2018, 18, 94-98.	0.1	0
1967	Ocrelizumab - pharmacoloical profile. Neurologie Pro Praxi, 2018, 19, 380-386.	0.0	0
1968	Demographic and disease characteristics of multiple sclerosis in the Southwest Region of Saudi Arabia. Journal of King Abdulaziz University, Islamic Economics, 2018, 23, 320-325.	0.5	8
1969	Multiple Sklerose: Diagnostik. Springer Reference Medizin, 2019, , 1-13.	0.0	0

#	Article	IF	Citations
1970	Diagnosis of Multiple Sclerosis: 2017 McDonald Diagnostic Criteria. Journal of the Korean Neurological Association, 2018, 36, 273-279.	0.0	1
1971	Myelopathies. , 2019, , 347-375.		0
1972	Diagnostic Dilemmas. , 2019, , 473-532.		0
1973	Flammer Syndrome and Autoimmune Inflammatory Conditions of the Central Nervous System: Multifactorial Interrelations. Advances in Predictive, Preventive and Personalised Medicine, 2019, , 145-163.	0.6	1
1974	Progressive Multiple Sclerosis: Drug Discovery. RSC Drug Discovery Series, 2019, , 111-133.	0.2	0
1975	Down-regulation of IRF3 expression in Relapse-Remitting MS patients. AIMS Medical Science, 2019, 6, 140-147.	0.2	0
1976	Multiple Sklerose und andere entzÃ¼ndliche demyelinisierende Erkrankungen des zentralen Nervensystems bei Kindern und Jugendlichen. Springer Reference Medizin, 2019, , 1-7.	0.0	0
1978	Multiple Sclerosis and the Heart. , 2019, , 1-12.		0
1979	Interferon beta: Medication which started the revolution in the treatment of multiple sclerosis. Medicinski Podmladak, 2019, 70, 53-57.	0.2	1
1980	Biomarkers for Multiple Sclerosis. RSC Drug Discovery Series, 2019, , 55-75.	0.2	0
1981	Clinically Isolated Syndrome of Multiple Sclerosis: Clinical and Paraclinical Features. UkraÃ¯nsÊ¹kij Å¾urnal Medicini BÃ¬ologÃ¬Ã¯ Ta Sportu, 2019, 4, 161-165.	0.0	0
1983	Neuroborreliosis mimicking demyelinating disease of the central nervous system: case reports. Neurologijos Seminarai, 2018, 22, 219-223.	0.0	0
1984	Histoire naturelle de la sclÃ©rose en plaques. , 2019, , 107-135.		0
1985	Synchronous Presentation of a Cervical Spinal Schwannoma and Primary Progressive Multiple Sclerosis in a 65-year-old Man. Cureus, 2019, 11, e4176.	0.2	1
1986	Experience with anti-B-cell therapy in the pathogenetic treatment of multiple sclerosis. Nevrologiya, Neiropsikhiatriya, Psikhosomatika, 2019, 11, 59-65.	0.2	0
1987	Teriflunomide in treating clinically isolated syndrome. Neurologie Pro Praxi, 2019, 20, 131-135.	0.0	0
1989	Motor and non-motor manifestations of benign multiple sclerosis: the results of a 5-year prospective study. ScienceRise: Medical Science, 2019, .	0.0	0
1990	Incorporating Clinical Practice Guidelines and Quality Measures Into High-Quality Cost-Effective Care for Patients With Multiple Sclerosis. CONTINUUM Lifelong Learning in Neurology, 2019, 25, 845-849.	0.4	1

#	Article	IF	Citations
1991	New treatment options for relapsing-remitting multiple sclerosis. PraktickÃ© LÃ©kÃ¡renstvÃ, 2019, 15, 70-73.	0.0	0
1992	Dysfunction of bloodbrain barrier and intrathecal immune response in patients with clinically isolated multiple sclerosis syndrome. Ukrains Kyi Visnyk Psykhonevrolohii, 2019, 27, 20-22.	0.0	0
1993	Is non-traditional therapy for multiple sclerosis overwhelming in Saudi Arabia. Journal of King Abdulaziz University, Islamic Economics, 2019, 24, 192-198.	0.5	5
1994	QUALITY OF LIFE VALIDITATION IN PATIENTS WITH MULTIPLE SCLEROSIS BEFORE AND AFTER THERAPEUTIC PHYSICAL TREATMENT. International Journal of Scientific and Engineering Research, 2019, 10, 1260-1265.	0.1	0
1995	Radiological profile of multiple sclerosis in a tertiary care center: A study from Eastern India. IP Indian Journal of Neurosciences, 2019, 5, 78-80.	0.0	0
1996	Significance of multiple sclerosis early treatment. Neurologie Pro Praxi, 2019, 20, 288-290.	0.0	0
1998	Magnetic Resonance Imaging in the Differential Diagnosis of Multiple Sclerosis and Other Demyelinating Diseases. Vestnik Rentgenologii I Radiologii, 2019, 100, 229-236.	0.1	2
2000	The emerging role of serum zinc in motor disability and radiological findings in patients with multiple sclerosis. Egyptian Journal of Neurology, Psychiatry and Neurosurgery, 2019, 55, .	0.4	2
2001	Clinical Updates and Recent Developments in Neuro-Ophthalmology. , 2020, , 201-249.		0
2002	Magnetic Resonance Imaging and Analysis in Multiple Sclerosis. Current Clinical Neurology, 2020, , 109-136.	0.1	3
2003	DEMOGRAPHIC, CLINICAL AND PARACLINICAL CHARACTERISTICS OF MULTIPLE SCLEROSIS MIMICS AMONG A SAMPLE OF EGYPTIAN PATIENTS. Al Azhar Medical Journal = Majallat Al-Tibb Al-Azhar, 2019, 48, 363-376.	0.0	0
2005	Clinical Features, Symptom Management, and Diagnosis. Current Clinical Neurology, 2020, , 89-108.	0.1	0
2006	Imaging in Neuro-ophthalmology. CONTINUUM Lifelong Learning in Neurology, 2019, 25, 1438-1490.	0.4	5
2007	Multiple Sclerosis in Children. Current Clinical Neurology, 2020, , 179-196.	0.1	1
2008	Natalizumab: safety and risk in patients with relapsing-remitting multiple sclerosis. European Journal of Hospital Pharmacy, 2021, 28, 112-114.	0.5	2
2009	Recurrent Optic Neuritis and Acute Encephalopathy with Myelin Oligodendrocyte Glycoprotein Antibodies in a Korean Child. Soonchunhyang Medical Science, 2019, 25, 121-124.	0.0	0
2010	Vanishing Pseudotumoral White Matter Lesions Presenting as Aphasia and Altered Mental Status in a 71-Year-Old Male. Cureus, 2019, 11, e6284.	0.2	0
2011	Use of a Zorb Bumper Ball in rehabilitation of a patient with ataxic multiple sclerosis: A case report. Journal of Neurology Neurological Science and Disorders, 0, , 057-061.	1.2	0

#	Article	IF	Citations
2012	AvaliaÃ§Ã£o da qualidade de vida em portadores de esclerose mÃºltipla: impacto da fadiga, ansiedade e depressÃ£o. Fisioterapia E Pesquisa, 2019, 26, 339-345.	0.3	4
2013	Long-Term Prognosis for MS 30 Years After Clinically Isolated Syndrome. Neurology Today: an Official Publication of the American Academy of Neurology, 2019, 19, 33-35.	0.0	0
2014	Diagnostik und Therapie neurologischer Erkrankungen bei Kindern und Jugendlichen. , 2020, , 421-443.		0
2015	Inflammatory and Infectious Lesions of the Brainstem. , 2020, , 217-245.		0
2016	Multiple Sclerosis and the Heart. , 2020, , 529-540.		0
2019	Prognostic significance of intrathecal oligoclonal immunoglobulin G in multiple sclerosis. Scripta Medica, 2020, 51, 147-151.	0.0	0
2020	Automated Detection of Cortical Lesions in Multiple Sclerosis Patients with 7T MRI. Lecture Notes in Computer Science, 2020, , 584-593.	1.0	9
2021	Cognitive Research on Early Multiple Sclerosis. , 2020, , 189-205.		0
2022	The role of vestibular evoked myogenic potential and the video head impulse test in patients with multiple sclerosis without radiologic findings. Neurological Sciences and Neurophysiology, 2020, 37, 170.	0.1	1
2023	Hindsight Is 20/20. Journal of Hospital Medicine, 2020, 15, 245-249.	0.7	0
2024	Diagnostic significance of intrathecally synthesized immunoglobulins against neurotropic viruses (MRZ-reaction) in diagnosis of multiple sclerosis. Russian Journal of Infection and Immunity, 2020, 9, 703-712.	0.2	1
2026	Acute Disseminated Encephalomyelitis (ADEM) versus Multiple Sclerosis (MS)- A Diagnostic Challenge in an Adult. Journal of Evolution of Medical and Dental Sciences, 2020, 9, 1672-1674.	0.1	1
2028	Multipl Sklerozda Epileptik NÃ¶betler. Kocaeli Ãœniversitesi SaÄŸlÄ±k Bilimleri Dergisi, 0, , 123-126.	0.3	0
2029	Should spinal cord MRI be systematically performed for diagnosis and follow up of multiple sclerosis? Yes. Revue Neurologique, 2020, 176, 487-489.	0.6	0
2031	High-dose vitamin B supplementation for persistent visual deficit in multiple sclerosis: a pilot study. Drug Discoveries and Therapeutics, 2020, 14, 122-128.	0.6	6
2032	The Effects of Different Kinds of Nutrition and Functional Foods on Multiple Sclerosis. Current Nutrition and Food Science, 2020, 16, 632-637.	0.3	0
2033	Clinical features and physical performance in multiple sclerosis patients with and without cognitive impairment: a cross-sectional study. International Journal of Rehabilitation Research, 2020, 43, 316-323.	0.7	2
2034	Neuritis Ã³pticas desmielinizantes y autoinmunes. Archivos De La Sociedad Espanola De Oftalmologia, 2020, 95, 386-395.	0.1	2

#	Article	IF	Citations
2035	Focus on Chinese herbal medicine therapy for multiple sclerosis by dialectical treatment. Chinese Medical Journal, 2021, 134, 278-280.	0.9	3
2036	The Canadian prospective cohort study to understand progression in multiple sclerosis (CanProCo): rationale, aims, and study design. BMC Neurology, 2021, 21, 418.	0.8	5
2037	Serum levels and genetic variation of IL-35 are associated with multiple sclerosis: a population-based caseâ€“control study. Immunologic Research, 2021, , 1.	1.3	1
2038	Myelin Oligodendrocyte Glycoprotein-Immunoglobulin G in the CSF. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, .	3.1	43
2039	Optical Coherence Tomography in the Differential Diagnosis of Patients with Multiple Sclerosis and Patients with MRI Nonspecific White Matter Lesions. Sensors, 2021, 21, 7127.	2.1	2
2040	Late Component of the Trigemino-Cervical Reflex. Journal of Clinical Neurophysiology, 2021, Publish Ahead of Print, .	0.9	0
2041	Effects of Pregnancy and Breastfeeding on Clinical Outcomes and MRI Measurements of Women with Multiple Sclerosis: An Exploratory Real-World Cohort Study. Neurology and Therapy, 2022, 11, 39-49.	1.4	12
2042	Multiple sclerosis diagnostic criteria: from Poser to the 2017 revised McDonald criteria. Presse Medicale, 2021, 50, 104089.	0.8	3
2043	Performance of the 2017 and 2010 Revised McDonald Criteria in Predicting MS Diagnosis After a Clinically Isolated Syndrome. Neurology, 2022, 98, .	1.5	31
2044	To be, or not to beâ€¦ Guillain-BarrÃ© Syndrome. Autoimmunity Reviews, 2021, 20, 102983.	2.5	7
2045	Cerebrospinal Fluid IgM and Oligoclonal IgG Bands in Multiple Sclerosis: A Meta-Analysis of Prevalence and Prognosis. Brain Sciences, 2021, 11, 1444.	1.1	5
2046	Factors driving delayed time to multiple sclerosis diagnosis: Results from a population-based study. Multiple Sclerosis and Related Disorders, 2022, 57, 103361.	0.9	11
2047	The wearing-off phenomenon of ocrelizumab in patients with multiple sclerosis. Multiple Sclerosis and Related Disorders, 2022, 57, 103364.	0.9	5
2048	Effectiveness and side effects of dimethyl fumarate in multiple sclerosis after 12 months of follow up: An Iranian clinical trial. Current Journal of Neurology, 0, , .	0.0	1
2050	DETERMINANTS OF DISABILITY IN PROGRESSIVE ONSET MULTIPLE SCLEROSIS. Noropsikiyatri Arsivi, 2020, 59, 10-13.	0.2	0
2051	Inner Retinal Layer Disease: Multiple Sclerosis. Beyoglu Eye Journal, 2020, 5, 93-101.	0.1	1
2053	Motor disability in patients with multiple sclerosis: transcranial magnetic stimulation study. Egyptian Journal of Neurology, Psychiatry and Neurosurgery, 2020, 56, .	0.4	4
2054	Optic Nerve in Multiple Sclerosis Diagnostic Criteria. Neurology, 2021, 96, 139-140.	1.5	3

#	Article	IF	Citations
2055	Delayed diagnosis of multiple sclerosis in a low prevalence country. Neurological Research, 2021, 43, 521-527.	0.6	9
2056	Prognostication and contemporary management of clinically isolated syndrome. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 391-397.	0.9	7
2057	Relevance of first-line drugs for treatment of multiple sclerosis in present-day conditions. Meditsinskiy Sovet, 2020, , 62-68.	0.1	1
2058	Advances in ophthalmic structural and functional measures in multiple sclerosis: do the potential ocular biomarkers meet the unmet needs?. Current Opinion in Neurology, 2021, 34, 97-107.	1.8	2
2059	Quantification of Brain Lesions in Multiple Sclerosis Patients using Segmentation by Convolutional Neural Networks. , 2020, , .		2
2060	Characteristics of pediatric multiple sclerosis: A tertiary referral center study. PLoS ONE, 2020, 15, e0243031.	1.1	4
2064	The Prevalence and Association of Depression and Anxiety With Multiple Sclerosis in Riyadh, Saudi Arabia: A Cross-Sectional Study. Cureus, 2020, 12, e12389.	0.2	4
2066	SwissTecLive: effectiveness and safety of dimethyl fumarate in the treatment of RRMS in the Swiss clinical practice setting. Heliyon, 2020, 6, e05819.	1.4	1
2067	Is somatosensory temporal discrimination threshold a biomarker of disease progression in multiple sclerosis?. Clinical Neurophysiology, 2020, 131, 2935-2936.	0.7	2
2068	Accelerated Isotropic Multiparametric Imaging by High Spatial Resolution 3D-QALAS With Compressed Sensing. Investigative Radiology, 2021, 56, 292-300.	3.5	23
2069	Improved algorithm for multiple sclerosis diagnosis in MRI using convolutional neural network. IET Image Processing, 2020, 14, 4507-4512.	1.4	12
2070	Rule Extraction in the Assessment of Brain MRI Lesions in Multiple Sclerosis: Preliminary Findings. Lecture Notes in Computer Science, 2021, , 277-286.	1.0	6
2071	An Autopsy Confirmed Neuromyelitis Optica Spectrum Disorder with Extensive Brain White Matter Lesion and Optic Neuritis but Intact Spinal Cord, Clinically Mimicking a Secondary Progressive Multiple Sclerosis-like Course. Internal Medicine, 2022, 61, 1415-1422.	0.3	1
2072	FEATURES OF LOCAL IMMUNE REACTIONS IN SKIN WITH UNDERLYING SOFT TISSUES IN PATIENTS WITH MULTIPLE SCLEROSIS. WiadomoÅ›ci Lekarskie, 2020, 73, 2109-2113.	0.1	0
2073	The risk of polypharmacy, comorbidities and drugâ€“drug interactions in women of childbearing age with multiple sclerosis. Therapeutic Advances in Neurological Disorders, 2020, 13, 175628642096950.	1.5	9
2074	Current status of neuroimaging of pediatric neurological disorders. Advances in Magnetic Resonance Technology and Applications, 2021, 2, 529-544.	0.0	0
2076	Immunmediierte Erkrankungen des Nervensystems. , 2020, , 37-87.		0
2077	Recommendations of the Polish Medical Society of Radiology and the Polish Society of Neurology for a protocol concerning routinely used magnetic resonance imaging in patients with multiple sclerosis. Polish Journal of Radiology, 2020, 85, 272-276.	0.5	0

#	Article	IF	Citations
2079	Multifractional Gaussian Process Based on Self-similarity Modelling for MS Subgroupsâ€™ Clustering with Fuzzy C-Means. Lecture Notes in Computer Science, 2020, , 426-441.	1.0	0
2081	Multiple Sklerose und andere entzÃ¼ndliche demyelinisierende Erkrankungen des zentralen Nervensystems. Springer Reference Medizin, 2020, , 2591-2597.	0.0	0
2082	Pediatric Multiple Sclerosis. , 2020, , 37-66.		0
2084	Magnetic resonance imaging of intraocular optic nerve disorders: review article. Polish Journal of Radiology, 2020, 85, 67-81.	0.5	5
2085	A Longitudinal Method for Simultaneous Whole-Brain and Lesion Segmentation in Multiple Sclerosis. Lecture Notes in Computer Science, 2020, , 119-128.	1.0	3
2086	Diagnostische Verfahren. , 2020, , 551-631.		0
2087	Detailed Evaluation of Macular Ganglion Cell Complex in Patients with Multiple Sclerosis. Noropsikiyatri Arsivi, 2020, 58, 176-183.	0.2	4
2089	An examination of the effects of a patient-designed-and-informed participant information sheet in comparison with a standard, researcher-designed information sheet on recruitment, retention and understanding: Protocol for a study-within-a-trial. HRB Open Research, 2020, 3, 4.	0.3	4
2092	Evaluation of Age-Dependent Immune Signatures in Patients With Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	3.1	24
2093	Interlimb Coordination Performance in Seated Position in Persons With Multiple Sclerosis: Reduced Amplitude Over 6 min and Higher Coordination Variability in Persons With Walking Fatigability. Frontiers in Human Neuroscience, 2021, 15, 765254.	1.0	1
2095	The Increasing Role of Kappa Free Light Chains in the Diagnosis of Multiple Sclerosis. Cells, 2021, 10, 3056.	1.8	17
2096	Serum neurofilament light chain correlates with myelin and axonal magnetic resonance imaging markers in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2022, 57, 103366.	0.9	8
2097	Vaccination Setting of Patients with Autoimmune Diseases in Times of Severe Acute Respiratory Syndrome Coronavirus Type 2 Pandemic Using the Example of Multiple Sclerosis Patients: A Longitudinal Multicenter Study. European Neurology, 2022, 85, 104-111.	0.6	4
2098	Humoral and T-cell responses to SARS-CoV-2 vaccination in multiple sclerosis patients treated with ocrelizumab. Multiple Sclerosis and Related Disorders, 2022, 57, 103382.	0.9	30
2099	Rituximab for people with multiple sclerosis. The Cochrane Library, 2021, 2021, CD013874.	1.5	9
2100	Molecular characterization of the gut microbiome in egyptian patients with remitting relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders, 2022, 57, 103354.	0.9	5
2101	Editorial of Special Issue â€œMultiple Sclerosis: Diagnosis and Treatment IIâ€: Biomedicines, 2021, 9, 1605.	1.4	1
2102	Circulating miRNAs as Potential Biomarkers Distinguishing Relapsingâ€“Remitting from Secondary Progressive Multiple Sclerosis. A Review. International Journal of Molecular Sciences, 2021, 22, 11887.	1.8	13

#	Article	IF	Citations
2103	Cumulative Roles for Epstein-Barr Virus, Human Endogenous Retroviruses, and Human Herpes Virus-6 in Driving an Inflammatory Cascade Underlying MS Pathogenesis. Frontiers in Immunology, 2021, 12, 757302.	2.2	27
2104	Â¿ Can COVID-19 exacerbate multiple sclerosis symptoms? A case series analysis. Multiple Sclerosis and Related Disorders, 2022, 57, 103368.	0.9	19
2105	A Clinically-Compatible Workflow for Computer-Aided Assessment of Brain Disease Activity in Multiple Sclerosis Patients. Frontiers in Medicine, 2021, 8, 740248.	1.2	7
2106	Dentate-nucleus gadolinium deposition on magnetic resonance imaging: ultrasonographic and clinical correlates in multiple sclerosis patients. Neurological Sciences, 2022, 43, 2631-2639.	0.9	3
2107	Aligned Expression of IFI16 and STING Genes in RRMS Patientsâ€™ Blood. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2020, 20, 878-886.	0.6	1
2108	Diagnostic features of initial demyelinating events associated with serum MOG-IgG. Journal of Neuroimmunology, 2020, 344, 577260.	1.1	0
2109	Serum prolactin in patients with relapsing remitting multiple sclerosis. Egyptian Journal of Neurology, Psychiatry and Neurosurgery, 2020, 56, .	0.4	1
2111	Search for viral agents in cerebrospinal fluid in patients with multiple sclerosis using real-time PCR and metagenomics. PLoS ONE, 2020, 15, e0240601.	1.1	5
2112	Two Multiple Sclerosis Relapses Affecting the Left Pontine-Mesencephalic Transition and Later the Right Mid Pons, With Distinct Eye Movement Abnormalities - The Importance Of Semiology Above Medical Imaging: Case Report. EMJ Radiology, 0, , .	0.0	0
2114	PET Imaging in Multiple Sclerosis. , 2021, , 893-916.		2
2116	Association of Serum Neurofilament Light Levels With Long-term Brain Atrophy in Patients With a First Multiple Sclerosis Episode. JAMA Network Open, 2020, 3, e2016278.	2.8	18
2118	C-reactive protein/albumin ratio in patients with multiple sclerosis and its relationship with disease subtype and disability. Journal of Surgery and Medicine, 2020, 4, 974-977.	0.0	4
2119	Pruritus in neuromyelitis optica spectrum disorders and multiple sclerosis. Journal of Clinical Neuroscience, 2020, 79, 108-112.	0.8	3
2120	Magnetic resonance spectroscopy of the normal appearing grey matter in the posterior cingulate gyrus in the prognosis and monitoring of disease activity in MS patients treated with interferon-Î² in a 3-year follow-up. Journal of Clinical Neuroscience, 2020, 79, 205-214.	0.8	1
2121	Migraine and multiple sclerosis - symptom or comorbidity. Neurologie Pro Praxi, 2020, 21, 283-286.	0.0	0
2122	Diagnostic options in retrobullar neuritis. Neurologie Pro Praxi, 2020, 21, 296-299.	0.0	0
2124	Efficacy and Safety of Teriflunomide in Chinese Patients with Relapsing Forms of Multiple Sclerosis: A Subgroup Analysis of the Phase 3 TOWER Study. Chinese Medical Journal, 2018, 131, 2776-2784.	0.9	2
2125	Fingolimod and changes in hematocrit, hemoglobin and red blood cells of patients with multiple sclerosis. American Journal of Clinical and Experimental Immunology, 2019, 8, 27-31.	0.2	0

#	Article	IF	Citations
2126	Effectiveness and side effects of dimethyl fumarate in multiple sclerosis after 12 months of follow up: An Iranian clinical trial. Iranian Journal of Neurology, 2019, 18, 154-158.	0.5	0
2127	Multiple Sclerosis Medications in the VHA: Delivering Specialty, High-Cost, Pharmacy Care in a National System. Federal Practitioner: for the Health Care Professionals of the VA, DoD, and PHS, 2020, 37, S36-S42.	0.6	0
2128	The Future of Progressive Multiple Sclerosis Therapies. Federal Practitioner: for the Health Care Professionals of the VA, DoD, and PHS, 2020, 37, S43-S49.	0.6	2
2129	Facioscapulohumeral muscular dystrophy (FSHD) and multiple sclerosis: a case report. Acta Myologica, 2020, 39, 29-31.	1.5	2
2130	Tumefactive multiple sclerosis versus high-grade glioma: A diagnostic dilemma. Surgical Neurology International, 2021, 12, 199.	0.2	0
2131	Serum Vitamin D Level among Multiple Sclerosis Patients in the Tropics: Experience from a Private Clinic in Addis Ababa, Ethiopia. Ethiopian Journal of Health Sciences, 2021, 31, 611-618.	0.2	2
2132	Neurofilament light chain as a biomarker for diagnosis of multiple sclerosis. EXCLI Journal, 2021, 20, 1308-1325.	0.5	0
2133	Consensus recommendation on the use of therapeutic plasma exchange for adult neurological diseases in Southeast Asia from the Southeast Asia therapeutic plasma exchange consortium. Journal of Central Nervous System Disease, 2021, 13, 117957352110573.	0.7	2
2134	Correlation of the symbol digit modalities test with the quality of life and depression in Japanese patients with multiple sclerosis. Multiple Sclerosis and Related Disorders, 2022, 57, 103427.	0.9	1
2135	The Role of Pediatric Rheumatologists in Autoimmune Brain Disease. Rheumatic Disease Clinics of North America, 2022, 48, 343-369.	0.8	0
2136	Diagnosis and Management of Central Nervous System Demyelinating Disorders. Neurologic Clinics, 2022, 40, 113-131.	0.8	4
2138	Automated Multiple Sclerosis Lesion Segmentation on MR Images via Mask R-CNN. , 2021, , .		4
2139	Diagnostic value of gadolinium contrast administration for spinal cord magnetic resonance imaging in multiple sclerosis patients and correlative markers of lesion enhancement. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2021, 7, 205521732110479.	0.5	0
2140	How is and how should healthcare for people with multiple sclerosis in Germany be designed?â€“The rationale and protocol for the mixed-methods study Multiple Sclerosisâ€“Patient-Oriented Care in Lower Saxony (MS-PoV). PLoS ONE, 2021, 16, e0259855.	1.1	1
2141	Clinically Isolated Brainstem Progressive Multifocal Leukoencephalopathy: Diagnostic Challenges. American Journal of Case Reports, 2022, 23, e935019.	0.3	3
2142	Body size perceptions & diet modification in youth with multiple sclerosis. Multiple Sclerosis and Related Disorders, 2021, 58, 103402.	0.9	2
2143	Crotalphine Attenuates Pain and Neuroinflammation Induced by Experimental Autoimmune Encephalomyelitis in Mice. Toxins, 2021, 13, 827.	1.5	7
2144	Recurrent ataxia and dysarthria in myelin oligodendrocyte glycoprotein antibody-associated disorder. BMJ Case Reports, 2021, 14, e245341.	0.2	0

#	Article	IF	Citations
2145	Pain, quality of life, and religiosity in people with multiple sclerosis. Neurological Sciences, 2022, 43, 3247-3254.	0.9	5
2146	White blood cell count profiles in multiple sclerosis during attacks before the initiation of acute and chronic treatments. Scientific Reports, 2021, 11, 22357.	1.6	17
2147	Quantification of normal-appearing white matter damage in early relapse-onset multiple sclerosis through neurite orientation dispersion and density imaging. Multiple Sclerosis and Related Disorders, 2022, 58, 103396.	0.9	6
2148	Detection of oligoclonal bands as a part of the diagnosis of multiple sclerosis â€“ case studies. Diagnostyka Laboratoryjna I WiadomoÅ›ci PTDL, 2021, 57, 1-8.	0.0	0
2150	Cognitive function and oral health in relapsingâ€“remitting multiple sclerosis. Clinical Oral Investigations, 2022, 26, 2899-2907.	1.4	1
2151	Acute Myelopathy in Childhood. Children, 2021, 8, 1055.	0.6	2
2152	Autoimmune conditions in the World Trade Center general responder cohort: A nested caseâ€control and standardized incidence ratio analysis. American Journal of Industrial Medicine, 2022, 65, 117-131.	1.0	2
2153	Serum Vitamin D as a Marker of Impaired Information Processing Speed and Early Disability in Multiple Sclerosis Patients. Brain Sciences, 2021, 11, 1521.	1.1	14
2154	Diffusely abnormal white matter in multiple sclerosis. Journal of Neuroimaging, 2022, 32, 5-16.	1.0	5
2155	A review of neurotoxicities associated with immunotherapy and a framework for evaluation. Neuro-Oncology Advances, 2021, 3, v108-v120.	0.4	6
2157	Changes in John Cunningham Virus Index in Multiple Sclerosis Patients Treated with Different Disease-Modifying Therapies. Current Neuropharmacology, 2022, 20, 1978-1987.	1.4	5
2158	Effect of natalizumab treatment on the rate of No Evidence of Disease Activity in young adults with multiple sclerosis in relation to pubertal stage. Journal of the Neurological Sciences, 2022, 432, 120074.	0.3	3
2159	Siponimod for multiple sclerosis. The Cochrane Library, 2021, 2021, CD013647.	1.5	5
2160	Measuring productivity loss in early relapsing-remitting multiple sclerosis. Multiple Sclerosis and Related Disorders, 2022, 58, 103398.	0.9	5
2161	OImaging features to distinguish AQP4-positive NMOSD and MS at disease onset: a retrospective analysis in a single-center cohort. European Journal of Radiology, 2021, 146, 110063.	1.2	0
2162	GANAB as a Novel Biomarker in Multiple Sclerosis: Correlation with Neuroinflammation and IFI35. Pharmaceuticals, 2021, 14, 1195.	1.7	6
2163	Progressive multifocal leukoencephalopathy and sphingosine 1-phosphate receptor modulators used in multiple sclerosis: an updated review of literature. Journal of Neurology, 2022, 269, 1678-1687.	1.8	15
2164	Amygdala network reorganization mediates the theory of mind performances in multiple sclerosis. Journal of Neuroscience Research, 2022, 100, 537-550.	1.3	2

#	Article	IF	Citations
2165	Humoral- and T-Cellâ€“Specific Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients With MS Using Different Disease-Modifying Therapies. Neurology, 2022, 98, .	1.5	125
2166	Circulatory antioxidant and oxidative stress markers are in correlation with demographics but not cognitive functions in multiple sclerosis patients. Multiple Sclerosis and Related Disorders, 2022, 57, 103432.	0.9	3
2167	Restless legs syndrome and related factors in people with multiple sclerosis in Turkey. Neurological Research, 2021, , 1-8.	0.6	0
2168	Frailty and Falls in People Living With Multiple Sclerosis. Archives of Physical Medicine and Rehabilitation, 2022, 103, 952-957.	0.5	6
2170	Impact of Ramadan fasting on disease activity in patients with multiple sclerosis: a multicenter study. Nutritional Neuroscience, 2021, , 1-10.	1.5	3
2171	The Clinical Significance of Cerebrospinal Fluid Reticulon 4 (RTN4) Levels in the Differential Diagnosis of Neurodegenerative Diseases. Journal of Clinical Medicine, 2021, 10, 5281.	1.0	10
2172	Effect of Multiple Sclerosis and Its Treatments on Male Fertility: Cues for Future Research. Journal of Clinical Medicine, 2021, 10, 5401.	1.0	6
2173	miR-132-3p, miR-106b-5p, and miR-19b-3p Are Associated with Brain-Derived Neurotrophic Factor Production and Clinical Activity in Multiple Sclerosis: A Pilot Study. Genetic Testing and Molecular Biomarkers, 2021, 25, 720-726.	0.3	10
2174	The Economic and societal burden of multiple sclerosis on lebanese society: a cost-of-illness and quality of life study protocol. Expert Review of Pharmacoeconomics and Outcomes Research, 2022, 22, 869-876.	0.7	4
2175	Tetracyclines Diminish In Vitro IFN-Î³ and IL-17-Producing Adaptive and Innate Immune Cells in Multiple Sclerosis. Frontiers in Immunology, 2021, 12, 739186.	2.2	11
2176	Retinal inter-eye difference and atrophy progression in multiple sclerosis diagnostics. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 216-219.	0.9	7
2178	Clinical Reasoning: A 57-Year-Old Man With Stepwise Progressive Paraparesis, Sensory Loss, Urinary Retention, and Constipation. Neurology, 2022, 98, .	1.5	4
2179	Populationâ€based incidence and clinicoâ€radiological characteristics of tumefactive demyelination in Olmsted County, Minnesota, United States. European Journal of Neurology, 2022, 29, 782-789.	1.7	11
2180	The no evidence of disease activity (NEDA) concept in MS: impact of spinal cord MRI. Journal of Neurology, 2022, 269, 3129-3135.	1.8	6
2181	Clinical case of COVID-19 in a patient treated with alemtuzumab. Meditsinskiy Sovet, 2021, , 148-152.	0.1	1
2182	Paramagnetic Rim Lesions in Multiple Sclerosis: Comparison of Visualization at 1.5-T and 3-T MRI. American Journal of Roentgenology, 2022, 219, 120-131.	1.0	22
2183	Immunogenicity and safety of mRNA COVID-19 vaccines in people with multiple sclerosis treated with different disease-modifying therapies. Neurotherapeutics, 2022, 19, 325-333.	2.1	32
2184	Effects of home-based virtual reality telerehabilitation system in people with multiple sclerosis: A randomized controlled trial. Journal of Telemedicine and Telecare, 2024, 30, 344-355.	1.4	16

#	Article	IF	Citations
2185	The Influence of Renal Function Impairment on Kappa Free Light Chains in Cerebrospinal Fluid. Journal of Central Nervous System Disease, 2021, 13, 117957352110421.	0.7	10
2186	T1/T2-Weighted Ratio in Multiple Sclerosis: A Longitudinal Study With Clinical Associations. SSRN Electronic Journal, 0, , .	0.4	1
2187	COGNITIVE FUNCTIONS IN MULTIPLE SCLEROSIS PATIENTS DEPENDING ON THE DIFFERENT RISK FACTORS PRESENCE. WiadomoÅ›ci Lekarskie, 2021, 74, 2444-2451.	0.1	1
2188	Multiple Sclerosis-Minimizing Errors in Radiological Diagnosis. Neurology India, 2021, 69, 1539.	0.2	5
2189	Multiple Sclerosis flare-ups Diagnostic and Management Approach in Emergency Department, Review Article. World Journal of Environmental Biosciences, 2021, 10, 9-12.	0.1	0
2191	The German Multiple Sclerosis and Pregnancy Registry: rationale, objective, design, and first results. Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642110549.	1.5	12
2192	Significance of Monoclonal Band in Cerebral Spinal Fluid. Clinical Chemistry, 2022, 68, 276-281.	1.5	1
2193	Role of Viral Infections in Multiple Sclerosis Pathogenesis among Indian Population. Neurology India, 2021, 69, 681.	0.2	4
2194	Real world comparison of teriflunomide and dimethyl fumarate in naÃ¯ve relapsing multiple sclerosis patients: Evidence from the Italian MS register. Multiple Sclerosis and Related Disorders, 2022, 58, 103489.	0.9	2
2195	Dysregulated B cell differentiation towards antibody-secreting cells in neuromyelitis optica spectrum disorder. Journal of Neuroinflammation, 2022, 19, 6.	3.1	12
2196	Vogt-Koyanagi-Harada disease and Radiologically Isolated Syndrome: A case report and literature review. Neuroimmunology Reports, 2022, 2, 100056.	0.2	0
2197	Evaluation of the times of disability progression and related factors in patients with primary progressive multiple sclerosis from Argentina. Multiple Sclerosis and Related Disorders, 2022, 58, 103483.	0.9	1
2198	OCT retinal nerve fiber layer thickness differentiates acute optic neuritis from MOG antibody-associated disease and Multiple Sclerosis. Multiple Sclerosis and Related Disorders, 2022, 58, 103525.	0.9	36
2199	Mind wandering in people with Multiple Sclerosis: A psychometric study. Multiple Sclerosis and Related Disorders, 2022, 58, 103521.	0.9	2
2200	The Dual Role of the Î²2-Adrenoreceptor in the Modulation of IL-17 and IFN-Î³ Production by T Cells in Multiple Sclerosis. International Journal of Molecular Sciences, 2022, 23, 668.	1.8	6
2201	Body mass index as a predictor of MS activity and progression among participants in BENEFIT. Multiple Sclerosis Journal, 2022, 28, 1277-1285.	1.4	12
2202	A Comparison Between Subjective and Objective Measurements of Spasticity in Neuromyelitis Optica Spectrum Disorder Patients. Multiple Sclerosis and Related Disorders, 2022, 58, 103517.	0.9	0
2203	Platelet-to-lymphocyte ratio differs between MS and NMOSD at disease onset and predict disability. Multiple Sclerosis and Related Disorders, 2022, 58, 103507.	0.9	8

#	Article	IF	Citations
2204	Serological markers exploration and real-world effectiveness and safety of teriflunomide in south Chinese patients with multiple sclerosis. Multiple Sclerosis and Related Disorders, 2022, 58, 103446.	0.9	3
2205	The central vein sign is present in most infratentorial multiple sclerosis plaques. Multiple Sclerosis and Related Disorders, 2022, 58, 103484.	0.9	3
2206	Prodromal emesis in MOG-antibody associated disorder. Multiple Sclerosis and Related Disorders, 2022, 58, 103463.	0.9	3
2207	Atherosclerosis and multiple sclerosis: An overview on the prevalence of risk factors. Multiple Sclerosis and Related Disorders, 2022, 58, 103488.	0.9	2
2208	Monitoring of safety and effectiveness of cladribine in multiple sclerosis patients over 50 years. Multiple Sclerosis and Related Disorders, 2022, 58, 103490.	0.9	6
2209	Seasonal variation in attacks of neuromyelitis optica spectrum disorders and multiple sclerosis: Evaluation of 794 attacks from a nationwide registry in Argentina. Multiple Sclerosis and Related Disorders, 2022, 58, 103466.	0.9	3
2210	Trans-omics analyses revealed key epigenetic genes associated with overall survival in secondary progressive multiple sclerosis. Journal of Neuroimmunology, 2022, 364, 577809.	1.1	0
2211	Liquordiagnostik: Wegweisend fÃ¼r die Differenzialdiagnose. , 0, , .		1
2213	The Critical Role of Imaging in Primary Progressive Multiple Sclerosis. Open Access Macedonian Journal of Medical Sciences, 2020, 8, 195-200.	0.1	0
2214	Efectos agudos de una sesiÃ³n de entrenamiento vibratorio sobre la espasticidad en personas con Esclerosis MÃºltiple: resultados preliminares.. Revista De InvestigaciÃ³n Y EducaciÃ³n En Ciencias De La Salud (RIECS), 2020, 5, 35-43.	0.0	0
2215	Tumefactive multiple sclerosis versus high-grade glioma: A diagnostic dilemma. , 2021, 12, 199.		3
2216	REVISION OF MULTIPLE SCLEROSIS CASES ACCORDING TO NEW 2017 MCDONALD CRITERIA AMONG DIAGNOSED PATIENTS IN SULAIMANI CITY. Journal of Sulaimani Medical College, 2021, 11, 323-333.	0.0	2
2217	Clinical Significance of Myelin Oligodendrocyte Glycoprotein Autoantibodies in Patients with Typical MS Lesions on MRI. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2021, 7, 205521732110487.	0.5	5
2218	Development of a Prognostic Model for Predicting Multiple Sclerosis After Optic Neuritis: A Secondary Analysis of Data From the Optic Neuritis Treatment Trial. Journal of Neuro-Ophthalmology, 2022, 42, 88-96.	0.4	2
2219	How to treat patients with psoriasis and concurrent multiple sclerosis?. Dermatologie Pro Praxi, 2021, 15, 144-147.	0.1	0
2220	Developing a clinicalâ€“environmentalâ€“genotypic prognostic index for relapsing-onset multiple sclerosis and clinically isolated syndrome. Brain Communications, 2021, 3, fcab288.	1.5	7
2222	The need for a strategic therapeutic approach: multiple sclerosis in check. Therapeutic Advances in Chronic Disease, 2022, 13, 204062232110630.	1.1	14
2223	Cerebrospinal Fluid Î±-Calcitonin Gene-Related Peptide: A Comparison between Alzheimerâ€™s Disease and Multiple Sclerosis. Biomolecules, 2022, 12, 199.	1.8	1

#	Article	IF	Citations
2224	T1/T2-weighted ratio is a surrogate marker of demyelination in multiple sclerosisâ€"yes. Multiple Sclerosis Journal, 2022, 28, 352-354.	1.4	6
2225	Fatigue is associated with physical inactivity in people with multiple sclerosis despite different environmental backgrounds: Merging and comparing cohorts from Turkey and Israel. Multiple Sclerosis and Related Disorders, 2022, 57, 103456.	0.9	4
2226	Transition to secondary progressive multiple sclerosis: The consequences for patients and healthcare systems, a healthcare professional survey. Health Science Reports, 2022, 5, e474.	0.6	3
2227	Are Neurophysiological Biomarkers Able to Discriminate Multiple Sclerosis Clinical Subtypes?. Biomedicines, 2022, 10, 231.	1.4	4
2228	Neurological update: treatment escalation in multiple sclerosis patients refractory to fingolimodâ€"potentials and risks of subsequent highly active agents. Journal of Neurology, 2022, 269, 2806-2818.	1.8	5
2229	Application of the â€œrisk of ambulatory disabilityâ€•(RoAD) score in a â€œrealâ€worldâ€•singleâ€•center multiple sclerosis cohort. CNS Neuroscience and Therapeutics, 2022, 28, 792-795.	1.9	0
2230	Masked face recognition in patients with relapsingâ€"remitting multiple sclerosis during the ongoing COVID-19 pandemic. Neurological Sciences, 2022, 43, 1549-1556.	0.9	3
2231	Brain Pathology in Multiple Sclerosis with High-Field-Strength MR Spectroscopic Imaging. Radiology, 2022, 303, 151-152.	3.6	2
2232	The effects of transcranial direct current stimulation on sleep in patients with multiple sclerosisâ€"A pilot study. Neurophysiologie Clinique, 2022, 52, 28-32.	1.0	8
2233	Cerebrospinal fluid evaluation in patients with progressive motor impairment due to critical central nervous system demyelinating lesions. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2022, 8, 205521732110521.	0.5	1
2234	DICAM promotes T _H 17 lymphocyte trafficking across the blood-brain barrier during autoimmune neuroinflammation. Science Translational Medicine, 2022, 14, eabj0473.	5.8	27
2235	The central vein sign helps in differentiating multiple sclerosis from its mimickers: lessons from Fabry disease. European Radiology, 2022, , 1.	2.3	4
2236	A Deep Learning Approach to Predicting Disease Progression in Multiple Sclerosis Using Magnetic Resonance Imaging. Investigative Radiology, 2022, 57, 423-432.	3.5	18
2237	Differential Expression of Serum Extracellular Vesicle miRNAs in Multiple Sclerosis: Disease-Stage Specificity and Relevance to Pathophysiology. International Journal of Molecular Sciences, 2022, 23, 1664.	1.8	11
2238	SARS-CoV-2 serology among people with multiple sclerosis on disease-modifying therapies after BBIBP-CorV (Sinopharm) inactivated virus vaccination: Same story, different vaccine. Multiple Sclerosis and Related Disorders, 2022, 57, 103417.	0.9	16
2239	Optic Nerve Lesion Length at the Acute Phase of Optic Neuritis Is Predictive of Retinal Neuronal Loss. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, .	3.1	16
2240	Neuroinflammation Is Associated with GFAP and sTREM2 Levels in Multiple Sclerosis. Biomolecules, 2022, 12, 222.	1.8	21
2241	Single nucleotide variants around the connective tissue growth factor (CTGF/CCN2) gene and their association with multiple sclerosis risk, disability scores, and rate of disease progression. Neurological Sciences, 2022, , 1.	0.9	0

#	Article	IF	Citations
2242	Cervical Spinal Cord Atrophy can be Accurately Quantified Using Head Images. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2022, 8, 205521732110707.	0.5	3
2243	Thrombotic Thrombocytopenic Purpura in Interferon Beta-1a-Treated Patient Diagnosed with Relapsing-Remitting Multiple Sclerosis: A Case Report. Life, 2022, 12, 80.	1.1	2
2244	Metabolomics as a promising tool for improving understanding of multiple sclerosis: A review of recent advances. Biomedical Journal, 2022, 45, 594-606.	1.4	13
2245	Brain magnetic resonance imaging surface-based analysis and cortical thickness measurement in relapsing remission multiple sclerosis. Egyptian Journal of Radiology and Nuclear Medicine, 2022, 53, .	0.3	4
2247	Evaluating Magnetic Resonance Diffusion Properties Together with Brain Volumetry May Predict Progression to Multiple Sclerosis. Academic Radiology, 2022, , .	1.3	0
2248	On the Effects of Transcranial Direct Current Stimulation on Cerebral Glucose Uptake During Walking: A Report of Three Patients With Multiple Sclerosis. Frontiers in Human Neuroscience, 2022, 16, 833619.	1.0	0
2249	Metabolomics and lipidomics approaches in human tears: A systematic review. Survey of Ophthalmology, 2022, 67, 1229-1243.	1.7	22
2250	Prevalence of Multiple sclerosis and its clinical and demographic characteristics in Kurdish populations in western Iran (2020). Multiple Sclerosis and Related Disorders, 2022, 57, 103441.	0.9	1
2251	Usefulness of two-dimensional measurements for the evaluation of brain volume and disability in multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2022, 8, 205521732110707.	0.5	2
2252	Updated Perspectives on the Challenges of Managing Multiple Sclerosis During Pregnancy. Degenerative Neurological and Neuromuscular Disease, 2022, Volume 12, 1-21.	0.7	3
2253	Validation of MRI radiological reports in pediatric MS according to the McDonald 2017 criteria: A Danish nationwide multicenter cohort study. Multiple Sclerosis and Related Disorders, 2022, 57, 103443.	0.9	0
2254	Facial myokymia as the presenting feature of multiple sclerosis. Practical Neurology, 2022, , practneurol-2021-003268.	0.5	2
2255	Oligoclonal Band Straightening Based on Optimized Hierarchical Warping for Multiple Sclerosis Diagnosis. Sensors, 2022, 22, 724.	2.1	1
2256	Diagnosis of multiple sclerosis: Progress or confusion?. Multiple Sclerosis and Related Disorders, 2022, 57, 103528.	0.9	1
2257	Single-Cell Transcriptome Profiling Unravels Distinct Peripheral Blood Immune Cell Signatures of RRMS and MOG Antibody-Associated Disease. Frontiers in Neurology, 2021, 12, 807646.	1.1	3
2258	Lesion Volume Quantification Using Two Convolutional Neural Networks in MRIs of Multiple Sclerosis Patients. Diagnostics, 2022, 12, 230.	1.3	7
2259	Multiple sclerosis therapies differentially affect SARS-CoV-2 vaccineâ€“induced antibody and T cell immunity and function. JCI Insight, 2022, 7, .	2.3	69
2260	From Diagnosis to Satisfaction in Multiple Sclerosis: A Swiss Patient Survey Highlighting the Importance of the First Diagnostic Consultation. Clinical and Translational Neuroscience, 2022, 6, 4.	0.4	0

#	Article	IF	Citations
2261	The usefulness of visual evoked potentials in the assessment of the pediatric multiple sclerosis. European Journal of Paediatric Neurology, 2022, 36, 130-136.	0.7	2
2262	Central Vein Sign Profile of Newly Developing Lesions in Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, .	3.1	17
2263	Clinical profile, imaging features and short term visual outcomes of Indian optic neuritis patients with and without seromarkers for myelin oligodendrocyte glycoprotein and neuromyelitis optica. Indian Journal of Ophthalmology, 2022, 70, 194.	0.5	4
2264	Clonally expanded B cells in multiple sclerosis bind EBV EBNA1 and GlialCAM. Nature, 2022, 603, 321-327.	13.7	343
2265	Diagnostic value of lumbar puncture for the etiological assessment of uveitis: a retrospective cohort of 188 patients. Graefe's Archive for Clinical and Experimental Ophthalmology, 2022, 260, 1651-1662.	1.0	1
2266	Mechanistic and Biomarker Studies to Demonstrate Immune Tolerance in Multiple Sclerosis. Frontiers in Immunology, 2021, 12, 787498.	2.2	5
2267	Constructing a Multiple Sclerosis Diagnosis Model Based on Microarray. Frontiers in Neurology, 2021, 12, 721788.	1.1	0
2268	Age-period-cohort analysis of the incidence of multiple sclerosis over twenty years in Lorraine, France. Scientific Reports, 2022, 12, 1001.	1.6	16
2269	Stereotyped Bâ€cell responses are linked to IgG constant region polymorphisms in multiple sclerosis. European Journal of Immunology, 2022, 52, 550-565.	1.6	10
2270	Automatic segmentation of white matter hyperintensities: validation and comparison with state-of-the-art methods on both Multiple Sclerosis and elderly subjects. NeuroImage: Clinical, 2022, 33, 102940.	1.4	17
2271	MIND Diet Adherence Might be Associated with a Reduced Odds of Multiple Sclerosis: Results from a Caseâ€“Control Study. Neurology and Therapy, 2022, 11, 397-412.	1.4	15
2272	Confirming a Historical Diagnosis of Multiple Sclerosis. Neurology: Clinical Practice, 2022, 12, 263-269.	0.8	4
2273	Serum molecular biomarkers in neuromyelitis optica and multiple sclerosis. Multiple Sclerosis and Related Disorders, 2022, 59, 103527.	0.9	3
2275	Cerebrospinal fluid biomarkers and cognitive functions at multiple sclerosis diagnosis. Journal of Neurology, 2022, 269, 3249-3257.	1.8	20
2276	Ofatumumab subcutaneous injection for the treatment of relapsing forms of multiple sclerosis. Expert Review of Clinical Immunology, 2022, 18, 105-114.	1.3	1
2279	Quality of life of patients with multiple sclerosis and neuromyelitis optica spectrum disorders: Cross-sectional and longitudinal analysis. Multiple Sclerosis and Related Disorders, 2022, 58, 103500.	0.9	9
2280	Epidemiological study of multiple sclerosis in the Illawarra region. Internal Medicine Journal, 2023, 53, 1010-1017.	0.5	1
2281	Quantifying the impact of upper limb tremor on the quality of life of people with multiple sclerosis: a comparison between the QUEST and MSIS-29 scales. Multiple Sclerosis and Related Disorders, 2022, 58, 103495.	0.9	1

#	Article	IF	Citations
2282	Spectral signature of multiple sclerosis. Preliminary studies of blood fraction by ATR FTIR technique. Biochemical and Biophysical Research Communications, 2022, 593, 40-45.	1.0	8
2283	A TLR/CD44 axis regulates T cell trafficking in experimental and human multiple sclerosis. IScience, 2022, 25, 103763.	1.9	12
2284	Comparing humoral immune response to SARSâ€CoV2 vaccines in people with multiple sclerosis and healthy controls: An Austrian prospective multicenter cohort study. European Journal of Neurology, 2022, 29, 1538-1544.	1.7	12
2285	Comparing diagnostic criteria for the diagnosis of neurocognitive disorders in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2022, 58, 103479.	0.9	9
2287	Physical exercise may improve problem-solving skills and emotional intelligence in patients with relapsing-remitting multiple sclerosis: A cross-sectional study. Multiple Sclerosis and Related Disorders, 2022, 59, 103641.	0.9	2
2288	Contribution of relapse-associated worsening to overall disability accrual in patients with relapsing-onset multiple sclerosis: A mediation analysis. Multiple Sclerosis and Related Disorders, 2022, 59, 103555.	0.9	3
2289	Two-dimensional measurements with cut-off values are useful for assessing brain volume, physical disability, and processing speed in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2022, 59, 103543.	0.9	8
2290	Health-related quality of life in neuromyelitis optica spectrum disorder patients in an Argentinean cohort. Multiple Sclerosis and Related Disorders, 2022, 59, 103647.	0.9	1
2291	Transverse myelitis as a first event of multiple sclerosis precipitated by Pfizer-BioNTech COVID-19 vaccination. Neuroimmunology Reports, 2022, 2, 100074.	0.2	2
2292	Optimizing EEG Source Reconstruction with Concurrent fMRI-Derived Spatial Priors. Brain Topography, 2022, 35, 282-301.	0.8	2
2293	CNS endothelial derived extracellular vesicles are biomarkers of active disease in multiple sclerosis. Fluids and Barriers of the CNS, 2022, 19, 13.	2.4	17
2294	Posttranslational modifications of proteins are key features in the identification of CSF biomarkers of multiple sclerosis. Journal of Neuroinflammation, 2022, 19, 44.	3.1	4
2295	Epstein-Barr Virus Load Correlates with Multiple Sclerosis-Associated Retrovirus Envelope Expression. Biomedicines, 2022, 10, 387.	1.4	7
2296	La moelle se traite-elle comme le cerveauÂ?. Pratique Neurologique - FMC, 2022, 13, 71-71.	0.1	0
2297	Carotid intima-media thickness measurements in patients with multiple sclerosis. Annals of Medicine and Surgery, 2022, 75, 103348.	0.5	0
2298	Astrocytes and Inflammatory T Helper Cells: A Dangerous Liaison in Multiple Sclerosis. Frontiers in Immunology, 2022, 13, 824411.	2.2	14
2299	Personalized Nutritional Intervention to Improve Mediterranean Diet Adherence in Female Patients with Multiple Sclerosis: A Randomized Controlled Study. Dietetics, 2022, 1, 25-38.	0.4	5
2300	Vascular dysfunction and dyslipidemia in multiple sclerosis: are they correlated with disease duration and disability status?. Egyptian Heart Journal, 2022, 74, 9.	0.4	6

#	Article	IF	Citations
2301	Comparing natural history of early and late onset pediatric multiple sclerosis. Annals of Neurology, 2022, , .	2.8	6
2302	Neuroradiological differentiation of white matter lesions in patients with multiple sclerosis and Fabry disease. Orphanet Journal of Rare Diseases, 2022, 17, 37.	1.2	1
2303	The health-related quality of life of children with multiple sclerosis is mediated by the health-related quality of life of their parents. Multiple Sclerosis Journal, 2022, 28, 1299-1310.	1.4	4
2304	Cerebrospinal fluid kappa free light chains as biomarker in multiple sclerosisâ€"from diagnosis to prediction of disease activity. Wiener Medizinische Wochenschrift, 2022, 172, 337-345.	0.5	9
2305	Central nervous system macrophages in progressive multiple sclerosis: relationship to neurodegeneration and therapeutics. Journal of Neuroinflammation, 2022, 19, 45.	3.1	51
2306	The Neuroimmunology of Multiple Sclerosis: Fictions and Facts. Frontiers in Neurology, 2021, 12, 796378.	1.1	6
2307	Peripheral helper T cells in the pathogenesis of multiple sclerosis. Multiple Sclerosis Journal, 2022, 28, 1340-1350.	1.4	3
2308	Cognitive impairment and markers of optical neurodegeneration in early multiple sclerosis. Neurological Sciences, 2022, 43, 4381-4386.	0.9	2
2309	Multimodal Evoked Potentials as Potential Biomarkers of Disease Activity in Patients With Clinically Isolated Syndrome. Frontiers in Neurology, 2021, 12, 678035.	1.1	3
2310	Effects of actual and imagined music-cued gait training on motor functioning and brain activity in people with multiple sclerosis: protocol of a randomised parallel multicentre trial. BMJ Open, 2022, 12, e056666.	0.8	1
2312	Correlation between functional MRI techniques and early disability in ambulatory patients with relapsingâ€"remitting MS. Egyptian Journal of Neurology, Psychiatry and Neurosurgery, 2022, 58, .	0.4	0
2313	Centrally-located transverse myelitis would facilitate the differentiation of NMOSD and MOG-AD from MS. Multiple Sclerosis and Related Disorders, 2022, 60, 103664.	0.9	2
2314	A national, multi-center study in Germany to assess implementation of infusion management, treatment satisfaction and quality of life in MS patients receiving alemtuzumab. Multiple Sclerosis and Related Disorders, 2022, 59, 103670.	0.9	4
2316	A comprehensive review of varicella-zoster virus, herpes simplex virus and cryptococcal infections associated with sphingosine-1-phosphate receptor modulators in multiple sclerosis patients. Multiple Sclerosis and Related Disorders, 2022, 59, 103675.	0.9	7
2317	Identification and Clinical Validation of Key Extracellular Proteins as the Potential Biomarkers in Relapsing-Remitting Multiple Sclerosis. Frontiers in Immunology, 2021, 12, 753929.	2.2	20
2318	Gadolinium-enhanced brain lesions in multiple sclerosis relapse. NeurologÃa, 2022, 37, 557-563.	0.3	2
2319	Stress Signal ULBP4, an NKG2D Ligand, Is Upregulated in Multiple Sclerosis and Shapes CD8 ⁺ T-Cell Behaviors. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, .	3.1	6
2320	Rapid quantification of global brain volumetry and relaxometry in patients with multiple sclerosis using synthetic magnetic resonance imaging. Quantitative Imaging in Medicine and Surgery, 2022, 12, 3104-3114.	1.1	1

#	Article	IF	Citations
2322	MAGNIMS recommendations for harmonization of MRI data in MS multicenter studies. NeuroImage: Clinical, 2022, 34, 102972.	1.4	11
2323	Recommendations to Address the Unique Clinical and Psychological Needs of Transgender Persons Living With Multiple Sclerosis. International Journal of MS Care, 2022, 24, 35-40.	0.4	5
2324	Co-occurrence of orbital myositis with optic neuritis in a patient subsequently diagnosed with multiple sclerosis. Neuroimmunology Reports, 2022, 2, 100082.	0.2	0
2325	Recovery of Chronic Inflammatory Demyelinating Polyneuropathy on Treatment With Ocrelizumab in a Patient With Co-Existing Multiple Sclerosis. Journal of Central Nervous System Disease, 2022, 14, 117957352210848.	0.7	0
2326	Should epileptic seizures as a first presentation be considered part of diagnostic criteria for relapsing remitting multiple sclerosis?. Neuroimmunology Reports, 2022, 2, 100086.	0.2	0
2327	An Update on Laboratory-Based Diagnostic Biomarkers for Multiple Sclerosis and Beyond. Clinical Chemistry, 2022, 68, 1134-1150.	1.5	10
2328	Patterns of white and gray structural abnormality associated with paediatric demyelinating disorders. NeuroImage: Clinical, 2022, 34, 103001.	1.4	0
2329	Fazialisparese und andere wichtige Hirnnervensyndrome. , 2022, , 215-230.		0
2330	Current and future applications of artificial intelligence in multiple sclerosis. , 2022, , 107-144.		2
2331	Clinico-epidemiologic characteristics of optic neuritis in a tertiary eye centre in Eastern India based on the status of serum aquaporin-4 antibody. Indian Journal of Ophthalmology, 2022, 70, 490.	0.5	0
2332	Exploring the Role of Toll-Like Receptor 10 in Risk of Relapsing-Remitting Multiple Sclerosis and its Association with Epstein-Barr Virus. SSRN Electronic Journal, 0, , .	0.4	0
2333	T1/T2-weighted ratio in multiple sclerosis: A longitudinal study with clinical associations. NeuroImage: Clinical, 2022, 34, 102967.	1.4	13
2334	Disabled in Society - A Scoping Review on Persons Living with Multiple Sclerosis and Disability. Journal of Multidisciplinary Healthcare, 2022, Volume 15, 375-390.	1.1	6
2335	Short-Range Structural Connections Are More Severely Damaged in Early-Stage MS. American Journal of Neuroradiology, 2022, 43, 361-367.	1.2	4
2336	A systematic review of self-concept change in multiple sclerosis. Neuropsychological Rehabilitation, 2022, 32, 1774-1813.	1.0	3
2337	ConfusiÃ³n diagnÃ³stica de lesiones desmielinizantes y diagnÃ³stico incidental de una nueva mutaciÃ³n patogÃ©nica del gen FLNA. NeurologÃa, 2022, , .	0.3	0
2338	Diagnostic utility of 3D DIR MRI in the estimation of MS lesions overall load with special emphasis on cortical subtypes. Egyptian Journal of Radiology and Nuclear Medicine, 2022, 53, .	0.3	1
2339	Novel anti-cytoplasmic antibodies in cerebrospinal fluid and serum of patients with chronic severe mental disorders. World Journal of Biological Psychiatry, 2022, 23, 794-801.	1.3	3

#	Article	IF	Citations
2340	A Unique Case of Radiologically Isolated Syndrome Diagnosed During a Follow-up of Cytomegalovirus Meningoencephalitis. Cureus, 2022, 14, e22191.	0.2	0
2341	Self-Reported safety of the BBIBP-CorV (Sinopharm) COVID-19 vaccine among Iranian people with multiple sclerosis. Human Vaccines and Immunotherapeutics, 2022, 18, 1-6.	1.4	10
2342	Cortical and white matter lesion topology influences focal corpus callosum atrophy in multiple sclerosis. Journal of Neuroimaging, 2022, 32, 471-479.	1.0	3
2343	Diplopia, Facial Weakness, and Ascending Paresthesia in a Young Male. Clinical Pediatrics, 2022, , 000992282210803.	0.4	0
2344	Establishing Diagnostic Criteria for Degenerative Cervical Myelopathy [AO Spine RECODE-DCM Research Priority Number 3]. Global Spine Journal, 2022, 12, 55S-63S.	1.2	21
2345	Diseaseâ€modifying therapies and T1 hypointense lesions in patients with multiple sclerosis: A systematic review and metaâ€analysis. CNS Neuroscience and Therapeutics, 2022, 28, 648-657.	1.9	2
2346	Does COVID-19 increase the long-term relapsing-remitting multiple sclerosis clinical activity? A cohort study. BMC Neurology, 2022, 22, 64.	0.8	9
2347	Twin study reveals non-heritable immune perturbations in multiple sclerosis. Nature, 2022, 603, 152-158.	13.7	45
2348	Treatment Strategies for Central Nervous System Effects in Primary and Secondary Haemophagocytic Lymphohistiocytosis in Children. Current Treatment Options in Neurology, 2022, 24, 55-76.	0.7	1
2349	Artificial double inversion recovery images can substitute conventionally acquired images: an MRI-histology study. Scientific Reports, 2022, 12, 2620.	1.6	4
2350	Comparison of Machine Learning Methods Using Spectralis OCT for Diagnosis and Disability Progression Prognosis in Multiple Sclerosis. Annals of Biomedical Engineering, 2022, 50, 507-528.	1.3	26
2351	Multiple sclerosis: two decades of progress. Lancet Neurology, The, 2022, 21, 211-214.	4.9	16
2352	Disrupted structural network of inferomedial temporal regions in relapsingâ€“remitting multiple sclerosis compared with neuromyelitis optica spectrum disorder. Scientific Reports, 2022, 12, 5152.	1.6	1
2353	The Role of Diet and Interventions on Multiple Sclerosis: A Review. Nutrients, 2022, 14, 1150.	1.7	52
2354	Do Hungarian multiple sclerosis care units fulfil international criteria?. PLoS ONE, 2022, 17, e0264328.	1.1	4
2355	Influence of Previous Disease-Modifying Drug Exposure on T-Lymphocyte Dynamic in Patients With Multiple Sclerosis Treated With Ocrelizumab. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, .	3.1	9
2356	The Application of Diffusion Kurtosis Imaging on the Heterogeneous White Matter in Relapsing-Remitting Multiple Sclerosis. Frontiers in Neuroscience, 2022, 16, 849425.	1.4	6
2357	Experiences of receiving a diagnosis of multiple sclerosis: a meta-synthesis of qualitative studies. Disability and Rehabilitation, 2023, 45, 772-783.	0.9	4

#	Article	IF	Citations
2358	High Levels of Cerebrospinal Fluid Kappa Free Light Chains Relate to IgM Intrathecal Synthesis and Might Have Prognostic Implications in Relapsing Multiple Sclerosis. Frontiers in Immunology, 2022, 13, 827738.	2.2	6
2359	Update on Multiple Sclerosis Molecular Biomarkers to Monitor Treatment Effects. Journal of Personalized Medicine, 2022, 12, 549.	1.1	4
2360	Rationale and design of the brain magnetic resonance imaging protocol for FutureMS: a longitudinal multi-centre study of newly diagnosed patients with relapsing-remitting multiple sclerosis in Scotland. Wellcome Open Research, 0, 7, 94.	0.9	6
2361	Demyelinating events following antiâ€tumor necrosis factor alpha therapy: Rare but challenging to treat. European Journal of Neurology, 2022, 29, 2047-2055.	1.7	4
2362	Deep Learning and the OPERA Trials for Multiple Sclerosis. Radiology, 2022, 302, 674-675.	3.6	0
2363	Emerging Biomarkers of Multiple Sclerosis in the Blood and the CSF: A Focus on Neurofilaments and Therapeutic Considerations. International Journal of Molecular Sciences, 2022, 23, 3383.	1.8	9
2364	Multi-lesion radiomics model for discrimination of relapsing-remitting multiple sclerosis and neuropsychiatric systemic lupus erythematosus. European Radiology, 2022, 32, 5700-5710.	2.3	11
2365	Association between dietary inflammatory index and risk of demyelinating autoimmune diseases. International Journal for Vitamin and Nutrition Research, 2024, 94, 19-26.	0.6	4
2366	Development of an ageâ€adjusted model for blood neurofilament light chain. Annals of Clinical and Translational Neurology, 2022, 9, 444-453.	1.7	19
2367	B-cell-depletion reverses dysbiosis of the microbiome in multiple sclerosis patients. Scientific Reports, 2022, 12, 3728.	1.6	10
2368	The Timing of Kinematic and Kinetic Parameters during Gait Cycle as a Marker of Early Gait Deterioration in Multiple Sclerosis Subjects with Mild Disability. Journal of Clinical Medicine, 2022, 11, 1892.	1.0	5
2369	Ermin deficiency leads to compromised myelin, inflammatory milieu, and susceptibility to demyelinating insult. Brain Pathology, 2022, 32, e13064.	2.1	5
2370	Predictors of unemployment status in people with relapsing multiple sclerosis: a single center experience. Neurological Sciences, 2022, 43, 4387-4392.	0.9	3
2371	Efficacy of Disease Modifying Therapies in Progressive MS and How Immune Senescence May Explain Their Failure. Frontiers in Neurology, 2022, 13, 854390.	1.1	9
2372	The degree of cortical plasticity correlates with cognitive performance in patients with Multiple Sclerosis. Brain Stimulation, 2022, 15, 403-413.	0.7	6
2373	Innovating Care in Multiple Sclerosis: Feasibility of Synchronous Internet-Based Teleconsultation for Longitudinal Clinical Monitoring. Journal of Personalized Medicine, 2022, 12, 433.	1.1	3
2374	Incidence and Prevalence of Multiple Sclerosis in MalmÃ¶, Southern Sweden. Multiple Sclerosis International, 2022, 2022, 1-7.	0.4	0
2375	Quantification of Blood-Brain-Barrier Permeability Dysregulation and Inflammatory Activity in MS Lesions by Dynamic-Contrast Enhanced MR Imaging. Basic and Clinical Neuroscience, 2022, 13, 117-128.	0.3	3

#	Article	IF	Citations
2376	Understanding Magnetic Resonance Imaging in Multiple Sclerosis (UMIMS): Development and Piloting of an Online Education Program About Magnetic Resonance Imaging for People With Multiple Sclerosis. Frontiers in Neurology, 2022, 13, 856240.	1.1	3
2377	Dynamics of Retinal Vessel Loss After Acute Optic Neuritis in Patients With Relapsing Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, .	3.1	13
2378	Decreased Intrathecal Concentrations of Free Light Chains Kappa in Multiple Sclerosis Patients Taking Very High Effective Disease-Modifying Treatment. Diagnostics, 2022, 12, 720.	1.3	2
2379	Ponesimod in the Treatment of Relapsing Forms of Multiple Sclerosis: An Update on the Emerging Clinical Data. Degenerative Neurological and Neuromuscular Disease, 2022, Volume 12, 61-73.	0.7	8
2380	Analysis of Plasma Using Flow Cytometry Reveals Increased Immune Cell-Derived Extracellular Vesicles in Untreated Relapsing-Remitting Multiple Sclerosis. Frontiers in Immunology, 2022, 13, 803921.	2.2	6
2381	Longitudinal tracking of axonal loss using diffusion magnetic resonance imaging in multiple sclerosis. Brain Communications, 2022, 4, fcac065.	1.5	1
2382	Hormone therapy and disease activity in Danish women with multiple sclerosis: A populationâ€based cohort study. European Journal of Neurology, 2022, 29, 1753-1762.	1.7	5
2383	Prevalence and Severity of Potential Drugâ€“Drug Interactions in Patients with Multiple Sclerosis with and without Polypharmacy. Pharmaceutics, 2022, 14, 592.	2.0	8
2384	Experimental laboratory biomarkers in multiple sclerosis. Wiener Medizinische Wochenschrift, 2022, , 1.	0.5	3
2385	Predictive MRI Biomarkers in MSâ€”A Critical Review. Medicina (Lithuania), 2022, 58, 377.	0.8	9
2386	Baseline Inflammatory Status Reveals Dichotomic Immune Mechanisms Involved In Primary-Progressive Multiple Sclerosis Pathology. Frontiers in Immunology, 2022, 13, 842354.	2.2	1
2387	Oligoclonal bands: clinical utility and interpretation cues. Critical Reviews in Clinical Laboratory Sciences, 2022, 59, 391-404.	2.7	15
2388	Multipl sklerozlu hastalarda dengenin deÄŸerlendirilmesinde Mini-BESTest ve manyetik rezonans gÃ¶rÃ¼ntÃ¼lemenin etkinliÄŸi. Turkish Journal of Clinics and Laboratory, 0, , .	0.2	0
2389	Evaluation of the Psychometric Properties of the Health Assessment Questionnaire (HAQ) in a Population of Individuals With Multiple Sclerosis. Frontiers in Neurology, 2022, 13, 847786.	1.1	2
2390	Analysis of CSF D-Dimer to Identify Intrathecal Fibrin-Driven Autoimmunity in Patients With Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, .	3.1	6
2391	â€˜Cross-sectional and longitudinal correlations between the Arm Function in Multiple Sclerosis Questionnaire (AMSQ) and other outcome measures in multiple sclerosis.â€™. Multiple Sclerosis and Related Disorders, 2022, 61, 103725.	0.9	1
2392	Challenges and Opportunities of Real-World Data: Statistical Analysis Plan for the Optimise:MS Multicenter Prospective Cohort Pharmacovigilance Study. Frontiers in Neurology, 2022, 13, 799531.	1.1	0
2393	Failure of alemtuzumab therapy in three patients with MOG antibody associated disease. BMC Neurology, 2022, 22, 84.	0.8	3

#	Article	IF	Citations
2395	Expression and diagnostic values of MIAT, H19, and NRON long non-coding RNAs in multiple sclerosis patients. Egyptian Journal of Medical Human Genetics, 2022, 23, .	0.5	6
2396	microRNA-92a promotes CNS autoimmunity by modulating the regulatory and inflammatory T cell balance. Journal of Clinical Investigation, 2022, 132, .	3.9	17
2397	Magnetic Resonance Imaging in Primary Progressive Multiple Sclerosis Patients. Clinical Neuroradiology, 2022, 32, 625-641.	1.0	13
2398	Sexual Dysfunction in Women with Neuromyelitis Optica Spectrum Disorders and Multiple Sclerosis. Sexuality and Disability, 0, , 1.	0.4	2
2399	The Role of Tau beyond Alzheimerâ€™s Disease: A Narrative Review. Biomedicines, 2022, 10, 760.	1.4	12
2400	MRI predictors for the conversion from contrast-enhancing to iron rim multiple sclerosis lesions. Journal of Neurology, 2022, , 1.	1.8	6
2401	Demyelinating Neurological Adverse Events following the Use of Anti-TNF-Î± Agents: A Double-Edged Sword. Case Reports in Neurological Medicine, 2022, 2022, 1-5.	0.3	5
2402	The role of cerebellar damage in explaining disability and cognition in multiple sclerosis phenotypes: a multiparametric MRI study. Journal of Neurology, 2022, 269, 3841-3857.	1.8	6
2403	Familial Cold Autoinflammatory Syndrome and Multiple Sclerosis. Clinical and Experimental Neuroimmunology, 0, , .	0.5	1
2404	Pre-analytical stability of serum biomarkers forÂneurological disease: neurofilament-light, glial fibrillary acidic protein and contactin-1. Clinical Chemistry and Laboratory Medicine, 2022, 60, 842-850.	1.4	22
2405	The effect of lesion filling on brain network analysis in multiple sclerosis using structural magnetic resonance imaging. Insights Into Imaging, 2022, 13, 63.	1.6	2
2406	Mesenchymal Stem Cell-Derived Extracellular Vesicles and Their Therapeutic Use in Central Nervous System Demyelinating Disorders. International Journal of Molecular Sciences, 2022, 23, 3829.	1.8	7
2407	Cognitive function in pediatric-onset relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). Multiple Sclerosis and Related Disorders, 2022, 59, 103689.	0.9	5
2409	Multiple Sclerosis and Microbiome. Biomolecules, 2022, 12, 433.	1.8	14
2410	Motor preparation impairment in multiple sclerosis: Evidence from the Bereitschaftspotential in simple and complex motor tasks. Neurophysiologie Clinique, 2022, 52, 137-146.	1.0	1
2413	Progression is independent of relapse activity in early multiple sclerosis: a real-life cohort study. Brain, 2022, 145, 2796-2805.	3.7	38
2414	Multiple sclerosis: relationship between locus of control and quality of life in persons with low versus high disability. Health Psychology and Behavioral Medicine, 2022, 10, 316-334.	0.8	1
2415	Clinical Features and Imaging Findings of Myelin Oligodendrocyte Glycoprotein-IgG-Associated Disorder (MOGAD). Frontiers in Aging Neuroscience, 2022, 14, 850743.	1.7	7

#	Article	IF	Citations
2416	Longitudinal relationships between disability and gait characteristics in people with MS. Scientific Reports, 2022, 12, 3653.	1.6	3
2417	Genetic Variants of the BAFF Gene and Risk of Fatigue Among Patients With Primary SjÃ¶grenâ€™s Syndrome. Frontiers in Immunology, 2022, 13, 836824.	2.2	5
2418	Radiological approach to non-compressive myelopathies. Egyptian Journal of Radiology and Nuclear Medicine, 2022, 53, .	0.3	1
2419	Multimodal magnetic resonance imaging quantification of gray matter alterations in relapsingâ€remitting multiple sclerosis and neuromyelitis optica spectrum disorder. Journal of Neuroscience Research, 2022, 100, 1395-1412.	1.3	3
2420	Towards imaging criteria that best differentiate MS from NMOSD and MOGAD: large multi-ethnic population and different clinical scenarios. Multiple Sclerosis and Related Disorders, 2022, 61, 103778.	0.9	5
2421	Evaluation of neuropsychiatric symptoms in patients with multiple sclerosis. Cukurova Medical Journal, 2022, 47, 208-218.	0.1	1
2422	Magnetic resonance imaging criteria at onset to differentiate pediatric multiple sclerosis from acute disseminated encephalomyelitis: A nationwide cohort study. Multiple Sclerosis and Related Disorders, 2022, 62, 103738.	0.9	5
2423	Direction and magnitude of displacement differ between slowly expanding and non-expanding multiple sclerosis lesions as compared to small vessel disease. Journal of Neurology, 2022, 269, 4459-4468.	1.8	4
2424	The Expanding Role of the Infectious Disease Expert in the Context of the MS Centre. Journal of Personalized Medicine, 2022, 12, 591.	1.1	0
2425	Identification of potential key genes and immune infiltration in Multiple sclerosis. Multiple Sclerosis and Related Disorders, 2022, 60, 103748.	0.9	2
2426	Potential application of hydrogel to the diagnosis and treatment of multiple sclerosis. Journal of Biological Engineering, 2022, 16, 10.	2.0	2
2427	Effective Connectivity within the Papez Circuit in the Multiple Sclerosis Patients: A Comparative Study Using Resting-State fMRI. Journal of Biomedical Physics and Engineering, 2022, 12, 149-160.	0.5	1
2428	Evolution of acute â€œblack holeâ€•lesions in patients with relapsingâ€“remitting multiple sclerosis. Acta Neurologica Belgica, 2022, , 1.	0.5	0
2429	Upper cervical cord atrophy is independent of cervical cord lesion volume in early multiple sclerosis: A two-year longitudinal study. Multiple Sclerosis and Related Disorders, 2022, 60, 103713.	0.9	4
2430	Cellular and Humoral Immunity to SARSâ€CoVâ€2 Infection in Multiple Sclerosis Patients on Ocrelizumab and Other Diseaseâ€Modifying Therapies: A Multiâ€Ethnic Observational Study. Annals of Neurology, 2022, 91, 782-795.	2.8	22
2431	Towards individualized monitoring of cognition in multiple sclerosis in the digital era: A one-year cohort study. Multiple Sclerosis and Related Disorders, 2022, 60, 103692.	0.9	5
2432	Kappa Free Light Chains in Cerebrospinal Fluid in Inflammatory and Non-Inflammatory Neurological Diseases. Brain Sciences, 2022, 12, 475.	1.1	9
2433	Personalized Disease Monitoring in Pediatric Onset Multiple Sclerosis Using the Saliva Free Light Chain Test. Frontiers in Immunology, 2022, 13, 821499.	2.2	2

#	Article	IF	Citations
2434	Temporal Incidence and Prevalence Trends of Multiple Sclerosis in Markazi Province, Iran. Multiple Sclerosis and Related Disorders, 2022, 60, 103691.	0.9	3
2435	Hidden Markov Model and multifractal method-based predictive quantization complexity models vis-Ã¡-vis the differential prognosis and differentiation of Multiple Sclerosisâ€™ subgroups. Knowledge-Based Systems, 2022, 246, 108694.	4.0	5
2436	Identifying unanswered questions and setting the agenda for future systematic research in Multiple Sclerosis. A worldwide, multi-stakeholder Priority Setting project. Multiple Sclerosis and Related Disorders, 2022, 60, 103688.	0.9	3
2437	CSF Kappa Free Light Chains: Cutoff Validation for Diagnosing Multiple Sclerosis. Mayo Clinic Proceedings, 2022, 97, 738-751.	1.4	17
2438	Quantitative effect of sex on disease activity and disability accumulation in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 716-722.	0.9	17
2439	Quantitative assessment of myelin density using [11C]MeDAS PET in patients with multiple sclerosis: a first-in-human study. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 3492-3507.	3.3	6
2440	Association of adverse childhood experiences with the development of multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 645-650.	0.9	4
2441	A multicenter study to evaluate the disease burden and health economics of inpatients with multiple sclerosis in China. Multiple Sclerosis and Related Disorders, 2022, 60, 103732.	0.9	3
2442	MS or not MS: T2-weighted imaging (T2WI)-based radiomic findings distinguish MS from its mimics. Multiple Sclerosis and Related Disorders, 2022, 61, 103756.	0.9	3
2443	Longitudinal assessment of the relationship between visual evoked potentials and cognitive performance in multiple sclerosis. Clinical Neurophysiology, 2022, 137, 66-74.	0.7	3
2444	Decision making process in multiple sclerosis: An Argentine pilot study. Multiple Sclerosis and Related Disorders, 2022, 61, 103751.	0.9	3
2445	Sociodemographic and clinical characteristics of people with multiple sclerosis and neuro-myelitis optica spectrum disorder in a central northern region of Chile: A prevalence study. Multiple Sclerosis and Related Disorders, 2022, 61, 103750.	0.9	2
2446	Prescription trends of disease-modifying treatments for multiple sclerosis in Iran over the past 30 years. Multiple Sclerosis and Related Disorders, 2022, 61, 103777.	0.9	6
2447	Progressive retinal changes in pediatric multiple sclerosis. Multiple Sclerosis and Related Disorders, 2022, 61, 103761.	0.9	2
2448	Prognostic biomarkers in primary progressive multiple sclerosis: Validating and scrutinizing multimodal evoked potentials. Clinical Neurophysiology, 2022, 137, 152-158.	0.7	4
2449	Impact of disease-modifying therapies on MRI outcomes in patients with relapsing -remitting multiple sclerosis: A systematic review and network meta-analysis. Multiple Sclerosis and Related Disorders, 2022, 61, 103760.	0.9	1
2450	Spermine alleviates experimental autoimmune encephalomyelitis via regulating T cell activation and differentiation. International Immunopharmacology, 2022, 107, 108702.	1.7	4
2451	Ocrelizumab - clinical evaluation and disease progression - 6,5 years data. Neurologie Pro Praxi, 2021, 22, 395-397.	0.0	0

#	Article	IF	Citations
2452	Distinct Immunological Features of Inflammatory Demyelinating Diseases of the Central Nervous System. NeuroImmunoModulation, 2022, 29, 220-230.	0.9	7
2453	Ocular manifestations of multiple sclerosis in patients from three countries: A Web-based survey. European Journal of Ophthalmology, 2021, , 112067212110694.	0.7	3
2454	HLA-DQA1*04:01 is related to a higher multiple sclerosis lesion load on T2/Flair MRI sequences. Arquivos De Neuro-Psiquiatria, 2021, 79, 1109-1115.	0.3	4
2455	Nitrosative Stress Molecules in Multiple Sclerosis: A Meta-Analysis. Biomedicines, 2021, 9, 1899.	1.4	2
2456	A Comparison of Magnetic Resonance Imaging Methods to Assess Multiple Sclerosis Lesions: Implications for Patient Characterization and Clinical Trial Design. Diagnostics, 2022, 12, 77.	1.3	7
2457	Helicobacter pylori antibodies and multiple sclerosis: a single-center study and a short review of the literature. Egyptian Journal of Neurology, Psychiatry and Neurosurgery, 2021, 57, .	0.4	0
2458	Early Diagnosis of Multiple Sclerosis Using Swept-Source Optical Coherence Tomography and Convolutional Neural Networks Trained with Data Augmentation. Sensors, 2022, 22, 167.	2.1	17
2459	Frequency of New Silent MRI Lesions in Myelin Oligodendrocyte Glycoprotein Antibody Disease and Aquaporin-4 Antibody Neuromyelitis Optica Spectrum Disorder. JAMA Network Open, 2021, 4, e2137833.	2.8	35
2460	Vitamin D and Depressive Symptoms in Adults with Multiple Sclerosis: A Scoping Review. International Journal of Environmental Research and Public Health, 2022, 19, 199.	1.2	3
2461	Immunoadsorption and plasma exchangeâ€"Efficient treatment options for neurological autoimmune diseases. Journal of Clinical Apheresis, 2022, 37, 70-81.	0.7	11
2462	The Role of Molecular Imaging as a Marker of Remyelination and Repair in Multiple Sclerosis. International Journal of Molecular Sciences, 2022, 23, 474.	1.8	2
2463	Immunomodulatory Effects Associated with Cladribine Treatment. Cells, 2021, 10, 3488.	1.8	14
2464	A young man with transitory hemiparesis and lung infiltrates. Breathe, 2021, 17, 210069.	0.6	0
2465	Phenotyping of multiple sclerosis lesions according to innate immune cell activation using 18 kDa translocator protein-PET. Brain Communications, 2022, 4, fcab301.	1.5	11
2466	Characteristic Personality Traits of Multiple Sclerosis Patientsâ€"An Unicentric Prospective Observational Cohort Study. Journal of Clinical Medicine, 2021, 10, 5932.	1.0	4
2467	Investigating the Relationship Between Balance and Upper Extremity Function in People with Multiple Sclerosis. , 2021, 1, 79-83.		0
2469	â€œWhat Is Hidden behind the Mask?â€•Facial Emotion Recognition at the Time of COVID-19 Pandemic in Cognitively Normal Multiple Sclerosis Patients. Diagnostics, 2022, 12, 47.	1.3	7
2470	Using Mnemonic in Management of Multiple Sclerosis. Journal of Neuroscience Nursing, 2022, 54, 48-51.	0.7	0

#	Article	IF	Citations
2471	Split-Belt Training but Not Cerebellar Anodal tDCS Improves Stability Control and Reduces Risk of Fall in Patients with Multiple Sclerosis. Brain Sciences, 2022, 12, 63.	1.1	6
2472	Osteopontin levels are associated with late-time lower regional brain volumes in multiple sclerosis. Scientific Reports, 2021, 11, 23604.	1.6	7
2473	A Comparison of IgG Index and Oligoclonal Band in the Cerebrospinal Fluid for Differentiating between RRMS and NMOSD. Brain Sciences, 2022, 12, 69.	1.1	1
2474	Primary Progressive Multiple Sclerosis in a Portuguese Patient With Neurofibromatosis Type 1. Cureus, 2021, 13, e20561.	0.2	2
2475	DeepMSWeb: A Web-Based Decision Support System via Deep Learning for Automatic Detection of MS Lesions. , 2021, , .		2
2476	The frequency and characteristics of multiple sclerosis misdiagnosis in Latin America: A referral center study in Buenos Aires, Argentina. Multiple Sclerosis Journal, 2022, 28, 1373-1381.	1.4	13
2477	Glymphatic system impairment in multiple sclerosis: relation with brain damage and disability. Brain, 2022, 145, 2785-2795.	3.7	78
2478	Attitudes of Patients with Multiple Sclerosis Towards Disease and Physical Activity Behaviors During the COVID-19 Pandemic. , 2021, 1, 84-89.		0
2479	Inadequate Vaccine Responses in Children With Multiple Sclerosis. Frontiers in Pediatrics, 2021, 9, 790159.	0.9	2
2480	Quantitative Susceptibility Mapping-Derived Radiomic Features in Discriminating Multiple Sclerosis From Neuromyelitis Optica Spectrum Disorder. Frontiers in Neuroscience, 2021, 15, 765634.	1.4	3
2481	The contribute of cerebrospinal fluid free light-chain assay in the diagnosis of multiple sclerosis and other neurological diseases in an Italian multicenter study. Multiple Sclerosis Journal, 2022, 28, 1364-1372.	1.4	6
2482	Multiple sclerosis and venous angioplasty for chronic cerebrospinal venous insufficiency: a case control study with ten years follow-up with patients at their own control. Veins and Lymphatics, 2021, 10, .	0.1	0
2483	Potential Contribution of IL-27 and IL-23 Gene Polymorphisms to Multiple Sclerosis Susceptibility: An Association Analysis at Genotype and Haplotype Level. Journal of Clinical Medicine, 2022, 11, 37.	1.0	5
2484	Immune response to SARS-CoV-2 vaccination in relation to peripheral immune cell profiles among patients with multiple sclerosis receiving ocrelizumab. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 978-985.	0.9	17
2486	Multiple Sclerosis Disease Diagnosis and Prognosis in 3D FLAIR MRI Using Deep Learning Network. SSRN Electronic Journal, 0, , .	0.4	0
2487	A multi-regression approach to improve optical coherence tomography diagnostic accuracy in multiple sclerosis patients without previous optic neuritis. NeuroImage: Clinical, 2022, 34, 103010.	1.4	5
2488	Internuclear Ophthalmoplegia Characterizes Multiple Sclerosis Rather Than Neuromyelitis Optica Spectrum Disease. Journal of Neuro-Ophthalmology, 2022, Publish Ahead of Print, .	0.4	1
2489	3-Dimensional Fluid and White Matter Suppression Magnetic Resonance Imaging Sequence Accelerated With Compressed Sensing Improves Multiple Sclerosis Cervical Spinal Cord Lesion Detection Compared With Standard 2-Dimensional Imaging. Investigative Radiology, 2022, 57, 575-584.	3.5	3

#	Article	IF	Citations
2490	Advanced diffusion-weighted imaging models better characterize white matter neurodegeneration and clinical outcomes in multiple sclerosis. Journal of Neurology, 2022, 269, 4729-4741.	1.8	4
2491	Treatment Challenges in Multiple Sclerosis â€“ A Continued Role for Glatiramer Acetate?. Frontiers in Neurology, 2022, 13, 844873.	1.1	4
2492	Spinal cord grey matter atrophy in Multiple Sclerosis clinical practice. Neuroscience Informatics, 2022, 2, 100071.	2.8	1
2493	Real-world outcomes of teriflunomide in relapsingâ€“remitting multiple sclerosis: a prospective cohort study. Journal of Neurology, 2022, 269, 4808-4816.	1.8	11
2494	Fractional anisotropy helps to differentiate the optic nerve impairment between neuromyelitis optica spectrum disorders and multiple sclerosis. European Radiology, 2022, , 1.	2.3	3
2495	Effects of exergaming on cognition, lower limb functional coordination, and stepping time in people with multiple sclerosis: a randomized controlled trial. Disability and Rehabilitation, 2023, 45, 1343-1351.	0.9	2
2496	Tumefactive multiple sclerosis versus high grade glioma: A diagnostic dilemma. , 2022, 13, 146.		2
2497	Multiple Sclerosis Treatment in the COVID-19 Era: A Risk-Benefit Approach. Neurology International, 2022, 14, 368-377.	1.3	5
2498	The Optic Nerve: Anatomy and Pathology. Seminars in Ultrasound, CT and MRI, 2022, 43, 378-388.	0.7	5
2499	B Cells Specific CpG Induces High IL-10 and IL-6 Expression In Vitro in Neuro-BehÃ§etâ€™s Disease. Cells, 2022, 11, 1306.	1.8	3
2500	Changes in expression of miRNAs from the DLK1-DIO3 locus are characteristic of relapsing-remitting multiple sclerosis regardless of the disease activity. Nevrologiya, Neiropsikhiatriya, Psikhosomatika, 2022, 14, 64-70.	0.2	0
2502	Brain atrophy patterns in multiple sclerosis patients treated with natalizumab and its clinical correlates. Brain and Behavior, 2022, 12, e2573.	1.0	5
2503	Phase II study of ketogenic diets in relapsing multiple sclerosis: safety, tolerability and potential clinical benefits. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 637-644.	0.9	29
2504	Pediatric multiple sclerosis: developments in timely diagnosis and prognostication. Expert Review of Neurotherapeutics, 2022, 22, 393-403.	1.4	5
2505	Lipocalin-2 does not influence EAE clinical score but it increases inflammation in central nervous system. Journal of Neuroimmunology, 2022, 368, 577872.	1.1	5
2506	Multiple sclerosis lesions and atrophy in the spinal cord: Distribution across vertebral levels and correlation with disability. NeuroImage: Clinical, 2022, 34, 103006.	1.4	11
2507	Relatively Early and Late-Onset Neuromyelitis Optica Spectrum Disorder in Central China: Clinical Characteristics and Prognostic Features. Frontiers in Neurology, 2022, 13, 859276.	1.1	2
2508	Protein Tyrosine Phosphatase Receptor Type Z in Central Nervous System Disease. International Journal of Molecular Sciences, 2022, 23, 4414.	1.8	9

#	Article	IF	Citations
2509	Harmonizing Magnetic Resonance Imaging Protocols for Veterans With Multiple Sclerosis. , 2022, , .		0
2510	Virus-specific antibody indices may supplement the total IgG index in diagnostics of multiple sclerosis. Journal of Neuroimmunology, 2022, 367, 577868.	1.1	2
2511	Periventricular gradient of T1 tissue alterations in multiple sclerosis. NeuroImage: Clinical, 2022, 34, 103009.	1.4	9
2512	Validity and reliability of Korean version of Modified Fatigue Impact Scale (MFIS) for Korean patients with multiple sclerosis. Multiple Sclerosis and Related Disorders, 2022, 62, 103811.	0.9	0
2513	Parkinsonism in multiple sclerosis patients: A prospective observational study. Multiple Sclerosis and Related Disorders, 2022, 62, 103796.	0.9	2
2585	Personality traits of patients with multiple sclerosis and their correlation with anxiety and depression levels: A crossâ€sectional caseâ€“control study. Brain and Behavior, 2022, 12, e2596.	1.0	4
2586	Advanced <scp>MRI</scp> quantification of neuroinflammatory disorders. Journal of Neuroscience Research, 2022, 100, 1389-1394.	1.3	1
2587	Dietary habits, nutritional status and risk of a first demyelinating event: an incident case-control study in a southern European cohort. Neurological Sciences, 2022, 43, 4373-4380.	0.9	3
2588	Italian translation and validation of fatigue symptoms and impacts questionnaire in relapsing multiple sclerosis (FSIQ-RMS). Neurological Sciences, 2022, 43, 4925-4932.	0.9	4
2589	Reader response: Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study. Neurology, 2019, 92, 542-543.	1.5	0
2590	Teaching Video NeuroImages: A patient with Holmes tremor due to demyelinating lesion of the inferior cerebellar peduncle. Neurology, 2019, 92, e2179-e2180.	1.5	2
2591	Editor Response: Asymptomatic Optic Nerve Lesions: An Underestimated Cause of Silent Retinal Atrophy in MS. Neurology, 2021, 96, 349-350.	1.5	0
2593	Incidence of Pediatric Multiple Sclerosis in Iran within 2000-2019.. Iranian Journal of Child Neurology, 2022, 16, 31-38.	0.2	0
2594	Kappa Free Light Chains, Soluble Interleukin-2 Receptor, and Interleukin-6 Help Explore Patients Presenting With Brain White Matter Hyperintensities. Frontiers in Immunology, 2022, 13, 864133.	2.2	5
2595	Oligoclonal Bands in Multiple System Atrophy: Case Report and Proposed Mechanisms of Immunogenicity. Frontiers in Neuroscience, 2022, 16, 852939.	1.4	1
2598	Outcome of COVID-19 infection in multiple sclerosis patients receiving disease-modifying therapies. Journal of Research in Medical Sciences, 2021, 26, 85.	0.4	1
2600	Neuroimaging Features and Associated Factors in Multiple Sclerosis Patients: A Perspective from a Private Care Center in Addis Ababa, Ethiopia.. Ethiopian Journal of Health Sciences, 2021, 31, 1043-1052.	0.2	1
2601	Pulmonary manifestations of autoimmune diseases. , 2022, , 265-294.		0

#	Article	IF	Citations
2602	Oligoclonal bands: An immunological and clinical approach. Advances in Clinical Chemistry, 2022, , 129-163.	1.8	5
2604	Imaging in Neuro-ophthalmology. , 2022, , 4419-4447.		0
2605	Usefulness of masseter vestibular evoked myogenic potentials in identifying brainstem dysfunction among individuals with multiple sclerosis. International Journal of Audiology, 2023, 62, 635-643.	0.9	3
2606	COVID-19 Vaccination in Multiple Sclerosis and Inflammatory Diseases: Effects from Disease-Modifying Therapy, Long-Term Seroprevalence and Breakthrough Infections. Vaccines, 2022, 10, 695.	2.1	16
2607	Case Report: Exacerbation of Relapses Following mRNA COVID-19 Vaccination in Multiple Sclerosis: A Case Series. Frontiers in Neurology, 2022, 13, 897275.	1.1	13
2608	Biological Markers in Early Multiple Sclerosis: the Paved Way for Radiologically Isolated Syndrome. Frontiers in Immunology, 2022, 13, 866092.	2.2	12
2609	SARS-CoV-2 and Multiple Sclerosis: Potential for Disease Exacerbation. Frontiers in Immunology, 2022, 13, 871276.	2.2	13
2610	Low Contrast Visual Evoked Potentials for Early Detection of Optic Neuritis. Frontiers in Neurology, 2022, 13, 804395.	1.1	0
2611	The reliability and validity of the 30-second chair stand test and modified four square step test in persons with multiple sclerosis. Physiotherapy Theory and Practice, 2023, 39, 2189-2195.	0.6	9
2612	The Impact of Resistance Training Program on Static Balance in Multiple Sclerosis Population: A Randomized Controlled Trial Study. Journal of Clinical Medicine, 2022, 11, 2405.	1.0	2
2613	<scp>ABCB1</scp> gene polymorphisms impact the effect of highâ€dose intravenous methylprednisolone therapy on optic neuritis associated with <scp>AQP4â€IgG</scp> â€positive neuromyelitis optica spectrum disorder. Journal of Clinical Pharmacy and Therapeutics, 2022, 47, 1379-1387.	0.7	2
2614	Fatigue, cognition and inflammatory biomarkers changes in response to computer-based cognitive training in multiple sclerosis patients: A randomized controlled trial. NeuroRehabilitation, 2022, 51, 315-324.	0.5	2
2615	Vaccination Coverage against Tetanus, Diphtheria, Pertussis and Poliomyelitis and Validity of Self-Reported Vaccination Status in Patients with Multiple Sclerosis. Journal of Personalized Medicine, 2022, 12, 677.	1.1	3
2616	Risk factors of white matter hyperintensities in migraine patients. BMC Neurology, 2022, 22, 159.	0.8	5
2617	Management of multiple sclerosis using disease-modifying therapies: a clinical review. British Journal of Neuroscience Nursing, 2022, 18, 84-96.	0.1	1
2618	Label-free Quantitative Proteomic Analysis of Cerebrospinal Fluid and Serum in Patients With Relapse-Remitting Multiple Sclerosis. Frontiers in Genetics, 2022, 13, 892491.	1.1	2
2619	Evaluation of cerebrospinal fluid neurofilament light chain levels in multiple sclerosis and non-demyelinating diseases of the central nervous system: clinical and biochemical perspective. Bosnian Journal of Basic Medical Sciences, 2022, , .	0.6	1
2620	Cost associated with a relapse-free patient in multiple sclerosis: A real-world health indicator. PLoS ONE, 2022, 17, e0267504.	1.1	0

#	Article	IF	Citations
2622	Uncertainty-Aware and Lesion-Specific Image Synthesis in Multiple Sclerosis Magnetic Resonance Imaging: A Multicentric Validation Study. Frontiers in Neuroscience, 2022, 16, 889808.	1.4	4
2623	A Comprehensive Update on Retinal Vasculitis: Etiologies, Manifestations and Treatments. Journal of Clinical Medicine, 2022, 11, 2525.	1.0	11
2624	Racial and Ethnic Disparities in Multiple Sclerosis Prevalence. Neurology, 2022, 98, .	1.5	48
2625	Clinical Characteristics and Outcomes of Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder With Brainstem Lesions as Heralding Prodrome. Frontiers in Neurology, 2022, 13, .	1.1	1
2626	Fluid and White Matter Suppression. Investigative Radiology, 2022, 57, 592-600.	3.5	4
2627	Targeted Delivery Platforms for the Treatment of Multiple Sclerosis. Molecular Pharmaceutics, 2022, 19, 1952-1976.	2.3	5
2628	General vaccination willingness and current vaccination status in relation to clinical and psychological variables in patients with multiple sclerosis. Vaccine, 2022, 40, 3236-3243.	1.7	1
2629	Fatigue, sleepiness and depression in multiple sclerosis: defining the overlaps for a better phenotyping. Journal of Neurology, 2022, 269, 4961-4971.	1.8	8
2630	Analysis of cerebrospinal fluid cells by flow cytometry: Comparison to conventional cytology. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, 2022, , .	0.2	0
2631	Cardiovascular autonomic dysfunction in multiple sclerosisâ€"findings and relationships with clinical outcomes and fatigue severity. Neurological Sciences, 2022, 43, 4829-4839.	0.9	7
2632	Fibrin-targeting molecular MRI in inflammatory CNS disorders. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 3692-3704.	3.3	5
2633	Demyelinating Syndromes in Systemic Lupus Erythematosus: Data From the â€œAttikonâ€•Lupus Cohort. Frontiers in Neurology, 2022, 13, .	1.1	8
2634	Cannabis and cannabinoids for symptomatic treatment for people with multiple sclerosis. The Cochrane Library, 2022, 5, CD013444.	1.5	12
2635	Cell-based flow cytometry assay for simultaneous detection of multiple autoantibodies in a single serum sample. Analytical Biochemistry, 2022, , 114721.	1.1	0
2636	Impact of the covid-19 pandemic on the psychological status and cortisol level of multiple sclerosis patients. Neuropsychological Rehabilitation, 2023, 33, 1120-1143.	1.0	0
2637	Enhancement of Regnase-1 expression with stem loopâ€"targeting antisense oligonucleotides alleviates inflammatory diseases. Science Translational Medicine, 2022, 14, eabo2137.	5.8	8
2638	Multiple sclerosis: Immunopathological heterogeneity and its implications. European Journal of Immunology, 2022, 52, 869-881.	1.6	3
2639	Inter-Laboratory Concordance of Cerebrospinal Fluid and Serum Kappa Free Light Chain Measurements. Biomolecules, 2022, 12, 677.	1.8	2

#	Article	IF	Citations
2640	Barriers to quality of life in patients with multiple sclerosis: a qualitative study. BMC Neurology, 2022, 22, 174.	0.8	8
2641	Voxel-wise lesion mapping of restless legs syndrome in multiple sclerosis. Neurological Sciences, 2022, 43, 4953-4959.	0.9	1
2642	Reproducibility of Lesion Count in Various Subregions on MRI Scans in Multiple Sclerosis. Frontiers in Neurology, 2022, 13, .	1.1	4
2643	Distinct Effector Programs of Brain-Homing CD8+ T Cells in Multiple Sclerosis. Cells, 2022, 11, 1634.	1.8	6
2644	Predominant domains and associated demographic and clinical characteristics in multiple sclerosis-related cognitive impairment in mildly disabled patients. Egyptian Journal of Neurology, Psychiatry and Neurosurgery, 2022, 58, .	0.4	5
2645	An Accurate Multiple Sclerosis Detection Model Based on Exemplar Multiple Parameters Local Phase Quantization: ExMPLPQ. Applied Sciences (Switzerland), 2022, 12, 4920.	1.3	22
2646	<scp>Higherâ€resolution</scp> quantification of white matter hypointensities by largeâ€scale transfer learning from <scp>2D</scp> images on the <scp>JPSCâ€AD</scp> cohort. Human Brain Mapping, 2022, 43, 3998-4012.	1.9	5
2647	Proteomics in Multiple Sclerosis: The Perspective of the Clinician. International Journal of Molecular Sciences, 2022, 23, 5162.	1.8	15
2648	Optic neuritis with potential for poor outcome. Practical Neurology, 2022, , practneurol-2021-003228.	0.5	0
2649	Burden of multiple sclerosis: impact on the patient, family and society. Multiple Sclerosis and Related Disorders, 2022, 63, 103864.	0.9	6
2650	Implication of genetic variants in primary microRNA processing sites in the risk of multiple sclerosis. EBioMedicine, 2022, 80, 104052.	2.7	7
2651	The prevalence of internuclear ophthalmoparesis in a population-based cohort of individuals with multiple sclerosis. Multiple Sclerosis and Related Disorders, 2022, 63, 103824.	0.9	5
2652	Validation of two new scales for the assessment of fatigue in Multiple Sclerosis: F-2-MS and FACIT-F. Multiple Sclerosis and Related Disorders, 2022, 63, 103826.	0.9	4
2653	Genetic biomarkers in multiple sclerosis: An umbrella review of meta-analyses of observational studies. Multiple Sclerosis and Related Disorders, 2022, 63, 103834.	0.9	2
2654	Development and validation of a simple and practical method for differentiating MS from other neuroinflammatory disorders based on lesion distribution on brain MRI. Journal of Clinical Neuroscience, 2022, 101, 32-36.	0.8	3
2655	Disease modifying therapy management of multiple sclerosis after stem cell therapies: A retrospective case series. Multiple Sclerosis and Related Disorders, 2022, 63, 103861.	0.9	1
2656	Brain-derived neurotrophic factor and neurofilament light chain in cerebrospinal fluid are inversely correlated with cognition in Multiple Sclerosis at the time of diagnosis. Multiple Sclerosis and Related Disorders, 2022, 63, 103822.	0.9	7
2657	Allostatic load index in patients with multiple sclerosis: A case-control study. Psychoneuroendocrinology, 2022, 142, 105788.	1.3	4

#	Article	IF	Citations
2658	Multiple Sklerose. , 2021, , 47-59.		0
2659	Defining milestones for the study of remyelination using the cuprizone mouse model: how early is early?. Multiple Sclerosis and Related Disorders, 2022, , 103886.	0.9	2
2660	Implications of lower extremity muscle power and force for walking and fatigability in multiple sclerosis â€“ An exploratory pilot-study. Clinical Biomechanics, 2022, 96, 105668.	0.5	4
2661	Increasing Incidence and Male to Female Sex Ratio of Multiple Sclerosis in Tehran, Iran: A Population-Based Study. Iranian Journal of Public Health, 0, , .	0.3	0
2662	Multiple sclerosis in children and adolescents. , 2018, 52, 7-13.		0
2663	Rare co-occurrence of multiple sclerosis and Wilsonâ€™s disease â€“ case report. BMC Neurology, 2022, 22, 178.	0.8	0
2664	Antinuclear antibodies positivity is not rare during multiple sclerosis and is associated with relapsing status and IgG oligoclonal bands positivity. Revue Neurologique, 2022, 178, 812-816.	0.6	2
2665	Association of the Processing Speed Test with depression and brain magnetic resonance imaging metrics in Japanese patients with multiple sclerosis. Clinical and Experimental Neuroimmunology, 0, , .	0.5	0
2666	Coupling cognitive and brainstem dysfunction in multiple sclerosis-related chronic neuropathic limb pain. Brain Communications, 2022, 4, .	1.5	3
2667	Association of Brain Atrophy With Disease Progression Independent of Relapse Activity in Patients With Relapsing Multiple Sclerosis. JAMA Neurology, 2022, 79, 682.	4.5	41
2668	Effects and optimal dosage of resistance training on strength, functional capacity, balance, general health perception, and fatigue in people with multiple sclerosis: a systematic review and meta-analysis. Disability and Rehabilitation, 2023, 45, 1595-1607.	0.9	7
2669	Incidental Findings in Head and Brain MRI of Military Pilots and Applicants: Consequences for Medical Flight Fitness. Aerospace Medicine and Human Performance, 2022, 93, 450-457.	0.2	0
2670	Thalamic Atrophy, Duration of Illness and Years of Education are the Best Predictors of Cognitive Impairment in Multiple Sclerosis. Clinical and Experimental Neuroimmunology, 0, , .	0.5	0
2671	The analysis of dynamic gene expression patterns in peripheral blood of multiple sclerosis patients indicates possible diagnostic and prognostic biomarkers. Molecular Immunology, 2022, 147, 147-156.	1.0	5
2672	Ocrelizumab for multiple sclerosis. The Cochrane Library, 2022, 2022, CD013247.	1.5	9
2673	Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis, the Ottawa Protocol. Current Protocols, 2022, 2, e437.	1.3	0
2674	Assessment of 2D conventional and synthetic MRI in multiple sclerosis. Neuroradiology, 2022, , .	1.1	2
2675	Association between inflammatory central nervous system lesions and Cerebellar Ataxia, Neuropathy and Vestibular Areflexia Syndrome (CANVAS): a case series. Journal of Neurology, 2022, , .	1.8	2

#	Article	IF	Citations
2676	The incidence and prevalence, diagnosis, and treatment of multiple sclerosis in China: a narrative review. Neurological Sciences, 2022, 43, 4695-4700.	0.9	8
2677	Concurrent CNS tumors and multiple sclerosis: retrospective single-center cohort study and lessons for the clinical management. Neurological Sciences, 2022, 43, 5513-5522.	0.9	2
2678	The role of non-coding RNAs in neuroinflammatory process in multiple sclerosis. Molecular Neurobiology, 2022, 59, 4651-4668.	1.9	3
2679	Isolated sixth nerve palsy: a rare first presentation in multiple sclerosis. BMJ Case Reports, 2022, 15, e247928.	0.2	0
2680	Increasing incidence and prevalence of multiple sclerosis in the Greater Hobart cohort of Tasmania, Australia. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 723-731.	0.9	10
2681	Serum MOG-IgG in children meeting multiple sclerosis diagnostic criteria. Multiple Sclerosis Journal, 2022, 28, 1697-1709.	1.4	12
2682	The clinical spectrum of haemorrhagic CNS inflammatory demyelinating lesions. Multiple Sclerosis Journal, 2022, 28, 1710-1718.	1.4	1
2683	Role of Chitinase 3â€“like 1 as a Biomarker in Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, .	3.1	17
2684	Pure Relapsing Short Myelitis. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, .	3.1	5
2685	Multiple Sclerosis: Systemic Challenges to Cost-Effective Care.. American Health and Drug Benefits, 2022, 15, 13-20.	0.5	0
2686	Slowly expanding lesions relate to persisting black-holes and clinical outcomes in relapse-onset multiple sclerosis. NeuroImage: Clinical, 2022, 35, 103048.	1.4	17
2687	Molecular biomarkers in multiple sclerosis. Arhiv Za Farmaciju, 2022, 72, 127-148.	0.2	0
2688	Sudomotor dysfunction in people with neuromyelitis optica spectrum disorders. European Journal of Neurology, 2022, 29, 2772-2780.	1.7	3
2689	Gut Microbiota as a Potential Predictive Biomarker in Relapsing-Remitting Multiple Sclerosis. Genes, 2022, 13, 930.	1.0	11
2690	Bulbar Symptoms as an Unusual Presentation of Multiple Sclerosis: A Case Report. European Journal of Case Reports in Internal Medicine, 0, , .	0.2	0
2691	Gait stability reflects motor tracts damage at early stages of multiple sclerosis. Multiple Sclerosis Journal, 2022, 28, 1773-1782.	1.4	4
2692	The Impact of COVID-19 on the Lives of Individuals With Multiple Sclerosis: 1 Year Into the Pandemic. International Journal of MS Care, 2022, 24, 139-144.	0.4	1
2693	Prospective longitudinal study on prognostic factors of visual recovery and structural change after a first episode of optic neuritis. European Journal of Neurology, 2022, 29, 2781-2791.	1.7	4

#	Article	IF	Citations
2694	Evaluation of the Psychometric Properties of the Revised Piper Fatigue Scale in Patients with Multiple Sclerosis. Healthcare (Switzerland), 2022, 10, 985.	1.0	2
2698	The integration of clinical data in the assessment of multiple sclerosisÂâ€“ÂA review. Computer Methods and Programs in Biomedicine, 2022, 221, 106900.	2.6	3
2699	The effect of cognitive performance on self-management behavior of multiple sclerosis patients. Multiple Sclerosis and Related Disorders, 2022, 63, 103880.	0.9	2
2700	Evolution of teriflunomide use in multiple sclerosis: A real-world experience. Journal of the Neurological Sciences, 2022, 438, 120292.	0.3	2
2701	Preferences for Disease-Modifying Therapies in Argentina: Cross-Sectional Conjoint Analysis of Patients and Neurologists. Value in Health Regional Issues, 2022, 31, 93-100.	0.5	3
2702	Quantitative susceptibility mapping of both ring and non-ring white matter lesions in relapsing remitting multiple sclerosis. Magnetic Resonance Imaging, 2022, 91, 45-51.	1.0	4
2704	Role of artificial intelligence in MS clinical practice. NeuroImage: Clinical, 2022, 35, 103065.	1.4	23
2705	Immunological consequences of cladribine treatment in multiple sclerosis: A real-world study. Multiple Sclerosis and Related Disorders, 2022, 64, 103931.	0.9	9
2706	Humoral and Cellular Response to Spike of Delta SARS-CoV-2 Variant in Vaccinated Patients With Multiple Sclerosis. Frontiers in Neurology, 2022, 13, .	1.1	18
2707	A Prospective Viewpoint on Neurological Diseases and Their Biomarkers. Molecules, 2022, 27, 3516.	1.7	9
2708	Early Successful Eye Movement Desensitization and Reprocessing (EMDR) Therapy for Verbal Memory Impairment in an Adjustment Disorder: A Case Report in a Newly-Diagnosed Multiple Sclerosis Patient. Reports, 2022, 5, 17.	0.2	1
2709	Antiherpes Viral Antibodies in the Serum of Patients with Multiple Sclerosis in Samara. , 2022, , .		0
2711	Resting state effective connectivity abnormalities of the Papez circuit and cognitive performance in multiple sclerosis. Molecular Psychiatry, 0, , .	4.1	3
2712	Hyper-Reflecting Foci in Multiple Sclerosis Retina Associate With Macrophage/Microglia-Derived Cytokines in Cerebrospinal Fluid. Frontiers in Immunology, 2022, 13, .	2.2	8
2713	A Narrative Review on Axonal Neuroprotection in Multiple Sclerosis. Neurology and Therapy, 2022, 11, 981-1042.	1.4	5
2714	Usability of a Hybrid System Combining P300-Based Brain-Computer Interface and Commercial Assistive Technologies to Enhance Communication in People With Multiple Sclerosis. Frontiers in Human Neuroscience, 2022, 16, .	1.0	2
2715	RGMa Participates in the Bloodâ€“Brain Barrier Dysfunction Through BMP/BMPR/YAP Signaling in Multiple Sclerosis. Frontiers in Immunology, 2022, 13, .	2.2	3
2716	Retinal Hyperreflecting Foci Associate With Cortical Pathology in Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, .	3.1	8

#	Article	IF	Citations
2717	Metabolomics of Cerebrospinal Fluid in Multiple Sclerosis Compared With Healthy Controls: A Pilot Study. Frontiers in Neurology, 0, 13, .	1.1	4
2718	Seroprevalence of MOG and AQP4 antibodies and outcomes in an Indian cohort of Pediatric Acquired Demyelinating Syndromes. Neuropediatrics, 0, 0, .	0.3	0
2719	Association of Serum Neurofilament Light Chain With Inner Retinal Layer Thinning in Multiple Sclerosis. Neurology, 2022, 99, .	1.5	7
2720	Oxidative Stress Markers in Cerebrospinal Fluid of Newly Diagnosed Multiple Sclerosis Patients and Their Link to Iron Deposition and Atrophy. Diagnostics, 2022, 12, 1365.	1.3	2
2721	Impact of Diminished Expression of circRNA on Multiple Sclerosis Pathomechanisms. Frontiers in Immunology, 2022, 13, .	2.2	7
2723	Therapeutic Advances in Multiple Sclerosis. Frontiers in Neurology, 0, 13, .	1.1	28
2724	Evaluation of adherence to treatment in patients with multiple sclerosis from Latin America. Multiple Sclerosis and Related Disorders, 2022, 63, 103915.	0.9	5
2726	CEST MRI and MALDI imaging reveal metabolic alterations in the cervical lymph nodes of EAE mice. Journal of Neuroinflammation, 2022, 19, .	3.1	1
2727	Predictors of Cladribine Effectiveness and Safety in Multiple Sclerosis: A Real-World, Multicenter, 2-Year Follow-Up Study. Neurology and Therapy, 2022, 11, 1193-1208.	1.4	17
2728	Distinguishing CNS neurosarcoidosis from multiple sclerosis and an approach to â€œoverlapâ€•cases. Journal of Neuroimmunology, 2022, 369, 577904.	1.1	5
2729	Diagnostic confusion of demyelinating lesions and incidental diagnosis of a new pathogenic mutation of the FLNA gene. NeurologÃa (English Edition), 2022, , .	0.2	0
2730	Physical activity in non-disabled people with early multiple sclerosis: A multicenter cross-sectional study. Multiple Sclerosis and Related Disorders, 2022, 64, 103941.	0.9	5
2731	Retinal inner nuclear layer thinning is decreased and associates with the clinical outcome in ocrelizumab-treated primary progressive multiple sclerosis. Journal of Neurology, 2022, 269, 5436-5442.	1.8	6
2732	Early B cells repopulation in multiple sclerosis patients treated with rituximab is not predictive of a risk of relapse or clinical progression. Journal of Neurology, 2022, 269, 5443-5453.	1.8	9
2733	Hiding in plain sight: The magnitude of unused disease modifying therapies in multiple sclerosis and strategies for reducing the economic burden of care. Multiple Sclerosis and Related Disorders, 2022, 63, 103920.	0.9	3
2734	Biomarker panel increases accuracy for identification of an MS relapse beyond sNfL. Multiple Sclerosis and Related Disorders, 2022, 63, 103922.	0.9	2
2735	Histoire naturelle, symptÃ´mes, formes cliniques et diagnostic deÂla sclÃ©rose en plaques. , 2022, , 337-353.		0
2736	Outils dâ€™imagerie dans les maladies neurodÃ©gÃ©nÃ©ratives. , 2022, , 73-85.		0

#	Article	IF	Citations
2737	SclÃ©rose en plaques. , 2022, , 329-336.		0
2738	CSF TNF and osteopontin levels correlate with the response to dimethyl fumarate in early multiple sclerosis. Therapeutic Advances in Neurological Disorders, 2022, 15, 175628642210921.	1.5	5
2740	Shannon entropy-based complexity quantification of nonlinear stochastic process. , 2022, , 231-245.		1
2741	Peripartum disease activity in moderately and severely disabled women with multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2022, 8, 205521732211049.	0.5	2
2742	A Deep Learning Approach for Gait Event Detection from a Single Shank-Worn IMU: Validation in Healthy and Neurological Cohorts. Sensors, 2022, 22, 3859.	2.1	18
2743	Multiple sclerosis in patients with hereditary spastic paraplegia: a case report and systematic review. Neurological Sciences, 2022, 43, 5501-5511.	0.9	2
2744	Validation of the French version of the Multiple Sclerosis Intimacy And Sexuality Questionnaire-19: A preliminary study. Multiple Sclerosis and Related Disorders, 2022, 65, 103986.	0.9	2
2745	Eating Hubs in Multiple Sclerosis: Exploring the Relationship Between Mediterranean Diet and Disability Status in Italy. Frontiers in Nutrition, 0, 9, .	1.6	6
2746	The alterations of cerebrospinal fluid TNF-alpha and TGF-beta2 levels in early relapsingâ€“remitting multiple sclerosis. Immunologic Research, 2022, 70, 708-713.	1.3	2
2747	A New Advanced <scp>MRI</scp> Biomarker for Remyelinated Lesions in Multiple Sclerosis. Annals of Neurology, 2022, 92, 486-502.	2.8	28
2748	Transcallosal and Corticospinal White Matter Disease and Its Association With Motor Impairment in Multiple Sclerosis. Frontiers in Neurology, 0, 13, .	1.1	2
2749	A doubleâ€blind, randomized, placeboâ€controlled phase 2 trial evaluating the selective dihydroorotate dehydrogenase inhibitor vidofludimus calcium in relapsingâ€remitting multiple sclerosis. Annals of Clinical and Translational Neurology, 2022, 9, 977-987.	1.7	7
2750	Efficacy of Transcranial Direct Current Stimulation (tDCS) on Balance and Gait in Multiple Sclerosis Patients: A Machine Learning Approach. Journal of Clinical Medicine, 2022, 11, 3505.	1.0	17
2751	Neuroimaging in cerebellar ataxia in childhood: A review. Journal of Neuroimaging, 0, , .	1.0	0
2752	Ocrelizumab in Patients with Active Primary Progressive Multiple Sclerosis: Clinical Outcomes and Immune Markers of Treatment Response. Cells, 2022, 11, 1959.	1.8	3
2753	Analysis of optical coherence tomography of the optic nerve head and of the retinal macular area in multiple sclerosis patients. Ophthalmology Journal, 2022, 15, 15-28.	0.1	0
2755	Role of Helical Structure in MBP Immunodominant Peptides for Efficient IgM Antibody Recognition in Multiple Sclerosis. Frontiers in Chemistry, 0, 10, .	1.8	0
2756	Transformer-Based Deep-Learning Algorithm for Discriminating Demyelinating Diseases of the Central Nervous System With Neuroimaging. Frontiers in Immunology, 0, 13, .	2.2	1

#	Article	IF	Citations
2757	Interrogating large multiple sclerosis registries and databases: what information can be gained?. Current Opinion in Neurology, 2022, 35, 271-277.	1.8	5
2759	The Seasonal Fluctuation of Fatigue in Multiple Sclerosis. Frontiers in Neurology, 0, 13, .	1.1	7
2760	The Sexual Dimorphism in Cerebrospinal Fluid Protein Content Does Not Affect Intrathecal IgG Synthesis in Multiple Sclerosis. Journal of Personalized Medicine, 2022, 12, 977.	1.1	1
2761	IL-10 Gene Polymorphisms and IL-10 Serum Levels in Patients with Multiple Sclerosis in Lithuania. Brain Sciences, 2022, 12, 800.	1.1	2
2762	The kappa free light chain index and oligoclonal bands have a similar role in the McDonald criteria. Brain, 2022, 145, 3931-3942.	3.7	12
2763	Clinical, Radiological and Pathological Characteristics Between Cerebral Small Vessel Disease and Multiple Sclerosis: A Review. Frontiers in Neurology, 0, 13, .	1.1	7
2764	<scp>Antiâ€CD20</scp> therapy for multiple sclerosisâ€associated uveitis: AÂcase series. European Journal of Neurology, 2022, 29, 3028-3038.	1.7	3
2765	Diagnosis of coexistent neurodegenerative dementias in multiple sclerosis. Brain Communications, 2022, 4, .	1.5	7
2766	â€œCan I exercise? Would it help? Would it not?â€: exploring the experiences of people with relapsing remitting multiple sclerosis engaging with physical activity during a relapse: a qualitative study. Disability and Rehabilitation, 2023, 45, 2095-2106.	0.9	1
2767	Evaluation of liver injury in multiple sclerosis patients receiving pulsed steroid therapy. Multiple Sclerosis and Related Disorders, 2022, 65, 103968.	0.9	2
2768	Investigation of Relationship of Stereoacuity with Retinal Nerve Fiber Layer Thickness and P100 Latency in Patients with Multiple Sclerosis with and Without Optic Neuritis. Turk Noroloji Dergisi = Turkish Journal of Neurology, 2022, 28, 169-175.	0.1	0
2769	Do patientsâ€™ and referral centersâ€™ characteristics influence multiple sclerosis phenotypes? Results from the Italian multiple sclerosis and related disorders register. Neurological Sciences, 0, , .	0.9	1
2770	COVID-19 severity is associated with worsened neurological outcomes in multiple sclerosis and related disorders. Multiple Sclerosis and Related Disorders, 2022, 63, 103946.	0.9	10
2771	The minnesota manual dexterity test as a bimanual performance measure in people with multiple sclerosis. Multiple Sclerosis and Related Disorders, 2022, 64, 103943.	0.9	3
2772	Male-specific coordinated changes in expression of miRNA genes, but not other genes within the DLK1-DIO3 locus in multiple sclerosis. Gene, 2022, 836, 146676.	1.0	1
2773	Teaching cases in differential diagnosis: Misdiagnosis of MS perpetuated for 14 years. Multiple Sclerosis and Related Disorders, 2022, 64, 103950.	0.9	0
2774	Racial disparities in hypertension management among multiple sclerosis patients. Multiple Sclerosis and Related Disorders, 2022, 64, 103972.	0.9	7
2775	Kappa-index: Real-life evaluation of a new tool for multiple sclerosis diagnosis. Clinical Immunology, 2022, 241, 109066.	1.4	1

#	Article	IF	Citations
2776	Long-term prognosis communication preferences in early-stage relapsing-remitting multiple sclerosis. Multiple Sclerosis and Related Disorders, 2022, 64, 103969.	0.9	2
2777	Disease Course and Outcomes in Patients With the Limited Form of Neuromyelitis Optica Spectrum Disorders and Negative AQP4-IgG Serology at Disease Onset: A Prospective Cohort Study. Journal of		

#	Article	IF	Citations
2794	Glioblastoma in Patients With Multiple Sclerosis. Neurohospitalist, The, 0, , 194187442211060.	0.3	0
2795	T cells from MS Patients with High Disease Severity Are Insensitive to an Immune-Suppressive Effect of Sulfatide. Molecular Neurobiology, 0, , .	1.9	0
2796	Update on Optic Neuritis in Adults. Advances in Ophthalmology and Optometry, 2022, , .	0.3	0
2797	Acute Thermoregulatory and Cardiovascular Response to Submaximal Exercise in People With Multiple Sclerosis. Frontiers in Immunology, 0, 13, .	2.2	1
2798	Acute Disseminated Encephalomyelitis with Prefrontal Cortex Involvement in a 9-Year-Old Child after COVID-19 Infection: A Case Report. Journal of Pediatric Neurology, 0, , .	0.0	0
2799	Predictors of progression from first demyelinating event to clinically definite multiple sclerosis. Brain Communications, 0, , .	1.5	2
2800	Abuse and revictimization in adulthood in multiple sclerosis: a cross-sectional study during pregnancy. Journal of Neurology, 2022, 269, 5901-5909.	1.8	1
2801	Increased Intrathecal Activity of Follicular Helper T Cells in Patients With Relapsing-Remitting Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, .	3.1	11
2802	Frailty among people with multiple sclerosis who are wheelchair users. PLoS ONE, 2022, 17, e0271688.	1.1	3
2803	Preventive exercise attenuates IL-2-driven mood disorders in multiple sclerosis. Neurobiology of Disease, 2022, 172, 105817.	2.1	8
2804	Real-World Assessment of Quality of Life in Patients with Relapsing Remitting Multiple Sclerosis Treated with Teriflunomide for Two Years: Patient-Reported Outcomes from the AURELIO Study in Greece. Neurology and Therapy, 2022, 11, 1375-1390.	1.4	4
2805	Innate immune cells and myelin profile in multiple sclerosis: a multi-tracer PET/MR study. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 4551-4566.	3.3	3
2806	Symptom-Level Disability Status Assessed with an Electronic Unsupervised Patient-Reported Expanded Disability Status Scale (ePR-EDSS) in Multiple Sclerosis Patientsâ€"The Example of Croatia. Journal of Clinical Medicine, 2022, 11, 4081.	1.0	1
2807	Assistive Technology in Multiple Sclerosis Patientsâ€"Two Points of View. Journal of Clinical Medicine, 2022, 11, 4068.	1.0	0
2808	Longâ€term outcome after <scp>COVID</scp>â€19 infection in multiple sclerosis: A nationâ€wide multicenter matchedâ€control study. European Journal of Neurology, 2022, 29, 3050-3060.	1.7	9
2809	Improved prediction of early cognitive impairment in multiple sclerosis combining blood and imaging biomarkers. Brain Communications, 2022, 4, .	1.5	16
2810	Prediction of high and low disease activity in early MS patients using multiple kernel learning identifies importance of lateral ventricle intensity. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2022, 8, 205521732211097.	0.5	3
2811	Impact of lower urinary tract symptoms in women with multiple sclerosis: an observational cross-sectional study. Physiotherapy Theory and Practice, 0, , 1-7.	0.6	0

#	Article	IF	Citations
2812	Improved detection of multiple sclerosis lesions with T2â€prepared double inversion recovery at 3T. Journal of Neuroimaging, 2022, 32, 902-909.	1.0	5
2815	Changes in prognosis of the Danish multiple sclerosis population over time. Multiple Sclerosis Journal, 2022, 28, 2190-2201.	1.4	8
2816	The Spectrum of Vestibular Disorders Presenting With Acute Continuous Vertigo. Frontiers in Neuroscience, 0, 16, .	1.4	2
2817	NMOSDâ€"Diagnostic Dilemmas Leading towards Final Diagnosis. Brain Sciences, 2022, 12, 885.	1.1	3
2818	Rationale for off-label treatments use in primary progressive multiple sclerosis: A review of the literature. Revue Neurologique, 2022, 178, 932-938.	0.6	2
2819	Newer disease modifying treatments in pediatric onset multiple sclerosis: Experience from a single center. European Journal of Paediatric Neurology, 2022, 39, 110-115.	0.7	3
2820	A disproportionality analysis for the association of central nervous system demyelinating diseases with COVID-19 vaccination using the World Health Organization pharmacovigilance database. Multiple Sclerosis Journal, 2022, 28, 2112-2123.	1.4	7
2821	Word finding, prosody and social cognition in multiple sclerosis. Journal of Neuropsychology, 2023, 17, 32-62.	0.6	3
2822	Macular ganglion cell-inner plexiform layer defect patterns in multiple sclerosis patients without optic neuritis: A Spectral-Domain-Optical Coherence Tomography Cross-Sectional, Case-Control, Pilot Study. European Journal of Ophthalmology, 0, , 112067212211128.	0.7	0
2823	Assessing clinical utility of machine learning and artificial intelligence approaches to analyze speech recordings in multiple sclerosis: A pilot study. Computers in Biology and Medicine, 2022, 148, 105853.	3.9	10
2824	Immunotherapy for people with clinically isolated syndrome or relapsing-remitting multiple sclerosis: treatment response by demographic, clinical, and biomarker subgroups (PROMISE)â€"a systematic review protocol. Systematic Reviews, 2022, 11, .	2.5	0
2825	Assessment of cervical spinal cord volume in pediatric-onset multiple sclerosis. Clinical Imaging, 2022, , .	0.8	0
2826	Comparison of Two Different Canine Anti-IgG Antibodies for Assessment of Oligoclonal Bands in Cerebrospinal Fluid and Serum of Dogs via Isoelectric Focusing Followed by an Immunoblot. Frontiers in Veterinary Science, 0, 9, .	0.9	1
2827	Bâ€cell repopulation dynamics and drug pharmacokinetics impact ‹scp›SARSâ€CoV‹/scp›â€2 vaccine efficacy in ‹scp›antiâ€CD20‹/scp›â€treated multiple sclerosis patients. European Journal of Neurology, 2022, 29, 3317-3328.	1.7	13
2828	Major depressive disorder: a rare presentation of multiple sclerosis. , 2022, , 100030.		0
2829	Effects of Acceptance and Commitment Therapy (ACT) and Mindfulness-Based Stress Reduction (MBSR) on symptoms and emotional competencies in individuals with multiple sclerosis. Multiple Sclerosis and Related Disorders, 2022, 67, 104029.	0.9	4
2830	Comparative Analysis of Neurodegeneration and Axonal Dysfunction Biomarkers in the Cerebrospinal Fluid of Patients with Multiple Sclerosis. Journal of Clinical Medicine, 2022, 11, 4122.	1.0	2
2831	COVID-19 vaccination in people with multiple sclerosis, real-life experience. Clinical Neurology and Neurosurgery, 2022, 220, 107374.	0.6	6

#	Article	IF	Citations
2832	Diagnostic Cerebrospinal Fluid Biomarker in Early and Late Onset Multiple Sclerosis. Biomedicines, 2022, 10, 1629.	1.4	3
2833	Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised controlled trial. Lancet Neurology, The, 2022, 21, 693-703.	4.9	45
2834	Humoral immune response to SARS-CoV-2 third vaccination in patients with multiple sclerosis and healthy controls: A prospective multicenter study. Multiple Sclerosis and Related Disorders, 2022, 65, 104009.	0.9	3
2835	Gait assessment in shaped pathways: The test-retest reliability and concurrent validity of the figure of eight test and L test in multiple sclerosis patients without mobility aids. Multiple Sclerosis and Related Disorders, 2022, 65, 103998.	0.9	1
2836	Pupil response speed as a marker of cognitive fatigue in early Multiple Sclerosisâˆ†. Multiple Sclerosis and Related Disorders, 2022, 65, 104001.	0.9	3
2837	COVID-19 infection and vaccination against COVID-19: Impact on managing demyelinating CNS disorders in Southern India- experience from a demyelinating disease registry.. Multiple Sclerosis and Related Disorders, 2022, 66, 104033.	0.9	2
2838	Multiple sclerosis and Moyamoya angiopathy: Mimic and misdiagnosis. Multiple Sclerosis and Related Disorders, 2022, 66, 104036.	0.9	2
2839	Case report: A patient with meningoencephalitis followed by asymptomatic anti-myelin oligodendrocyte glycoprotein antibody-related disorder. Journal of Neurorestoratology, 2022, 10, 100007.	1.1	0
2840	Oligoclonal bands, age 11â€“17 years, occipital lesion, and female sex differentiate pediatric multiple sclerosis from acute disseminated encephalomyelitis: A nationwide cohort study. Multiple Sclerosis and Related Disorders, 2022, 66, 104008.	0.9	3
2842	Multiple sclerosis and neuromyelitis optica spectrum disorders. , 2023, , 575-608.		1
2843	Burden of neurological disease. , 2023, , 1047-1064.		0
2844	White Matter Disease in a Young Adult Presenting as Rapidly Progressive Parkinsonism. Annals of the Academy of Medicine, Singapore, 2019, 48, 274-278.	0.2	0
2845	Proposing a Framework to Understand the Role of Imaging in Degenerative Cervical Myelopathy: Enhancement of MRI Protocols Needed for Accurate Diagnosis and Evaluation. Spine, 2022, 47, 1259-1262.	1.0	9
2846	Human T-bet+ B cell development is associated with BTK activity and suppressed by evobrutinib. JCI Insight, 2022, 7, .	2.3	12
2847	Consensus on early detection of disease progression in patients with multiple sclerosis. Frontiers in Neurology, 0, 13, .	1.1	3
2848	Brainstem lesions are associated with diffuse spinal cord involvement in early multiple sclerosis. BMC Neurology, 2022, 22, .	0.8	0
2849	Serotonergic drug repurposing in multiple sclerosis: A new possibility for disease-modifying therapy. Frontiers in Neurology, 0, 13, .	1.1	4
2850	More Than Meets the Eye: Isolated Bilateral Abducens Nerve Palsy as the Initial Presentation of Multiple Sclerosis. Cureus, 2022, , .	0.2	0

#	Article	IF	Citations
2851	Functional connectivity in the dorsal network of the cervical spinal cord is correlated with diffusion tensor imaging indices in relapsing-remitting multiple sclerosis. NeuroImage: Clinical, 2022, 35, 103127.	1.4	5
2853	Optical Coherence Tomography and Optical Coherence Tomography with Angiography in Multiple Sclerosis. Healthcare (Switzerland), 2022, 10, 1386.	1.0	9
2854	Role of Multiple Vitamin D-Related Polymorphisms in Multiple Sclerosis Severity: Preliminary Findings. Genes, 2022, 13, 1307.	1.0	0
2855	18F-FDOPA and MRI Findings in a Case of Multiple Sclerosis. Clinical Nuclear Medicine, 2022, 47, 974-976.	0.7	2
2856	Relationship between cognition and treatment adherence to disease-modifying therapy in multiple sclerosis: a prospective, cross-sectional study. Scientific Reports, 2022, 12, .	1.6	3
2857	Recent advances in the longitudinal segmentation of multiple sclerosis lesions on magnetic resonance imaging: a review. Neuroradiology, 2022, 64, 2103-2117.	1.1	8
2858	High-dimensional immune profiling identifies a biomarker to monitor dimethyl fumarate response in multiple sclerosis. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	10
2859	Cautious optimism for the future of migraine treatment. Internal Medicine Journal, 2022, 52, 1112-1114.	0.5	0
2860	Acute posterior multifocal placoid pigment epitheliopathy resembling multiple sclerosis. Practical Neurology, 2022, 22, 515-517.	0.5	0
2861	The relationship between stress, anxiety, and depression levels and pseudobulbar affect in patients with Multiple Sclerosis. Contemporary Nurse, 0, , 1-27.	0.4	1
2862	Can strength training modify voluntary activation, contractile properties and spasticity in Multiple Sclerosis?: A randomized controlled trial.. Physiology and Behavior, 2022, 255, 113932.	1.0	2
2863	Immune aging in multiple sclerosis is characterized by abnormal CD4 T cell activation and increased frequencies of cytotoxic CD4 T cells with advancing age. EBioMedicine, 2022, 82, 104179.	2.7	17
2864	Clinical and diagnostic spectrum of optic neuritis: A single-center retrospective study of disorders associated with multiple sclerosis, anti-aquaporin-4 and anti-myelin oligodendrocyte glycoprotein antibodies. Clinical Neurology and Neurosurgery, 2022, 221, 107381.	0.6	0
2865	Is BDNF related to spatial-temporal gait parameters in people with multiple sclerosis? An observational study. Multiple Sclerosis and Related Disorders, 2022, 66, 104064.	0.9	1
2866	How to choose initial treatment in multiple sclerosis patients: a case-based approach. Arquivos De Neuro-Psiquiatria, 2022, 80, 159-172.	0.3	0
2867	Differential diagnosis of demyelinating diseases: what's new?. Arquivos De Neuro-Psiquiatria, 2022, 80, 137-142.	0.3	4
2868	Neurologic adverse events of cancer immunotherapy. Arquivos De Neuro-Psiquiatria, 2022, 80, 270-280.	0.3	1
2869	D1 Receptor Blockade Suppresses the Function of Th-17 Cells in Multiple Sclerosis. Neuroscience and Behavioral Physiology, 2022, 52, 494-499.	0.2	0

#	Article	IF	Citations
2870	The relationship between cognition, education, and employment in multiple sclerosis patients. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2022, 8, 205521732211183.	0.5	3
2871	Trail Making Test Could Predict Impairment in Cognitive Domains in Patients with Multiple Sclerosis: A Study of Diagnostic Accuracy. Archives of Clinical Neuropsychology, 2023, 38, 37-48.	0.3	5
2872	Validation of a Denoising Method Using Deep Learningâ€"Based Reconstruction to Quantify Multiple Sclerosis Lesion Load on Fast FLAIR Imaging. American Journal of Neuroradiology, 2022, 43, 1099-1106.	1.2	2
2873	Potential Utility of Natural Products against Oxidative Stress in Animal Models of Multiple Sclerosis. Antioxidants, 2022, 11, 1495.	2.2	7
2874	Association between speech rate measures and cognitive function in people with relapsing and progressive multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2022, 8, 205521732211198.	0.5	1
2875	Disease-Modifying Treatments and Time to Loss of Ambulatory Function in Patients With Primary Progressive Multiple Sclerosis. JAMA Neurology, 2022, 79, 869.	4.5	4
2876	Characteristic retinal atrophy pattern allows differentiation between pediatric MOGAD and MS after a single optic neuritis episode. Journal of Neurology, 2022, 269, 6366-6376.	1.8	2
2878	No increase of serum neurofilament light in relapsing-remitting multiple sclerosis patients switching from standard to extended-interval dosing of natalizumab. Multiple Sclerosis Journal, 2022, 28, 2070-2080.	1.4	10
2879	The Association of IL7R rs6897932 with Risk of Multiple Sclerosis in Southern Chinese. Neuropsychiatric Disease and Treatment, 0, Volume 18, 1855-1859.	1.0	1
2880	Neurodegeneration in multiple sclerosis. WIREs Mechanisms of Disease, 2023, 15, .	1.5	28
2881	High-dimensional investigation of the cerebrospinal fluid to explore and monitor CNS immune responses. Genome Medicine, 2022, 14, .	3.6	9
2882	Microvascular changes in the macular and parafoveal areas of multiple sclerosis patients without optic neuritis. Scientific Reports, 2022, 12, .	1.6	10
2883	Correlates of patient-reported cognitive performance with regard to disability. Scientific Reports, 2022, 12, .	1.6	2
2884	Seroprevalence of antiâ€myelin oligodendrocyte glycoprotein antibodies in adults with myelitis. Annals of Clinical and Translational Neurology, 2022, 9, 1481-1486.	1.7	5
2885	Potentially preventable hospitalizations and use of preventive services among people with multiple sclerosis: Large cohort study, USA. Multiple Sclerosis and Related Disorders, 2022, 68, 104105.	0.9	3
2887	Full-field electroretinogram in evaluation of the outer retina in patients with multiple sclerosis. International Journal of Health Sciences, 0, , 8704-8713.	0.0	0
2888	Factors Associated With Treatment-Related Changes in Voice Volume in People With Multiple Sclerosis. International Journal of MS Care, 2023, 25, 1-7.	0.4	1
2889	Highâ€resolution HLA class II sequencing of Swedish multiple sclerosis patients. International Journal of Immunogenetics, 2022, 49, 333-339.	0.8	2

#	Article	IF	Citations
2890	Triplanar U-Net with lesion-wise voting for the segmentation of new lesions on longitudinal MRI studies. Frontiers in Neuroscience, 0, 16, .	1.4	6
2891	Abducens Nerve Palsy as a Presenting Symptom of Multiple Sclerosis. TÃ¼rk Oftalmoloji Dergisi, 2022, 52, 291-294.	0.4	1
2892	Relation between retina, cognition and brain volumes in MS: a consequence of asymptomatic optic nerve lesions. Journal of Neurology, 0, , .	1.8	0
2893	Onset of various CNS inflammatory demyelination diseases following COVID-19 vaccinations. Multiple Sclerosis and Related Disorders, 2022, 68, 104141.	0.9	6
2894	Machine learning classification of multiple sclerosis in children using optical coherence tomography. Multiple Sclerosis Journal, 2022, 28, 2253-2262.	1.4	5
2895	COVID-19 and its implications on the clinico-radiological course of multiple sclerosis: A caseâ€“control study. Medicina ClÃnica, 2023, 160, 187-192.	0.3	3
2896	Retinal Layer Thinning After Optic Neuritis Is Associated With Future Relapse Remission in Relapsing Multiple Sclerosis. Neurology, 2022, 99, .	1.5	1
2897	Occlusive Retinal Vasculitis in Patients with Multiple Sclerosis. Ocular Immunology and Inflammation, 0, , 1-8.	1.0	1
2898	The comorbidity and cognition in multiple sclerosis (CCOMS) neuroimaging protocol: Study rationale, MRI acquisition, and minimal image processing pipelines. , 0, 1, .		4
2899	Progressive Multiple Sclerosis. CONTINUUM Lifelong Learning in Neurology, 2022, 28, 1083-1103.	0.4	6
2900	Changes of retinal structure and visual function in patients with demyelinating transverse myelitis. Neurological Sciences, 0, , .	0.9	2
2901	Six-Minute Walk as a Measure of Walking Capacity and Endurance in Patients With Pediatric-Onset Multiple Sclerosis. Neurology, 2022, 99, .	1.5	3
2902	Paramagnetic rims are a promising diagnostic imaging biomarker in multiple sclerosis. Multiple Sclerosis Journal, 2022, 28, 2212-2220.	1.4	16
2903	Ocrelizumab-induced vulvovaginal pyoderma gangrenosum in a patient with relapsing-remitting multiple sclerosis. JAAD Case Reports, 2022, 28, 24-27.	0.4	3
2904	Differentiating central nervous system demyelinating disorders: The role of clinical, laboratory, imaging characteristics and peripheral blood type I interferon activity. Frontiers in Pharmacology, 0, 13, .	1.6	6
2905	Increased intrathecal neurofilament light and immunoglobulin M predict severe disability in relapsing-remitting multiple sclerosis. Frontiers in Immunology, 0, 13, .	2.2	2
2906	Goal-Setting in Multiple Sclerosis-Related Spasticity Treated with Botulinum Toxin: The GASEPTOX Study. Toxins, 2022, 14, 582.	1.5	4
2907	Screening for severe drug-drug interactions in patients with multiple sclerosis: A comparison of three drug interaction databases. Frontiers in Pharmacology, 0, 13, .	1.6	5

#	Article	IF	Citations
2909	Pediatric Acquired Demyelinating Disorders. CONTINUUM Lifelong Learning in Neurology, 2022, 28, 1104-1130.	0.4	2
2910	MULTÄ°PL SKLEROZDA ANALOJÄ°K AKIL YÃœRÃœTME. SÃ¼leyman Demirel Ãœniversitesi TÄ±p FakÃ¼ltesi Dergisi, 0, , .	0.0	0
2911	Juvenile Idiopathic Arthritis, Uveitis and Multiple Sclerosis: Description of Two Patients and Literature Review. Biomedicines, 2022, 10, 2041.	1.4	1
2912	Effect of GBCA Use on Detection and Diagnostic Performance of the Central Vein Sign: Evaluation Using a 3-T FLAIR* Sequence in Patients With Suspected Multiple Sclerosis. American Journal of Roentgenology, 2023, 220, 115-125.	1.0	3
2913	Diagnosis of Multiple Sclerosis. CONTINUUM Lifelong Learning in Neurology, 2022, 28, 1006-1024.	0.4	2
2914	Myelin Oligodendrocyte Glycoproteinâ€“Associated Disorders. CONTINUUM Lifelong Learning in Neurology, 2022, 28, 1171-1193.	0.4	4
2915	Epsteinâ€“Barr virus and multiple sclerosis. Nature Reviews Microbiology, 2023, 21, 51-64.	13.6	151
2916	Myelin oligodendrocyte glycoprotein-associated disease is associated with BANK1, RNASET2 and TNIP1 polymorphisms. Journal of Neuroimmunology, 2022, 372, 577937.	1.1	4
2917	Relaxometry and brain myelin quantification with synthetic MRI in MS subtypes and their associations with spinal cord atrophy. NeuroImage: Clinical, 2022, 36, 103166.	1.4	2
2918	Younger age at multiple sclerosis onset is associated with worse outcomes at age 50. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 1112-1119.	0.9	1
2919	Fatigue in Multiple Sclerosis Is Associated with Reduced Expression of Interleukin-10 and Worse Prospective Disease Activity. Biomedicines, 2022, 10, 2058.	1.4	7
2920	Multiple sclerosis diagnosis and phenotype identification by multivariate classification of in vivo frontal cortex metabolite profiles. Scientific Reports, 2022, 12, .	1.6	1
2921	Biomarkers in Multiple Sclerosis. , 0, , .		1
2922	Progressive motor impairment from â€œcriticalâ€•demyelinating lesions of the cervicomedullary junction. Multiple Sclerosis Journal, 2023, 29, 74-80.	1.4	2
2923	The CELLO trial: Protocol of a planned phase 4 study to assess the efficacy of Ocrelizumab in patients with radiologically isolated syndrome. Multiple Sclerosis and Related Disorders, 2022, 68, 104143.	0.9	7
2924	Dual Mechanism of Action of Curcumin in Experimental Models of Multiple Sclerosis. International Journal of Molecular Sciences, 2022, 23, 8658.	1.8	12
2925	In vivo confocal microscopy of corneal nerve fiber damage in early course of multiple sclerosis. International Ophthalmology, 0, , .	0.6	0
2926	Results of a study of the quality of life in patients with highly active multiple sclerosis in Russia. Nevrologiya, Neiropsikhiatriya, Psikhosomatika, 2022, 14, 9-15.	0.2	0

#	Article	IF	Citations
2927	CSF Î²-amyloid is not a prognostic marker in multiple sclerosis patients. Multiple Sclerosis and Related Disorders, 2022, 68, 104096.	0.9	2
2928	Peripheral Nerve Involvement at First Diagnosis of Multiple Sclerosis. Investigative Radiology, 2023, 58, 173-179.	3.5	1
2929	Cognitive impairment in multiple sclerosis phenotypes: Neuropsychological assessment in a portuguese sample. Applied Neuropsychology Adult, 0, , 1-10.	0.7	1
2930	Accuracy of QuantiFERON SARS-CoV-2 research use only assay and characterization of the CD4+ and CD8+ TÂcell-SARS-CoV-2 response: comparison with a homemade interferon-Î³ release assay. International Journal of Infectious Diseases, 2022, 122, 841-849.	1.5	24
2931	Genetics of multiple sclerosis: lessons from polygenicity. Lancet Neurology, The, 2022, 21, 830-842.	4.9	26
2932	CTGF/CCN2 has a possible detrimental role in the inflammation and the remyelination failure in the early stages of multiple sclerosis. Journal of Neuroimmunology, 2022, 371, 577936.	1.1	1
2933	Spectrum of pediatric acquired demyelinating syndromes (PADS) of the central nervous system in a tropical developing country: A 10-year retrospective study. Journal of Clinical Neuroscience, 2022, 104, 74-81.	0.8	1
2934	Central nervous system (CNS) inflammatory demyelinating diseases (IDDs) associated with COVID-19: A case series and review. Journal of Neuroimmunology, 2022, 371, 577939.	1.1	13
2935	Longitudinal visualization for exploratory analysis of multiple sclerosis lesions. Computers and Graphics, 2022, 107, 208-219.	1.4	3
2936	The heterogeneity of tissue destruction between iron rim lesions and non-iron rim lesions in multiple sclerosis: A diffusion MRI study. Multiple Sclerosis and Related Disorders, 2022, 66, 104070.	0.9	7
2937	Clinical use of CSF neopterin levels in CNS demyelinating diseases. Journal of the Neurological Sciences, 2022, 441, 120385.	0.3	2
2938	Association of self-reported adherence to the Mediterranean diet with anthropometric indices, comorbidities, and degree of disability in patients with multiple sclerosis. Multiple Sclerosis and Related Disorders, 2022, 66, 104060.	0.9	7
2939	Seeing is believing: Identifying remyelination in the central nervous system. Current Opinion in Pharmacology, 2022, 66, 102269.	1.7	2
2940	Identification of disability status in persons with multiple sclerosis by lower limb neuromuscular function â€“ Emphasis on rate of force development. Multiple Sclerosis and Related Disorders, 2022, 67, 104082.	0.9	9
2941	Central vein sign in patients with inflammatory lesion of the upper cervical spinal cord on susceptibility weighted imaging at 3 tesla. Preliminary results. Magnetic Resonance Imaging, 2022, 93, 11-14.	1.0	3
2942	MR imaging in children with transverse myelitis and acquired demyelinating syndromes. Multiple Sclerosis and Related Disorders, 2022, 67, 104068.	0.9	2
2943	Risk factors for development of lymphopenia in dimethyl fumarate-treated patients with multiple sclerosis. Multiple Sclerosis and Related Disorders, 2022, 67, 104081.	0.9	2
2944	Pattern of thalamic nuclei atrophy in early relapse-onset multiple sclerosis. Multiple Sclerosis and Related Disorders, 2022, 67, 104083.	0.9	0

#	Article	IF	Citations
2945	Validation of a brief cross-cultural cognitive screening test in Multiple Sclerosis. Multiple Sclerosis and Related Disorders, 2022, 67, 104091.	0.9	3
2946	The age at onset of relapsing-remitting multiple sclerosis has increased over the last five decades. Multiple Sclerosis and Related Disorders, 2022, 68, 104103.	0.9	21
2947	Delayed cognitive processing and treatment status quo bias in early-stage multiple sclerosis. Multiple Sclerosis and Related Disorders, 2022, 68, 104138.	0.9	1
2948	Effects of hippotherapy simulation exercise vs. conventional home exercises on muscle strength and balance in people with multiple sclerosis: A randomized controlled trial. Multiple Sclerosis and Related Disorders, 2022, 68, 104111.	0.9	3
2949	Associated factors of potential drug-drug interactions and drugâ€“food interactions in patients with multiple sclerosis. Therapeutic Advances in Chronic Disease, 2022, 13, 204062232211083.	1.1	4
2950	Dynamics of Inflammatory and Neurodegenerative Biomarkers after Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis. International Journal of Molecular Sciences, 2022, 23, 10946.	1.8	6
2951	Factors and strategies affecting motor imagery ability in people with multiple sclerosis: a systematic review. Physiotherapy, 2022, , .	0.2	3
2952	Correlation between patientâ€reported manual ability and three objective measures of upper limb function in people with multiple sclerosis. European Journal of Neurology, 2023, 30, 172-178.	1.7	3
2953	Validity and reliability characteristics of the Silhouettes Fatigue Scale in measuring multiple sclerosisâ€related fatigue in Turkishâ€speaking adults. Acta Neurologica Scandinavica, 2022, 146, 671-679.	1.0	0
2954	Functional Performance, Leg Muscle Strength, and Core Muscle Endurance in Multiple Sclerosis Patients With Mild Disability: A Cross-Sectional Study. Motor Control, 2022, 26, 729-747.	0.3	1
2955	Re-examining the characteristics of pediatric multiple sclerosis in the era of antibody-associated demyelinating syndromes. European Journal of Paediatric Neurology, 2022, 41, 8-18.	0.7	2
2956	sNFL applicability as additional monitoring tool in natalizumab extended interval dosing regimen for RRMS patients. Multiple Sclerosis and Related Disorders, 2022, 67, 104176.	0.9	1
2957	Transcranial direct current stimulation for spasticity in patients with multiple sclerosis: Exploring novel routes. Multiple Sclerosis and Related Disorders, 2022, 67, 104191.	0.9	1
2958	Improvement in the multiple sclerosis functional composite score by multi-function swing suspension training program. Multiple Sclerosis and Related Disorders, 2022, 67, 104174.	0.9	0
2959	Interpreting the clinical importance of the relationship between subjective fatigue and cognitive impairment in multiple sclerosis (MS): How BICAMS performance is affected by MS-related fatigue. Multiple Sclerosis and Related Disorders, 2022, 67, 104161.	0.9	1
2960	Cognitive-motor interference in people with mild to moderate multiple sclerosis, in comparison with healthy controls. Multiple Sclerosis and Related Disorders, 2022, 67, 104181.	0.9	1
2961	Clinical onset of CNS demyelinating disease after COVID-19 vaccination: denovo disease?. Multiple Sclerosis and Related Disorders, 2022, 67, 104175.	0.9	4
2962	Stages of brain volume loss and performance in the Brief International Cognitive Assessment for Multiple Sclerosis. Multiple Sclerosis and Related Disorders, 2022, 67, 104183.	0.9	5

#	Article	IF	Citations
2963	Prevalence of multiple sclerosis in Guangzhou, China: A population-based case-finding prospective study. Multiple Sclerosis and Related Disorders, 2022, 68, 104151.	0.9	0
2964	Cut-off evaluation of intrathecal oligoclonal bands of IgM in relapsing-remitting multiple sclerosis; a retrospective study. Multiple Sclerosis and Related Disorders, 2022, 68, 104188.	0.9	1
2965	Multiple sclerosis and migraine: Links, management and implications. Multiple Sclerosis and Related Disorders, 2022, 68, 104152.	0.9	9
2966	Relapses after SARS-CoV-2 vaccination in patients with neuromyelitis optica spectrum disorder and multiple sclerosis. Multiple Sclerosis and Related Disorders, 2022, 68, 104167.	0.9	8
2967	Core stability-based balance training and kinesio taping for balance, trunk control, fear of falling and walking capacity in patients with multiple sclerosis: A randomized single-blinded study. Multiple Sclerosis and Related Disorders, 2022, 68, 104178.	0.9	1
2968	Epsteinâ€“Barr virus antibody in newly diagnosed multiple sclerosis patients and its association with relapse severity and lesion location. Multiple Sclerosis and Related Disorders, 2022, 68, 104149.	0.9	2
2969	â€˜That would have been the perfect thing after diagnosisâ€™: development of a digital lifestyle management application in multiple sclerosis. Therapeutic Advances in Neurological Disorders, 2022, 15, 175628642211187.	1.5	2
2970	Expression analysis of miRNAs from the DLK1-DIO3 locus in CD4+ and CD14+ cells in patients with relapsing-remitting multiple sclerosis. Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova, 2022, 122, 52.	0.1	1
2971	Detection of lesions in the optic nerve with magnetic resonance imaging using a 3D convolutional neural network. NeuroImage: Clinical, 2022, 36, 103187.	1.4	2
2972	A comparative assessment of myelin-sensitive measures in multiple sclerosis patients and healthy subjects. NeuroImage: Clinical, 2022, 36, 103177.	1.4	4
2973	Differential diagnosis of multiple sclerosis in children. Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova, 2022, 122, 60.	0.1	0
2974	Functional connectivity dynamics reflect disability and multi-domain clinical impairment in patients with relapsing-remitting multiple sclerosis. NeuroImage: Clinical, 2022, 36, 103203.	1.4	4
2975	Pathologie inflammatoire duÂsystÃ¨me nerveux central. , 2022, , 57-74.		0
2976	Cortical lesions, central vein sign, and paramagnetic rim lesions in multiple sclerosis: Emerging machine learning techniques and future avenues. NeuroImage: Clinical, 2022, 36, 103205.	1.4	12
2977	Immunotherapy-responsive recurrent extensive white matter disease without neuronal or glial surface antibodies: A case report. Neuroimmunology Reports, 2022, 2, 100142.	0.2	0
2978	Timely intervention, monitoring and education MATTERS in MS (TIME MATTERS in MS): Development of a globally applicable quality improvement tool. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2022, 8, 205521732211240.	0.5	1
2980	Is It Time for Ocrelizumab Extended Interval Dosing in Relapsing Remitting MS? Evidence from An Italian Multicenter Experience During the COVID-19 Pandemic. Neurotherapeutics, 2022, 19, 1535-1545.	2.1	10
2981	The Brave New World of Early Treatment of Multiple Sclerosis: Using the Molecular Biomarkers CXCL13 and Neurofilament Light to Optimize Immunotherapy. Biomedicines, 2022, 10, 2099.	1.4	5

#	Article	IF	Citations
2982	Somatosensory evoked potentials and their relation to microstructural damage in patients with multiple sclerosisâ€"A whole brain DTI study. Frontiers in Neurology, 0, 13, .	1.1	0
2983	Reliability and acceptance of dreaMS, a software application for people with multiple sclerosis: a feasibility study. Journal of Neurology, 2023, 270, 262-271.	1.8	10
2984	Optical Coherence Tomography in Chronic Relapsing Inflammatory Optic Neuropathy, Neuromyelitis Optica and Multiple Sclerosis: A Comparative Study. Brain Sciences, 2022, 12, 1140.	1.1	5
2985	Validation of cognitive screening questionnaire for neurological disorders (CSQND) for screening of cognitive complaints among patients with multiple sclerosis. Egyptian Journal of Neurology, Psychiatry and Neurosurgery, 2022, 58, .	0.4	0
2986	Factors Related to the Progression of Clinically Isolated Syndrome to Multiple Sclerosis: A Retrospective Study in Lithuania. Medicina (Lithuania), 2022, 58, 1178.	0.8	2
2987	Application of the International Interocular Difference Thresholds into Practice: Localising the Patient Experience. Neuro-Ophthalmology, 0, , 1-8.	0.4	0
2988	Hybrid and vaccineâ€induced immunity against <scp>SARâ€CoV</scp>â€2 in <scp>MS</scp> patients on different diseaseâ€modifying therapies. Annals of Clinical and Translational Neurology, 2022, 9, 1643-1659.	1.7	9
2989	Gadolinium-enhanced brain lesions in multiple sclerosis relapse. NeurologÃa (English Edition), 2022, 37, 557-563.	0.2	1
2990	Breastfeeding and Risk of Multiple Sclerosis: A Systematic Review and Meta-Analysis of Observational Studies. Neuroepidemiology, 2022, 56, 391-401.	1.1	2
2991	Rapid, non-contact multifocal visual assessment in multiple sclerosis. Neurological Sciences, 0, , .	0.9	2
2992	Evaluation of CSF kappa free light chains for the diagnosis of multiple sclerosis (MS): a comparison with oligoclonal bands (OCB) detection via isoelectric focusing (IEF) coupled with immunoblotting. Journal of Clinical Pathology, 0, , jclinpath-2022-208354.	1.0	2
2994	T Lymphocyte Serotonin 5-HT7 Receptor Is Dysregulated in Natalizumab-Treated Multiple Sclerosis Patients. Biomedicines, 2022, 10, 2418.	1.4	1
2995	Autoreactive lymphocytes in multiple sclerosis: Pathogenesis and treatment target. Frontiers in Immunology, 0, 13, .	2.2	21
2996	An algorithm to determine the date when the McDonald criteria are met for the diagnosis of relapsing-remitting multiple sclerosis. Revue Neurologique, 2022, 178, 1090-1097.	0.6	1
2997	The Prevalence, Demographics, Clinical Features, Neuroimaging, and Inter-ethnic Differences of MOGAD in Malaysia with Global Perspectives. Multiple Sclerosis and Related Disorders, 2022, 67, 104168.	0.9	5
2998	Model of the Relationship of Religiosity and Happiness of Multiple Sclerosis Patients from Poland: The Role of Mediating and Moderating Variables. Religions, 2022, 13, 862.	0.3	0
2999	Torso based balance weighting versus tailored physical therapy program in postural control in patients with multiple sclerosis. , 2022, 22, 142-147.		0
3000	The mSteps pilot study: Analysis of the distance walked using a novel smartphone application in multiple sclerosis. Multiple Sclerosis Journal, 0, , 135245852211240.	1.4	2

#	Article	IF	Citations
3001	Optic neuritis and autoimmune optic neuropathies: advances in diagnosis and treatment. Lancet Neurology, The, 2023, 22, 89-100.	4.9	53
3002	Vaccination willingness in association with personality traits in patients with multiple sclerosis in the course of SARS-CoV-2 pandemic. Scientific Reports, 2022, 12, .	1.6	4
3003	Neurodegeneration and humoral response proteins in cerebrospinal fluid associate with pediatric-onset multiple sclerosis and not monophasic demyelinating syndromes in childhood. Multiple Sclerosis Journal, 0, , 135245852211253.	1.4	0
3004	Investigating Functional Network Abnormalities and Associations With Disability in Multiple Sclerosis. Neurology, 2022, 99, .	1.5	4
3005	Immunoadsorption versus double-dose methylprednisolone in refractory multiple sclerosis relapses. Journal of Neuroinflammation, 2022, 19, .	3.1	7
3006	Optic Neuritis in Multiple Sclerosisâ€"A Review of Molecular Mechanisms Involved in the Degenerative Process. Current Issues in Molecular Biology, 2022, 44, 3959-3979.	1.0	8
3007	Multiple sclerosis in sarcoidosis patients: Two case reports. Clinical Case Reports (discontinued), 2022, 10, .	0.2	1
3008	ÐÐµÐ¹Ñ€Ð¾Ð¾Ñ„Ñ„Ð°Ð»ÑŒÐ¾Ð¼Ð¸ÐµÐ»Ð¸Ñ‚ Ð°ÑÐ¿ÐµÐºÑ‚Ñ‹ Ñ€Ð¾Ð·Ð½Ð¸Ñ†Ñ‹ Ð¸ Ð»ÐµÑ‡ÐµÐ½Ð¸Ñ. Archi		
3009	Evaluation of Disability Progression in Multiple Sclerosis via Magnetic-Resonance-Based Deep Learning Techniques. International Journal of Molecular Sciences, 2022, 23, 10651.	1.8	2
3010	The role of machine learning in developing non-magnetic resonance imaging based biomarkers for multiple sclerosis: aÂsystematicÂreview. BMC Medical Informatics and Decision Making, 2022, 22, .	1.5	9
3011	Astrocytic SARM1 promotes neuroinflammation and axonal demyelination in experimental autoimmune encephalomyelitis through inhibiting GDNF signaling. Cell Death and Disease, 2022, 13, .	2.7	7
3012	The Translatability of Multiple Sclerosis Animal Models for Biomarkers Discovery and Their Clinical Use. International Journal of Molecular Sciences, 2022, 23, 11532.	1.8	13
3013	Intrathecal B cell-related markers for an optimized biological investigation of multiple sclerosis patients. Scientific Reports, 2022, 12, .	1.6	2
3014	Association of spinal cord lesions with cognition in multiple sclerosis. Cukurova Medical Journal, 2022, 47, 1040-1049.	0.1	0
3015	Cytokine Secretion Dynamics of Isolated PBMC after Cladribine Exposure in RRMS Patients. International Journal of Molecular Sciences, 2022, 23, 10262.	1.8	0
3016	Good prospects for optic neuropathies. Lancet Neurology, The, 2022, 21, 1068-1070.	4.9	0
3017	Discontinuation of second- versus first-line disease-modifying treatment in middle-aged patients with multiple sclerosis. Journal of Neurology, 2023, 270, 413-422.	1.8	7
3018	MRI Findings and Topographic Distribution of Lesions in Metronidazole-Induced Encephalopathy. Cureus, 2022, , .	0.2	0

#	Article	IF	Citations
3019	Response to the letter synthetic double inversion recovery (DIR) and phase-sensitive inversion recovery (PSIR) images showed better delineation of multiple sclerosis plaques. Neuroradiology, 2022, 64, 1915-1916.	1.1	1
3020	IL-27 shapes the immune properties of human astrocytes and their impact on encountered human T lymphocytes. Journal of Neuroinflammation, 2022, 19, .	3.1	6
3021	Treatable Ataxias: How to Find the Needle in the Haystack?. Journal of Movement Disorders, 2022, 15, 206-226.	0.7	2
3022	Predictive Factors for Magnetic Resonance Imaging Changes Suggestive of Demyelination in Adult Patients with Uveitis Scanned Prior to Commencing Adalimumab Therapy. Ocular Immunology and Inflammation, 0, , 1-9.	1.0	0
3023	Progressive motor neuron syndromes with single CNS lesions and CSF oligoclonal bands: never forget solitary sclerosis!. Neurological Sciences, 2022, 43, 6951-6954.	0.9	2
3024	Safety and efficacy of tyrosine kinase inhibitors for the treatment of multiple sclerosis: A systematic review and meta-analysis from randomized controlled trials. Frontiers in Neurology, 0, 13, .	1.1	1
3025	Clinical and Genetic Analysis in Pediatric Patients with Multiple Sclerosis and Related Conditions: Focus on DR Genes of the Major Histocompatibility Complex. The Open Neurology Journal, 2022, 16, .	0.4	0
3026	Sensitivity and Specificity of Central Vein Sign as a Diagnostic Biomarker in Egyptian Patients with Multiple Sclerosis. Neuropsychiatric Disease and Treatment, 0, Volume 18, 1985-1992.	1.0	1
3027	Neurofilament light chain in blood as a diagnostic and predictive biomarker for multiple sclerosis: A systematic review and meta-analysis. PLoS ONE, 2022, 17, e0274565.	1.1	16
3028	Exposure to natalizumab throughout pregnancy: effectiveness and safety in an Italian cohort of women with multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 0, , jnnp-2022-329657.	0.9	11
3029	Reduced brain oxygen metabolism in patients with multiple sclerosis: Evidence from dual-calibrated functional MRI. Journal of Cerebral Blood Flow and Metabolism, 2023, 43, 115-128.	2.4	8
3030	Cognitive-motor telerehabilitation in multiple sclerosis (CoMoTeMS): study protocol for a randomised controlled trial. Trials, 2022, 23, .	0.7	0
3031	Investigation of Neuropathic Pain Distribution and Related Factors in People with Multiple Sclerosis. , 2022, 2, 46-51.		1
3032	Relationship Between Upper Extremity Functions and Gait in People with Multiple Sclerosis. , 2022, 2, 41-45.		0
3033	Rehabilitation to Improve Gaze and Postural Stability in People With Multiple Sclerosis: A Randomized Clinical Trial. Neurorehabilitation and Neural Repair, 2022, 36, 678-688.	1.4	2
3034	Diagnosis and classification of optic neuritis. Lancet Neurology, The, 2022, 21, 1120-1134.	4.9	72
3035	Heterogeneity on long-term disability trajectories in patients with secondary progressive MS: a latent class analysis from Big MS Data network. Journal of Neurology, Neurosurgery and Psychiatry, 2023, 94, 23-30.	0.9	7
3036	Seizures and multiple sclerosisâ€‘more than an epidemiological association (Review). Experimental and Therapeutic Medicine, 2022, 24, .	0.8	1

#	Article	IF	Citations
3037	Clinical and epidemiological features of multiple sclerosis in Republic of Ingushetia. Ã›Å¾no-Rossijskij Å¾urnal TerapevtiÄeskoj Praktiki, 2022, 3, 76-84.	0.1	0
3038	COVID-19 and the risk of CNS demyelinating diseases: A systematic review. Frontiers in Neurology, 0, 13, .	1.1	12
3040	Early predictors of disability in paediatric multiple sclerosis: evidence from a multi-national registry. Journal of Neurology, Neurosurgery and Psychiatry, 0, , jnnp-2022-329713.	0.9	0
3041	Evidence for an Intrathecal Immunoglobulin Synthesis by Kappa Free Light Chains in Neurological Patients with an Isolated Band in Isoelectric Focusing. Biomedicines, 2022, 10, 2202.	1.4	0
3042	Relationship between cerebrospinal fluid biomarkers of inflammation and tissue damage in primary progressive multiple sclerosis. Multiple Sclerosis and Related Disorders, 2022, 68, 104209.	0.9	7
3043	Bilateral horizontal gaze palsy as the only manifestation of demyelination in the central nervous system. Russian Neurological Journal, 2022, 27, 81-85.	0.1	0
3044	Biomarkers of demyelination and axonal damage are decreased after autologous hematopoietic stem cell transplantation for multiple sclerosis. Multiple Sclerosis and Related Disorders, 2022, 68, 104210.	0.9	2
3045	Disease activity after discontinuation of disease-modifying therapies in patients with multiple sclerosis in Argentina: data from the nationwide registry RelevarEM. Neurological Research, 0, , 1-6.	0.6	1
3046	Replacing sitting with light-intensity physical activity throughout the day versus 1 bout of vigorous-intensity exercise: similar cardiometabolic health effects in multiple sclerosis. A randomised cross-over study. Disability and Rehabilitation, 2023, 45, 3293-3302.	0.9	2
3047	Differentiating Multiple Sclerosis From AQP4-Neuromyelitis Optica Spectrum Disorder and MOG-Antibody Disease With Imaging. Neurology, 2023, 100, .	1.5	22
3048	Sensitivity and specificity of visual evoked potentials for early diagnosis of demyelinating diseases. Neurology Perspectives, 2022, 2, 193-198.	0.2	0
3049	Dorsal medulla surface texture: Differentiating neuromyelitis optica spectrum disorder from multiple sclerosis. Journal of Neuroimaging, 2022, 32, 1090-1097.	1.0	6
3050	COVID-19 Pandemisi ve Karantina DÃ¶neminde Ã‡ocuklarda OtoimmÃ¼n HastalÄ±klarÄ±n SÄ±klÄ±ÄŸÄ±nÄ±n Pandemi Ã–ncesi DÃ¶neme GÃ¶re DeÄŸiÅŸimi. OsmangazÄ° Journal of Medicine, 0, , .	0.1	0
3051	Asymptomatic MRI lesions in pediatric-onset AQP4-IgG positive NMOSD. Multiple Sclerosis and Related Disorders, 2022, 68, 104215.	0.9	3
3052	Cognitive dual-task cost depends on the complexity of the cognitive task, but not on age and disease. Frontiers in Neurology, 0, 13, .	1.1	3
3053	Cholesterol levels in plasma and cerebrospinal fluid in patients with clinically isolated syndrome and relapsing-remitting multiple sclerosis. Neurobiology of Disease, 2022, 174, 105889.	2.1	6
3054	Identification of specific causes of myelopathy in a large cohort of patients initially diagnosed with transverse myelitis. Journal of the Neurological Sciences, 2022, 442, 120425.	0.3	8
3055	Remission of idiopathic retroperitoneal fibrosis by ofatumumab as a disease-modifying therapy for multiple sclerosis. ENeurologicalSci, 2022, 29, 100428.	0.5	1

#	Article	IF	Citations
3056	Neurologic autoimmune diseases. , 2022, , 887-975.		0
3057	Millsâ€™ syndrome. Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova, 2022, 122, 138.	0.1	0
3058	An Analysis of Clinico-radiological Features and Outcome in Patients with Longitudinally Extensive Transverse Myelitis. Neurology India, 2022, 70, 1925.	0.2	0
3059	Effects of pulsed electromagnetic field therapy on fatigue, walking performance, depression, and quality of life in adults with multiple sclerosis: a randomized placebo-controlled trial. Brazilian Journal of Physical Therapy, 2022, 26, 100449.	1.1	2
3061	Oligoclonal M bands and cervical spinal cord lesions predict early secondary progressive multiple sclerosis. Frontiers in Neurology, 0, 13, .	1.1	0
3062	Diagnostic performance of artificial intelligence in multiple sclerosis: a systematic review and meta-analysis. Neurological Sciences, 0, , .	0.9	4
3063	A gene regulatory network approach harmonizes genetic and epigenetic signals and reveals repurposable drug candidates for multiple sclerosis. Human Molecular Genetics, 2023, 32, 998-1009.	1.4	5
3064	Effect of Nordic Walking Training on Walking Capacity and Quality of Life for People With Multiple Sclerosis. International Journal of MS Care, 2023, 25, 118-123.	0.4	3
3065	An Update on Diagnostic Laboratory Biomarkers for Multiple Sclerosis. Current Neurology and Neuroscience Reports, 2022, 22, 675-688.	2.0	9
3066	Early remission in multiple sclerosis is linked to altered coherence of the Cerebellar Network. Journal of Translational Medicine, 2022, 20, .	1.8	2
3068	Reliability and validity of the Turkish version of speech pathology-specific questionnaire for persons with multiple sclerosis (SMS-TR). International Journal of Speech-Language Pathology, 0, , 1-8.	0.6	1
3069	Toward In Vivo MRI of the Tissue Proton Exchange Rate in Humans. Biosensors, 2022, 12, 815.	2.3	2
3070	Prior optic neuritis detection on peripapillary ring scans using deep learning. Annals of Clinical and Translational Neurology, 2022, 9, 1682-1691.	1.7	2
3071	Isokinetic Resistance Training for Ankle Plantarflexor Spasticity and Muscle Weakness in People With Multiple Sclerosis: A Proof-of-Concept Case Series. Physical Therapy, 2022, 103, .	1.1	0
3072	Correlation analysis between foveal avascular zone and near peripheral retinal hypoperfusion in multiple sclerosis: a wide field optical coherence tomography angiography study. Frontiers in Medicine, 0, 9, .	1.2	2
3073	Change in upper limb function in people with multiple sclerosis treated with nabiximols: a quantitative kinematic pilot study. Neurological Sciences, 2023, 44, 685-691.	0.9	1
3074	Lesion follows function: video-oculography compared with MRI to diagnose internuclear ophthalmoplegia in patients with multiple sclerosis. Journal of Neurology, 0, , .	1.8	0
3076	The association between PD-1 gene polymorphisms and susceptibility to multiple sclerosis. Immunological Medicine, 2023, 46, 69-76.	1.4	2

#	Article	IF	Citations
3077	Microglial/macrophage activation in the cerebrospinal fluid of neuromyelitis optica spectrum disorders. Brain and Behavior, 2022, 12, .	1.0	2
3078	Updates and advances in multiple sclerosis neurotherapeutics. Neurodegenerative Disease Management, 2023, 13, 47-70.	1.2	29
3079	Immunopathogenesis, Diagnosis, and Treatment of Multiple Sclerosis. Neurologic Clinics, 2023, 41, 87-106.	0.8	3
3080	Persistent â€œMRI-negativeâ€•lupus myelitis-disease presentation, immunological profile and outcome. Frontiers in Neurology, 0, 13, .	1.1	1
3081	Multiple Sclerosis Followed by Neuromyelitis Optica Spectrum Disorder. Neurology: Neuroimmunology and NeuroInflammation, 2023, 10, e200037.	3.1	0
3082	Neurofilament Light Chain Levels Are Predictive of Clinical Conversion in Radiologically Isolated Syndrome. Neurology: Neuroimmunology and NeuroInflammation, 2023, 10, .	3.1	12
3083	Automated segmentation of multiple sclerosis lesions based on convolutional neural networks. Computer Methods in Biomechanics and Biomedical Engineering: Imaging and Visualization, 2023, 11, 1359-1377.	1.3	1
3084	Somatosensory evoked potentials and magnetic resonance imaging of the central nervous system in early multiple sclerosis. Journal of Neurology, 0, , .	1.8	3
3085	Diagnosis and treatment of progressive multiple sclerosis: A position paper. European Journal of Neurology, 2023, 30, 9-21.	1.7	4
3086	Validation of the Czech Version of the Dysphagia in Multiple Sclerosis Questionnaire (DYMUS). Dysphagia, 0, , .	1.0	1
3087	Involvement of NINJ2 Protein in Inflammation and Bloodâ€“Brain Barrier Transmigration of Monocytes in Multiple Sclerosis. Genes, 2022, 13, 1946.	1.0	4
3088	Serum and CSF Biomarkers Predict Active Early Cognitive Decline Rather Than Established Cognitive Impairment at the Moment of RRMS Diagnosis. Diagnostics, 2022, 12, 2571.	1.3	4
3089	Whole-Brain Propagation Delays in Multiple Sclerosis, a Combined Tractography-Magnetoencephalography Study. Journal of Neuroscience, 2022, 42, 8807-8816.	1.7	15
3090	No seasonality in the risk of multiple sclerosis in an equatorial country: A caseâ€“control ecological study. Multiple Sclerosis Journal, 2023, 29, 343-351.	1.4	2
3091	Investigating the influence of an <scp>effortâ€“reward</scp> interaction on cognitive fatigue in individuals with multiple sclerosis. Journal of Neuropsychology, 0, , .	0.6	0
3092	Fecal Lcn-2 level is a sensitive biological indicator for gut dysbiosis and intestinal inflammation in multiple sclerosis. Frontiers in Immunology, 0, 13, .	2.2	9
3093	Measurement of D-dimer in cerebrospinal fluid using a luminescent oxygen channeling immunoassay. Frontiers in Neurology, 0, 13, .	1.1	1
3094	New lesion segmentation for multiple sclerosis brain images with imaging and lesion-aware augmentation. Frontiers in Neuroscience, 0, 16, .	1.4	7

#	Article	IF	Citations
3095	Multiple Sclerosis Diagnosis Using Machine Learning and Deep Learning: Challenges and Opportunities. Sensors, 2022, 22, 7856.	2.1	20
3096	Investigating the role of common and rare variants in multiplex multiple sclerosis families reveals an increased burden of common risk variation. Scientific Reports, 2022, 12, .	1.6	1
3097	A Review of Compartmentalised Inflammation and Tertiary Lymphoid Structures in the Pathophysiology of Multiple Sclerosis. Biomedicines, 2022, 10, 2604.	1.4	6
3098	Semisupervised white matter hyperintensities segmentation on MRI. Human Brain Mapping, 2023, 44, 1344-1358.	1.9	2
3099	Metabolic syndrome parameters and multiple sclerosis disease outcomes: A Portuguese cross-sectional study. Multiple Sclerosis and Related Disorders, 2023, 69, 104370.	0.9	2
3100	Correlation between ERÎ± gene polymorphism and multiple sclerosis and neuromyelitis optica. Medicine (United States), 2022, 101, e31126.	0.4	2
3101	Patient's perspective in clinical practice to assess and predict disability in multiple sclerosis. Scientific Reports, 2022, 12, .	1.6	0
3102	Primary angiitis of the central nervous system as a mimic of multiple sclerosis: A case report. Journal of Neuroimmunology, 2022, , 577991.	1.1	0
3103	Inflammatory Optic Neuropathy as a Presenting Feature of Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy. Neurohospitalist, The, 0, , 194187442211326.	0.3	0
3104	Genetic risk variants for multiple sclerosis are linked to differences in alternative pre-mRNA splicing. Frontiers in Immunology, 0, 13, .	2.2	5
3105	Tablet app-based dexterity training in multiple sclerosis (TAD-MS): a randomized controlled trial. Disability and Rehabilitation: Assistive Technology, 0, , 1-11.	1.3	3
3106	Trans-Endothelial Migration of Memory T Cells Is Impaired in Alemtuzumab-Treated Multiple Sclerosis Patients. Journal of Clinical Medicine, 2022, 11, 6266.	1.0	4
3107	CSF CXCL13 and Chitinase 3-like-1 Levels Predict Disease Course in Relapsing Multiple Sclerosis. Molecular Neurobiology, 2023, 60, 36-50.	1.9	10
3108	Case Report and Clinical Reasoning: Fulminant Liver Failure and Invasive Aspergillosis Following Ocrelizumab Treatment in a 21 Year-Old Woman. Neurohospitalist, The, 2023, 13, 96-102.	0.3	2
3109	Clinical Reasoning: A 6-Year-Old Girl With Right-Sided Pain and Weakness. Neurology, 2023, 100, 97-102.	1.5	0
3110	Quantification and Proximal-to-Distal Distribution Pattern of Tibial Nerve Lesions in Relapsing-Remitting Multiple Sclerosis. Clinical Neuroradiology, 2023, 33, 383-392.	1.0	4
3111	Trends in the environmental risks associated with earlier onset in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2022, 68, 104250.	0.9	3
3112	Involvement of the central nervous system in patient with chronic inï¬,ammatory demyelinating polyneuropathy: a case report. Diagnostic Radiology and Radiotherapy, 2022, 13, 77-87.	0.0	0

#	Article	IF	Citations
3113	Effect of Estimated Blood Volume and Body Mass Index on GFAP and NfL Levels in the Serum and CSF of Patients With Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2023, 10, .	3.1	11
3115	Development of the Web-Based Spanish Version of the Barthel Index in Patients with Multiple Sclerosis. International Journal of Environmental Research and Public Health, 2022, 19, 13965.	1.2	0
3116	A proposed new taxonomy of cognitive phenotypes in multiple sclerosis: The International Classification of Cognitive Disorders in MS (IC-CoDiMS). Multiple Sclerosis Journal, 2023, 29, 615-627.	1.4	13
3117	Toward an Automatic Assessment of Cognitive Dysfunction in Relapsingâ€“Remitting Multiple Sclerosis Patients Using Eye Movement Analysis. Sensors, 2022, 22, 8220.	2.1	1
3118	Oral healthâ€related quality of life is more strongly correlated with mental health than with oral health in relapsingâ€“remitting multiple sclerosis. Journal of Oral Rehabilitation, 2023, 50, 62-68.	1.3	1
3119	Brain age gap in neuromyelitis optica spectrum disorders and multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2023, 94, 31-37.	0.9	3
3120	Quantitative spinal cord MRI and sexual dysfunction in multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2022, 8, 205521732211321.	0.5	3
3121	Dynamic changes in kynurenine pathway metabolites in multiple sclerosis: A systematic review. Frontiers in Immunology, 0, 13, .	2.2	6
3122	Glucocorticoids and COVID-19. Pharmacological Research, 2022, 185, 106511.	3.1	11
3123	Contemporary study of multiple sclerosis disability in South East Wales. Journal of Neurology, Neurosurgery and Psychiatry, 2023, 94, 272-279.	0.9	0
3124	Perturbation-based Balance Training to improve postural responses and falls in people with multiple sclerosis: a randomized controlled trial. Disability and Rehabilitation, 2023, 45, 3649-3655.	0.9	0
3125	Argentinean consensus recommendations for the use of telemedicine in clinical practice in adult people with multiple sclerosis. Neurological Sciences, 0, , .	0.9	0
3126	MCAM+ brain endothelial cells contribute to neuroinflammation by recruiting pathogenic CD4+ T lymphocytes. Brain, 2023, 146, 1483-1495.	3.7	9
3127	Performance in information processing speed is associated with parietal white matter tract integrity in multiple sclerosis. Frontiers in Neurology, 0, 13, .	1.1	1
3128	Training-dependent plasticity and far transfer effect enhanced by Bobath rehabilitation in Multiple Sclerosis. Multiple Sclerosis and Related Disorders, 2022, 68, 104241.	0.9	1
3129	K index utility as diagnostic and prognostic biomarker in the assessment of patients with suspected Multiple Sclerosis. Journal of Neuroimmunology, 2022, 373, 577992.	1.1	3
3130	Epidemiologic trends of multiple sclerosis in Puerto Rico (2013â€“2020). Multiple Sclerosis and Related Disorders, 2022, 68, 104240.	0.9	2
3131	B-lymphocyte-guided retreatment contributes to establish good effectiveness and safety profile in MS patients treated with rituximab. Multiple Sclerosis and Related Disorders, 2022, 68, 104218.	0.9	1

#	Article	IF	Citations
3132	Objective perimetry and progression of multiple sclerosis. ENeurologicalSci, 2022, 29, 100430.	0.5	0
3133	Posterior tibial nerve stimulation as a neuromodulation therapy in treatment of neurogenic overactive bladder in multiple sclerosis: A prospective randomized controlled study. Multiple Sclerosis and Related Disorders, 2022, 68, 104252.	0.9	2
3134	Modulation of salivary ICAM-1 and SIRT1 by disease modifying drugs in undepressed relapsing-remitting multiple sclerosis patients. Multiple Sclerosis and Related Disorders, 2022, 68, 104257.	0.9	1
3135	Brain volumetric correlates of remotely versus in-person administered symbol digit modalities test in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2022, 68, 104247.	0.9	1
3136	Ocrelizumab treatment in newly diagnosed multiple sclerosis patients with previous Hodgkin's lymphoma. Neuroimmunology Reports, 2022, 2, 100151.	0.2	0
3137	Feasibility of a smartphone app to monitor patient reported outcomes in multiple sclerosis: The haMSter interventional trial. Digital Health, 2022, 8, 205520762211353.	0.9	2
3138	Demyelinating syndromes and movement disorders. , 2023, , 567-584.		0
3139	Reply to the Letter: â€œAbnormal cerebrospinal fluid composition can accompany CNS involvement in COVID-19â€• Arquivos De Neuro-Psiquiatria, 2022, 80, 979-981.	0.3	0
3140	Bright light therapy as a non-pharmacological treatment option for multiple sclerosis-related fatigue: A randomized sham-controlled trial. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2022, 8, 205521732211332.	0.5	4
3141	Association of the retinal vasculature, intrathecal immunity, and disability in multiple sclerosis. Frontiers in Immunology, 0, 13, .	2.2	5
3142	Optical coherence tomography as a prognostic tool for disability progression in MS: a systematic review. Journal of Neurology, 2023, 270, 1178-1186.	1.8	1
3143	Multiple sclerosis patientsâ€™ response to COVID-19 pandemic and vaccination in Egypt. Egyptian Journal of Neurology, Psychiatry and Neurosurgery, 2022, 58, .	0.4	4
3144	Commercial volumetric MRI reporting tools in multiple sclerosis: a systematic review of the evidence. Neuroradiology, 2023, 65, 5-24.	1.1	9
3145	Serum Neurofilament Light Chain and Glial Fibrillary Acidic Protein as Biomarkers in Primary Progressive Multiple Sclerosis and Hereditary Spastic Paraplegia Type 4. International Journal of Molecular Sciences, 2022, 23, 13466.	1.8	1
3146	Limb apraxia in individuals with multiple sclerosis: Is there a role of semi-immersive virtual reality in treating the Cinderella of neuropsychology?. Multiple Sclerosis and Related Disorders, 2023, 69, 104405.	0.9	5
3147	Maternal Multiple Sclerosis and Offspringâ€™s Cognitive and Behavioral Development: What Do We Know until Now?. Children, 2022, 9, 1716.	0.6	2
3148	Synthetic Post-Contrast Imaging through Artificial Intelligence: Clinical Applications of Virtual and Augmented Contrast Media. Pharmaceutics, 2022, 14, 2378.	2.0	7
3149	Persistence with Botulinum Toxin Treatment for Spasticity Symptoms in Multiple Sclerosis. Toxins, 2022, 14, 774.	1.5	2

#	Article	IF	Citations
3150	The Impact of Highly Effective Treatment in Pediatric-Onset Multiple Sclerosis: A Case Series. Children, 2022, 9, 1698.	0.6	1
3151	Myelitis features and outcomes in CNS demyelinating disorders: Comparison between multiple sclerosis, MOGAD, and AQP4-IgG-positive NMOSD. Frontiers in Neurology, 0, 13, .	1.1	15
3152	Alterations of Thalamic Nuclei Volumes and the Intrinsic Thalamic Structural Network in Patients with Multiple Sclerosis-Related Fatigue. Brain Sciences, 2022, 12, 1538.	1.1	2
3153	Working memory dysfunction differs between secondary progressive and relapsing multiple sclerosis: Effects of clinical phenotype, age, disease duration, and disability. Multiple Sclerosis and Related Disorders, 2023, 69, 104411.	0.9	3
3154	In silico clinical trials for relapsing-remitting multiple sclerosis with MS TreatSim. BMC Medical Informatics and Decision Making, 2023, 22, .	1.5	7
3155	Brief international cognitive assessment for MS (BICAMS) and global brain volumes in early stages of MS â€“ A longitudinal correlation study. Multiple Sclerosis and Related Disorders, 2023, 69, 104398.	0.9	2
3156	A continuum of languishing to flourishing: exploring experiences of psychological resilience in multiple sclerosis family caregivers. International Journal of Qualitative Studies on Health and Well-being, 2022, 17, .	0.6	4
3157	Immuneâ€mediated diseases involving central and peripheral nervous systems. European Journal of Neurology, 2023, 30, 490-500.	1.7	2
3158	Machine learning-optimized Combinatorial MRI scale (COMRISv2) correlates highly with cognitive and physical disability scales in Multiple Sclerosis patients. Frontiers in Radiology, 0, 2, .	1.2	0
3159	Resting-state functional MRI in multicenter studies on multiple sclerosis: a report on raw data quality and functional connectivity features from the Italian Neuroimaging Network Initiative. Journal of Neurology, 2023, 270, 1047-1066.	1.8	3
3160	Ensemble machine learning identifies genetic loci associated with future worsening of disability in people with multiple sclerosis. Scientific Reports, 2022, 12, .	1.6	4
3161	Multiplex Analysis of Serum Cytokine Profiles in Systemic Lupus Erythematosus and Multiple Sclerosis. International Journal of Molecular Sciences, 2022, 23, 13829.	1.8	13
3162	Analysis of herpesvirus infection and genome single nucleotide polymorphism risk factors in multiple sclerosis, Volga federal district, Russia. Frontiers in Immunology, 0, 13, .	2.2	3
3163	The relation between the symbol digit modalities test, fatigue, depression, and anxiety symptoms in a Belgian MS cohort. Acta Neurologica Belgica, 0, , .	0.5	3
3164	Neurofilament light chains in serum as biomarkers of axonal damage in early MS lesions: a histologicalâ€“serological correlative study. Journal of Neurology, 2023, 270, 1416-1429.	1.8	2
3165	Serum GFAP and NfL Levels Differentiate Subsequent Progression and Disease Activity in Patients With Progressive Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2023, 10, .	3.1	42
3167	Mitochondrial Impairments in Peripheral Blood Mononuclear Cells of Multiple Sclerosis Patients. Biology, 2022, 11, 1633.	1.3	2
3169	Kappa Free Light Chain Biomarkers Are Efficient for the Diagnosis of Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2023, 10, .	3.1	15

#	Article	IF	Citations
3170	Integration of small RNAs from plasma and cerebrospinal fluid for classification of multiple sclerosis. Frontiers in Genetics, 0, 13, .	1.1	0
3171	VEP Score of a Left Eye Had Predictive Values for Achieving NEDA-3 over Ten Years in Patients with Multiple Sclerosis. Sensors, 2022, 22, 8849.	2.1	1
3172	Health-related quality of life in Japanese patients with multiple sclerosis. Journal of Neurology, 0, , .	1.8	0
3173	What is the potential of paramagnetic rim lesions as diagnostic indicators in multiple sclerosis?. Expert Review of Neurotherapeutics, 2022, 22, 829-837.	1.4	14
3174	Objective and subjective measures of daily physical activity in persons with Multiple Sclerosis beginning a rehabilitation regime: A cross-sectional study. Multiple Sclerosis and Related Disorders, 2022, 68, 104394.	0.9	1
3175	Characteristics of cognitive impairment in multiple sclerosis patients depending on different risk factors. Psychiatry Neurology and Medical Psychology, 2021, , 39-48.	0.1	0
3176	Chasing shadows: Cytologically detected shadow cells in the cerebrospinal fluid of patients with multiple sclerosis. Multiple Sclerosis and Related Disorders, 2023, 69, 104420.	0.9	1
3178	Dimethyl Fumarate Delays Multiple Sclerosis in Radiologically Isolated Syndrome. Annals of Neurology, 2023, 93, 604-614.	2.8	27
3179	Prognostic Significance of Neurofilament light in Fingolimod therapy for Multiple Sclerosis: A Systemic Review and Meta-Analysis based on Randomized Control Trials. Multiple Sclerosis and Related Disorders, 2022, , 104416.	0.9	1
3180	Longitudinal Postvaccine SARS-CoV-2 Immunoglobulin G Titers, Memory B-Cell Responses, and Risk of COVID-19 in Multiple Sclerosis Over 1 Year. Neurology: Neuroimmunology and NeuroInflammation, 2023, 10, .	3.1	11
3182	Multiple sclerosis progression: time for a new mechanism-driven framework. Lancet Neurology, The, 2023, 22, 78-88.	4.9	113
3183	Optical coherence tomography (OCT) measurements and cognitive performance in multiple sclerosis: a systematic review and meta-analysis. Journal of Neurology, 2023, 270, 1266-1285.	1.8	5
3184	Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder: Onset Following Acute COVID-19 Infection, a Case Series. Neurology and Therapy, 2023, 12, 319-327.	1.4	6
3185	Experience of remote rehabilitation for patients with multiple sclerosis. Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova, 2022, 122, 69.	0.1	0
3186	Patient Satisfaction in a Multidisciplinary Multiple Sclerosis Care Unit: A Swiss Single-centre Study. US Neurology, 2022, 18, 142.	0.2	0
3187	Comparative effectiveness of natalizumab versus ocrelizumab in multiple sclerosis: a real-world propensity scoreâ€“matched study. Therapeutic Advances in Neurological Disorders, 2022, 15, 175628642211429.	1.5	0
3188	Successful rapid desensitization of a pediatric multiple sclerosis patient with anaphylaxis to ocrelizumab. Annals of Indian Academy of Neurology, 2022, 25, 1210.	0.2	1
3189	Effect of immersive virtual reality training on hand-to-mouth task performance in people with Multiple Sclerosis: A quantitative kinematic study. Multiple Sclerosis and Related Disorders, 2023, 69, 104455.	0.9	6

#	Article	IF	Citations
3190	Changes in diffusion tensor imaging indices in basal ganglia and thalamus of patients with Relapsing-Remitting Multiple Sclerosis and relation with clinical conditions: A case-control study. European Journal of Radiology Open, 2023, 10, 100465.	0.7	1
3191	Early onset multiple sclerosis and the effect of disease onset age on neurological disability in multiple sclerosis. Clinical Neurology and Neurosurgery, 2023, 224, 107528.	0.6	0
3192	Mobility and balance rehabilitation in multiple sclerosis: A systematic review and dose-response meta-analysis. Multiple Sclerosis and Related Disorders, 2023, 69, 104424.	0.9	4
3193	Relapsing-remitting and primary progressive multiple sclerosis treated with ocrelizumab: A comparative study. Multiple Sclerosis and Related Disorders, 2023, 69, 104441.	0.9	2
3194	Effect of multiple sclerosis disease-modifying therapies on the real-world effectiveness of two doses of BBIBP-CorV (Sinopharm) vaccine. Journal of the Neurological Sciences, 2023, 444, 120518.	0.3	1
3195	Liposome-based nanoparticles impact on regulatory and effector phenotypes of macrophages and T cells in multiple Sclerosis patients. Biomaterials, 2023, 292, 121930.	5.7	3
3196	Health economic outcomes of switching to alemtuzumab from other disease-modifying therapies in people withÂmultiple sclerosis in the USA. Journal of Comparative Effectiveness Research, 2023, 12, .	0.6	0
3197	Facial emotion impairment in multiple sclerosis is linked to modifying observation strategies of emotional faces. Multiple Sclerosis and Related Disorders, 2023, 69, 104439.	0.9	1
3198	Experiences of health tracking in mobile apps for multiple sclerosis: A qualitative content analysis of user reviews. Multiple Sclerosis and Related Disorders, 2023, 69, 104435.	0.9	1
3199	Sensitivity of conventional cognitive tests in multiple sclerosis: Application of item response theory. Multiple Sclerosis and Related Disorders, 2023, 69, 104440.	0.9	0
3200	Clinical correlates of state and trait anxiety in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2023, 69, 104431.	0.9	1
3201	Cognitive fatigue-related sensory gating deficits in people with multiple sclerosis. Neurobiology of Disease, 2023, 176, 105950.	2.1	1
3202	Age-related blood transcriptional regulators affect disease progression in pediatric multiple sclerosis. Neurobiology of Disease, 2023, 176, 105953.	2.1	0
3203	Arzneimittelversorgung bei Multipler Sklerose. , 2022, , 139-159.		0
3204	Macronutrients, vitamins and minerals in the diet of multiple sclerosis patients. Postepy Psychiatrii I Neurologii, 2022, 31, 128-137.	0.2	0
3205	Circulating <scp>CCR6</scp>⁺<scp>ILC</scp> proportions are lower in multiple sclerosis patients. Clinical and Translational Immunology, 2022, 11, .	1.7	3
3206	Fragiles but Resilient. The Key Strategies to Cope with Pandemic in Persons with Multiple Sclerosis. A Controlled Web Survey. Journal of Neurological Research and Therapy, 2021, 3, 31-49.	0.2	0
3207	Association between brain volume and disability over time in multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2022, 8, 205521732211442.	0.5	0

#	Article	IF	Citations
3208	Multiple sclerosis in children. Vestnik Nevrologii, Psihiatrii I Nejrohirurgii, 2022, , 870-877.	0.0	0
3209	Percentage brain volume change in multiple sclerosis mainly reflects white matter and cortical volume. Annals of Clinical and Translational Neurology, 0, , .	1.7	1
3210	High-dose immunosuppressive therapy with autologous hematopoietic stem cell transplantation in multiple sclerosis: preliminary clinical results of approbation of the method. Russian Neurological Journal, 2022, 27, 25-35.	0.1	1
3211	Improving the detection of new lesions in multiple sclerosis with a cascaded 3D fully convolutional neural network approach. Frontiers in Neuroscience, 0, 16, .	1.4	2
3212	Blood Metabolomics May Discriminate a Sub-Group of Patients with First Demyelinating Episode in the Context of RRMS with Increased Disability and MRI Characteristics Indicative of Poor Prognosis. International Journal of Molecular Sciences, 2022, 23, 14578.	1.8	0
3213	Early Immunotherapy and Longer Corticosteroid Treatment Are Associated With Lower Risk of Relapsing Disease Course in Pediatric MOGAD. Neurology: Neuroimmunology and NeuroInflammation, 2023, 10, .	3.1	14
3214	Mass cytometry reveals cladribine-induced resets among innate lymphoid cells in multiple sclerosis. Scientific Reports, 2022, 12, .	1.6	3
3215	Immune Response after COVID-19 mRNA Vaccination in Multiple Sclerosis Patients Treated with DMTs. Biomedicines, 2022, 10, 3034.	1.4	0
3216	Conceptualization, use, and outcomes associated with compassion in the care of people with multiple sclerosis: a scoping review. Journal of Neurology, 0, , .	1.8	0
3218	Microstates in multiple sclerosis: an electrophysiological signature of altered large-scale networks functioning?. Brain Communications, 2022, 5, .	1.5	2
3219	External validation of a clinical prediction model in multiple sclerosis. Multiple Sclerosis Journal, 0, , 135245852211360.	1.4	0
3220	Not all roads lead to the immune system: the genetic basis of multiple sclerosis severity. Brain, 2023, 146, 2316-2331.	3.7	14
3221	Excess costs of multiple sclerosis: a register-based study in Sweden. European Journal of Health Economics, 2023, 24, 1357-1371.	1.4	0
3222	Ï‡-Separation Imaging for Diagnosis of Multiple Sclerosis versus Neuromyelitis Optica Spectrum Disorder. Radiology, 2023, 307, .	3.6	5
3223	Demyelinating diseases of the central nervous system registry for patients with traditional Chinese medicine: Rationale and design of a prospective, multicenter, observational study. Frontiers in Pharmacology, 0, 13, .	1.6	0
3224	Myelin heterogeneity for assessing normal appearing white matter myelin damage in multiple sclerosis. Journal of Neuroimaging, 2023, 33, 227-234.	1.0	1
3225	Serum Neurofilament Identifies Patients With Multiple Sclerosis With Severe Focal Axonal Damage in a 6-Year Longitudinal Cohort. Neurology: Neuroimmunology and NeuroInflammation, 2023, 10, .	3.1	4
3226	Turning and multitask gait unmask gait disturbance in mildâ€toâ€moderate multiple sclerosis: Underlying specific cortical thinning and connecting fibers damage. Human Brain Mapping, 0, , .	1.9	3

#	Article	IF	Citations
3227	Barriers to exercise and the role of general practitioner: A cross-sectional survey among people with multiple sclerosis. Frontiers in Neurology, 0, 13, .	1.1	2
3228	Endocannabinoid levels in peripheral blood mononuclear cells of multiple sclerosis patients treated with dimethyl fumarate. Scientific Reports, 2022, 12, .	1.6	0
3229	Treatment of multiple sclerosisâ€“related trigeminal neuralgia with onabotulinumtoxinA. Headache, 2022, 62, 1322-1328.	1.8	4
3230	Present and future of the diagnostic work-up of multiple sclerosis: the imaging perspective. Journal of Neurology, 2023, 270, 1286-1299.	1.8	12
3231	Clinical and MRI measures to identify non-acute MOG-antibody disease in adults. Brain, 2023, 146, 2489-2501.	3.7	5
3232	Effect of fingolimod therapy on quantitative macular changes among patients with relapsing-remitting multiple sclerosis: a four-year follow-up study from Oman. BMC Ophthalmology, 2022, 22, .	0.6	1
3233	Multiple sclerosis iron rim lesions are linked to impaired cervical spinal cord integrity using the T1/T2â€weighted ratio. Journal of Neuroimaging, 2023, 33, 240-246.	1.0	4
3234	Two Single Nucleotide Polymorphisms in the Purinergic Receptor P2X7 Gene Are Associated with Disease Severity in Multiple Sclerosis. International Journal of Molecular Sciences, 2022, 23, 15381.	1.8	3
3235	Molecular models of multiple sclerosis severity identify heterogeneity of pathogenic mechanisms. Nature Communications, 2022, 13, .	5.8	5
3236	Evaluation of Selected Oxidant/Antioxidant Parameters in Patients with Relapsing-Remitting Multiple Sclerosis Undergoing Disease-Modifying Therapies. Antioxidants, 2022, 11, 2416.	2.2	1
3237	Neuroaxonal and Glial Markers in Patients of the Same Age With Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2023, 10, .	3.1	6
3238	Redox State of Human Serum Albumin in Multiple Sclerosis: A Pilot Study. International Journal of Molecular Sciences, 2022, 23, 15806.	1.8	3
3239	Frequent somatic mosaicism in T lymphocyte subsets in individuals with and without multiple sclerosis. Frontiers in Immunology, 0, 13, .	2.2	3
3240	The Clinical and Epidemiological Profile of Paediatric-Onset Multiple Sclerosis in Poland. Journal of Clinical Medicine, 2022, 11, 7494.	1.0	1
3241	A novel eye-movement impairment in multiple sclerosis indicating widespread cortical damage. Brain, 2023, 146, 2476-2488.	3.7	4
3242	Longitudinal characterisation of B and T-cell immune responses after the booster dose of COVID-19 mRNA-vaccine in people with multiple sclerosis using different disease-modifying therapies. Journal of Neurology, Neurosurgery and Psychiatry, 2023, 94, 290-299.	0.9	12
3244	Selective vulnerability of brainstem and cervical spinal cord regions in people with non-progressive multiple sclerosis of Black or African American and European ancestry. Multiple Sclerosis Journal, 2023, 29, 691-701.	1.4	2
3246	Berlin Registry of Neuroimmunological entities (BERLimmun): protocol of a prospective observational study. BMC Neurology, 2022, 22, .	0.8	0

#	Article	IF	Citations
3247	Evaluating the central vein sign in paediatric-onset multiple sclerosis: A case series study. Multiple Sclerosis Journal, 0, , 135245852211423.	1.4	5
3248	Relationship between paramagnetic rim lesions and slowly expanding lesions in multiple sclerosis. Multiple Sclerosis Journal, 2023, 29, 352-362.	1.4	20
3249	Frequency of NMOSD misdiagnosis in a cohort from Latin America: Impact and evaluation of different contributors. Multiple Sclerosis Journal, 0, , 135245852211362.	1.4	4
3250	Cerebrospinal fluid kappa free light chains for the diagnosis of multiple sclerosis: A consensus statement. Multiple Sclerosis Journal, 2023, 29, 182-195.	1.4	12
3251	Magnetization transfer saturation reveals subclinical optic nerve injury in pediatric-onset multiple sclerosis. Multiple Sclerosis Journal, 2023, 29, 212-220.	1.4	2
3252	Behandlung der Neuromyelitis-optica-Spektrum-Erkrankung: RÃ¼ckblick auf das Komplementsystem und andere Aspekte der Pathogenese. Wiener Medizinische Wochenschrift, 2024, 174, 4-15.	0.5	1
3253	Task-based functional MRI challenges in clinical neuroscience: Choice of the best head motion correction approach in multiple sclerosis. Frontiers in Neuroscience, 0, 16, .	1.4	1
3255	The different damage patterns of short-, middle- and long-range connections between patients with relapse-remitting multiple sclerosis and neuromyelitis optica spectrum disorder. Frontiers in Immunology, 0, 13, .	2.2	0
3256	Polysomnographic diagnosis of REM sleep behavior disorder: a change is needed. Sleep, 2023, 46, .	0.6	1
3257	Anterior horn atrophy in the cervical spinal cord: A new biomarker in progressive multiple sclerosis. Multiple Sclerosis Journal, 2023, 29, 702-718.	1.4	1
3258	Estimated prevalence of AQP4 positive neuromyelitis optica spectrum disorder and MOG antibody associated disease in SÃ£o Paulo, Brazil. Multiple Sclerosis and Related Disorders, 2023, 70, 104488.	0.9	7
3259	Investigation of image-derived input functions for non-invasive quantification of myelin density using [11C]MeDAS PET. NeuroImage, 2022, 264, 119772.	2.1	3
3261	Adipokines in multiple sclerosis patients are related to clinical and radiological measures. Journal of Neurology, 2023, 270, 2018-2030.	1.8	2
3262	The efficacy and safety of ginger supplementation in patients with multiple sclerosis: A rationale and study protocol for a doubleâ€blind randomized controlled trial. Health Science Reports, 2023, 6, .	0.6	2
3263	Association Between Body Mass Index and Response to Disease-Modifying Therapies in Patients With Relapsing-Remitting Multiple Sclerosis at King Abdulaziz University Hospital: A Retrospective Study. Cureus, 2022, , .	0.2	0
3264	Energy expenditure and perceived effort during uphill and downhill walking in people with multiple sclerosis. European Journal of Physical and Rehabilitation Medicine, 0, , .	1.1	0
3265	Association of paramagnetic rim lesions and retinal layer thickness in patients with multiple sclerosis. Multiple Sclerosis Journal, 2023, 29, 374-384.	1.4	3
3266	CNS inflammatory demyelinating events after COVID-19 vaccines: A case series and systematic review. Frontiers in Neurology, 0, 13, .	1.1	11

#	Article	IF	Citations
3268	Where's the Vision? The Importance of Visual Outcomes in Neurologic Disorders. Neurology, 2023, 100, 244-253.	1.5	1
3270	Clinical Neuroimaging in Pediatric Dysimmune Disorders of the Central Nervous System. Seminars in Roentgenology, 2022, , .	0.2	0
3271	New Contrast Enhancement Method for Multiple Sclerosis Lesion Detection. Journal of Digital Imaging, 0, , .	1.6	1
3272	Effect of exergaming in people with restless legs syndrome with multiple sclerosis: A single-blind randomized controlled trial. Multiple Sclerosis and Related Disorders, 2023, 70, 104480.	0.9	2
3273	Exercise therapy for fatigue in multiple sclerosis. The Cochrane Library, 2022, 2022, .	1.5	0
3274	Vitamin D Supplementation Practices among Multiple Sclerosis Patients and Professionals. Journal of Clinical Medicine, 2022, 11, 7278.	1.0	4
3275	Burden and trends of multiple sclerosis in China from 1990 to 2019: a systematic analysis for the Global Burden of Disease Study 2019. BMJ Open, 2022, 12, e066335.	0.8	2
3277	Neural precursor cells tune striatal connectivity through the release of IGFBPL1. Nature Communications, 2022, 13, .	5.8	5
3278	Cerebrospinal fluid kappa free light chains for the diagnosis of multiple sclerosis: A systematic review and meta-analysis. Multiple Sclerosis Journal, 2023, 29, 169-181.	1.4	15
3279	Dropout rate in randomised controlled trials of balance and gait rehabilitation in multiple sclerosis: is it expected to be different for virtual reality-based interventions? A systematic review with meta-analysis and meta-regression. Virtual Reality, 0, , .	4.1	2
3280	Integrated single-cell transcriptomics of cerebrospinal fluid cells in treatment-naÃ¯ve multiple sclerosis. Journal of Neuroinflammation, 2022, 19, .	3.1	2
3281	Multi-Disease Validation of the RUDAS for Cognitive Screening in Alzheimerâ€™s Disease, Parkinsonâ€™s Disease, and Multiple Sclerosis. Journal of Alzheimer's Disease, 2022, , 1-13.	1.2	3
3282	Radial diffusivity reflects general decline rather than specific cognitive deterioration in multiple sclerosis. Scientific Reports, 2022, 12, .	1.6	1
3283	Advances in nanotechnology versus stem cell therapy for the theranostics of multiple sclerosis disease. Applied Nanoscience (Switzerland), 2023, 13, 4043-4073.	1.6	3
3284	Improvement in time to multiple sclerosis diagnosis: 25-year retrospective analysis from New York State MS Consortium (NYSMSC). Multiple Sclerosis Journal, 2023, 29, 753-756.	1.4	5
3285	Vaccine-based clinical protection against SARS-CoV-2 infection and the humoral immune response: A 1-year follow-up study of patients with multiple sclerosis receiving ocrelizumab. Frontiers in Immunology, 0, 13, .	2.2	6
3286	Enlarged choroid plexus related to cortical atrophy in multiple sclerosis. European Radiology, 2023, 33, 2916-2926.	2.3	9
3287	Quantitative susceptibility mapping of the normal-appearing white matter as a potential new marker of disability progression in multiple sclerosis. European Radiology, 2023, 33, 5368-5377.	2.3	3

#	Article	IF	Citations
3288	Psychophysical Evaluation of Visual vs. Computerâ€Aided Detection of Brain Lesions on Magnetic Resonance Images. Journal of Magnetic Resonance Imaging, 2023, 58, 642-649.	1.9	2
3289	Validity of serum neurofilament light chain as a prognostic biomarker of disease activity in multiple sclerosis. Journal of Neurology, 2023, 270, 1908-1930.	1.8	6
3290	Obesity is associated with myelin oligodendrocyte glycoprotein antibody-associated disease in acute optic neuritis. Scientific Reports, 2022, 12, .	1.6	4
3291	Determinants of early working impairments in multiple sclerosis. Frontiers in Neurology, 0, 13, .	1.1	2
3292	A case for including optic nerve lesions in the McDonald criteria. , 0, , .		0
3293	Significance of Myelin Oligodendrocyte Glycoprotein Antibodies in CSF. Neurology, 2023, 100, .	1.5	22
3294	Central nervous system tumefactive demyelinating lesions: Risk factors of relapse and follow-up observations. Frontiers in Immunology, 0, 13, .	2.2	1
3295	Myelin Basic Protein in Oligodendrocyte-Derived Extracellular Vesicles as a Diagnostic and Prognostic Biomarker in Multiple Sclerosis: A Pilot Study. International Journal of Molecular Sciences, 2023, 24, 894.	1.8	10
3296	A Systematic Review and Meta-Analysis of the Brief Cognitive Assessment for Multiple Sclerosis (BICAMS) International Validations. Journal of Clinical Medicine, 2023, 12, 703.	1.0	4
3297	The gut microbiota in multiple sclerosis varies with disease activity. Genome Medicine, 2023, 15, .	3.6	23
3298	Lower corticospinal excitability and greater fatigue among people with multiple sclerosis experiencing pain. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2023, 9, 205521732211433.	0.5	1
3299	XCL1, a serum biomarker in neurological diseases; HTLV-1-associated myelopathy and multiple sclerosis. Microbial Pathogenesis, 2023, 174, 105962.	1.3	1
3300	An Overview of the History, Pathophysiology, and Pharmacological Interventions of Multiple Sclerosis. Cureus, 2023, , .	0.2	4
3301	Elevated neurofilament light chain CSF/serum ratio indicates impaired CSF outflow in idiopathic intracranial hypertension. Fluids and Barriers of the CNS, 2023, 20, .	2.4	0
3302	Retinal ganglion cell loss is associated with future disability worsening in early relapsingâ€“remitting multiple sclerosis. European Journal of Neurology, 2023, 30, 982-990.	1.7	2
3303	Cerebral Venous Sinus Thrombosis induced By Hypercoagulation in Patient With Systemic Lupus Erythematosus: A Case Report and Literature Review. Journal of Blood Medicine, 0, Volume 14, 1-6.	0.7	0
3304	Lesion location across diagnostic regions in multiple sclerosis. NeuroImage: Clinical, 2023, 37, 103311.	1.4	4
3306	Pediatric Multiple Sclerosisâ€”Experience of a Tertiary Care Center. Neuropediatrics, 2023, 54, 058-063.	0.3	1

#	Article	IF	Citations
3307	Differential DNA methylation associated with multiple sclerosis and disease modifying treatments in an underrepresented minority population. Frontiers in Genetics, 0, 13, .	1.1	1
3308	Combining in vivo proton exchange rate (kex) MRI with quantitative susceptibility mapping to further stratify the gadolinium-negative multiple sclerosis lesions. Frontiers in Neuroscience, 0, 16, .	1.4	1
3309	Palliative care in multiple sclerosis. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2023, , 129-138.	1.0	0
3310	Leukocyte Telomere Length Predicts Severe Disability in Relapsing-Remitting Multiple Sclerosis and Correlates with Mitochondrial DNA Copy Number. International Journal of Molecular Sciences, 2023, 24, 916.	1.8	3
3311	Hepatotoxicity of Drugs Used in Multiple Sclerosis, Diagnostic Challenge, and the Role of HLA Genotype Susceptibility. International Journal of Molecular Sciences, 2023, 24, 852.	1.8	4
3312	Sixteen syndrome: a rare presentation of central demyelination. BMJ Case Reports, 2023, 16, e250440.	0.2	0
3313	Early Predictors of Disability and Cognition in Multiple Sclerosis Patients: A Long-Term Retrospective Analysis. Journal of Clinical Medicine, 2023, 12, 685.	1.0	2
3314	Subtypes of relapsing-remitting multiple sclerosis identified by network analysis. Frontiers in Digital Health, 0, 4, .	1.5	0
3315	Therapy of women with multiple sclerosis: an analysis of the use of drugs that may have adverse effects on the unborn child in the event of (unplanned) pregnancy. Therapeutic Advances in Drug Safety, 2023, 14, 204209862211438.	1.0	2
3316	The Relationship between Depression, Anxiety, Fatigue, and the Symbol Digit Modalities Test in Persons with Multiple Sclerosis. , 2023, 2, 74-79.		0
3317	Relationship Between Dual-task Walking and Cognitive Functions in Persons with Multiple Sclerosis. , 2023, 2, 57-61.		0
3318	Dimethyl Fumarate Treatment Reduces the Amount but Not the Avidity of the Epsteinâ€“Barr Virus Capsid-Antigen-Specific Antibody Response in Multiple Sclerosis: A Pilot Study. International Journal of Molecular Sciences, 2023, 24, 1500.	1.8	2
3319	Resilience, Stress, Well-Being, and Sleep Quality in Multiple Sclerosis. Journal of Clinical Medicine, 2023, 12, 716.	1.0	6
3320	Paradigm shifts in multiple sclerosis management: Implications for daily clinical practice. Revue Neurologique, 2023, 179, 256-264.	0.6	2
3321	Clinical-Radiological Mismatch in Multiple Sclerosis Patients during Acute Relapse: Discrepancy between Clinical Symptoms and Active, Topographically Fitting MRI Lesions. Journal of Clinical Medicine, 2023, 12, 739.	1.0	0
3322	Effects of multi-task training on motor and cognitive performances in multiple sclerosis patients without clinical disability: a single-blinded randomized controlled trial. Acta Neurologica Belgica, 0, , .	0.5	1
3323	Protocol for an exploratory, randomised, single-blind clinical trial of aerobic exercise to promote remyelination in multiple sclerosis. BMJ Open, 2023, 13, e061539.	0.8	0
3324	Determining the Prognostic Characteristics of People with Multiple Sclerosis with Bowel and Bladder Dysfunction as the Initial Presentation: A Cohort Study. , 2023, 2, 62-67.		0

#	Article	IF	Citations
3325	Effect of smoking on disease activity in multiple sclerosis patients treated with dimethyl fumarate or fingolimod. Multiple Sclerosis and Related Disorders, 2023, 70, 104513.	0.9	0
3326	Assessment of Motor Evoked Potentials in Multiple Sclerosis. Sensors, 2023, 23, 497.	2.1	4
3327	Cerebrospinal fluid proteomics indicates immune dysregulation and neuronal dysfunction in antibody associated autoimmune encephalitis. Journal of Autoimmunity, 2023, 135, 102985.	3.0	2
3328	Efficacy and safety of repeated low-dose rituximab therapy in relapsing-remitting multiple sclerosis: A retrospective case series study. Multiple Sclerosis and Related Disorders, 2023, 70, 104518.	0.9	2
3329	Assessment of intelligence quotient in patients with neuromyelitis optica spectrum disease and multiple sclerosis. Multiple Sclerosis and Related Disorders, 2023, 70, 104492.	0.9	0
3330	Multiple sclerosis-related heat sensitivity linked to absence of DMT prescription and subjective hand impairment but not autonomic or corticospinal dysfunction. Multiple Sclerosis and Related Disorders, 2023, 70, 104514.	0.9	0
3331	Factors associated with the misdiagnosis of neuromyelitis optica spectrum disorder. Multiple Sclerosis and Related Disorders, 2023, 70, 104498.	0.9	6
3332	The epidemiology and burden of neuromyelitis optica spectrum disorder, multiple sclerosis, and MOG antibody-associated disease in a province in Thailand: A population-based study. Multiple Sclerosis and Related Disorders, 2023, 70, 104511.	0.9	5
3333	Utility of the tibial nerve somatosensory evoked potentials in differentiating between neuromyelitis optica spectrum disorders and multiple sclerosis. Multiple Sclerosis and Related Disorders, 2023, 70, 104503.	0.9	0
3334	Characterization of a late-onset multiple sclerosis Portuguese cohort. Multiple Sclerosis and Related Disorders, 2023, 70, 104506.	0.9	4
3335	Late-onset multiple sclerosis in Iran: A report on demographic and disease characteristics. Multiple Sclerosis and Related Disorders, 2023, 70, 104493.	0.9	6
3336	Cognitive impairment in multiple sclerosis: Utility of electroencephalography. Multiple Sclerosis and Related Disorders, 2023, 70, 104502.	0.9	1
3337	Neuro rehabilitation effectiveness based on virtual reality and tele rehabilitation in people with multiple sclerosis in Argentina: Reavitelem study. Multiple Sclerosis and Related Disorders, 2023, 70, 104499.	0.9	2
3338	Chinese herbal medicine for people with multiple sclerosis: Protocol for a systematic review and meta-analysis. European Journal of Integrative Medicine, 2023, 58, 102220.	0.8	1
3339	Molecular biomarkers and cognitive impairment in multiple sclerosis: State of the field, limitations, and future direction â€“ A systematic review and meta-analysis. Neuroscience and Biobehavioral Reviews, 2023, 146, 105035.	2.9	6
3340	Demographic and diseaseâ€related factors impact on cerebrospinal fluid neurofilament light chain levels in multiple sclerosis. Brain and Behavior, 2023, 13, .	1.0	2
3341	Is there a role for herpes simplex virus type 1 in multiple sclerosis?. Microbes and Infection, 2023, 25, 105084.	1.0	3
3342	Analysis of Rituximab Use, Time Between Rituximab and SARS-CoV-2 Vaccination, and COVID-19 Hospitalization or Death in Patients With Multiple Sclerosis. JAMA Network Open, 2022, 5, e2248664.	2.8	17

#	Article	IF	Citations
3343	Automatic detection of active and inactive multiple sclerosis plaques using the Bayesian approach in susceptibility-weighted imaging. Acta Radiologica, 0, , 028418512211430.	0.5	0
3344	Novel CSF Biomarkers Tracking Autoimmune Inflammatory and Neurodegenerative Aspects of CNS Diseases. Diagnostics, 2023, 13, 73.	1.3	2
3345	Optic neuritis: current challenges in diagnosis and management. Current Opinion in Neurology, 2023, 36, 10-18.	1.8	4
3346	Association of daily physical activity with brain volumes and cervical spinal cord areas in multiple sclerosis. Multiple Sclerosis Journal, 0, , 135245852211437.	1.4	2
3347	Turning When Using Smartphone in Persons With and Those Without Neurologic Conditions: Observational Study. Journal of Medical Internet Research, 0, 25, e41082.	2.1	3
3348	Contrast-Enhanced 3D Spin Echo T1-Weighted Sequence Outperforms 3D Gradient Echo T1-Weighted Sequence for the Detection of Multiple Sclerosis Lesions on 3.0 T Brain MRI. Investigative Radiology, 2023, 58, 314-319.	3.5	1
3349	Novel Moving Steady-State Visual Evoked Potential Stimulus to Assess Afferent and Efferent Dysfunction in Multiple Sclerosis. IEEE Transactions on Neural Systems and Rehabilitation Engineering, 2023, 31, 1297-1301.	2.7	0
3350	What is a clinically isolated syndrome in the 21st century?. Multiple Sclerosis Journal, 2023, 29, 641-642.	1.4	0
3351	Tumefactive Demyelination in MOG Abâ€“Associated Disease, Multiple Sclerosis, and AQP-4-IgGâ€“Positive Neuromyelitis Optica Spectrum Disorder. Neurology, 2023, 100, .	1.5	16
3352	Cerebrospinal fluid neurofilament light chains and CXCL13 as predictive factors for clinical course of multiple sclerosis. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, 2023, 167, 30-35.	0.2	2
3353	High levels of kappa free light chain synthesis predict cognitive decline in relapsing-remitting multiple sclerosis. Frontiers in Immunology, 0, 14, .	2.2	3
3354	Multiple Sclerosis in Mongolia; the First Study Exploring Predictors of Disability and Depression in Mongolian MS Patients. Pathophysiology, 2023, 30, 15-26.	1.0	0
3355	T₁/T₂ ratio from 3T MRI improves multiple sclerosis cortical lesion contrast. Journal of Neuroimaging, 2023, 33, 434-445.	1.0	0
3356	Saudi Consensus Recommendations on the Management of Multiple Sclerosis: Diagnosis and Radiology/Imaging. Clinical and Translational Neuroscience, 2023, 7, 5.	0.4	0
3358	Cortical lesions at diagnosis predict longâ€term cognitive impairment in multiple sclerosis: A 20â€year study. European Journal of Neurology, 2023, 30, 1378-1388.	1.7	3
3359	In Vivo Corneal Confocal Microscopy in Multiple Sclerosis: Can it Differentiate Disease Relapse in Multiple Sclerosis?. American Journal of Ophthalmology, 2023, 250, 138-148.	1.7	1
3361	Clinically Isolated Syndrome and Frontal Lobe Arteriovenous Malformation Presenting With Behavior Issues. Journal of Medical Cases, 2023, 14, 1-6.	0.4	0
3362	Correspondence among gray matter atrophy and atlas-based neurotransmitter maps is clinically relevant in multiple sclerosis. Molecular Psychiatry, 2023, 28, 1770-1782.	4.1	10

#	Article	IF	Citations
3363	Family health conditions and parental occupational status modify the relationship between pediatric-onset multiple sclerosis and parental health-related quality of life. Multiple Sclerosis Journal, 2023, 29, 447-456.	1.4	1
3364	Fully Automatic Method for Reliable Spinal Cord Compartment Segmentation in Multiple Sclerosis. American Journal of Neuroradiology, 2023, 44, 218-227.	1.2	1
3365	Retinal layer thickness predicts disability accumulation in early relapsing multiple sclerosis. European Journal of Neurology, 2023, 30, 1025-1034.	1.7	7
3366	An Updated Evaluation of Intrathecal IgG Synthesis Markers in Relation to Oligoclonal Bands. Diagnostics, 2023, 13, 389.	1.3	1
3367	Cerebrospinal Fluid Biomarkers in Differential Diagnosis of Multiple Sclerosis and Systemic Inflammatory Diseases with Central Nervous System Involvement. Biomedicines, 2023, 11, 425.	1.4	4
3368	Diagnostic and prognostic value of the RUNXOR/RUNX1 axis in multiple sclerosis. Neurobiology of Disease, 2023, 178, 106032.	2.1	7
3369	Longitudinal assessment of cervical spinal cord compartments in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2023, 71, 104545.	0.9	1
3370	Accurate Diagnosis of Cortical and Infratentorial Lesions in Multiple Sclerosis Using Accelerated Fluid and White Matter Suppression Imaging. Investigative Radiology, 2023, 58, 337-345.	3.5	2
3371	Disease associations of excessive daytime sleepiness in multiple sclerosis: A prospective study. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2023, 9, 205521732311595.	0.5	0
3372	Retrochiasmatic Optic Pathway. , 2023, , 309-332.		0
3374	An investigation of the association between focal damage and global network properties in cognitively impaired and cognitively preserved patients with multiple sclerosis. Frontiers in Neuroscience, 0, 17, .	1.4	0
3375	Multiple Sclerosis: Inflammatory and Neuroglial Aspects. Current Issues in Molecular Biology, 2023, 45, 1443-1470.	1.0	10
3376	Neutrophil to lymphocyte ratio may be a useful marker in distinguishing MOGAD and MS and platelet to lymphocyte ratio associated with MOGAD activity. Multiple Sclerosis and Related Disorders, 2023, 71, 104570.	0.9	3
3377	â€œIt's on the tip of my tongue!â€•exploring confrontation naming difficulties in patients with multiple sclerosis. Multiple Sclerosis and Related Disorders, 2023, 71, 104579.	0.9	1
3378	The societal costs of multiple sclerosis in Lebanon: a cross-sectional study. Expert Review of Pharmacoeconomics and Outcomes Research, 2023, 23, 419-430.	0.7	0
3379	Navigating Through the Recent Diagnostic Criteria for MOGAD. Neurology, 2023, 100, 689-690.	1.5	0
3380	Evaluation of transorbital sonography measures of optic nerve diameter in the context of global and regional brain volume in multiple sclerosis. Scientific Reports, 2023, 13, .	1.6	1
3381	In-vivo characterization of macro- and microstructural injury of the subventricular zone in relapsing-remitting and progressive multiple sclerosis. Frontiers in Neuroscience, 0, 17, .	1.4	0

#	Article	IF	Citations
3382	Frailty and relapse activity in multiple sclerosis: A longitudinal observation. Multiple Sclerosis and Related Disorders, 2023, 72, 104603.	0.9	0
3383	Salivary Oxidative Status and the Neutrophil/Lymphocyte Ratio in Multiple Sclerosis. Turk Noroloji Dergisi = Turkish Journal of Neurology, 2023, 29, 30-39.	0.1	0
3384	ADC restriction is not associated with clinical response to plasma exchange following a cerebral attack of multiple sclerosis. Multiple Sclerosis and Related Disorders, 2023, 73, 104676.	0.9	0
3385	Clinical and fringe benefits of rituximab in multiple sclerosis treatment in a poor resource setting: Case series and cost analysis. Multiple Sclerosis and Related Disorders, 2023, 73, 104673.	0.9	1
3386	Neuroimmunological Disorders. Neurologic Clinics, 2023, 41, 315-330.	0.8	2
3387	The role of multiple sclerosis therapies on the dynamic of human gut microbiota. Journal of Neuroimmunology, 2023, 378, 578087.	1.1	4
3388	Neural bases of motor fatigue in multiple sclerosis: A multimodal approach using neuromuscular assessment and TMS-EEG. Neurobiology of Disease, 2023, 180, 106073.	2.1	8
3389	Application of diagnostic criteria for optic neuritis. Lancet Neurology, The, 2023, 22, 375-376.	4.9	0
3390	rTMS ameliorates depression/anxiety-like behaviors in experimental autoimmune encephalitis by inhibiting neurotoxic reactive astrocytes. Journal of Affective Disorders, 2023, 331, 352-361.	2.0	0
3391	Early neurofilament light and glial fibrillary acidic protein levels improve predictive models of multiple sclerosis outcomes. Multiple Sclerosis and Related Disorders, 2023, 74, 104695.	0.9	3
3392	Determination of sensitivities and specificities of cerebrospinal fluid free light chains to diagnose multiple sclerosis- a multicentric case-control study. Multiple Sclerosis and Related Disorders, 2023, 74, 104717.	0.9	0
3393	Cerebrospinal fluid sulfatide isoforms lack diagnostic utility in separating progressive from relapsing-remitting multiple sclerosis. Multiple Sclerosis and Related Disorders, 2023, 74, 104705.	0.9	1
3394	Clinical diagnostic utility of transcranial magnetic stimulation in neurological disorders. Updated report of an IFCN committee. Clinical Neurophysiology, 2023, 150, 131-175.	0.7	37
3395	Do cardiovascular disease comorbidities affect the cognitive function of Multiple Sclerosis patients?. Journal of Clinical Neuroscience, 2023, 112, 20-24.	0.8	2
3396	Automated Computerized Neuropsychological Diagnostics in Multiple Sclerosis. Zeitschrift FÃ¼r Neuropsychologie = Journal of Neuropsychology, 2022, 33, 138-148.	0.2	0
3397	The prevalence and incidence of multiple sclerosis over the past 20 years in northern Japan. Multiple Sclerosis and Related Disorders, 2023, 73, 104696.	0.9	1
3398	Neurodiagnostic Studies in Children. , 2022, , 725-754.		0
3399	Neuro-immune crosstalk in depressive symptoms of multiple sclerosis. Neurobiology of Disease, 2023, 177, 106005.	2.1	3

#	Article	IF	Citations
3400	Pregnancy planning and management for women with multiple sclerosis: what has changed over the last 15 years? An Italian single-center experience. Multiple Sclerosis and Related Disorders, 2023, 70, 104526.	0.9	3
3401	Feasibility and usability of a new home-based immersive virtual reality headset-based dexterity training in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2023, 71, 104525.	0.9	5
3402	Sexual dysfunction in female and male people with multiple sclerosis: disability, depression and hormonal status matter. European Journal of Neurology, 2023, 30, 991-1000.	1.7	1
3403	Change in Insomnia and Depressive Symptoms During COVID-19: A Prospective Longitudinal Study of Iranian Women with Multiple Sclerosis. Behavioral Sleep Medicine, 2023, 21, 741-756.	1.1	0
3404	Assessment of oligoclonal bands in cerebrospinal fluid and serum of dogs with meningoencephalitis of unknown origin. PLoS ONE, 2023, 18, e0280864.	1.1	2
3405	Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria. Lancet Neurology, The, 2023, 22, 268-282.	4.9	250
3406	Multiple sclerosis and circadian rhythms: Can diet act as a treatment?. Acta Physiologica, 2023, 237, .	1.8	5
3407	Specific alterations in NKG2D+ T lymphocytes in relapsing-remitting and progressive multiple sclerosis patients. Multiple Sclerosis and Related Disorders, 2023, 71, 104542.	0.9	2
3408	Should trigeminal neuralgia be considered a clinically isolated syndrome?. Multiple Sclerosis Journal, 2023, 29, 637-641.	1.4	1
3409	Brain and Spinal Cord MRI Findings in Thai Multiple Sclerosis Patients. Journal of Imaging, 2023, 9, 27.	1.7	2
3410	A Multicenter Longitudinal <scp>MRI</scp> Study Assessing <scp>LeManâ€PV</scp> Software Accuracy in the Detection of White Matter Lesions in Multiple Sclerosis Patients. Journal of Magnetic Resonance Imaging, 2023, 58, 864-876.	1.9	4
3411	Antibodies to calnexin and mutated calreticulin are common in human sera. Current Research in Translational Medicine, 2023, 71, 103380.	1.2	1
3412	Decipher potential biomarkers of diagnosis and disease activity for NMOSD with AQP4 using LC-MS/MS and Simoa. International Immunopharmacology, 2023, 116, 109761.	1.7	1
3413	Clinically Manifest Infections Do Not Increase the Relapse Risk in People with Multiple Sclerosis Treated with Disease-Modifying Therapies: A Prospective Study. Journal of Clinical Medicine, 2023, 12, 1023.	1.0	2
3414	Omics approaches to understanding the efficacy and safety of disease-modifying treatments in multiple sclerosis. Frontiers in Genetics, 0, 14, .	1.1	4
3415	Overlapping anti-NMDAR encephalitis and multiple sclerosis: A case report and literature review. Frontiers in Immunology, 0, 14, .	2.2	5
3416	Switch to ocrelizumab in MS patients treated with natalizumab in extended interval dosing at high risk of PML: A 96-week follow-up pilot study. Frontiers in Immunology, 0, 14, .	2.2	0
3417	Gut Microbiota Changes during Dimethyl Fumarate Treatment in Patients with Multiple Sclerosis. International Journal of Molecular Sciences, 2023, 24, 2720.	1.8	10

#	Article	IF	Citations
3418	Volumetric changes in hypothalamic subunits in patients with relapsing remitting multiple sclerosis. Neuroradiology, 2023, 65, 899-905.	1.1	2
3419	Multifaceted Analysis of Cerebrospinal Fluid and Serum from Progressive Multiple Sclerosis Patients: Potential Role of Vitamin C and Metal Ion Imbalance in the Divergence of Primary Progressive Multiple Sclerosis and Secondary Progressive Multiple Sclerosis. Journal of Proteome Research, 2023, 22, 743-757.	1.8	0
3420	How does neurovascular unit dysfunction contribute to multiple sclerosis?. Neurobiology of Disease, 2023, 178, 106028.	2.1	15
3421	Longitudinal Assessment of Multiple Sclerosis Lesion Load With Synthetic Magnetic Resonance Imagingâ€"A Multicenter Validation Study. Investigative Radiology, 2023, 58, 320-326.	3.5	4
3422	Phenotyping variants of tumefactive demyelinating lesions according to clinical and radiological featuresâ€"A case series. Frontiers in Neurology, 0, 14, .	1.1	0
3423	The uncertainty period preceding the clinical defined SPMS diagnosis and the applicability of objective classifiers â€“ A Danish single center study. Multiple Sclerosis and Related Disorders, 2023, 71, 104546.	0.9	0
3424	Cerebrospinal fluid immunoglobulins in primary progressive multiple sclerosis are pathogenic. Brain, 2023, 146, 1979-1992.	3.7	4
3425	In-person and remote administrations of the symbol digit modalities test are interchangeable among persons with multiple sclerosis. Multiple Sclerosis and Related Disorders, 2023, 71, 104553.	0.9	2
3426	A unified classification approach rating clinical utility of protein biomarkers across neurologic diseases. EBioMedicine, 2023, 89, 104456.	2.7	6
3427	Medication adherence to disease-modifying therapies among a cohort of Jordanian patients with relapsing-remitting multiple sclerosis: a multicentre cross-sectional study. International Journal of Pharmacy Practice, 2023, 31, 198-205.	0.3	0
3428	Reader Response: Frequency of Asymptomatic Optic Nerve Enhancement in a Large Retrospective Cohort of Patients With Aquaporin-4+ NMOSD. Neurology, 2023, 100, 309-310.	1.5	0
3429	Multicenter Evaluation of AI-generated DIR and PSIR for Cortical and Juxtacortical Multiple Sclerosis Lesion Detection. Radiology, 2023, 307, .	3.6	6
3430	Microchimerism in multiple sclerosis: The association between sex of offspring and MRI features in women with multiple sclerosis. Frontiers in Neuroscience, 0, 17, .	1.4	1
3431	Neuropathologically informed imaging of cortical grey matter lesions in MS â€“ A pilot study. Multiple Sclerosis and Related Disorders, 2023, 71, 104555.	0.9	0
3432	The Importance of Optical Coherence Tomography in the Diagnosis of Atypical or Subclinical Optic Neuritis: A Case Series Study. Journal of Clinical Medicine, 2023, 12, 1309.	1.0	0
3433	Faster progression to multiple sclerosis disability is linked to neuronal pathways associated with neurodegeneration: An ethnicity study. PLoS ONE, 2023, 18, e0280515.	1.1	3
3434	Antibodies to expanded virus antigen panels show elevated diagnostic sensitivities in multiple sclerosis and optic neuritis. Immunology Letters, 2023, 254, 54-64.	1.1	2
3435	Longâ€term clinical, imaging and cognitive outcomes association with <scp>MS</scp> immunopathology. Annals of Clinical and Translational Neurology, 2023, 10, 339-352.	1.7	0

#	Article	IF	Citations
3437	The role of systemic Ä±mmune Ä±nflammatory Ä±ndex in showing active lesion Ä±n patients with multiple sclerosis. BMC Neurology, 2023, 23, .	0.8	7
3438	Incremental validity of brief and abbreviated neuropsychological tests toward predicting functional outcomes in multiple sclerosis. Applied Neuropsychology Adult, 0, , 1-11.	0.7	0
3439	Effect of deep gray matter atrophy on information processing speed in early relapsing-remitting multiple sclerosis. Multiple Sclerosis and Related Disorders, 2023, 71, 104560.	0.9	2
3440	Association of volumetric MRI measures and disability in MS patients of the same age: Descriptions from a birth year cohort. Multiple Sclerosis and Related Disorders, 2023, 71, 104568.	0.9	2
3441	Predictive factors of multiple sclerosis relapse after the first demyelinating event: A 5-year follow-up. Multiple Sclerosis and Related Disorders, 2023, 71, 104566.	0.9	0
3442	High serum neurofilament light chain levels correlate with brain atrophy and physical disability in multiple sclerosis. European Journal of Neurology, 2023, 30, 1389-1399.	1.7	3
3443	ATR-FTIR spectroscopy of plasma supported by multivariate analysis discriminates multiple sclerosis disease. Scientific Reports, 2023, 13, .	1.6	1
3444	Evaluation of the safety profile of COVID-19 vaccines in patients with MS, NMOSD, and MOGAD. Neurological Sciences, 2023, 44, 1841-1848.	0.9	1
3445	Intrathecal versus Peripheral Inflammatory Protein Profile in MS Patients at Diagnosis: A Comprehensive Investigation on Serum and CSF. International Journal of Molecular Sciences, 2023, 24, 3768.	1.8	1
3446	Prominent role of executive functioning on the Phonemic Fluency Test in people with multiple sclerosis. Journal of the International Neuropsychological Society, 0, , 1-5.	1.2	0
3447	Immunization status in patients with multiple sclerosis: AÂcrossâ€sectional, monocenter study in Austria. European Journal of Neurology, 2023, 30, 1400-1408.	1.7	1
3448	Neuropsychiatric Status of Patients With Multiple Sclerosis Across Disease Duration Intervals. Journal of Neuropsychiatry and Clinical Neurosciences, 2023, 35, 250-255.	0.9	0
3449	Case report: First manifestation of multiple sclerosis temporally correlated with COVID-19 vaccination. Frontiers in Neurology, 0, 14, .	1.1	5
3450	Risk HLA Variants Affect the T-Cell Repertoire in Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2023, 10, e200093.	3.1	1
3451	Imaging of Central Nervous System Demyelinating Disorders. CONTINUUM Lifelong Learning in Neurology, 2023, 29, 292-323.	0.4	0
3452	Magnetic transferrin nanoparticles (MTNs) assay as a novel isolation approach for exosomal biomarkers in neurological diseases. Biomaterials Research, 2023, 27, .	3.2	10
3453	Modifiable risk factors of COVID-19 in patients with multiple sclerosis: a single-centre caseâ€“control study. Journal of Neurology, 2023, 270, 1835-1842.	1.8	4
3454	Lessons from immunotherapies in multiple sclerosis. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2023, , 293-311.	1.0	0

#	Article	IF	Citations
3455	CNS demyelinating events in primary SjÃ¶gren's syndrome: A single-center case series on the clinical phenotype. Frontiers in Neurology, 0, 14, .	1.1	2
3456	Effects of Tele-Pilates and Tele-Yoga on Biochemicals, Physical, and Psychological Parameters of Females with Multiple Sclerosis. Journal of Clinical Medicine, 2023, 12, 1585.	1.0	4
3457	Serum Neurofilaments and OCT Metrics Predict EDSS-Plus Score Progression in Early Relapse-Remitting Multiple Sclerosis. Biomedicines, 2023, 11, 606.	1.4	2
3458	Microstructural alterations in different types of lesions and their perilesional white matter in relapsing-remitting multiple sclerosis based on diffusion kurtosis imaging. Multiple Sclerosis and Related Disorders, 2023, 71, 104572.	0.9	1
3459	High-Dose Intravenous Steroid Treatment Seems to Have No Long-Term Negative Effect on Bone Mineral Density of Young and Newly Diagnosed Multiple Sclerosis Patients: A Pilot Study. Biomedicines, 2023, 11, 603.	1.4	2
3460	Concurrent diagnoses of Tuberous sclerosis and multiple sclerosis. Multiple Sclerosis and Related Disorders, 2023, 71, 104586.	0.9	1
3462	Achieving no evidence of disease activity-3 in highly active multiple sclerosis patients treated with cladribine and monoclonal antibodies. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2023, 9, 205521732311547.	0.5	0
3463	Aglycosylated extracellular loop of inwardly rectifying potassium channel 4.1 (KCNJ10) provides a target for autoimmune neuroinflammation. Brain Communications, 2023, 5, .	1.5	0
3464	Visual Outcomes Following Plasma Exchange for Optic Neuritis: An International Multicenter Retrospective Analysis of 395 Optic Neuritis Attacks. American Journal of Ophthalmology, 2023, 252, 213-224.	1.7	7
3465	Neural Surface Antibodies and Neurodegeneration: Clinical Commonalities and Pathophysiological Relationships. Biomedicines, 2023, 11, 666.	1.4	3
3466	Using The Virtual Brain to study the relationship between structural and functional connectivity in patients with multiple sclerosis: a multicenter study. Cerebral Cortex, 2023, 33, 7322-7334.	1.6	1
3468	The Acute Optic Neuritis Network (ACON): Study protocol of a non-interventional prospective multicenter study on diagnosis and treatment of acute optic neuritis. Frontiers in Neurology, 0, 14, .	1.1	4
3469	A case of primary progressive multiple sclerosis with improvement in cognitive impairment by anti-CD20 monoclonal antibody therapy. Clinical Neurology, 2023, 63, 152-158.	0.0	0
3470	Acute central nervous system inflammation following COVID-19 vaccination: An observational cohort study. Multiple Sclerosis Journal, 2023, 29, 595-605.	1.4	3
3471	Cognitive skill learning in multiple sclerosis: A meaningful component of the neuropsychological profile. Brain and Cognition, 2023, 166, 105959.	0.8	1
3472	Association of Serum Neurofilament Light Chain Levels at Disease Onset With Disability Worsening in Patients With a First Demyelinating Multiple Sclerosis Event Not Treated With High-Efficacy Drugs. JAMA Neurology, 2023, 80, 397.	4.5	3
3473	A 10-Year Single-Center Study of the Clinical Characteristics of Optic Neuritis-Related NMOSD, MS, and Double Seronegative Optic Neuritis, Together with Factors Predicting Visual Outcomes. Vision (Switzerland), 2023, 7, 16.	0.5	0
3474	The serum kynurenine pathway metabolic profile is associated with overweight and obesity in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2023, 72, 104592.	0.9	1

#	Article	IF	Citations
3475	The radiologically isolated syndrome: revised diagnostic criteria. Brain, 2023, 146, 3431-3443.	3.7	22
3476	Synergy between health technology assessments and clinical guidelines for multiple sclerosis. Clinical and Translational Science, 2023, 16, 835-849.	1.5	3
3477	Diffusion tensor imaging metrics associated with future disability in multiple sclerosis. Scientific Reports, 2023, 13, .	1.6	2
3478	Multiple sclerosis versus cerebral small vessel disease in MRI: a practical approach using qualitative and quantitative signal intensity differences in white matter lesions. Acta Radiologica, 2024, 65, 106-114.	0.5	1
3479	COVID-19 and its implications on the clinico-radiological course of multiple sclerosis: A caseâ€“control study. Medicina ClÃnica (English Edition), 2023, 160, 187-192.	0.1	0
3480	Sudden Death Associated With Possible Flare-Ups of Multiple Sclerosis After COVID-19 Vaccination and Infection: A Case Report and Literature Review. Journal of Korean Medical Science, 2023, 38, .	1.1	2
3481	The evaluation of small fibers in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2023, 72, 104602.	0.9	0
3482	Artificial intelligence technologies in monitoring pathomorphological changes in the central nervous system in multiple sclerosis. Science and Innovations, 2023, , 75-83.	0.1	0
3483	Explaining the burden of psychosocial factors on the worsening symptoms of MS: a qualitative study of patients' experiences. BMC Neurology, 2023, 23, .	0.8	2
3484	MRI Signal Intensity Varies Along the Course of the Normal Optic Nerve. Journal of Neuro-Ophthalmology, 2023, 43, 509-513.	0.4	0
3485	Choroid plexus volume is enlarged in clinically isolated syndrome patients with optic neuritis. Multiple Sclerosis Journal, 2023, 29, 540-548.	1.4	4
3486	Epidemiological and Immune Profile Analysis of Italian Subjects with Endometriosis and Multiple Sclerosis. Journal of Clinical Medicine, 2023, 12, 2043.	1.0	2
3487	Eight-and-a-half syndrome as the first presentation of multiple sclerosis in anÂAsian male: a case report. Journal of Medical Case Reports, 2023, 17, .	0.4	0
3489	Changes in Retinal Thickness and Brain Volume during 6.8-Year Escalating Therapy for Multiple Sclerosis. Acta Neurologica Scandinavica, 2023, 2023, 1-8.	1.0	1
3490	Central vein sign and diffusion MRI differentiate microstructural features within white matter lesions of multiple sclerosis patients with comorbidities. Frontiers in Neurology, 0, 14, .	1.1	1
3491	Association Between Multiple Sclerosis and the Symptoms of Vertigo and Facial Nerve Palsy. Ear, Nose and Throat Journal, 0, , 014556132211483.	0.4	1
3492	Individual reserve in aging and neurological disease. Journal of Neurology, 2023, 270, 3179-3191.	1.8	5
3493	The clinical-radiological paradox in multiple sclerosis: myth or truth?. Arquivos De Neuro-Psiquiatria, 2023, 81, 055-061.	0.3	2

#	Article	IF	Citations
3494	The effect of ginger (Zingiber officinale) supplementation on clinical, biochemical, and anthropometric parameters in patients with multiple sclerosis: a double-blind randomized controlled trial. Food and Function, 2023, 14, 3701-3711.	2.1	3
3495	Results of treatment with alemtuzumab in a Spanish cohort of patients with multiple sclerosis in the real world: The RealMS study. Frontiers in Neurology, 0, 14, .	1.1	1
3496	Functional or â€œPsychogenicâ€•Neurological Symptoms in Children and Adolescents. , 2023, , 193-204.		0
3497	Editorial: Automatic methods for multiple sclerosis new lesions detection and segmentation. Frontiers in Neuroscience, 0, 17, .	1.4	2
3499	Inflammatory Activity After Diverse Fertility Treatments. Neurology: Neuroimmunology and NeuroInflammation, 2023, 10, .	3.1	8
3500	A highly challenging balance training intervention for people with multiple sclerosis: a feasibility trial. Pilot and Feasibility Studies, 2023, 9, .	0.5	0
3501	Magnetic-resonance imaging semiology of cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) in subjects from Russian Federation. Russian Neurological Journal, 2023, 28, 13-24.	0.1	0
3502	Neurophysiological and clinical biomarkers of secondary progressive multiple sclerosis: A cross-sectional study. Frontiers in Neurology, 0, 14, .	1.1	0
3504	A prospective study of cellular immune response to booster COVID-19 vaccination in multiple sclerosis patients treated with a broad spectrum of disease-modifying therapies. Journal of Neurology, 2023, 270, 2380-2391.	1.8	8
3505	Toll-like receptor 10 is down-regulated in serum of patients with relapsingâ€“remitting multiple sclerosis but not associated with Epstein-Barr virus. Journal of NeuroVirology, 0, , .	1.0	0
3506	Visually Evoked Potential as Prognostic Biomarker for Neuroaxonal Damage in Multiple Sclerosis From a Multicenter Longitudinal Cohort. Neurology: Neuroimmunology and NeuroInflammation, 2023, 10, .	3.1	3
3507	Potential Protective Role of Pregnancy and Breastfeeding in Delaying Onset Symptoms Related to Multiple Sclerosis. Medicina (Lithuania), 2023, 59, 619.	0.8	0
3508	Prefrontal hemodynamics during forward and backward walking, with and without a cognitive task, in people with multiple sclerosis. European Journal of Physical and Rehabilitation Medicine, 2023, 59, .	1.1	0
3509	Performance of McDonald 2017 multiple sclerosis diagnostic criteria and evaluation of genetic ancestry in patients with a first demyelinating event in Argentina. Multiple Sclerosis Journal, 2023, 29, 559-567.	1.4	1
3510	An update on the use of sphingosine 1-phosphate receptor modulators for the treatment of relapsing multiple sclerosis. Expert Opinion on Pharmacotherapy, 2023, 24, 495-509.	0.9	12
3513	Assessment of cognitive performance in multiple sclerosis using smartphone-based training games: a feasibility study. Journal of Neurology, 2023, 270, 3451-3463.	1.8	2
3514	Patterns of inflammation, microstructural alterations, and sodium accumulation define multiple sclerosis subtypes after 15 years from onset. Frontiers in Neuroinformatics, 0, 17, .	1.3	0
3515	Multiple Sclerosis Disease Evolution Assessment in Brain MRI Lesions Based on Texture and Multi-Scale Amplitude Modulation-Frequency Modulation (AM-FM) Features. IEEE Access, 2023, 11, 29918-29933.	2.6	1

#	Article	IF	Citations
3516	Multiple sclerosis and COVID-19: A retrospective study in Iran. PLoS ONE, 2023, 18, e0283538.	1.1	5
3517	Identification of the pathogenesis features of various phenotypes of multiple sclerosis based on the study of the morphological functional connectivity of subcortical gray matter structures. , 2023, 3, 27-42.		0
3518	Locomotor Strategy to Perform 6-Minute Walk Test in People with Multiple Sclerosis: A Prospective Observational Study. Sensors, 2023, 23, 3407.	2.1	1
3519	Retrospective cohort study to devise a treatment decision score predicting adverse 24-month radiological activity in early multiple sclerosis. Therapeutic Advances in Neurological Disorders, 2023, 16, 175628642311618.	1.5	4
3522	Acute Lower Extremity Weakness in a Pediatric Gymnast. Clinical Pediatrics, 0, , 000992282311622.	0.4	0
3523	Natalizumab continuation versus switching to ocrelizumab after PML risk stratification in RRMS patients: a natural experiment. Journal of Neurology, 0, , .	1.8	0
3524	Disease characteristics of idiopathic transverse myelitis with serum neuronal and astroglial damage biomarkers. Scientific Reports, 2023, 13, .	1.6	2
3526	Effectiveness of Repetitive Transcranial Magnetic Stimulation (rTMS) Add-On Therapy to a Standard Treatment in Individuals with Multiple Sclerosis and Concomitant Symptoms of Depressionâ€"Results from a Randomized Clinical Trial and Pilot Study. Journal of Clinical Medicine, 2023, 12, 2525.	1.0	1
3527	Cognitive deficits in multiple sclerosis: Auditory and visual attention and inhibitory control. Applied Neuropsychology Adult, 0, , 1-8.	0.7	0
3528	Twelve Weeks of Intermittent Caloric Restriction Diet Mitigates Neuroinflammation in Midlife Individuals with Multiple Sclerosis: A Pilot Study with Implications for Prevention of Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2023, 93, 263-273.	1.2	2
3530	Chitinase-3-like 1-protein in CSF: a novel biomarker for progression in patients with multiple sclerosis. Neurological Sciences, 2023, 44, 3243-3252.	0.9	4
3531	Multiple Sclerosis Patientsâ€™ COVID-19 Catching Ratios and Disease Profiles. KahramanmaraÅŸ SÃ¼tÃ§Ã¼ Ä°mam Ãœniversitesi TÄ±p FakÃ¼ltesi Dergisi, 0, , .	0.1	0
3532	Utility of the visual system to monitor neurodegeneration in multiple sclerosis. Frontiers in Molecular Neuroscience, 0, 16, .	1.4	1
3533	On a 5-year-old girl with multiple sclerosis treated with natalizumab. Neurological Sciences, 0, , .	0.9	0
3534	Double inversion recovery to detect cervical spinal cord multiple sclerosis lesions. Journal of Neuroimaging, 0, , .	1.0	0
3535	Droplet-based forward genetic screening of astrocyteâ€"microglia cross-talk. Science, 2023, 379, 1023-1030.	6.0	35
3536	Multiple sclerosis presenting with progressive visual impairment independent of relapse activity: A case report. Neuroimmunology Reports, 2023, 3, 100172.	0.2	0
3537	Swept-Source Optical Coherence Tomography Thresholds in Differentiating Clinical Outcomes in a Real-World Cohort of Treatment-NaÃ¯ve Multiple Sclerosis Patients. Brain Sciences, 2023, 13, 591.	1.1	0

#	Article	IF	Citations
3539	Protein biomarkers in multiple sclerosis. Encephalitis, 2023, 3, 54-63.	0.3	2
3540	Efficacy and safety of monoclonal antibody therapy in patients with neuromyelitis optica spectrum disorder: A systematic review and network meta-analysis. Frontiers in Neurology, 0, 14, .	1.1	0
3541	Shared imaging markers of fatigue across multiple sclerosis, aquaporin-4 antibody neuromyelitis optica spectrum disorder and MOG antibody disease. Brain Communications, 0, , .	1.5	0
3542	Antibodies against the flotillin-1/2 complex in patients with multiple sclerosis. Brain Communications, 2023, 5, .	1.5	0
3543	Multiple Sclerosis: A Review with a Focus on the Middle East and North Africa Region. , 2023, , 1-22.		0
3544	How does multiple sclerosis affect sexual satisfaction in patients' spouses?. Frontiers in Psychology, 0, 14, .	1.1	1
3545	Alpha Calcitonin Gene-related Peptide, Neuropeptide Y, and Substance P as Biomarkers for Diagnosis and Disease Activity and Severity in Multiple Sclerosis. CNS and Neurological Disorders - Drug Targets, 2024, 23, 512-524.	0.8	0
3546	Short- and Long-Term Humoral and Cellular Immune Responses to SARS-CoV-2 Vaccination in Patients with Multiple Sclerosis Treated with Disease-Modifying Therapies. Vaccines, 2023, 11, 786.	2.1	2
3547	Serum proteins for monitoring and predicting visual function in patients with recent optic neuritis. Scientific Reports, 2023, 13, .	1.6	1
3548	THE ROLE OF MRI IN DIFFERENTIATING DEMYELINATING AND INFLAMMATORY (NOT INFECTIOUS) MYELOPATHIES. Seminars in Ultrasound, CT and MRI, 2023, , .	0.7	0
3549	Multiplex Analysis of Cerebrospinal Fluid and Serum Exosomes MicroRNAs of Untreated Relapsing Remitting Multiple Sclerosis (RRMS) and Proposing Noninvasive Diagnostic Biomarkers. NeuroMolecular Medicine, 2023, 25, 402-414.	1.8	4
3550	Preserved T cell but attenuated antibody response in MS patients on fingolimod and ocrelizumab following 2nd and 3rd SARS-CoV-2 mRNA vaccine. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2023, 9, 205521732311651.	0.5	1
3551	Guidelines on the Use of Therapeutic Apheresis in Clinical Practice â€“ EvidenceâBased Approach from the Writing Committee of the American Society for Apheresis: The Ninth Special Issue. Journal of Clinical Apheresis, 2023, 38, 77-278.	0.7	81
3552	Diet-related inflammation increases the odds of multiple sclerosis: Results from a large population-based prevalent case-control study in Jordan. Frontiers in Nutrition, 0, 10, .	1.6	1
3554	Optical coherence tomography angiography measurements in multiple sclerosis: a systematic review and meta-analysis. Journal of Neuroinflammation, 2023, 20, .	3.1	10
3556	Update on the diagnosis and treatment of neuromyelits optica spectrum disorders (NMOSD)Ââ€“ revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part I: Diagnosis and differential diagnosis. Journal of Neurology, 2023, 270, 3341-3368.	1.8	23
3557	COVID-19 infection after SARS-CoV-2 mRNA vaccination in Multiple Sclerosis, AQP4-antibody NMOSD and MOGAD patients during the Omicron subvariant BA.1/2 wave in Singapore. Journal of Neurology, 2023, 270, 2817-2825.	1.8	3
3558	Effectiveness and safety profile of cladribine in an Italian real-life cohort of relapsingâ€“remitting multiple sclerosis patients: a monocentric longitudinal observational study. Journal of Neurology, 2023, 270, 3553-3564.	1.8	4

#	Article	IF	Citations
3559	Assessment of Functional Capacity of Immune System in Patients with Multiple Sclerosis using QuantiFERON Monitor. Journal of Immunology Research, 2023, 2023, 1-8.	0.9	1
3560	Safety and Effectiveness of Cladribine in Multiple Sclerosis: Real-World Clinical Experience From 5 Tertiary Hospitals in Portugal. Clinical Neuropharmacology, 2023, 46, 105-111.	0.2	3
3561	Effect of Previous Disease-Modifying Therapy on Treatment Effectiveness for Patients Treated With Ocrelizumab. Neurology: Neuroimmunology and NeuroInflammation, 2023, 10, .	3.1	2
3562	Association of body mass index and physical activity with fatigue, depression, and anxiety among Iranian patients with multiple sclerosis. Frontiers in Neurology, 0, 14, .	1.1	1
3563	Pilot Lightweight Denoising Algorithm for Multiple Sclerosis on Spine MRI. Journal of Digital Imaging, 0, , .	1.6	0
3564	Functional and structural readouts for early detection of retinal involvement in multiple sclerosis. Frontiers in Integrative Neuroscience, 0, 17, .	1.0	0
3565	The prevalence and risk factors of anxiety in multiple sclerosis: A systematic review and meta-analysis. Frontiers in Neuroscience, 0, 17, .	1.4	4
3566	Incorporating the Central Vein Sign Into the Diagnostic Criteria for Multiple Sclerosis. JAMA Neurology, 2023, 80, 657.	4.5	3
3568	Diagnosis of multiple sclerosis using optical coherence tomography supported by artificial intelligence. Multiple Sclerosis and Related Disorders, 2023, 74, 104725.	0.9	4
3569	Differential Associations of Mobility With Fronto-Striatal Integrity and Lesion Load in Older Adults With and Without Multiple Sclerosis. Neurorehabilitation and Neural Repair, 2023, 37, 205-217.	1.4	1
3570	Decision Making About Disease-Modifying Treatments for Relapsing-Remitting Multiple Sclerosis: Stated Preferences and Real-World Choices. Patient, 0, , .	1.1	0
3571	Validation of an iPad version of the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS). Multiple Sclerosis and Related Disorders, 2023, 74, 104723.	0.9	0
3572	Top Ten Tips Palliative Care Clinicians Should Know about Multiple Sclerosis. Journal of Palliative Medicine, 2023, 26, 1555-1561.	0.6	1
3573	Clinical and Imaging Outcomes after Vitamin D Supplementation in Patients with Multiple Sclerosis: A Systematic Review. Nutrients, 2023, 15, 1945.	1.7	4
3574	Granulocyte activation markers in cerebrospinal fluid differentiate acute neuromyelitis spectrum disorder from multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2023, 94, 726-737.	0.9	0
3575	Trigeminal neuralgia in multiple sclerosis: Association with demyelination and progression. Multiple Sclerosis and Related Disorders, 2023, 74, 104727.	0.9	5
3576	Using quantitative magnetic resonance imaging to track cerebral alterations in multiple sclerosis brain: A longitudinal study. Brain and Behavior, 2023, 13, .	1.0	1
3577	Perception of Quality of Life and Fatigue in Multiple Sclerosis Patients Treated with High-Dose Vitamin D. Clinical and Translational Neuroscience, 2023, 7, 12.	0.4	1

#	Article	IF	Citations
3578	Kappa free light chain and neurofilament light independently predict early multiple sclerosis disease activityâ€"a cohort study. EBioMedicine, 2023, 91, 104573.	2.7	0
3579	Imaging cortical lesions in multiple sclerosis. Current Opinion in Neurology, 2023, 36, 222-228.	1.8	1
3580	White blood cell count profiles in anti-aquaporin-4 antibody seropositive neuromyelitis optica spectrum disorder and anti-myelin oligodendrocyte glycoprotein antibody-associated disease. Scientific Reports, 2023, 13, .	1.6	2
3581	Efficacy and safety of divozilimab during 24-week treatment of multiple sclerosis patients in randomized double-blind placebo-controlled clinical trial BCD-132-2. Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova, 2023, 123, 37.	0.1	2
3582	Free light chains as a reliable biomarker of intrathecal synthesis in the diagnosis of CNS inflammatory diseases. Journal of Neuroimmunology, 2023, 379, 578091.	1.1	2
3631	Functional MRI of Multiple Sclerosis. , 2023, , 781-798.		0
3639	A randomized double-blind placebo-controlled trial of low-dose interleukin-2 in relapsingâ€"remitting multiple sclerosis. Journal of Neurology, 2023, 270, 4403-4414.	1.8	6
3640	Demyelinating and Inflammatory Disorders. , 2024, , 329-348.		0
3641	Multiple Sclerosis Is Misdiagnosed as Migraine. , 2023, , 125-129.		0
3645	Reply: Do we need new MRI criteria for diagnosing radiologically isolated syndrome?. Brain, 0, , .	3.7	0
3670	Tumefactive Demyelinating Lesion Around aÂDevelopmental Venous Anomaly. Clinical Neuroradiology, 0, , .	1.0	0
3677	Intrathecal kappa free light chain synthesis is associated with worse prognosis in relapsingâ€"remitting multiple sclerosis. Journal of Neurology, 0, , .	1.8	2
3699	Clinical cases on functional neurosurgery and motor speech disorders. , 2023, , 357-418.		0
3701	Associations and interactions with herpesviruses and parasites (helminths) in people with multiple sclerosis. , 2023, , 89-103.		0
3702	Monoclonal antibodies in multiple sclerosis treatment. , 2023, , 191-207.		0
3703	The neuroimmunology of fatigue in multiple sclerosis. , 2023, , 55-72.		0
3704	Imaging characteristics of neuroimmunological disorders. , 2023, , 331-409.		0
3707	Biomarkers in multiple sclerosis. , 2023, , 27-53.		0

#	Article	IF	Citations
3714	A multimodal marker for cognitive functioning in multiple sclerosis: the role of NfL, GFAP and conventional MRI in predicting cognitive functioning in a prospective clinical cohort. Journal of Neurology, 2023, 270, 3851-3861.	1.8	2
3730	Pathologies neurologiques. , 2022, , 195-229.		0
3744	Case Report: Multiple Sclerosis Presenting as Unilateral Gaze-evoked Nystagmus. Optometry and Vision Science, 2023, 100, 419-421.	0.6	0
3762	Case report: Chorea and cognitive decline in a young woman: instrumental and genetic assessment of a case originally diagnosed as multiple sclerosis. Frontiers in Genetics, 0, 14, .	1.1	0
3769	Serum levels of neurofilament light chains in pediatric multiple sclerosis: a systematic review and meta-analysis. Journal of Neurology, 0, , .	1.8	0
3771	Meningeal inflammation as a driver of cortical grey matter pathology and clinical progression in multiple sclerosis. Nature Reviews Neurology, 2023, 19, 461-476.	4.9	2
3796	EntzÃ¼ndliche und erregerbedingte Erkrankungen. , 2023, , 223-260.		0
3805	Cerebral lesions sites in neurosarcoidosis: a lesion mapping study. Journal of Neurology, 0, , .	1.8	0
3816	Expert Variability and Deep Learning Performance in Spinal Cord Lesion Segmentation for Multiple Sclerosis Patients. , 2023, , .		0
3831	Computer-Aided Diagnosis and Prediction in Brain Disorders. Neuromethods, 2023, , 459-490.	0.2	0
3832	Machine Learning in Multiple Sclerosis. Neuromethods, 2023, , 899-919.	0.2	0
3868	Rhombomere 5 r5. , 2023, , 313-336.		0
3892	Optic Neuritis: A Review. , 2023, , .		0
3897	Cortical thickness and cognition in older people with multiple sclerosis. Journal of Neurology, 0, , .	1.8	0
3901	The Benefits and Risks of Switching from Fingolimod to Siponimod for the Treatment of Relapsingâ€“Remitting and Secondary Progressive Multiple Sclerosis. Drugs in R and D, 2023, 23, 331-338.	1.1	2
3902	Sex-related differences in upper limb motor function in healthy subjects and multiple sclerosis patients: a multiparametric MRI study. Journal of Neurology, 2023, 270, 5235-5250.	1.8	1
3903	A dynamic interpretation of ÎºFLC index for the diagnosis of multiple sclerosis: a change of perspective. Journal of Neurology, 0, , .	1.8	1
3904	Contemporary Cerebrospinal Fluid Analysis in Multiple Sclerosis. , 2023, , 243-252.		0

#	Article	IF	Citations
3912	Real-life evaluation of the 2017 McDonald criteria for relapsingâ€“remitting multiple sclerosis after a clinically isolated syndrome confirms a gain in time-to-diagnosis. Journal of Neurology, 0, , .	1.8	0
3915	Novel Structural-Scale Uncertainty Measures and Error Retention Curves: Application to Multiple Sclerosis. , 2023, , .		1
3940	Use of gadolinium-based contrast agents in multiple sclerosis: a review by the ESMRMB-GREC and ESNR Multiple Sclerosis Working Group. European Radiology, 2024, 34, 1726-1735.	2.3	6
3954	Multiple sclerosis lesions that impair memory map to a connected memory circuit. Journal of Neurology, 2023, 270, 5211-5222.	1.8	1
3955	Recent advances in nanotechnology and its application for neuro-disease: a review. Applied Nanoscience (Switzerland), 2023, 13, 6631-6665.	1.6	1
3970	Pediatric Multiple Sclerosis: Changing the Trajectory of Progression. Current Neurology and Neuroscience Reports, 0, , .	2.0	1
3977	Schmerzen im Gesicht. , 2023, , 9-16.		0
3979	Elefant im Raum vs. falsche FÃhrte. , 2023, , 87-95.		0
3997	Spinal cord motor disorders. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2023, , 3-42.	1.0	0
3998	Multiple sclerosis: Motor dysfunction. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2023, , 119-147.	1.0	2
4007	Clinical characteristics and treatment approaches in patients with Susac syndrome: a scoping review of cases. Journal of Neurology, 2023, 270, 5719-5730.	1.8	1
4008	Breastfeeding in Immune-Mediated Demyelinating Disorders of the Central Nervous System. , 2023, , 299-314.		0
4102	Identification and management of subclinical disease activity in early multiple sclerosis: a review. Journal of Neurology, 0, , .	1.8	1
4115	Vitamin D mechanisms of protection in multiple sclerosis. , 2024, , 1129-1166.		0
4117	20.ÂNeurological Disorders. , 2023, , .		0
4122	Vitamin D and the epidemiology of multiple sclerosis. , 2024, , 1167-1184.		0
4147	SARS-CoV-2 vaccination and multiple sclerosis: a large multicentric study on relapse risk after the third booster dose. Journal of Neurology, 0, , .	1.8	0
4161	The elusive nature of the oligoclonal bands in multiple sclerosis. Journal of Neurology, 2024, 271, 116-124.	1.8	0

#	Article	IF	Citations
4162	Neuroimaging in the Pregnant Patient. , 2023, , 39-100.		0
4176	Neuroradiologische Bildgebung. , 2023, , 61-77.		0
4187	Differential Diagnosis: â€œWhat Is the Lesion?â€• , 2023, , 137-281.		0
4212	Disease-modifying treatment, long-term outcomes and transition to progressive multiple sclerosis: data based on the New York State MS Consortium. Journal of Neurology, 2024, 271, 711-722.	1.8	0
4247	Kopf. , 2023, , 1-46.		0
4252	Editorial: New cerebrospinal fluid research to uncover mechanisms driving neurological and psychiatric diseases, volume II. Frontiers in Neurology, 0, 14, .	1.1	0
4261	Chronic Lymphocytic Inflammation With Pontine Perivascular Enhancement Responsive to Steroids (CLIPPERS). , 2023, , .		0
4266	Commentary: Solomon AJ et al. Differential diagnosis of suspected multiple sclerosis: An updated consensus approach. Lancet Neurol 2023; 22(8): 750â€“768. Multiple Sclerosis Journal, 2023, 29, 1047-1048.	1.4	0
4272	Peering further into the mindâ€™s eye: combining visual evoked potential and optical coherence tomography measures enhances insight into the variance in cognitive functioning in multiple sclerosis. Journal of Neurology, 0, , .	1.8	0
4284	Increasing age of multiple sclerosis onset from 1920 to 2022: a population-based study. Journal of Neurology, 0, , .	1.8	0
4339	Twenty Years of Subcutaneous Interferon-Beta-1a for Multiple Sclerosis: Contemporary Perspectives. Neurology and Therapy, 2024, 13, 283-322.	1.4	0
4366	Late-onset multiple sclerosis: disability trajectories in relapsingâ€“remitting patients of the Italian MS Registry. Journal of Neurology, 2024, 271, 1630-1637.	1.8	0
4369	Treatment guidelines and considerations for pediatric multiple sclerosis. , 2024, , 207-235.		0
4402	Multiple Sklerose. , 2024, , 69-84.		0
4416	Autoimmune Disease. , 2024, , 421-442.		0
4425	Obsessiveâ€“compulsive symptoms and brain lesions compatible with multiple sclerosis. Journal of Neural Transmission, 2024, 131, 281-286.	1.4	0
4431	Therapeutic Targeting of B Cells and Plasma Cells with a Focus on Multiple Sclerosis and Other Autoimmune Conditions. , 2024, , 425-435.		0
4432	Beyond MS. , 2024, , 97-133.		0

#	Article	IF	Citations
4436	Introduction to multiple sclerosis. , 2024, , 1-33.		0
4438	Neuroimaging in multiple sclerosis and related disorders. , 2024, , 289-320.		0
4458	Demyelinating Diseases of the CNS (Brain and Spine). IDKD Springer Series, 2024, , 189-202.	0.8	0
4460	Multiple Sclerosis and Health-Related Quality of Life. , 2023, , 4542-4544.		0
4472	Diagnosis and Analysis of Multiple Sclerosis Disease Using Artificial Intelligence. Studies in Computational Intelligence, 2024, , 125-150.	0.7	0
4473	Optic Disc Signsâ€"Cupping, Swelling, Inflammation, and Pallor. , 2023, , 423-472.		0
4476	The Emerging Applications of Machine Learning in the Diagnosis of Multiple Sclerosis. Studies in Computational Intelligence, 2024, , 113-124.	0.7	0
4484	The role of ethnicity and native-country income in multiple sclerosis: the Italian multicentre study (MS-MigIT). Journal of Neurology, 0, , .	1.8	0
4513	Automated Segmentation of Multiple Sclerosis Lesions using Deep Learning. , 2023, , .		0
4527	Astrocyte Activation and Drug Target in Pathophysiology of Multiple Sclerosis. Methods in Molecular Biology, 2024, , 431-455.	0.4	0
4559	Optic Neuritisâ€"The Dawn of New Era. , 2024, , .		0